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Abstract 
 
Current epidemiological data showing that the use of the injectable contraceptive progestin Depot-
medroxyprogesterone acetate (DMPA) is associated with increased HIV-1 acquisition is controversial. 
However, animal and ex vivo data reveal plausible biological mechanisms whereby MPA may 
increase HIV-1 acquisition. Relatively high levels of endogenous progesterone (P4) found in the luteal 
phase of the menstrual cycle have also been linked to increased HIV-1 acquisition in animal, clinical 
and ex vivo models. One of the central hypotheses of the present study was that the mechanism of 
MPA-induced increase in HIV-1 infection occurs via a different mechanism to that of the luteal phase. 
Furthermore, MPA has been shown to activate both the glucocorticoid receptor (GR) and its target, 
the progesterone receptor (PR) isoform B (PR-B), which are both transcription factors and regulate 
genes involved in immune function. Both the GR and PR are expressed in the cervix, the primary site 
of heterosexual HIV-1 infection. PR is regulated by endogenous estrogen (E2), of which the 
concentrations fluctuate throughout the menstrual cycle, and GR expression also varies in response to 
stress hormones, leading to conditions of varied relative levels of GR/PR. The immune-related 
consequences of changing the relative levels of GR and PR-B are not well understood. Therefore 
another hypothesis of this study was that changing the relative levels of GR/PR-B modulates HIV-1 
infection and immunomodulatory gene expression in response to the GR/PR agonist, MPA. Since GR 
and PR-B recognize similar DNA target sequences and may regulate the same genes at the same time, 
the final hypothesis of the present study was that GR and PR-B reciprocally modulate each other’s 
activity, through possible association. 
 
To investigate the effects of exogenous hormones on HIV-1 infection and mechanisms thereof, 
peripheral blood mononuclear cells (PBMCs) and TZM-bl cervical cells were used as model systems 
for HIV-1 infection. These cells were stimulated with P4 and E2 at concentrations mimicking the 
menstrual cycle phases or with levels of MPA at the upper range of peak serum levels detected in 
DMPA users. Cells were infected with the R-tropic HIV-1 infectious molecular clone, HIV-1Bal_Renilla 
and luciferase assays were used to measure HIV-1 infection. Levels of HIV-1 CD4 receptor and 
CCR5 co-receptor protein or mRNA were measured by flow cytometry or qPCR, respectively, while 
activation of CD4+ T cells using the activation marker CD69 was measured by flow cytometry in 
PBMCs. To investigate the effects of changing GR/PR-B levels on HIV-1 infection and immune gene 
regulation, GR/PR levels were altered in End1/E6E7 immortalized endocervical and HeLa/TZM-bl 
cervical carcinoma cells by GR siRNA knockdown with or without the simultaneous over-expression 
of PR-B, and cells were stimulated with MPA or the GR agonist Dexamethasone. mRNA expression 
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of key immunomodulatory genes in End1/E6E7 and HeLa cells was measured by qPCR. The 
modulation of GR activity by PR-B was assessed by promoter-reporter assay in COS1 and U2OS cells 
over-expressing GR and PR and stimulated with GR- and/or PR-specific ligands. Association of GR 
and PR-B was measured by co-immunoprecipitation in COS1 and MCF-7 cells, while co-localization 
of GR and PR-B was measured by confocal microscopy and super-resolution structured illumination 
microscopy in COS1 cells. 
 
MPA significantly increased HIV-1 infection in both PBMCs and TZM-bl cells, while luteal phase 
hormones did so to a lesser extent. However, MPA but not luteal phase hormones increased the ratio 
of CD4+/CD8+ T cells in PBMCs. MPA but not luteal phase hormones also increased CCR5 protein 
expression on CD4+ T cells in PBMCs and total CCR5 mRNA expression in TZM-bl cells. In 
addition, MPA but not luteal phase hormones increased activation of CD4+ T cells in PBMCs. Using 
a GR antagonist or GR siRNA, it was shown that the GR but not PR-B is required for MPA-, but not 
luteal phase hormone-induced increased HIV-1 infection in PBMCs and TZM-bls. The presence of 
PR-B altered the anti-inflammatory, GR-mediated regulation of some key immunomodulatory genes, 
including GILZ and IL-6, in End1/E6E7 and HeLa cells in response to MPA. In general, basal 
(unliganded) expression of immunomodulatory genes exhibited a pro-inflammatory profile in the 
presence of PR-B. Co-immunoprecipitation assays showed that GR and PR-B appeared to associate. 
Confocal microscopy suggested GR and PR co-localized in the nucleus in response to GR- and/or PR-
specific ligands, while super-resolution microscopy showed that co-localization occurred in select 
regions within the nucleus.  
 
Taken together, MPA increases HIV-1 infection in a manner different from that of luteal phase 
hormones, most likely involving increased CD4+ T cell frequency (CD4+/CD8+ ratio), activation and 
increased expression of CCR5 on CD4+ T cells, and requiring the GR. Furthermore, PR-B modulates 
GR-mediated immune function gene regulation, via potential association and region-specific nuclear 
co-localization. This suggests that the relative levels of GR/PR may play an important role in 
determining the inflammatory and immune responses and HIV-1 infection in HIV-1 target cells, both 
in DMPA users and women not using hormonal contraception.  
  
iv 
 
Plagiarism Declaration 
 
 
I, Alexis Joanna Bick, hereby declare that the work within this thesis is my original work, unless 
otherwise acknowledged, and that neither this thesis nor part thereof has been submitted for another 
degree at any other university. 
 
 
 
Signature:     Date: 19/02/2018 
  
v 
 
Acknowledgements 
 
I wish to convey my deepest heartfelt gratitude to a great number of people who have helped me in 
different ways throughout this challenging PhD. 
Firstly, to my supervisor, Prof Janet Hapgood: thank you for taking me on as a student and for 
teaching me so much about science and myself. I am humbled by your dedication to your work, your 
powerful big-picture thinking and the ease and elegance with which you write. 
To my co-supervisor, Dr Chanel Avenant: thank you for your guidance on the bench and off, for 
your patience and considerate nature. I have the most profound respect for your scientific 
understanding and lab skills, and I really enjoyed working with you. 
I also gratefully acknowledge my funders, without whom I would not have been able to undertake my 
studies: The National Research Foundation, the Poliomyelitis Research Foundation, the University of 
Cape Town doctoral research Associateship, the Carnegie Corporation, and other financial support 
through grants to my supervisor from the National Institute of Health and the University of Cape 
Town. Thank you to the staff at the Postgraduate Funding Office for processing so many of my 
applications over the years. 
I appreciate the assistance of the Interlibrary Loans Desk at the University of Cape Town for their 
help tracking down some very old papers. I think the most ancient one was from 1969! 
Thank you to the scientific officers at the Department of Molecular and Cell Biology who have 
always ensured the facilities are run smoothly. A kind thanks especially to Faezah Davids and Madhu 
Chauhan for their friendliness towards me. I have loved my time working in the mammalian tissue 
culture facility. Thank you to the administrative staff members at MCB, who have always been 
helpful and kind. 
Thank you to Dr Michele Tomasicchio for running my FACS samples on the flow cytometer at the 
Lung Infection and Immunity Unit at the University of Cape Town. Thank you also to Assoc Prof 
Dirk Lang and especially Mrs Susan Cooper at the Confocal and Light Microscope Unit, Department 
of Human Biology, at the University of Cape Town, for assistance and training with the confocal 
microscope. Kind thanks also to Dr John Woodland for assisting me with the super-resolution 
microscopy at the Central Analytical Facility Fluorescence Microscopy Unit at the University of 
Stellenbosch. 
Thank you to my lab colleagues who have turned into dear friends: Dr Roslyn Ray, TJ Nhundu, 
Calvin Kemp, Mosoko Moliki, Dr Michelle Maritz and Dr John Woodland. I have treasured many 
good laughs, deep conversations, coffees, baked goods, “crazy hours”, balcony sunrises and random 
dances. I admire your endurance, hard work and patience and I have learnt a great deal from all of 
you. 
Many thanks also to past and present members of the Hapgood laboratory, who have helped me learn, 
listened to me present my data so many times, endured lab meetings and journal clubs and have 
created a pleasant working environment: Dr Michele Tomasicchio, Dr Lance Wehmeyer, Dr Marike 
Janse van Rensburg, Dr John Woodland, Dr Yashini Govender, Gcina Dlamini, Salndave Skosana, 
vi 
 
Maleshigo Komane, Kim Enfield, Michael Kuipa and Leo Maritz. To our superb lab manager, Karen 
van der Merwe, I don’t know how our lab functioned without you! Thank you for everything. 
I appreciate the kind insight and encouragement from Dr Zenda Woodman, Dr Donita Africander and 
Dr Renate Louw-du Toit. Thank you also to my dear friends, Dr Delroy Guzha and Debbie Race. 
A huge thank you to those who have found the humour in science and the PhD journey: PhD Comics, 
whatshallwecallgradschool, Cyanide and Happiness, The Far Side, Lego grad student and many many 
more. It was a comfort to feel like I wasn’t alone and that I hadn’t lost my sense of humour. Thank 
you to Rebecca Skloot, Ben Goldacre and David Bodanis for sparking a love for science writing. 
Thank you also to my family: my parents, Geoff and Erichka, my siblings, Simon and Lindsay, and 
their families. My respect for education has come from you. (And a special mention to Kelsey the 
cat!) 
Finally, a very special thank you to my boyfriend James Hall, who has had a seemingly endless 
supply of encouragement, love, pride and support. Thank you for loving me. 
  
vii 
 
Table of Contents 
 
Abstract           ii 
Plagiarism Declaration         iv 
Acknowledgements          v 
List of Abbreviations          xii 
Thesis Outline           xv 
Chapter 1: Literature Review        1 
1.1 HIV-1 prevalence in South Africa       1 
1.2 The female reproductive tract (FRT)       3 
1.2.1 Structure         3 
1.2.2 HIV-1 infection in the FRT       4 
1.2.3 Immune function of mucosal surfaces      5 
1.3 The menstrual cycle         7 
1.3.1 Hormonal regulation and biological events of the menstrual cycle  7 
1.3.2 Immune function and susceptibility to infection across the menstrual cycle 10 
1.4 Hormonal contraception         14 
1.4.1 MPA and other progestins       16 
1.4.2 Association between DMPA use and HIV-1 acquisition    21 
1.4.3 Mechanisms of increased HIV-1 infection by MPA    23 
1.5 Steroid hormone receptors (SRs)       27 
1.5.1 Function, regulation and expression of the GR and PR    28 
1.5.2 Classic mechanisms of action of SRs      29 
1.5.3 Cross-talk between SRs        32 
1.5.4 Variations in SR levels in the FRT      34 
1.6 Thesis rationale and hypotheses        35 
  
Chapter 2: Materials and Methods       39 
2.1 Ethics and biosafety         39 
2.2 Compounds and antibodies        39 
2.3 Plasmids          40 
2.3.1 Plasmid transformation and purification      41 
viii 
 
2.3.2 Restriction enzyme digestion       41 
2.4 Mammalian cell culture         41 
2.4.1 Cell lines         42 
2.4.2 PBMCs          43 
2.4.3 Cervical explants        43 
2.5 Transfections          44 
2.5.1 Promoter-reporter assays       44 
2.5.2 Small interfering RNA (siRNA) transfections     45 
2.6 Protein assays          45 
2.6.1 Protein isolation        45 
2.6.1.1 Cell lines         45 
2.6.1.2 PBMCs          46 
2.6.1.3 Cervical explants        46 
2.6.2 Western blotting        47 
2.6.3 Co-immunoprecipitation (Co-IP) assay      48 
2.6.4 IL-6 ELISA         48 
2.6.5 Flow cytometry         48 
2.7 Gene expression assays         49 
2.7.1 RNA isolation         49 
2.7.2 cDNA synthesis        50 
2.7.3 Quantitative real-time RT-PCR (qRT-PCR or qPCR)    50 
2.8 HIV-1 infection assays         52 
2.8.1 Preparation of virus and determination of viral titres    52 
2.8.2 PBMC infection assay        52 
2.8.3 TZM-bl infection assay         53 
2.8.4 Media add-back onto TZM-bl cells infection assay    54 
2.9 Immunofluorescence         54 
2.9.1 Slide preparation        54 
2.9.2 Confocal microscopy        55 
2.9.3 Super-resolution structured illumination microscopy (SR-SIM)   55 
2.10 Statistical analysis         56 
 
Chapter 3: Both MPA used in injectable contraception and exogenous hormones mimicking 
the luteal phase of the menstrual cycle increase HIV-1 infection, but via 
potentially different mechanisms      57 
3.1 Background and aims         57 
ix 
 
3.2 Luteal phase E2/P4 and MPA increase HIV-1 infection in PBMCs   58 
3.3 Menstrual cycle phase hormones and MPA differentially regulate markers relevant to HIV-1 
infection and immune function        60 
3.3.1 Menstrual cycle phase hormones and MPA differentially regulate the frequency of 
immune cell populations and their activation in PBMCs    60 
3.3.2  Menstrual cycle phase hormones and MPA differentially regulate co-receptor 
expression in PBMCs and TZM-bl cells      64 
3.3.3 Menstrual cycle phase hormones and MPA differentially regulate pro-inflammatory 
IL-6 gene expression in PBMCs and TZM-bl cells    69 
3.4 The GR is required for the increased HIV-1 infection in response to MPA, but not menstrual 
cycle phase hormones          70 
3.4.1 Increased HIV-1 infection in response to stimulation with MPA but not luteal or 
follicular phase E2/P4 is mediated via the GR     70 
3.4.2 GR protein levels are decreased in response to MPA but not menstrual cycle phase 
hormones in PBMCs        72 
 
Chapter 4: MPA-induced and basal HIV-1 infection and immunomodulatory gene 
expression change when the relative levels of GR and PR are altered  74 
4.1 Background and aims         74 
4.2 MPA-induced HIV-1 infection changes when the relative levels of GR/PR are altered in 
TZM-bl cells          76 
4.2.1 The increase in HIV-1 infection with MPA, but not luteal phase E2/P4, depends on 
GR but not PR-B levels        76 
4.2.2 HIV-1 infection in the absence of exogenous hormones changes when the relative 
levels of GR/PR are altered       78 
4.3 Altering the relative levels of GR/PR modifies the MPA-induced expression of genes relevant 
to HIV-1 infection and immune function in TZM-bl cells     80 
4.3.1 Basal HIV-1 CD4 receptor, but not CCR5 or CXCR4 co-receptor, expression changes 
when GR/PR levels are altered in TZM-bl cells in the absence of exogenous 
hormones         80 
4.3.2 MPA-induced immunomodulatory gene expression changes when GR/PR levels are 
altered in End1/E6E7 and HeLa cells      81 
4.3.3 Basal immunomodulatory gene expression changes when GR/PR levels are altered in 
End1/E6E7 and HeLa cells       90 
4.4 Differences in HIV-1 infection with changing GR/PR levels is mediated by soluble factors, 
but likely not IL-6         93 
x 
 
Chapter 5: Modulation of GR activity by PR potentially occurs via GR-PR association and 
co-localization         98 
5.1 Background and aims         98 
5.2 PR-A and PR-B individually repress GR-mediated activity on the TAT-GRE-LUC reporter 
gene in COS1 and U2OS cells over-expressing GR and/or PR    99 
5.3 GR and PR associate in the same protein complex     103 
5.4 GR and PR are co-expressed within the same cells     106 
5.5 PR is mostly nuclear while GR is located in both the cytoplasm and nucleus  108 
5.6 GR and PR co-localize in the nucleus in response to GR- and/or PR-specific ligands 109 
 
Chapter 6: Discussion         117 
6.1 MPA and luteal phase hormones both increase HIV-1 infection, but via potentially different 
mechanisms          117 
6.1.1 MPA and luteal phase E2/P4 increase HIV-1 infection     118 
6.1.2 MPA-induced HIV-1 infection most likely occurs through increased frequency of CD4+ T 
cells, increased CD4/CD8 ratios and increased CCR5 and CD69 on CD4+ T cells, while 
luteal phase E2/P4 increases HIV-1 infection via a different, unidentified mechanism 122 
6.1.3 MPA- but not luteal phase E2/P4-induced HIV-1 infection is mediated by the GR  127 
6.2 HIV-1 infection in the absence of exogenous MPA or E2/P4 increases with low GR/high PR 
and may involve the regulation of soluble factors      129 
6.3 GR-mediated gene regulation in response to MPA is altered in the presence of PR-B  132 
6.4 Unliganded GR-mediated gene regulation is altered in the presence of unliganded PR-B 136 
6.5 GR and PR may associate within the same protein complexes within the nucleus  139 
 
Chapter 7: Conclusions and Future Perspectives      142 
7.1 Conclusions          142 
7.2 Future perspectives         146 
 
Appendices 
Appendix A: Supporting data from other researchers in the Hapgood laboratory  149 
A1. PBMCs           149 
A2. Cell lines          150 
A3. Cervical explants         151 
xi 
 
 
Appendix B: Supporting data from the present author     153 
B1.  Confirmation of HIV-1 infection in PBMCs      153 
B2. GR and PR are expressed in pre- and post-menopausal cervical explant tissue  157 
B3. Establishing GR knockdown and immune function gene regulation by the GR in End1/E6E7 
and HeLa cells          158 
B4. Establishing PR-B over-expression and TAT-GRE-LUC reporter gene regulation by the PR-B 
in End1/E6E7 and HeLa cells        161 
B5.  Over-expression strategies in U2OS cells do not generate good GR-mediated responses 168 
B6. Endogenously GR- and PR-expressing cell lines, MCF-7 and T47D, do not generate good GR 
responses          169 
 
Appendix C: Gating strategy used for flow cytometry     175 
Appendix D: Cervical explant donor information      179 
Appendix E:  Approval letters from the Human Research Ethics Committee  181 
 
References           184 
  
xii 
 
List of abbreviations 
 
AF  activation function domain 
AIDS  acquired immunodeficiency syndrome 
ANOVA analysis of variance 
AP-1  activator protein 1 
APS  ammonium persulphate 
AR  androgen receptor 
ARE  androgen response element 
ATCC  American type culture collection 
bp  base pair 
BPE  bovine pituitary extract 
CCR5  C-C chemokine receptor type 5 
cDNA  complementary DNA 
ChIP  chromatin immunoprecipitation 
CO2  Carbon dioxide 
Co-IP  co-immunoprecipitation 
CORT  cortisol 
cs  charcoal-stripped 
CTD  carboxy terminal domain 
CVL  cervico-vaginal lavage 
CXCR4 C-X-C chemokine receptor type 4 
DBD  DNA binding domain 
DEPC  diethylpyrocarbonate 
DEX  dexamethasone 
DMEM  Dulbecco’s modified Eagle’s medium 
DMPA  depot-medroxyprogesterone acetate 
DNA  deoxyribose nucleic acid 
E2  17β-estradiol 
EC50  effective concentration required for 50% of maximal response 
ECL  enhanced chemiluminescence 
EDTA  ethylenediaminetetra-acetic acid 
ELISA  enzyme-linked immunosorbent assay 
ER  estrogen receptor 
ERE  estrogen response element 
EtBr  ethidium bromide 
EtOH  ethanol 
FACS  fluorescent activated cell sorting 
FCS  fetal calf serum 
FRT  female reproductive tract 
FSH  follicle stimulating hormone 
GAPDH glyceraldehyde phosphate dehydrogenase 
GBS  GR binding sequence 
GC  glucocorticoid 
GILZ  glucocorticoid induced leucine zipper 
GR  glucocorticoid receptor 
xiii 
 
GRE  glucocorticoid response element 
GRIP-1  glucocorticoid receptor interacting protein 1 
h  hour/s 
HAT  histone acetyltransferase 
HCl  hydrochloric acid 
HDAC  histone deacetylase 
HIV-1  human immunodeficiency virus type 1 
HPV  human papillomavirus 
HREC  human research ethics committee 
HRP  horseradish peroxidase 
HRT  hormone replacement therapy 
HSP90  heat shock protein 90 
HSV  herpes simplex virus 
IFN  interferon 
IκBα  inhibitor of NFκB type α 
IL  interleukin 
i.m.  intra-muscular 
KD  equilibrium dissociation constant 
kDa  kiloDalton 
Ki  dissociation constant 
KSFM  keratinocyte serum-free medium 
LBD  ligand binding domain 
LH  luteinizing hormone 
LNG  levonorgestrel 
LTR  long terminal repeat 
LUC  luciferase 
M  Molar 
MAPK  mitogen activated protein kinase 
MDM  monocyte-derived macrophage 
min  minute/s 
MKP1  mitogen activated protein kinase phosphatase 1 
mL  millilitre 
mM  milliMolar 
MMTV  mouse mammary tumour virus 
MOPS  4-morpholine-propanesulfonic acid 
MPA  medroxyprogesterone acetate 
MR  mineralocorticoid receptor 
mRNA  messenger RNA 
MTT  3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide 
NCoR  nuclear receptor co-repressor 
NET  norethisterone 
NET-A  norethisterone acetate 
NET-EN  norethisterone enanthate 
NFκB  nuclear factor kappa B 
nGRE  negative GRE 
nM  nanoMolar 
NTD  amino-terminal domain 
p24   HIV-1 viral core protein 
xiv 
 
P4  progesterone 
PAGE  polyacrylamide gel electrophoresis 
PBMCs  peripheral blood mononuclear cells 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PR  progesterone receptor 
PRE  progesterone response element 
qRT-PCR  quantitative reverse transcription PCR 
R5020  promegestone 
RANTES  regulated upon activation, normal T cell expressed and secreted 
RBA  relative binding affinity 
RLU  relative light units 
RNA   ribonucleic acid 
RPMI  Roswell Park Memorial Institute 
s  seconds 
s.c.  sub-cutaneously 
SDS  sodium dodecyl sulphate 
SEM   standard error of the mean 
SHIV   simian-human immunodeficiency virus 
siRNA  small interfering RNA 
SIV   simian immunodeficiency virus 
SLPI   secretory leukocyte proteinase inhibitor 
SMRT   silencing mediator for retinoid or thyroid-hormone receptor 
SR   steroid receptor 
SRC  steroid receptor coactivator 
STI   sexually transmitted infection 
TAT  tyrosine aminotransferase 
TBS   TRIS-buffered saline 
TBST   TRIS-buffered saline-tween 
TNFα  tumour necrosis factor alpha 
μL  microlitre 
UTR  untranslated region 
VpR   HIV-1 viral accessory protein R 
v/v   volume per unit volume 
WHO  World Health Organization 
w/v   weight per unit volume 
  
xv 
 
Thesis Outline 
 
This thesis comprises of six chapters and five appendices. There are three results chapters and 
supplementary results are included in the appendix. 
Chapter 1: Literature Review. This chapter outlines the current literature on mechanisms of GR- and 
PR-mediated gene regulation, the immune responses of the FRT mucosae, and HIV-1 infection in 
response to endogenous sex hormones and hormonal contraception with the injectable MPA. The 
rationale behind the research conducted is also discussed and the main hypotheses are stated. 
Chapter 2: Materials and Methods. This chapter describes in detail the methods used to obtain the 
results in the subsequent chapters. 
Chapter 3: Results: Both MPA used in injectable contraception and exogenous hormones mimicking 
the luteal phase of the menstrual cycle increase HIV-1 infection, but via potentially different 
mechanisms. This chapter investigates HIV-1 infection in peripheral blood and an infectable cervical 
cell line model in response to MPA or hormones representing the luteal and follicular phases of the 
menstrual cycle, and analyzes potential biological mechanisms of infection through regulation of key 
markers relevant to HIV-1 infection. 
Chapter 4: Results: MPA-induced and basal HIV-1 infection and immunomodulatory gene expression 
change when the relative levels of GR and PR are altered. This chapter explores the effects of 
molecular manipulation of relative GR/PR levels in cervical cell lines on HIV-1 infection, expression 
of markers relevant to HIV-1 infection and immunomodulatory gene expression.  
Chapter 5: Results: Modulation of GR activity by PR potentially occurs via GR-PR association and 
co-localization. This chapter investigates potential interactions and cellular co-localization of the GR 
and PR in the absence and presence of hormone ligands. 
 
Chapter 6: Discussion. This chapter critically discusses the results obtained in the previous three 
chapters and contextualizes the findings from this thesis within the fields of biological mechanisms of 
HIV-1 infection and cross-talk between the GR and PR.  
 
Chapter 7: Conclusions and Future Perspectives. This chapter draws concluding remarks from the 
observations presented in this thesis and proposes new avenues of research arising from this work. 
 
Appendix A: Supporting data from other researchers in the Hapgood laboratory. This appendix 
consists of supporting data carried out by other researchers in the present author’s laboratory, and 
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shows the endogenous steroid receptor levels of the various model systems (End1/E6E7, HeLa, 
TZMBL, PBMCs, cervical explants) used in this study. 
Appendix B: Supporting data from the present author. This appendix includes supplementary data 
carried out by the present author and consists of pilot experiments, important controls and the 
investigation of possible model cell line strategies in which relative GR/PR levels could be altered. 
Appendix C: Gating strategy used for flow cytometry analysis. This appendix consists of flow 
diagrams indicating how samples from a representative PBMC donor were gated for marker-negative 
cell populations and analysed for flow cytometry. 
Appendix D:  Cervical explant donor information. This appendix lists the endogenous hormone levels, 
STI status and menstrual cycle phase of the donors whose cervical explant tissue was used for 
quantification of endogenous GR/PR protein levels. 
Appendix E: Approval letters from the Human Research Ethics Committee. This appendix contains 
scanned copies of the approval letters received from the University of Cape Town’s Human Research 
Ethics Committee for the doctoral research as a sub-study of an existing study. 
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Chapter 1 
Literature Review 
 
 
 
 
1.1 HIV-1 prevalence in South Africa 
 
With 38.8 million people worldwide living with HIV/AIDS in 2015, HIV-1 infection, incidence and 
prevalence remain a global health concern (Collaborators et al. 2016). From about 1.8 million new 
infections recorded globally in 2015, approximately 75% of these occurred in Sub-Saharan Africa 
(Collaborators et al. 2016), thereby burdening this region with the highest incidence of HIV-1 and 
AIDS (Fig. 1.1.). South Africa in particular has the highest HIV-1 prevalence, with about 7 million 
infected people in 2015 (UNAIDS South Africa , Avert 2016). HIV-1 incidence in South Africa is in 
the 98-99
th
 percentile, in the range of 707-1043 per 100 000 people (Fig. 1.1.).  
 
 
 
Figure 1.1. Global incidence of HIV-1 per 100 000 people by country in 2015. Incidence was 
calculated as cumulative new HIV infections during the year divided by the total mid-year population. Colour 
blocks indicate the 0–50th, 50–70th, 70–80th, 80–90th, 90th–92nd, 92nd–94th, 96–98th, 98–99th, and 99–100th 
percentiles. Several islands, all in blue colours, have been excluded from the map, including Singapore, Fiji, 
Malta and the Caribbean. Taken from (Collaborators et al. 2016). 
 
2 
 
 
Globally more than half of new infections occur in women (Joint United Nationals Programme on 
HIV/AIDS (UNAIDS) 2016). This trend is also observed in South Africa, where the prevalence of 
HIV-1 is higher in women than men (Shisana et al. 2014). This difference is highest for women of 
reproductive age, between ages 20-34 (Shisana et al. 2014) (Fig. 1.2). 
 
 
 
Figure 1.2. HIV-1 prevalence in South African men and women in 2012. HIV-1 prevalence is 
indicated as percentage. Prevalence is higher in females than males for all age groups except 50-54 and over 60 
years. The highest prevalence occurs in females aged 30-34 years. Taken from (Shisana et al. 2014). 
 
 
 
Men and women differ considerably in their immune responses and susceptibility to infectious 
diseases (Klein and Flanagan 2016, Roved et al. 2017). This phenomenon is largely a consequence of 
different endogenous sex steroid hormones, estrogen (E2) and progesterone (P4) in women and 
testosterone in men. In addition to regulating reproduction, female sex hormones regulate immune 
function in the female reproductive tract. 
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1.2 The female reproductive tract (FRT) 
 
The FRT consists of several organs co-ordinating in function to regulate reproductive processes 
including egg maturation and release, implantation of fertilized eggs, foetal development and 
maintenance of pregnancy, parturition and in the absence of pregnancy, menstruation. These 
processes are intricately regulated by the endogenous sex steroid hormones, E2 and P4. The FRT also 
functions to protect against bacterial, viral and yeast pathogens (Wira et al. 2005b). During 
heterosexual intercourse, the FRT is the first line of defence against sexually transmitted infections, 
including HIV-1, by providing both a physical barrier and a protective immune microenvironment 
(Wira et al. 2005b, Wira et al. 2005c, Hickey et al. 2011).  
 
 
1.2.1 Structure 
 
The organs of the FRT are classified as upper FRT (ovaries, fallopian tubes, uterus) or lower FRT 
(vagina, cervix, Fig. 1.2.1) (Miller and Shattock 2003, Lee et al. 2015, Wira et al. 2015). The cervix is 
further divided into the endocervix (uterine side) and ectocervix (vaginal side, Fig. 1.2.1) and is 
believed to be the primary site of HIV-1 infection (Pudney et al. 2005). 
 
The mucosal surfaces lining the FRT are comprised of stratified squamous epithelium in the vagina 
and ectocervix, and columnar epithelium in the endometrium and endocervix (Fig. 1.2.1) (Hladik and 
Hope 2009, Nguyen et al. 2014, Wira et al. 2014a). The mucosal epithelium is structurally supported 
by the underlying lamina propria and stromal connective tissue. Epithelial barrier integrity is 
promoted by tight junctions between cells (Kaushic 2009, Kaushic 2011). An additional physical 
barrier is the secretion of thick mucus by the cervix (Fig. 1.2.1) (Hickey et al. 2011, Wira et al. 2015).  
 
The cervical transformation zone, also known as the squamo-columnar junction, is the area in which 
the cells change from multi-layer squamous cells to monolayer columnar cells (Fig. 1.2.1). This thin 
layer of columnar epithelium and the large number of CD4+ T cells populating the transformation 
zone make the cervix an important site for initial HIV-1 infection (Pudney et al. 2005, Haynes and 
Shattock 2008, Wira et al. 2010, Lee et al. 2015). 
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Figure 1.2.1. Anatomical structure, epithelium and immune cells of the FRT. Ovaries are shown in 
yellow, with connective tissue in light pink and the FRT lumen in dark pink. Compartments of the lower FRT 
(vagina and ectocervix) are lined with squamous epithelium, while the upper FRT (endocervix and uterine 
endometrium) is lined with columnar epithelium. The transformation zone occurs where epithelial cells change 
from squamous to columnar. Immune cells shown include HIV-1 target CD4+ T cells. Innate immunity in the 
vagina is represented by antimicrobial peptides, Lactobacilli and mucus. Taken from (Nguyen et al. 2014). 
 
 
 
1.2.2 HIV-1 infection in the FRT 
 
Infection with the retrovirus HIV-1 in the FRT occurs through sexual transmission. Despite low 
transmission rates (1:200-1:2000), more new cases arise through vaginal intercourse than other types 
of transmission (Hladik and McElrath 2008, Hladik and Hope 2009). HIV-1 crosses through genital 
epithelial cells at regions of compromised barrier integrity via shearing, microabrasions, impaired 
tight junction function, ulcerations and/or other sexually transmitted infections (Hladik and Hope 
2009, Kaushic 2009, Nazli et al. 2010, Kaushic 2011, Rodriguez-Garcia et al. 2013b). HIV-1 uptake 
via transcytosis in genital epithelial cells has been demonstrated (Ferreira et al. 2015), however HIV-1 
does not actively replicate in epithelial cells (Dezzutti et al. 2001, Dezzutti and Hladik 2013, Ferreira 
et al. 2015). 
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Infection occurs through viral envelope proteins binding to host CD4 receptors (Sattentau et al. 1986) 
on the surface of target cells, which are typically CD4+ T cells, macrophages or dendritic cells (DCs) 
(Givan et al. 1997, Howell et al. 1997, Hladik and Hope 2009, Nguyen et al. 2014, Wira et al. 2015). 
Importantly, women have greater frequencies of systemic CD4+ cells than men (Maini et al. 1996). 
Upon CD4 receptor binding, viral envelope proteins undergo a conformational change to permit 
binding to one of two host co-receptors: either C-C chemokine receptor type 5 (CCR5) or C-X-C 
chemokine receptor type 4 (CXCR4) (Cullen 2001). The preference of the transmitting virus to utilize 
either CCR5 or CXCR4 classifies the virus as R5-tropic or X4-tropic, respectively, or even dual-
tropic (Berger et al. 1998). Usually a single virus variant is transmitted to the new host, and the 
transmitting virus is predominantly R5-tropic, although a small percentage of infections occur through 
X4-tropic viruses (Carrington et al. 1999, Keele et al. 2008, Salazar-Gonzalez et al. 2009, Grivel et al. 
2011). R5-virus transmission is likely to be augmented by the high frequency of CCR5-expressing 
immune cells in the FRT (Patterson et al. 1998, Shacklett and Greenblatt 2011).  
 
Following co-receptor binding, a second conformational change facilitates viral fusion to the host 
membrane, after which the virion is shed and viral RNA undergoes reverse transcription, integration 
into the host genome and transcription of viral genes (Haseltine and Wong-Staal 1988, Briggs and 
Krausslich 2011). Infected cells then carry the virus to other local T lymphocytes or migrate to nearby 
lymph nodes and the circulatory vascular system (Hladik and Hope 2009). 
 
 
1.2.3 Immune function of mucosal surfaces 
 
In order to perform the dual functions of promoting reproductive processes and protecting against 
pathogens, the FRT has evolved multiple innate and adaptive immune responses, in addition to the 
protective barrier function of mucosal epithelium (Wira et al. 2005b, Wira et al. 2010, Wira et al. 
2011). 
 
The innate immune response of the FRT provides the initial rapid defence against pathogens and 
consists of several non-specific mechanisms. These include the production of the bactericidal enzyme 
lysozyme, mucus and antimicrobial peptides (Fig. 1.2.1) such as secretory leukocyte protease 
inhibitor (SLPI) and human beta-defensin 2 (HBD2) through toll-like receptor (TLR)-mediated 
signalling in epithelial cells (Wira et al. 2005b). SLP1 and HBD2 exhibit potent anti-HIV activity 
(Hocini et al. 2000, Quinones-Mateu et al. 2003, Weinberg et al. 2006). In addition local flora such as 
Lactobacillus species producing lactic acid and H2O2 maintain a low pH in the vagina that is hostile to 
invading pathogens (Fig. 1.2.1) (Reis Machado et al. 2014, Vitali et al. 2017). The innate immune 
response is also regulated by the actions of specific immune cells, specifically plasmacytoid dendritic 
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cells (pDCs), neutrophils, macrophages and natural killer (NK) cells, which function in a general 
manner to destroy invading pathogens (Wira et al. 2005b). 
 
Cells involved in adaptive immunity include T cells and antibody-producing B cells. The adaptive 
immune response occurs through several co-ordinated processes, starting with pathogen antigen 
recognition by antigen-presenting cells (APCs) which present to T cells thereby inducing their 
activation and subsequent cytokine and antibody production (Wira et al. 2005b). Immune protection is 
mediated by humoral (antibody production by B cells) and/or cell-mediated (pathogen destruction by 
T cells) functions (Wira et al. 2005b). In this way, the adaptive immune system generates an 
immunological memory to pathogenic antigens that will promote a rapid response upon subsequent 
challenges (Hapgood et al. 2018). APCs such as DCs link the adaptive and innate responses. 
 
T cells are arguably the adaptive immune cells most relevant to HIV-1 infection and are the major 
component (30-60%) of immune cells expressed in all FRT tissues (Givan et al. 1997). T cells are 
broadly categorized as CD8+ cytotoxic T cells, which kill infected cells, and CD4+ helper T cells, 
which support the function of other immune cells and are primary targets for HIV-1 infection 
(Hapgood et al. 2018). CD4+ and CD8+ T cells are found in the lamina propria and squamous 
epithelium of the vagina, ectocervix and endocervix (Miller and Shattock 2003, Pudney et al. 2005, 
Hladik and Hope 2009, Hafner et al. 2013, Reis Machado et al. 2014), with many of these cells also 
expressing the CCR5 co-receptor (Patterson et al. 1998, Shacklett and Greenblatt 2011). 
 
Cytokines and chemotactic cytokines (chemokines) are soluble signalling molecules that are secreted 
by many cell types from both the innate and adaptive immune systems, including FRT epithelial cells, 
natural killer (NK) cells and T cells (Fahey et al. 2005, Wira et al. 2005b, Wira et al. 2005c). 
Cytokines are involved in a number of cellular functions including recruiting circulating immune cells 
to migrate to the FRT and inducing their maturation and differentiation (Wira et al. 2005b, Wira et al. 
2005c). Common cytokines and chemokines expressed in FRT immunity include interleukins (ILs) 
1β, 6, 8, tumour necrosis factor α (TNFα), regulated upon activation, normal T cell expressed and 
secreted (RANTES), macrophage inflammatory protein (MIP) 1β, MIP 3α, monocyte chemotactic 
protein (MCP) 1, granulocyte-macrophage colony-stimulating factor (GM-CSF), and migration 
inhibitory factor (MIF). Cytokines and chemokines are generally classified as pro-inflammatory 
molecules that promote inflammatory functions, or anti-inflammatory cytokines which serve to reduce 
inflammation. 
 
Importantly, the innate and adaptive immune responses in the upper and lower FRT are regulated by 
the female sex hormones, E2 and P4, and therefore the factors and cells involved in these immune 
responses are intricately varied during the menstrual cycle (see section 1.3.2) (Kutteh et al. 1998, 
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Beagley and Gockel 2003, Wira et al. 2005a, Wira et al. 2005b, Ochiel et al. 2008, Wira et al. 2010, 
Weinberg et al. 2011, Wira et al. 2011, Dunbar et al. 2012, Oertelt-Prigione 2012, Hafner et al. 2013, 
Rodriguez-Garcia et al. 2013a, Rodriguez-Garcia et al. 2013b, Goode et al. 2014, Nguyen et al. 2014, 
Wira et al. 2014a, Wira et al. 2014b, Tan et al. 2015, Wira et al. 2015). 
 
 
1.3 The menstrual cycle 
 
The female menstrual cycle is a series of hormonally controlled events that regulate the reproductive 
system in premenopausal women, and is typically 28 days long. The menstrual cycle is classically 
charted from the first day of menstruation and is divided into two ovarian phases: follicular and luteal, 
which are separated by ovulation (Fig. 1.3). The corresponding uterine phases are the proliferative and 
secretory phases (Fig. 1.3). 
 
 
1.3.1 Hormonal regulation and biological events of the menstrual cycle 
 
The menstrual cycle is regulated by endogenous sex steroid hormones: the gonadotropic hormones, 
gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH) and follicle-stimulating hormone 
(FSH), prostaglandins and the ovarian hormones, E2 and P4. These hormones form part of the 
hypothalamic-pituitary-gonadal (HPG) axis. The fluctuations in sex hormones during the menstrual 
cycle cause a series of biological events in the ovaries and uterus (Fig. 1.3).  
 
GnRH secreted in a pulsatile manner from the hypothalamus stimulates pulsatile secretion of LH and 
FSH from the pituitary gland (Owen 1975, Chabbert Buffet et al. 1998, Mihm et al. 2011). During the 
follicular phase, FSH promotes E2 secretion from the developing dominant follicle in ovarian 
granulosa cells, and E2 levels peak during the mid-cycle (Moghissi et al. 1972, Owen 1975, Wira et al. 
2015). At the same time the endometrial tissue proliferates in response to increasing E2 levels (Owen 
1975, Chabbert Buffet et al. 1998, Mihm et al. 2011). The steep rise in LH levels, or LH surge, is 
required for ovulation to occur, whereby an ovum is released from the mature Graafian follicle 
(Speroff and Vande Wiele 1971, Wira et al. 2015) (Fig. 1.3). LH and FSH levels are regulated by both 
positive and negative feedback in response to estrogens and P4 (Speroff and Vande Wiele 1971, 
Chabbert Buffet et al. 1998, Mihm et al. 2011).  
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Figure 1.3. Biological events, phases and hormone levels of the female menstrual cycle. The cycle 
begins at menses/menstruation where the uterine lining is shed and corresponding hormone levels are low. 
During the follicular/proliferative phase, ovarian follicles develop as FSH and E2 levels increase, culminating in 
the LH surge that precedes ovulation. The uterine lining proliferates in anticipation of embryo implantation. In 
the absence of fertilization, P4 levels rise during the luteal/secretory phase and the ovum degenerates. LH: 
luteinizing hormone; FSH: follicle stimulating hormone. Taken from http://science.taskermilward.org.uk/ 
mod1/KS4Biology/B1/Topic%201%20lessons/B1_14.htm 
 
 
 
During the luteal phase, endometrial blood vessels proliferate and coil, and endometrial stromal cells 
differentiate (known as decidualization), in anticipation of implantation of a fertilized embryo 
(Chabbert Buffet et al. 1998, Mihm et al. 2011, Hapgood et al. 2018). During this period from about 
Day 20-24, known as the implantation window, the uterus is receptive toward implantation (Chabbert 
Buffet et al. 1998).  
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Following ovulation, the corpus luteum (empty follicle and some surrounding cells) secretes P4, which 
increases in concentration until P4 levels peak at the mid-luteal phase (Moghissi et al. 1972, Chabbert 
Buffet et al. 1998, Farage et al. 2009, Wira et al. 2015). If fertilization has occurred, the corpus luteum 
continues to secrete P4 under control of LH which is induced by human chorionic gonadotropin (hCG) 
produced by the developing trophoblast, thereby maintaining pregnancy (Kumar and Magon 2012). In 
the absence of fertilization, however, the corpus luteum degrades (called luteolysis) and stops 
secreting P4 (Mihm et al. 2011, Wira et al. 2015). Thereafter E2 and P4 levels decline from the mid-
luteal phase, culminating in the degradation and shedding of the uterine lining during menstruation, 
and thereafter the cycle repeats (Chabbert Buffet et al. 1998, Mihm et al. 2011, Wira et al. 2015). 
 
In addition to LH, FSH, E2 and P4 and prostaglandins, the functions of additional hormonal regulators 
such as inhibins and activins provide further complexity to the hormonal regulation of the menstrual 
cycle (Chabbert Buffet et al. 1998, Farage et al. 2009, Mihm et al. 2011, Messinis et al. 2014). 
 
E2 and P4 are master regulators of female reproduction and the menstrual cycle, with P4 regulating 
mammary gland development, and the establishment and maintenance of pregnancy, while E2 controls 
ovulation, gonadotropic hormone release and other metabolic, neurological and cardiovascular 
functions (Hapgood et al. 2018). The biological effects of E2 and P4 are mediated by binding and 
activating their respective steroid receptors (SRs), the estrogen receptor (ER) and progesterone 
receptor (PR) (Chabbert Buffet et al. 1998, Stanczyk et al. 2013, Wira et al. 2015). 
 
The serum levels of E2 peak during the follicular phase, while P4 levels peak during the luteal phase 
(Speroff and Vande Wiele 1971, Thorneycroft et al. 1971, Moghissi et al. 1972, Owen 1975, Altemus 
et al. 1997, Chabbert Buffet et al. 1998, Sturgeon et al. 2004, Farage et al. 2009, Kuhl 2011, Weinberg 
et al. 2011, Hafner et al. 2013, Thurman et al. 2016). Thus the follicular phase is regarded as E2-
dominant, while the luteal phase is classified as the P4-dominant phase (Speroff and Vande Wiele 
1971, Thurman et al. 2016). The serum concentration of endogenous E2 ranges from 50-1500 pM 
during the follicular phase and 50-1100 pM across the luteal phase of the menstrual cycle (Stricker et 
al. 2006) (Fig. 1.3). Endogenous P4 concentrations range from 0.4-1.6 nM during the follicular phase 
to a wide range of 1-72 nM during the luteal phase (Altemus et al. 1997, Stricker et al. 2006, Hafner 
et al. 2013, Thurman et al. 2016).  
 
During pregnancy, serum P4 levels are even higher and range from 400-600 nM (Kuhl 1990, Sheffield 
et al. 2009, Africander et al. 2011b) but can reach as high as 1 μM (Goebelsmann 1986) to 4-10 μM at 
the umbilical cord (Dawood and Helmkamp 1977, Goebelsmann 1986). Serum E2 levels during 
pregnancy range from 22-110 pM (Lindberg et al. 1974). In postmenopausal women, serum E2 and P4 
levels remain quite low, with E2 levels at about 15 pM (Edlefsen et al. 2010, Hafner et al. 2013) and 
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P4 levels at about 230 pM (Edlefsen et al. 2010). The wide ranges in reported concentrations are likely 
to reflect the large inter-individual biological variation between women and studies. Nevertheless, 
serum E2 and P4 levels fluctuate in a specific pattern during the menstrual cycle, and therefore will 
regulate different biological responses at different stages of the cycle. 
 
 
1.3.2 Immune function and susceptibility to infection across the menstrual cycle 
 
The FRT is uniquely equipped to respond to sexually transmitted pathogens, foreign sperm and a 
foetus that is immunologically dissimilar (Wira et al. 2005b). It is hypothesized that the period 7-10 
days following ovulation (i.e. during the luteal phase) provides a “window of vulnerability” for 
infection, in which sex hormones suppress immunity in order to support fertilization and implantation 
(Wira and Fahey 2008, Wira et al. 2010, Rodriguez-Garcia et al. 2013b, Wira et al. 2014b). 
 
In support of this hypothesis are multiple studies, indicated below, showing that immune cell 
frequency and function, innate immunity factors, co-receptor expression, cytokine production, gene 
expression and HIV-1 infectivity vary with fluctuating sex hormone levels across the menstrual cycle. 
The frequency of immune cells differs between peripheral blood and FRT tissues, and also between 
the upper and lower FRT (Givan et al. 1997, Wira and Fahey 2008, Hafner et al. 2013, Nguyen et al. 
2014, Wira et al. 2015). Regardless of their localization, their proportions and/or functions have been 
shown to be sensitive to changes in female sex hormone levels in several reports.  
 
In peripheral blood samples from naturally cycling women, the proportion of CD4+ T cells was 
higher during the luteal phase in some reports (Faas et al. 2000, Weinberg et al. 2011) but higher 
during the follicular phase in another report (Lee et al. 2010). Some studies showed that CD8+ T cell 
numbers were higher during the luteal phase (Faas et al. 2000, Weinberg et al. 2011), but another 
study showed no change in the proportion of CD8+ T cells or B cells (Lee et al. 2010). The proportion 
and activity of NK cells in peripheral blood was increased during the luteal phase in some studies 
(Faas et al. 2000, Lee et al. 2010, Lee et al. 2015) but during the follicular phase in other studies 
(Souza et al. 2001, Yovel et al. 2001). Some reports have shown no change in total numbers of 
peripheral leukocytes (Tikare et al. 2008) or lymphocytes (Mathur et al. 1979, Lopez-Karpovitchs et 
al. 1993, Bouman et al. 2001, Rajnee et al. 2010) across the menstrual cycle, while others found 
increased total leukocytes (Bouman et al. 2001, Begum and Ashwini 2012, Nowak et al. 2016) or 
lymphocytes (Rosemary et al. 2014) during the luteal phase. In contrast, another report showed higher 
leukocyte numbers during the follicular phase (Rajnee et al. 2010). Numbers of monocytes were 
reported to be higher during the luteal phase (Mathur et al. 1979, Northern et al. 1994). In addition, in 
ovariectomized rhesus macaques treated with E2 or P4 pellets, where P4 serum levels reached mid-
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luteal concentrations, decreased frequencies of CD4+ and CD8+ T cells and those expressing the 
activation markers CD69 or CD25 were observed in PBMCs after P4 treatment (Attanasio et al. 2002).  
Collectively some of these studies suggest that the menstrual cycle may have effects in immune cells 
from PBMCs, while some do not.  
 
Immune cells from different FRT compartments in naturally cycling women are also sensitive to 
endogenous hormone levels across the menstrual cycle. The presence of higher numbers of important 
immune cells, such as CD4+ T cells and cells expressing the CCR5 co-receptor, at the time of HIV-1 
exposure might increase the chance of infection (Wira et al. 2014b). In the endometrium, for example, 
there have been reports that the number of CD68+ macrophages (Bonatz et al. 1992) and the size of 
lymphoid aggregates (consisting of B cells and CD8+ T cells) in endometrial sections (Yeaman et al. 
1997) were increased during the luteal phase. However, cytotoxic T cell function was lower in 
hysterectomy samples from the luteal phase (White et al. 1997). Other research using hysterectomy 
samples observed lower expression of CD4 and CCR5 in uterine epithelial cells from the luteal phase 
(Yeaman et al. 2003) and higher CD4 expression during the follicular phase but no change in CCR5 
expression in ectocervical epithelial cells (Yeaman et al. 2004). Other reports have shown that the 
luteal phase exhibits higher frequency of endocervical CCR5+ CD4+ T cells from cytobrush samples 
(Byrne et al. 2016), frequency of CD4+CCR7
hi
 memory T cells in cervico-vaginal lavage (CVL) 
samples (Swaims-Kohlmeier et al. 2016), frequency of CCR5+CD3+ cells, CCR5+CD14+ cells and 
CCR5 mRNA in PBMCs and vaginal biopsies (Sheffield et al. 2009), frequency of regulatory T cells 
in PBMCs (Weinberg et al. 2011), and levels of CCR5 mRNA from endometrial biopsies (Dominguez 
et al. 2003) compared to the follicular phase. However, some studies have shown no differences in 
immune cell frequencies in vaginal and/or cervical explants in humans (Givan et al. 1997, Poppe et al. 
1998, Patton et al. 2000, Pudney et al. 2005, Thurman et al. 2016) or from tissue sections in rhesus 
macaques (Ma et al. 2001). Studies using exogenous P4 stimulation have also yielded differing results. 
In one study, ~100 nM P4 increased CCR5 mRNA levels in CD14+ monocytes from PBMCs 
(Patterson et al. 1998), while in another study, 10-100 nM P4 reduced CCR5 protein in PBMCs from 
both HIV-1 positive and negative women (Cabrera-Munoz et al. 2012). High P4 levels (100 nM-10 
μM) inhibited IL-2-induced CCR5 protein expression in activated T cells (Vassiliadou et al. 1999), 
while a combination of menstrual cycle hormones (2 nM E2, 200 pM P4, 4 nM testosterone) did not 
change CD4, CCR5 or CXCR4 levels in the Jurkat T cell line (Ragupathy et al. 2013). However the 
latter study used a concentration of E2 higher than the physiological range. Taken together, some 
studies show different effects on immune cell frequency or CCR5 levels with different menstrual 
cycle phases, in different FRT compartments, while some do not. It is therefore difficult to say 
conclusively whether or not menstrual cycle status has an effect, and it might be that there is no 
significant effect on immune function. The different findings between studies for both PBMCs and 
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FRT compartments may reflect differences in endogenous E2/P4 concentrations, tissue composition, 
immune activation status, sampling time, sample group and/or other variables. 
 
The menstrual cycle is also thought to influence the expression of innate immune factors (Hafner et al. 
2013). For example, cervical mucus is thickest and most viscous during the luteal phase (Wira et al. 
2015). Furthermore in cervico-vaginal samples, levels of the antibodies immunoglobulin (Ig) A and 
IgG, IL-6, IL-8, SLP1, HBD2 and lactoferrin are lowest at the mid-cycle around ovulation and highest 
during the follicular phase (Angstwurm et al. 1997, Ahmed et al. 2001, Keller et al. 2007, Hel et al. 
2010, Wira et al. 2010, Hafner et al. 2013, Wira et al. 2015), although other studies indicated higher 
peripheral blood IL-6 levels during the luteal phase (Konecna et al. 2000, Sikora et al. 2015). Another 
report showed no change in IL-6 levels but increased IL-1α, IL-1β and TNFα after ovulation (i.e. 
luteal phase) in purified monocytes (Willis et al. 2003). There is also evidence that APC function is 
modulated by sex hormones during menstrual cycle phases (Wira and Rossoll 1995, Beagley and 
Gockel 2003, Ochiel et al. 2008, Hel et al. 2010, Hafner et al. 2013). Furthermore, epithelial thickness 
in the vagina is greater when E2 levels are high during the follicular phase and ovulation (Hel et al. 
2010, Rodriguez-Garcia et al. 2013b). These data are consistent with recent transcriptomics and/or 
proteomics studies in human cervical tissue (Yildiz-Arslan et al. 2016) or pigtail macaque vaginal 
tissue (Vishwanathan et al. 2015) showing that the luteal phase was associated with higher expression 
of genes, proteins and/or pathways involved in inflammation and immune cell regulation. 
 
Differential susceptibility to HIV-1 infection during the menstrual cycle is a major concern for 
women’s health. Studies in non-human primate models have indicated that rhesus (Sodora et al. 1998) 
and pigtail (Vishwanathan et al. 2011) macaques are more susceptible to SIV infection in the luteal 
than the follicular phase. Similarly, SHIV infection in pigtail macaques occurred more frequently in 
the premenstrual phase (Kersh et al. 2014). In an ex vivo cervical tissue explant model, productive 
HIV-1 infection was associated with the luteal phase (Saba et al. 2013). One report showed increased 
X4- but not R5-tropic HIV-1 replication in activated PBMCs stimulated with high levels of P4 (1 μM) 
ex vivo (Huijbregts et al. 2013). Other studies using exogenous hormone stimulation have shown that 
a combination of menstrual cycle hormones (2 nM E2, 200 pM P4, 4 nM testosterone) increased HIV-
1 replication in the Jurkat T cell line (Ragupathy et al. 2013), but luteal phase hormones (100 nM P4 
plus 1 nM E2) or high P4 levels (100 nM-10 μM) decreased HIV-1 replication in PBMCs (Asin et al. 
2008) or activated T cells (Vassiliadou et al. 1999), respectively. The differences between studies 
using endogenous versus exogenous hormones may critically depend on species, concentrations of 
hormones, composition of mixed cell populations, sampling time, duration of exogenous hormone 
stimulation and/or other experimental differences. Nevertheless it appears that S/HIV infection is 
higher during the P4-high luteal phase. 
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There is also evidence that menstrual cycle phase can influence HIV-1 shedding, where free virus is 
deposited into cervico-vaginal fluid. Several studies analyzing HIV-1 RNA cervico-vaginal lavages 
(CVLs) in normally cycling HIV-1 positive women suggest that HIV-1 shedding is increased during 
the luteal compared to the follicular phase (Reichelderfer et al. 2000, Benki et al. 2004, Curlin et al. 
2013) or periovulatory phase (Money et al. 2003), although other reports suggest no effect (Mostad et 
al. 1998, Villanueva et al. 2002, Sheth et al. 2014). Thus the risk of female-to-male transmission may 
be higher for HIV-1 positive women in the luteal phase. 
 
During pregnancy, P4 levels are 10-40 times higher than in the luteal phase (see section 1.3.1). High 
P4 levels play an important role in maternal immunosuppression in order to tolerate foetal growth 
(Szekeres-Bartho et al. 1983, Hel et al. 2010, Weinberg et al. 2011, Oertelt-Prigione 2012). This 
occurs through an immune shift from a Th1 response (cytotoxic CD8+ T cell functions) to a Th2 
response (B cell-mediated antibody production) (Jones et al. 2008, Hapgood et al. 2018). Pregnant 
women have an increased susceptibility to HIV-1 infection (Gray et al. 2005, Mugo et al. 2011). 
Taken together, there is a growing body of evidence to suggest a link between high P4 levels, either 
during the luteal phase or during pregnancy, and suppressed immune function as well as increased 
susceptibility to infection.  
 
Consistent with this, there is evidence that suggests E2 is protective against HIV-1 infection via 
multiple potential mechanisms involving immune function (Wira et al. 2014a). For example, 
exogenous E2 (10-50 nM) is protective against HIV-1 infection in purified CD4+ T cells and 
macrophages (Rodriguez-Garcia et al. 2013a, Tasker et al. 2014) and against SIV in macaques (Smith 
et al. 2000b, Smith et al. 2004). Additionally, exogenous E2 thickens the vaginal epithelium in 
macaque models, while P4 is associated with epithelial thinning (Smith et al. 2000b, Smith et al. 2004, 
McNicholl et al. 2014, Radzio et al. 2014)). Furthermore HIV-1 uptake was lower in human genital 
epithelial cells when stimulated with 1 nM E2 compared to 100 nM P4 (Ferreira et al. 2015). In 
another study, E2-stimulated macaques (0.02 mg/kg) exhibited lower expression of the immune 
markers CCR5 and integrin α4β7 on CD4+ T cells than DMPA-treated macaques (Goode et al. 2014). 
Cell line studies showed that exogenous E2 repressed cytokine production induced by TLR3 in 
endometrial epithelial cells at 10 nM (Lesmeister et al. 2005), and in uterine epithelial cells, 50 nM E2 
reduced transepithelial resistance (TER), increased SLP1, decreased HBD2 (Wira et al. 2010, Patel et 
al. 2013, Wira et al. 2014a) and repressed IL-1β-mediated inflammatory responses (Schaefer et al. 
2005). E2 is also protective against Herpes simplex virus (HSV)-2 infection in mice models and 
immortalized vaginal Vk2/E6E7 cells (Gillgrass et al. 2005, Gillgrass et al. 2010, Kaushic et al. 2011, 
Anipindi et al. 2016, Lee et al. 2016). However since many of these studies used a supraphysiological 
concentration of 50 nM E2, these effects may not necessarily be physiologically relevant in vivo, 
where E2 concentrations range from 50 pM- 1.5 nM (see section 1.3.1). 
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Taken together the clinical and in vitro data suggest that the cycling female sex hormones may play a 
role in the regulation of local and systemic immune responses, and therefore susceptibility to 
infections, with P4 generally suppressing immunity and increasing susceptibility and E2 generally 
protecting against infection.  
 
 
1.4 Hormonal contraception 
 
Women of reproductive age can protect themselves against unintended pregnancies by the use of 
contraception. Further benefits of contraception include reduced maternal and infant mortality and 
morbidity and a decreased need for unsafe abortions (World Health Organization 2017). Non-
hormonal methods of contraception include condoms, copper T intrauterine devices (Cu-IUDs), 
withdrawal and male sterilization through vasectomy. Hormonal contraceptives control the levels of 
the sex steroid hormones, E2 and/or P4, in women. P4 levels are maintained at low or undetectable 
concentrations (<636 pM) (Kirton and Cornette 1974, Fotherby et al. 1984, Jain et al. 2004). 
Typically hormonal contraceptives are administered as synthetic progestin-only or a combination of 
estrogen (usually estradiol) plus progestin. There are various doses and methods of administration of 
hormonal contraceptives, including as combined oral contraceptives (COCs), intramuscular or 
subcutaneous injections, intrauterine devices (IUDs), intra-vaginal rings (IVRs), subdermal implants 
and patches (Sitruk-Ware 2007). 
 
Injectable contraceptives are the most commonly used method of hormonal contraception in Sub-
Saharan Africa (Fig. 1.4.1) (United Nations Department of Economic and Social Affairs Population 
Division 2015), with about 38% of contraceptive users (an estimated 16.5 million women between the 
ages of 15-49) using injectable contraceptives in 2014 (United Nations 2015).  
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Figure 1.4.1. Top methods of hormonal and non-hormonal contraception used per country. Non-
hormonal (male condom, IUD, male sterilization or vasectomy, female sterilization or fallopian tube ligation, 
rhythm, withdrawal) and hormonal (the pill, injectable) methods of contraception are indicated by different 
colours. Injectable contraceptives (purple) are the most commonly used in Sub-Saharan Africa, including South 
Africa, and other regions such as Peru, Bolivia (South America), Indonesia, Burma (South-East Asia) and 
Afghanistan (Middle East). No information is available for Greenland and some other countries (grey). Data is 
from http://www.un.org/en/ development/desa/population/publications/dataset/contraception/wcu2015.shtml 
and image is adapted from https://onlinedoctor.superdrug.com/birth-control-around-the-world/. 
 
 
There are two main intramuscular injectable progestin-only contraceptives: 150 mg 
medroxyprogesterone acetate (MPA) administered at three monthly intervals as Depo-Provera or 
Depot-MPA (DMPA or DMPA-IM) and 200 mg norethisterone enanthate (NET-EN), administered at 
two-month intervals as Nur-Isterate (Affandi 2002, Hapgood et al. 2018). NET is only used in some 
countries, like South Africa (Smit et al. 2001, Morrison et al. 2012, Hapgood et al. 2018). A new 
lower-dose subcutaneous formulation of 104 mg MPA (DMPA-SC), marketed as Sayana Press, is also 
a three-monthly injectable contraceptive that is currently being introduced in several developing 
African and non-African countries (Spieler 2014, Hapgood et al. 2018). The long intervals between 
injections and relatively easy concealment make injectable contraceptives a popular choice in rural 
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areas where access to healthcare frequently requires travelling long distances, and where 
contraceptive use may be culturally opposed. 
 
The main biological mechanisms of action behind progestin contraceptives are thickening cervical 
mucus, thereby hindering sperm mobility; inhibiting ovulation by inhibiting the mid-cycle LH surge; 
and inducing secretory changes in E2-primed endometrium (Kuhl 1990, Bassol et al. 1995, Petta et al. 
1998, Rivera et al. 1999, Kuhl 2005, Sitruk-Ware 2006, Sitruk-Ware and Nath 2010, Kuhl 2011, 
Mueck and Sitruk-Ware 2011). Interestingly, while multiple genes are regulated by progestins, the 
exact target genes that account for progestogenic effects are unknown (Hapgood et al. 2018). 
However, the anti-estrogenic effects of progestins are mediated by the PR and its effect on both E2 
and the ER. Progestin-bound PRs suppress ER gene expression and increase E2 metabolism by up-
regulating 17β-hydroxysteroid dehydrogenase (HSD) expression (Kuhl 2005, Africander et al. 2011b, 
Kuhl 2011). The ER also plays a role in the response to progestins, given that E2-activated ER 
regulates PR gene expression (Kuhl 2005, Africander et al. 2011b, Kuhl 2011). Thus progestins 
inhibit pregnancy through multiple genotropic and biological mechanisms. 
 
 
1.4.1 MPA and other progestins 
 
The therapeutic use of the endogenous hormone P4 is limited owing to its short biological half-life as 
a result of its rapid metabolism (Kuhl 2005, Kuhl 2011, Stanczyk et al. 2013). Consequently, 
synthetic progestins with improved bioavailability were developed to mimic the functions of 
endogenous P4. Progestogens (that is, endogenous progesterone and synthetic progestins) are defined 
as pro-gestational hormones that maintain pregnancy (Sitruk-Ware 1986). The first progestin, 
ethisterone, was synthesized in 1938, and MPA later in 1957 (Kuhl 2011).  
 
Progestins are generally classified by generations according to when they were synthesized: thus 
MPA and NET are regarded as first-generation progestins, while levonorgestrel (LNG), etonogestrel 
(ETG) and nestorone (NES) are second, third and fourth generation progestins, respectively (Sitruk-
Ware 2004, Sitruk-Ware 2006, Sitruk-Ware and Nath 2010, Africander et al. 2011b, Stanczyk et al. 
2013). Newer generations of progestins are typically used in newer administration technologies, for 
example, IUDs (LNG), implants (ETG, LNG) and IVRs (NES) (Sitruk-Ware 2007). 
 
Progestins are also used in hormone replacement therapy (HRT) in postmenopausal women, but are 
frequently combined with estrogens (Africander et al. 2011b, Stanczyk et al. 2013). The progestin 
protects against unwanted endometrial proliferation, while the estrogen protects against 
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cardiovascular diseases and risk of breast cancer (Rossouw et al. 2002, Beral and Million Women 
Study 2003, Sitruk-Ware 2004, Africander et al. 2011b, Stanczyk and Bhavnani 2014). 
 
MPA, currently used in both contraceptives and HRT, has been in use for more than 30 years 
(Stanczyk and Bhavnani 2014). As a contraceptive, MPA is most commonly administered as a three-
monthly 150 mg intramuscular injection, although other doses and routes of administration have been 
used, for example high oral doses of 100-1000 mg in breast cancer patients (Bick et al.) 
(unpublished). Analysis of published peak serum MPA concentrations following intramuscular 
administration shows that there is wide inter-individual and inter-study variation in MPA serum levels 
(Fig. 1.4.1.1) (Bick et al.) (unpublished). Within the first four weeks post-administration, most studies 
report serum MPA levels of 10-40 nM, however some studies show MPA serum levels as high as 100 
nM (Fig. 1.4.1.1) (Bick et al.) (unpublished). MPA serum levels plateau after one month at 
concentrations of about 2.6 nM (Mishell 1996). The minimum threshold concentration needed for 
contraceptive efficacy of most progestins is poorly defined (Cherala et al. 2016), but concentrations of 
MPA maintained above 0.5 nM (0.2 ng/ml) for three months is considered highly effective (Polis et 
al. 2017). No information is available on MPA concentrations in target FRT tissues. However, it could 
be that MPA accumulates in target tissues in vivo and therefore local concentrations could be higher 
than in peripheral blood. 
 
Peak MPA serum levels are difficult to compare between studies due to differences in study design, 
such as method of quantification, time of sampling post-injection, and number of injections, or 
differences in the population of women assessed, such as ethnicity, body weight and lactation status 
(Hapgood et al. 2018). Considering method of quantification, most recent studies (20 years or less) 
tend to use liquid chromatography/tandem mass spectrometry-based methods while older studies (20-
40 years old) typically use radioimmunoassay methods with or without prior organic solvent 
extraction. However, there does not appear to be a pattern suggesting that MPA concentrations are 
higher or over-estimated in older than younger studies (Fig. 1.4.1.1). This suggests that the large 
range in published serum concentrations is likely due to biological variation between women and 
between studies. 
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Figure 1.4.1.1. MPA serum concentrations in the first 30 days following 150 mg intramuscular 
injection of DMPA. MPA serum concentrations, shown as both ng/ml (left axis) and nM (right axis), were 
compiled from 17 published studies, each represented by a different colour, indicated in the legend table below.  
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progesterone
MPA R5020
NET
testosterone
ETG
LNG
NES
Progestins are synthesized either as derivatives of progesterone (such as MPA) or testosterone (such 
as NET) and are therefore slightly different in structure (Schindler et al. 2003, Africander et al. 2011b, 
Kuhl 2011, Stanczyk et al. 2013, Hapgood et al. 2014a) (Fig. 1.4.1.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4.1.2. Chemical structures of progestins derived from progesterone or testosterone. 
MPA: medroxyprogesterone acetate, R5020: promegestone, NET: norethisterone, LNG: levonorgestrel, ETG: 
etonogestrel, NES: nestorone. Arrows indicate synthetic derivatives of the parent compound. Images are from 
(Schindler et al. 2003) and (Kuhl 2011). 
 
 
Progestins were designed to act like P4 and therefore act as agonist ligands for the PR (Hapgood et al. 
2014a). However due to variations in their structure (Fig. 1.4.1.2), different progestins have been 
shown to exhibit varying degrees of off-target glucocorticoid, androgenic and mineralocorticoid 
activities (Schindler et al. 2003, Stanczyk 2003, Africander et al. 2011b, Kuhl 2011, Africander et al. 
2013, Stanczyk et al. 2013, Africander et al. 2014, Hapgood et al. 2014a, Louw-du Toit et al. 2017, 
Hapgood et al. 2018). These effects are due to differential relative binding affinities (RBAs) to other 
SRs, the glucocorticoid receptor (GR), androgen receptor (AR) and mineralocorticoid receptor (MR), 
respectively. These SRs are ligand-activated transcription factors that regulate expression of target 
genes. However the binding affinity does not necessarily correlate with biological effects (Africander 
et al. 2011b, Hapgood et al. 2014a, Hapgood et al. 2018), for example, the antagonist RU486 binds 
both GR and PR with high affinity but does not elicit a biological response. Therefore the biological 
response to a given progestin will depend on a number of variables: the concentration of available 
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receptors, the concentration of the progestin and other competing hormone ligands, the extent of 
progestin binding to serum proteins, the concentration of other signalling factors and the cell type 
(Africander et al. 2011b, Stanczyk et al. 2013, Hapgood et al. 2014a, Hapgood et al. 2018).  
 
The biocharacter of a ligand is determined from two pharmacological properties, potency and 
efficacy, using dose response analysis (Fig. 1.4.1.3). Efficacy is defined as the maximal effect or 
response generated by a ligand for its receptor (Africander et al. 2011b, Hapgood et al. 2014a, 
Hapgood et al. 2018) (Fig. 1.4.1.3). Thus efficacy is used to classify a ligand as a full agonist, which 
can elicit a maximal response, or a partial agonist, which elicits a less than maximal response 
(Africander et al. 2011b, Hapgood et al. 2014a, Hapgood et al. 2018) (Fig. 1.4.1.3). Potency, or EC50, 
is defined as the concentration of the ligand required to generate 50% of the maximal response 
(Africander et al. 2011b, Hapgood et al. 2014a, Hapgood et al. 2018) (Fig. 1.4.1.3). The potency 
depends on the cell type, gene promoter and receptor concentration and is variable between 
experiments (Africander et al. 2011b, Hapgood et al. 2014a). Therefore the potency of different 
progestins is compared relative to a reference ligand, which is usually set to 100% (Hapgood et al. 
2018). The RBAs and biological activities via different SRs of P4, MPA and NET are indicated in 
Table 1.4.1  
 
 
 
 
 
 
 
 
 
 
Figure 1.4.1.3. Schematic sigmoidal dose response curve indicating the efficacy (maximal 
response) and potency (EC50) of a full and partial agonist via a given receptor. A full agonist (solid 
black curve) elicits a maximal response (efficacy) which is usually set to 100% (solid black line), while a partial 
agonist (dotted blue curve) generates a less than maximal response. The effect can be, for example, mRNA 
levels or reporter gene activity. An antagonist (solid red curve) binds to the receptor and inhibits effects induced 
by agonists. The potency (EC50) is the ligand concentration on the x-axis which corresponds to 50% of the 
maximal response on the y-axis. Taken from (Africander et al. 2011b).  
 
 
All progestins were designed to be full agonists for the PR, and exhibit greater potency than P4 for the 
PR (Africander et al. 2011b, Kuhl 2011, Hapgood et al. 2014a). However, MPA binds to the 
glucocorticoid receptor (GR) with higher affinity than the endogenous glucocorticoid cortisol 
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(Kontula et al. 1983, Fuhrmann et al. 1995), unlike NET which has almost no GR binding and no GR 
activity (Koubovec et al. 2005, Ronacher et al. 2009). MPA can act as a potent partial to full agonist 
for the GR, depending on the cellular context, while P4 is a partial agonist with low potency 
(Bamberger et al. 1999, Koubovec et al. 2005, Ronacher et al. 2009). 
 
The differences in structure, SR affinity and consequently the off-target effects via activation of SRs 
other than the PR imply that progestins cannot be grouped together as a single class, with MPA as a 
notable outlier (Stanczyk 2003, Hapgood et al. 2004, Stanczyk et al. 2013). 
 
 
Table 1.4.1. Biological activities of some progestogens and their RBAs for different SRs 
RBAs are indicated relative to the reference ligand set to 100% (PR: P4, AR: dihydrotestosterone, GR: 
dexamethasone, MR: aldosterone). Data from cell lines, pre-clinical studies and animal models are from 
(Stanczyk 2003, Koubovec et al. 2004, Koubovec et al. 2005, Ronacher et al. 2009, Africander et al. 2011b, 
Kuhl 2011, Africander et al. 2013, Stanczyk et al. 2013, Africander et al. 2014, Hapgood et al. 2014a). -, not 
effective; (+), weakly effective; +, effective; ++, strongly effective; ±, literature inconsistent. Data for ER not 
shown. Table is modified from (Hapgood et al. 2018). 
 
 
Given that the GR mediates the expression of important immune function and inflammatory genes 
(Zhou and Cidlowski 2005, Baschant and Tuckermann 2010, Chinenov et al. 2013) (see sections 
1.5.2-1.5.3), the off-target activation of the GR by MPA is likely to have alarming effects on immune 
function in DMPA users. 
 
 
1.4.2 Association between DMPA use and HIV-1 acquisition 
 
The topics of DMPA use, increased HIV-1 acquisition risk and likely biological mechanisms of 
increased infection (see section 1.4.3) have been extensively and exhaustively evaluated in a recent 
review (Hapgood et al. 2018). The parts of that review most relevant to the present study are 
summarized here.  
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Globally, regions with the highest injectable contraceptive use overlap geographically with the areas 
of highest HIV-1 prevalence (Butler et al 2013). A multitude of observational and epidemiological 
studies has recently emerged to assess the potential association between MPA use and HIV-1 
acquisition, with conflicting results. Some studies showed no effect (Kleinschmidt et al. 2007, 
Morrison et al. 2007, Myer et al. 2007, Reid et al. 2010, Morrison et al. 2012, Lutalo et al. 2013, Wall 
et al. 2015), while others showed increased HIV-1 acquisition risk for DMPA users (Leclerc et al. 
2008, Morrison et al. 2010, Heffron et al. 2012, Wand and Ramjee 2012, McCoy et al. 2013, Crook et 
al. 2014, Noguchi et al. 2015, Byrne et al. 2016). Several reasons have been put forward to explain the 
different findings between studies, including confounding variables such as reporting of condom 
usage (Myer et al. 2007, Ralph et al. 2015), sexually transmitted infection (STI) status (HSV-2, 
bacterial vaginosis, Neisseria gonorrhoea, Chlamydia trachomatis, Trichomonas vaginalis and 
syphilis), age, socio-demographic variables, and limitations of study design and analysis (Polis et al. 
2013b, Noguchi et al. 2015, Polis et al. 2016). Some studies combine injectable contraceptives 
together and do not distinguish between DMPA and NET-EN (Reid et al. 2010, Heffron et al. 2012, 
Balkus et al. 2016, Polis et al. 2016).  
 
Importantly, the most recent meta-analyses of higher quality observational studies have indicated that 
DMPA use is associated with a significant increased risk of HIV-1 acquisition (Heffron et al. 2012, 
Polis and Curtis 2013, Polis et al. 2013a, Polis et al. 2014, Morrison et al. 2015, Ralph et al. 2015, 
Polis et al. 2016). The latest meta-analysis shows a significant 40% increased risk, with a 95% 
confidence interval ranging from 23-59% (Polis et al. 2016).  
 
Studies assessing the risk of other hormonal contraceptives have shown no association between HIV-1 
acquisition risk and the injectable, NET-EN although studies are limited (Polis et al. 2014, Morrison 
et al. 2015, Ralph et al. 2015, Polis et al. 2016) and there is no or insufficient data on the risk for the 
lower dose DMPA-SC (Polis et al. 2017, Hapgood et al. 2018). Despite this, in 2017 the World Health 
Organization (WHO) changed the medical eligibility criteria of all progestin-only injectable 
contraceptives (including DMPA-IM, DMPA-SC and NET-EN) from Category 1 (injectable 
contraceptive use has no restriction) to Category 2 (where the benefits of using this method “generally 
outweigh the theoretical or proven risks”) (World Health Organization 2017). In their guidance 
statement, the WHO recommends that women considering injectable contraceptive methods should be 
counselled about the concerns over increased HIV-1 acquisition and how to minimise their risk of 
exposure (World Health Organization 2017). 
 
A recently initiated clinical trial, Evidence for Contraceptive Options and HIV Outcomes (ECHO), 
may provide more information on the relative HIV-1 incidence and contraceptive efficiency for 
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DMPA-IM compared to the LNG implant (Jadelle) and the Cu-IUD, although this study has no 
control group of women not using contraception (ECHO 2016).   
 
The current meta-analyses have also indicated that there is no association between HIV-1 acquisition 
and use of combined oral contraceptives (COCs) (Polis and Curtis 2013, Polis et al. 2013a, Polis et al. 
2014, Morrison et al. 2015, Ralph et al. 2015, Polis et al. 2016). Accordingly, the medical eligibility 
criteria of COCs remain at Category 1 (World Health Organization 2017). The evidence supporting a 
policy change from MPA use to other progestins such as NET or LNG is a subject of ongoing 
research (Hapgood et al. 2004, Hapgood 2013, Noguchi et al. 2015, Hapgood et al. 2018). It is 
recognized that cessation of contraceptive use would increase rates of mother and child mortality and 
morbidity (Jain 2012), thus there is an urgent need to promote informed contraceptive choices in areas 
where HIV-1 risk is high (Hapgood 2013). 
 
In support of the clinical observational data are in vitro, ex vivo and non-human primate studies 
suggesting MPA increases HIV-1/SIV replication. For example, primate studies frequently use pre-
treatment with DMPA to enhance SIV infection (Abel et al. 2004, Trunova et al. 2006, Genesca et al. 
2007). Furthermore MPA has been shown to increase HIV-1 infectious molecular clone replication in 
activated human PBMCs (Huijbregts et al. 2013) and single-cycle HIV-1 pseudovirus replication in 
non-activated PBMCs (Sampah et al. 2015), and increase HIV-1 transcytosis in primary genital 
epithelial cells in vitro (Ferreira et al. 2015). 
 
Taken together, the association between DMPA use and HIV-1 acquisition risk in clinical 
observational studies raises concerns about a potential causal relationship and provides impetus to 
investigate the possible mechanisms by which MPA could increase HIV-1 susceptibility. 
 
 
1.4.3 Mechanisms of increased HIV-1 infection by MPA 
 
Several plausible biological mechanisms have been proposed to explain how MPA could enhance 
HIV-1 acquisition, with increasing lines of evidence to support each mechanism (Blish and Baeten 
2011, Murphy et al. 2014, Irvin and Herold 2015, Hapgood et al. 2018). These include: 
 
1. Changing the FRT defensive barrier, structural integrity and permeability 
2. Changing levels of soluble defence molecules secreted in the FRT, such as mucus, 
antimicrobials, antibodies, cytokines and chemokines 
3. Changing the frequency/expression of the HIV-1 co-receptor CCR5 on key immune cells 
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4. Changing the frequency/activation of adaptive immune cells that reside in or migrate to the 
FRT, or circulating in the peripheral blood, such as T cells and monocytes 
5. Changing the function of innate immune cells, such as NK cells, pDCs, macrophages 
6. Changing viral replication in target cells 
7. Changing the functions of the vaginal microbiome and enhanced risk of STIs 
8. Changing uptake of the virus across the epithelial barrier 
 
Some of these biological mechanisms are represented in Fig. 1.4.3 (Hapgood et al. 2018) and may 
contribute to a compromised local immune system that facilitates the transmission of HIV-1 in the 
FRT. 
 
 
 
 
Figure 1.4.3. Proposed mechanisms by which MPA can increase HIV-1 acquisition in the 
FRT. Increased HIV-1 infection in the FRT of DMPA users can occur through multiple mechanisms, including 
(1) MPA reducing epithelial barrier integrity, via decreasing expression of proteins relevant to barrier function, 
(2) MPA decreasing levels of innate immune factors such as antimicrobials, and changing levels of secreted 
inflammatory mediators, (3) MPA increasing the frequency of HIV-1 target cells such as CCR5-expressing T 
cells, (4) MPA decreasing the function of adaptive immune cells, such as APCs and B cells, (5) MPA changing 
the frequency and/or function of innate immune cells, such as macrophages, (6) Increased replication in infected 
target cells, such as CD4+ T cells, (7) MPA changing the vaginal microbiome such as Lactobacillus species, and 
increasing HSV-2 infection, and (8) MPA increasing transcytosis across single-layer epithelium. Figure adapted 
from (Hapgood et al. 2018). 
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Importantly, several studies have investigated the dose-dependent effects of MPA using PBMCs and 
cell lines in vitro. The potency of MPA has been reported as 0.5-100 nM for modulating immune 
function gene expression in cell lines (Hapgood et al. 2014b, Louw-du Toit et al. 2014, Irvin and 
Herold 2015) and PBMCs (Kleynhans et al. 2011, Huijbregts et al. 2013, Hapgood et al. 2014b, 
Huijbregts et al. 2014), inhibiting some immune cell functions in PBMCs (Huijbregts et al. 2014, 
Quispe Calla et al. 2015), and inducing apoptosis in CD4+ T cells (Tomasicchio et al. 2013). Together 
these data suggest that the in vitro effects of MPA are relevant to physiological doses of MPA in the 
serum of DMPA users. 
 
Limited studies using other progestins such as LNG and NET showed no effects on T cell function 
and/or immune function gene expression (Huijbregts et al. 2013, Tomasicchio et al. 2013, Hapgood et 
al. 2014b, Huijbregts et al. 2014). 
 
One of the proposed mechanisms by which MPA can increase susceptibility to HIV-1 infection is 
through thinning of vaginal epithelium, which would place the virus in closer physical proximity to 
underlying target cells. DMPA use in non-human primate and rodent models has been shown to 
decrease the thickness of vaginal epithelium in several studies (Parr et al. 1994, Hild-Petito et al. 
1998, Mauck et al. 1999, Kaushic et al. 2003, Kaushic 2011, Butler et al. 2015, Dietz Ostergaard et al. 
2015, Butler et al. 2016, Hapgood et al. 2018). However, this effect is modest or undetectable in 
humans (Mauck et al. 1999, Miller et al. 2000, Chandra et al. 2013, Bahamondes and Bahamondes 
2014, Bahamondes et al. 2014, Mitchell et al. 2014, Irvin and Herold 2015, Hapgood et al. 2018). 
There is however some evidence that MPA modulates the vaginal microbiome functions (Kaushic 
2011, Achilles and Hillier 2013, Brooks et al. 2016, Roxby et al. 2016), for example the study 
showing that DMPA users had decreased H2O2-producing Lactobacilli (Mitchell et al. 2014). 
 
Another proposed mechanism for enhanced HIV-1 acquisition by MPA is increased STI risk. Some 
reports suggest DMPA use is associated with increased risk of HSV-2 (Baeten et al. 2001, Gillgrass et 
al. 2003, Grabowski et al. 2015, Borgdorff et al. 2016), Chlamydia (Morrison et al. 2004) and 
bacterial vaginosis (Cherpes et al. 2008b, Achilles and Hillier 2013), although the available meta-
analyses suggest no conclusive association (Mohllajee et al. 2006, Morrison et al. 2009). 
 
Another mechanism by which MPA can increase HIV-1 susceptibility is through changes in the local 
FRT or systemic immunity, which would affect the function of the FRT to protect against infections. 
This is significant since higher proportions of susceptible CD4+ and CCR5+ target cells in the FRT at 
the time of HIV-1 exposure could facilitate infection (Wira et al. 2014b). However, the available 
clinical, animal and ex vivo studies appear to be inconsistent, with some studies but not others 
showing an effect for MPA on CCR5 expression and/or target cell frequency. For example, a study 
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showed that PBMCs from DMPA users have increased CCR5 expression in CD4+ and CD8+ T cells, 
despite no increase in the frequency of CD4/8+CCR5+ cells, compared to women using no hormonal 
contraception (Sciaranghella et al. 2015). In FRT samples, injectable contraceptive (predominantly 
DMPA) users express increased CCR5+CD4+ T cells in the cervix (Byrne et al. 2016) and increased 
CCR5-expressing leukocytes in the vagina (Chandra et al. 2013) than normally cycling women. In a 
rhesus macaque model, DMPA-treated animals exhibited a higher frequency of CCR5+CD4+ cells in 
vaginal tissue than E2-treated macaques (Goode et al. 2014). However, other studies did not observe 
increased CCR5+ CD4+ T cells in the endocervix or endometrium (Smith-McCune et al. 2017) or 
increased vaginal CD3+, HLA-DR+ or CCR5+ cells (Mitchell et al 2014). A study using PBMCs 
stimulated ex vivo with exogenous MPA also did not observe an effect on CCR5/CXCR4 in CD4+ T 
cells (Sampah et al. 2015).  
 
Similarly, effects of MPA on innate immune factors such as antimicrobials (HBD2, SLP1) and 
antibodies (IgG, IgA) have been shown in some studies but not others. For example, in CVL samples 
from DMPA users, HBD2 levels were decreased in some studies (Morrison et al. 2014, Fichorova et 
al. 2015), but appeared to increase in another study (Francis et al. 2016). Decreased FRT SLP1 levels 
were observed in some (Li et al. 2008) but not other (Morrison et al. 2014, Deese et al. 2015, 
Fichorova et al. 2015, Francis et al. 2016, Roxby et al. 2016) studies. MPA use decreases production 
and transepithelial transport of IgG and IgA (Hel et al. 2010, Hapgood et al. 2018), although increased 
levels were observed in CVL samples from DMPA users in a recent study (Francis et al. 2016). Taken 
together, there appears to be large variability between studies, with some studies showing effects for 
MPA while others do not. This could suggest that overall there may be no effect, and that differences 
between studies are due to differences in MPA serum concentrations, time of sampling, duration on 
MPA, immune cell activation and other factors between individuals. 
 
Whether MPA elicits a pro-inflammatory or immunosuppressive (anti-inflammatory) effect in the 
FRT of DMPA users is controversial. Some studies have reported increased expression of pro-
inflammatory cytokines and chemokines such as IL-6 and IL-8 in DMPA users (Morrison et al. 2014, 
Deese et al. 2015, Francis et al. 2016), while others showed suppressed expression of pro-
inflammatory mediators in DMPA users or other models (Trunova et al. 2006, Hughes et al. 2008, 
Kleynhans et al. 2011, Hapgood 2013, Huijbregts et al. 2013, Kleynhans et al. 2013, Huijbregts et al. 
2014, Walong et al. 2016), or no effect in DMPA users (Arnold et al. 2016, Weinberg et al. 2016). 
Decreased levels of pro-inflammatory mediators in DMPA users could suppress host immunity to 
HIV-1 infection (Hapgood 2013), whereas increased levels of pro-inflammatory mediators in DMPA 
users could result in increased recruitment of HIV-1 target cells (Morrison et al. 2014). 
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However, in multiple ex vivo studies, MPA suppresses T cell and pDC function in humans and 
macaques (Trunova et al. 2006, Cherpes et al. 2008a, Hughes et al. 2008, Kleynhans et al. 2011, 
Vicetti Miguel et al. 2012, Kleynhans et al. 2013, Huijbregts et al. 2014, Weinberg et al. 2016). 
Furthermore, in cell line models and PBMCs, exogenous stimulation with MPA, unlike NET or P4, 
decreased expression of pro-inflammatory genes (such as IL-6, IL-8, RANTES, IL-12) and increases 
expression of anti-inflammatory genes (such as GILZ, IL-10) (Kleynhans et al. 2011, Huijbregts et al. 
2013, Govender 2014, Govender et al. 2014, Hapgood et al. 2014b, Louw-du Toit et al. 2014, Ray 
2015, Grandi et al. 2016). 
 
These data imply that MPA is immunosuppressive in multiple systems (Hapgood et al. 2018). Of 
particular interest to this study is the observation that the immunosuppressive effects of MPA occur 
via the GR in some cell line studies. GR activation will influence the regulation of multiple genes in 
many physiological systems and could promote activation of multiple signalling pathways via cross-
talk with other members of the SR family.  
 
 
1.5 Steroid hormone receptors (SRs) 
 
The family of SRs belongs to the nuclear receptor superfamily and consists of the glucocorticoid 
receptor (GR), progesterone receptor (PR), androgen receptor (AR), estrogen receptor (ER) and 
mineralocorticoid receptor (MR) (Evans 1988, Lu et al. 2006, Huang et al. 2010). These receptors 
function as ligand-activated transcription factors (TFs) and share similar structures (Fig. 1.5) 
(Griekspoor et al. 2007, Africander et al. 2011b). All SRs consist of a moderately conserved ligand-
binding domain (LBD) at the carboxy-terminal domain (CTD), a highly conserved DNA-binding 
domain (DBD), hinge region and variable amino terminal domain (NTD) (Fig. 1.5) (Africander et al. 
2011b, Stanczyk et al. 2013). Both the LBD and NTD contain activator function (AF) domains, which 
play a role in transcriptional activity of the SR (Lavery and McEwan 2005). The sequence homology 
of the LBD between SRs means that promiscuous ligand binding can occur and as such, hormone 
ligands can elicit off-target effects by binding to other SRs. This effect is particularly pronounced for 
the GR and PR, since they share 55% LBD amino acid sequence homology and 90% DBD homology 
(Evans 1988, Stanczyk et al. 2013) and both recognize the same DNA sequences (Strahle et al. 1987, 
Beato et al. 1989). 
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Figure 1.5. The structures of nuclear steroid receptors. SRs contain several functional domains, 
including NTD (A/B), DBD (C), hinge region (D) and LBD (E) at the CTD. ERα also has an additional CTD 
domain (F). Numbers indicate the protein length in amino acids. Adapted from (Griekspoor et al. 2007). 
 
 
1.5.1 Function, regulation and expression of the GR and PR 
 
The GR is a key regulator of the immune system by mediating anti-inflammatory responses to 
glucocorticoids (GCs) such as endogenous cortisol or the synthetic GC, Dex. GCs are important for 
metabolic, bone, renal, central nervous system, reproductive and immune function, with 
predominantly immunosuppressive effects (Baschant and Tuckermann 2010, Cruz-Topete and 
Cidlowski 2015). 
 
The PR plays an important role in regulation of the female reproductive system, including mammary 
gland development, and mediates responses to progestogens. GCs acting via the GR, and 
progestogens acting via the PR, carry out their effects through mediating gene expression in target 
tissues. The PR is only expressed in some tissues, including the female reproductive tract, brain, 
mammary gland and pituitary gland (Lu et al. 2006). Conversely, GR is ubiquitously expressed (Lu et 
al. 2006) and is essential for life as GR knockout mice are not viable (Cole et al. 1995).  
 
There is a single gene for GR, but multiple isoforms exist as a result of alternative splicing (Pujols et 
al. 2002, Lu and Cidlowski 2005, Zhou and Cidlowski 2005, Duma et al. 2006, Cao et al. 2013, 
Kadmiel and Cidlowski 2013, Cruz-Topete and Cidlowski 2015, Hapgood et al. 2016, 
Scheschowitsch et al. 2017). The 95 kDa GR isoform, GRα, is the most predominantly expressed. The 
GR is regulated both post-transcriptionally (Turner et al. 2010, Turner et al. 2014) and undergoes 
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post-translational modifications (PTMs), such as phosphorylation (Faus and Haendler 2006, Chen et 
al. 2008, Beck et al. 2009, Anbalagan et al. 2012). GR activity is regulated by phosphorylation at key 
residues (Avenant et al. 2010a, Avenant et al. 2010b). 
 
The gene for PR is regulated by E2 and ERα (Aronica and Katzenellenbogen 1991, Schultz et al. 
2003) and contains two distinct E2-regulated promoters, resulting in the transcription of two isoforms 
of PR, A and B (Kastner et al. 1990). These translate into two proteins, PR-A (94 kDa) and PR-B (114 
kDa) which are identical except for the additional 164 amino acids on the N-terminus of PR-B (Fig. 
1.5) (Kastner et al. 1990, Giangrande et al. 1997). This extra region harbours a third AF domain, 
rendering PR-B more transcriptionally active than PR-A (Sartorius et al. 1994). Like the GR, PR also 
undergoes PTMs (Bagchi et al. 1992, Lange et al. 2000, Faus and Haendler 2006, Anbalagan et al. 
2012, Abdel-Hafiz and Horwitz 2014). PR-A and PR-B can form homo- and heterodimers with each 
other, as well as mixed ligand heterodimers (Sartorius et al. 1994, Leonhardt et al. 1998, Scarpin et al. 
2009, Jacobsen and Horwitz 2012). The PR isoforms have also been shown to have differential cell- 
and promoter-specific effects on transcription (Wen et al. 1994, Giangrande and McDonnell 1999, 
Lim et al. 1999, Graham and Clarke 2002, Tung et al. 2006, Jacobsen and Horwitz 2012). 
Interestingly, PR-A represses the activity of PR-B (Tung et al. 1993) as well as other SRs including 
the GR (Vegeto et al. 1993) and MR (McDonnell et al. 1994). Consequently, the ratio of PR-A:PR-B 
can also influence the response to progestins on PR target genes, as demonstrated in breast cancer and 
myometrial cells (Graham et al. 2005, Jacobsen et al. 2005, Khan et al. 2012, Tan et al. 2012). 
 
 
1.5.2 Classic mechanisms of action of SRs 
 
Traditionally, SRs including the GR and PR regulate transcription through classical mechanisms of 
transactivation (up-regulation) and transrepression (down-regulation). A schematic model 
representing transactivation and transrepression is shown in Figure 1.5.2 (Nixon et al. 2012). In the 
absence of ligand, GR is mostly cytoplasmic, while PR is located in the nucleus (Renoir et al. 1990, 
Griekspoor et al. 2007), although there is evidence that some of the unliganded GR resides in the 
nucleus (Pekki et al. 1992), and this effect may depend on GR levels (Hapgood et al. 2016). The GR 
is retained in the cytoplasm in a chaperone complex which includes heat shock protein (HSP) 90 
(Oakley and Cidlowski 1993, Griekspoor et al. 2007, Kadmiel and Cidlowski 2013). A small 
proportion of HSP90-bound PR is located in the cytoplasm (Passinen et al. 1999).  
 
Upon ligand binding to the LBD, the GR undergoes a conformational change, dissociates from the 
chaperone complex and translocates to the nucleus (Zhou and Cidlowski 2005, Griekspoor et al. 
2007). Here, classical transactivation is achieved by the ligand-bound SR DBD binding directly to its 
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hormone response elements (HREs) in target genes, that is, glucocorticoid response elements (GREs) 
for GR or progesterone response elements (PREs) for PR. GR typically binds to GREs as a dimer, 
(Zhou and Cidlowski 2005), and recruits co-activators and chromatin remodelling factors to activate 
transcription (Kadmiel and Cidlowski 2013, Cruz-Topete and Cidlowski 2015). In addition to the 
above mechanism, PR can bind to PREs or PRE ½ sites as a monomer (Jacobsen and Horwitz 2012). 
 
The most well-established mechanism of transrepression is tethering, whereby the SR binds to another 
transcription factor via protein-protein interactions and inhibits its activity. This has been 
demonstrated for activator protein 1 (AP1) and nuclear factor kappa B (NFκB). Since NFκB is a key 
mediator of inflammatory gene expression, both GR and PR can modulate inflammatory responses by 
repressing NFκB-driven gene regulation through direct binding to NFκB subunits (Kalkhoven et al. 
1996, De Bosscher et al. 2000, Nissen and Yamamoto 2000). The SR recruits co-repressors and 
chromatin remodelling factors to condense chromatin and inhibit transcription (Chinenov et al. 2013). 
Transrepression can also occur through direct GR binding to negative GREs (nGREs) (Surjit et al. 
2011). 
 
However, recent studies show that the mechanisms behind GR-mediated gene regulation are much 
more complex (Schoneveld et al. 2004, Newton et al. 2010, Nixon et al. 2013, Cruz-Topete and 
Cidlowski 2015, Newton et al. 2017, Scheschowitsch et al. 2017, Weikum et al. 2017a, Weikum et al. 
2017b). For example, the GR can mediate transactivation through direct binding to a simple GRE, a 
composite GRE or a GRE ½ site as well as through tethering and co-factor-assisted tethering 
(Scheschowitsch et al. 2017). Furthermore transrepression can occur through multiple mechanisms 
including direct binding to a composite GRE, or nGRE, competition with other factors, sequestering 
TFs, tethering and co-factor-assisted tethering (Scheschowitsch et al. 2017). The GR can also repress 
gene expression through transactivation mechanisms (King et al. 2012, Vandevyver et al. 2013, Nacht 
et al. 2017, Weikum et al. 2017a). Furthermore, GR-mediated gene regulation is modulated by the 
adjacent sequences and chromatin landscape (Meijsing et al. 2009, Burd and Archer 2013, Sacta et al. 
2016, Telorac et al. 2016, Love et al. 2017), the GR dimerization interface (Watson et al. 2013), and 
ability to form homo- or heterodimers (Nixon et al. 2013, Robertson et al. 2013a, Schiller et al. 2014, 
Lim et al. 2015) or even tetramers (Presman et al. 2016). Recently the term GR binding site (GBS) 
has been introduced, to refer to a short DNA sequence that binds GR with high affinity in vitro, while 
GRE refers to a longer DNA sequence that generates a GR response in vivo (Weikum et al. 2017b). 
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Figure 1.5.2. Classical model of transactivation and transrepression mechanisms mediated by 
the ligand-activated GR. The lipophilic steroid diffuses across the cell membrane into the cytoplasm, where 
it binds to the SR (in this case, the GR). The GR can activate cellular responses via non-genomic mechanisms, 
such as suppression of JNK (1). The ligand-activated GR also translocates into the nucleus, where it binds 
directly the GREs in target transactivation genes thereby activating their transcription (2), or as a monomer 
tethered to pro-inflammatory transcription factors NFKB/AP-1 to repress target transrepression genes (3). MKP-
1: mitogen activated protein kinase phosphatase 1; IκBα: inhibitor of NFκB; IL10: interleukin 10; TNFα: 
tumour necrosis factor α; iNOS: inducible nitric oxide synthase. Taken from (Nixon et al. 2012). 
 
 
 
Consistent with its role in mediating anti-inflammatory responses to GCs, the GR has been established 
to transactivate anti-inflammatory genes and repress pro-inflammatory genes, notably cytokines and 
chemokines (Chinenov et al. 2013). For example, GR mediates the up-regulation of the anti-
inflammatory genes interleukin (IL)-10 (Visser et al. 1998), glucocorticoid-induced leucine zipper 
(GILZ) (Wang et al. 2004), mitogen activated protein kinase phosphatase 1 (MKP1) (Kassel et al. 
2001) and inhibitor of NFκB (IκBα) (Heck et al. 1997). GR has also been shown to mediate the 
repression of the pro-inflammatory genes IL-6 (De Bosscher et al. 2003) and IL-8 (Mukaida et al. 
1994). 
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Owing to the role of the PR in mediating the reproductive functions and mammary gland 
development, many identified PR-regulated target genes are involved in these processes, such as 
prolactin receptor (PRLR) and β-casein, although PR also regulates the expression of genes involved 
in cell growth and proliferation, such as epidermal growth factor (EGF), transforming growth factor β 
(TGFβ), insulin-like growth factor binding protein 1 (IGFBP1), cyclin-dependent kinase inhibitor 1A 
(p21), receptor activator of NFκB ligand (RANKL) and v-myc myelocytomatosis viral oncogene 
homolog (avian) (MYC) (Moore et al. 1997, Jacobsen and Horwitz 2012, Moore et al. 2012, Obr and 
Edwards 2012, Wetendorf and DeMayo 2012, Yin et al. 2012, Lain et al. 2013). Some PR-regulated 
genes are regulated by both PR isoforms, like p21, while others are preferentially regulated by PR-B, 
such as FK506 binding protein 5 (FKBP5), or by PR-A such as IGFBP1 (Jacobsen and Horwitz 
2012). 
 
Thus the mechanism of gene regulation by the GR and PR is a complex process with multiple players, 
including transcriptional machinery, chromatin remodelers, co-activators and co-repressors, with 
capacity for regulation at each step. 
 
 
1.5.3 Cross-talk between SRs 
 
The biological responses mediated by SRs can also involve non-genomic, transcription-independent 
and/or ligand-independent mechanisms of action (Leonhardt et al. 2003, Nilsen and Brinton 2003, 
Stellato 2004, Boonyaratanakornkit and Edwards 2007, Boonyaratanakornkit et al. 2008, Gellersen et 
al. 2009, Africander et al. 2011b, Hapgood et al. 2016, Hapgood et al. 2018). These effects generally 
involve the modulation of signalling cascades through the phosphorylation/de-phosphorylation action 
of kinases and phosphatases. Non-genomic SR activities allow for rapid responses without changing 
SR levels and promote the integration of multiple physiological functions (Hapgood et al. 2016).  
 
This capacity for SRs to modulate the activity of other transcription factors gives rise to cross-talk 
(McKay and Cidlowski 1998, Lange 2004, De Bosscher et al. 2006, Kassel and Herrlich 2007, Beck 
et al. 2009, Bagamasbad and Denver 2011, Ratman et al. 2013, Hapgood et al. 2016). Cross-talk can 
refer to a positive or negative, direct or indirect modulation of the activity of other TFs (Kassel and 
Herrlich 2007). Indirect modulation can occur through activation of signalling pathways converging 
on SR target genes, while direct modulation can occur through direct interactions between SRs 
thereby modulating their activity. This cross-talk therefore contributes to the complexity of biological 
responses to multiple hormones in vivo. 
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Multiple studies show mechanisms of direct cross-talk between the GR and ER. For example, in 
MCF-7 breast cancer cells, Dex modulates ER transcriptional activity (Karmakar et al. 2013) and 
similarly E2 inhibits GR mRNA and protein expression (Krishnan et al. 2001) while ER mediates 
proteasomal degradation of GR (Kinyamu and Archer 2003). Some studies have also shown that 
ER/E2 can modulate GR/GC-mediated responses on inflammatory genes (Feldman et al. 2007, Cvoro 
et al. 2011, Eritja et al. 2012, Whirledge and Cidlowski 2013). Furthermore GR has been shown to 
interact with ERα (Karmakar et al. 2013). In addition, the GR has been shown to form a heterodimer 
with the MR (Liu et al. 1995, Trapp and Holsboer 1996, Ou et al. 2001, Savory et al. 2001) and the 
AR (Chen et al. 1997). 
 
There is also substantial evidence of cross-talk between the PR and ER. Early studies showed that 
stimulation with E2 increased PR protein expression in human breast cancer (MCF-7) and rat uterine 
cells (Horwitz and McGuire 1978, Aronica and Katzenellenbogen 1991). Subsequently it has been 
demonstrated at the genomic level that ER is recruited to EREs within the PR promoter sequence, 
thereby inducing its transcription (Petz et al. 2002, Schultz et al. 2003, Flötotto et al. 2004, Petz et al. 
2004). In a mechanism of reciprocal regulation, PR regulates (frequently represses) ER-mediated 
transcriptional activity via association between ER and PR and/or regulation of signalling pathways 
and/or recruitment of repressors (Kraus et al. 1995, Lee and Gorski 1996, Ballare et al. 2003, Vallejo 
et al. 2005, De Amicis et al. 2009, Mohammed et al. 2015, Diep et al. 2016). One study also showed 
that progestin metabolites modulate ER protein levels in MCF-7 cells (Pawlak and Wiebe 2007). 
 
Of importance to this study is the extent of cross-talk between the GR and the PR, owing to their 
mutual activation by the progestin MPA. Several genes have been shown to be ligand-dependently 
regulated by both GR and PR, including the mouse mammary tumour virus (MMTV), tyrosine 
aminotransferase (TAT), chicken lysozyme, rabbit uteroglobin and human metallothionein (MetIIA) 
genes (von der Ahe et al. 1985, Strahle et al. 1987, Jacobsen and Horwitz 2012). Microarray studies 
using Dex, R5020 or P4 stimulation showed that these hormones regulate the expression of both 
overlapping and unique gene sets, in endometrial cancer Ishikawa H cells and T47D breast cancer 
cells (Wan and Nordeen 2002, Davies et al. 2006). In these studies it is presumed that R5020-induced 
gene regulation is via the PR, however the genes regulated in response to P4 could be via the GR 
and/or PR. 
 
The GR- and PR-mediated regulation of the MMTV promoter, which contains 4 GRE/PREs, has been 
well characterized. Despite both binding to the MMTV promoter, the GR and PR still exhibit selective 
gene regulation in different contexts (Cato et al. 1986, Cato et al. 1988, Nordeen et al. 1989, Archer et 
al. 1994a, Archer et al. 1994b, Archer et al. 1995, Mymryk et al. 1995, Le Ricousse et al. 1996, 
Lambert and Nordeen 1998, Nelson et al. 1999). Reasons for this selectivity include differential 
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interaction with co-factors (Szapary et al. 2008) including preferential use for different steroid 
receptor coactivator (SRC) coactivators (SRC2 for GR and SRC1 for PR), (Li et al. 2003), chromatin 
structure (Archer et al. 1994b, Archer et al. 1995, Mymryk et al. 1995, Smith et al. 1997), surrounding 
sequences (Cato et al. 1988, Chalepakis et al. 1988), and the low amino-terminal end homology  
(Song et al. 2001). Crucial to this study, different levels of receptors within a given cell would also 
contribute to different GR/PR-mediated responses on the same gene (Strahle et al. 1989). 
 
 
1.5.4 Variations in SR levels in the FRT 
 
Cross talk between the GR and PR is likely to be highly important in the FRT, if both of these 
receptors are expressed, because these receptors could simultaneously mediate the regulation of 
immune function and/or reproductive genes.  
 
Previous research has indicated that PR protein is differentially expressed in FRT tissues throughout 
the menstrual cycle. However these studies generally used immunohistochemistry techniques that 
may be prone to antibody cross-reactivity. In general, higher PR protein levels were observed during 
the follicular phase compared to the luteal phase in multiple FRT tissues, including the fallopian tube 
and myometrium (Pino et al. 1984, Englund et al. 1998, Tone et al. 2011), vagina (Konishi et al. 
1991) and endocervical columnar cells (Sanborn et al. 1976). In the endometrium, higher PR mRNA 
or protein levels were observed during the follicular phase in some (Lessey et al. 1988, Ingamells et 
al. 1996, Mylonas et al. 2007) but not all (Snijders et al. 1992, Marshburn et al. 2005) studies. In the 
ectocervix, higher PR levels were detected in ectocervical epithelium during the luteal phase 
compared to the follicular phase (Konishi et al. 1991). The PR isoforms are generally expressed at 
similar levels in reproductive tissues (Scarpin et al. 2009) but there is evidence that PR-A levels are 
preferentially decreased in the endometrium during the luteal phase (Mangal et al. 1997, Mote et al. 
1999). GR protein has been detected in VEN-100 primary endocervical cells (Govender 2014) and 
ectocervical explants (Ray 2015) by other researchers in the present author’s laboratory, consistent 
with the notion that GR is reportedly ubiquitously expressed in all tissues (Lu et al. 2006). 
 
Collectively these studies show a trend that PR levels are lower during the luteal phase compared to 
the follicular phase in some FRT tissues. Interestingly, different PR levels are observed in the 
ectocervix compared to the endocervix during the luteal phase. This implies that throughout the 
menstrual cycle there will be conditions where the relative levels of GR/PR are higher or lower. 
Changes in the relative levels of GR/PR in the cervix, the primary site for HIV-1 infection, may 
therefore influence immunomodulatory gene expression and potentially also susceptibility to 
infection. 
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1.6 Thesis rationale and hypotheses 
 
The current epidemiological research showing that use of DMPA is associated with increased HIV-1 
acquisition is still controversial, despite the most recent meta-analyses showing increased risk 
(Morrison et al. 2015, Ralph et al. 2015, Polis et al. 2016). However, biochemical and other basic 
research show that MPA increases HIV-1 infection ex vivo (Huijbregts et al. 2013, Sampah et al. 
2015) and SIV/SHIV infection in non-human primate models (Trunova et al. 2006, Smith et al. 2015, 
Butler et al. 2016). Several studies have also linked the luteal phase of the menstrual cycle – 
characterized by relatively high levels of endogenous P4 in the luteal phase compared to the follicular 
phase – with increased HIV-1 or SHIV acquisition in various models (Marx et al. 1996, Vishwanathan 
et al. 2011, Saba et al. 2013, Kersh et al. 2014, McNicholl et al. 2014, Radzio et al. 2014). Since MPA 
is a derivative of P4 and was designed to imitate the physiological properties of P4, MPA may prevent 
pregnancy in a manner similar to the high-P4 state of the luteal phase. However, very limited research 
is available comparing contraception with MPA and menstrual cycle phases, or P4 alone, within the 
same study (Huijbregts et al. 2013, Byrne et al. 2016, Francis et al. 2016). This leads to the interesting 
question whether the increase in HIV-1 acquisition is comparable between DMPA and the luteal 
phase and whether infection occurs via similar or different molecular mechanisms, possibly based on 
the differential GR activity of P4 and MPA. Therefore, the first central hypothesis of the current 
study is that both MPA and luteal phase hormones increase HIV-1 infection, but through 
potentially different mechanisms. 
 
In order to address this hypothesis, human PBMCs from female donors were used as a model for 
systemic HIV-1 infection. PBMCs are a useful model since they contain a multitude of immune cells 
relevant to HIV-1 infection (Kleiveland 2015). These include CD4+ T cells, CD8+ T cells and CD14+ 
monocytes and cells expressing the CCR5 co-receptor. CD4+ T cells are the predominant target cells 
for HIV-1 infection, since the CD4 receptor is used by the virus for initial entry (Sattentau et al. 
1986). However, HIV-1 infection has also been demonstrated in other cells such as macrophages 
(Givan et al. 1997, Howell et al. 1997, Hladik and Hope 2009, Nguyen et al. 2014, Wira et al. 2015). 
Since CD8+ T cells are cytotoxic towards HIV-1, the CD4/CD8 ratio is an important parameter to 
consider the balance between frequency of infectable cells (CD4+) and cells combating infection 
(CD8+). Monocytes are important to study since they play a role in the establishment of infection and 
disease progression and secrete cytokines that modulate T cell function (Campbell et al. 2014). Levels 
of the co-receptor CCR5 are crucial determinants of efficient viral entry (Sciaranghella et al. 2015). 
Therefore CCR5 expression and the frequency of CCR5-expressing cells were also investigated. In 
addition the activation status of target immune cells was investigated as a possible mechanism by 
which MPA could affect HIV-1 infectivity. Activated target cells are more susceptible to HIV-1 
infection, because they are primed to recruit infectable target cells (McKinnon and Kaul 2012). 
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Therefore a marker for activation, CD69, was measured in PBMCs. CD69 is an early activation 
marker that is expressed within 4 hours and for up to 14 days thereafter (Ziegler et al. 1994, Caruso et 
al. 1997, Nielsen et al. 1998, Clausen et al. 2003). 
 
TZM-bl human cervical epithelial cells were used as a model of infectable cells in which to study 
possible biological mechanisms of infection. These cells have been engineered to stably express CD4, 
CCR5 and CXCR4, and a luciferase gene linked to the HIV-1 LTR promoter (Platt et al. 1998) and 
are therefore readily infectable. Furthermore as a single cell type, TZM-bl cells do not undergo 
activation like T cells, allowing additional insight into CCR5 regulation independent of T cell-specific 
signalling. HIV-1 infection was assessed using the laboratory-adapted R-tropic HIV-1 infectious 
molecular clone, HIV-1BaL_Renilla using luciferase assays as a proxy for HIV-1 replication. This clone 
was used in order to represent the transmitting founder virus, which is predominantly R5-tropic and 
therefore utilizes the CCR5 co-receptor for initial infection (Carrington et al. 1999, Keele et al. 2008, 
Salazar-Gonzalez et al. 2009, Grivel et al. 2011). Combinations of E2/P4 were used to mimic the luteal 
phase (10 nM P4/400 pM E2) or the follicular phase (1 nM P4/400 pM E2) of the menstrual cycle, 
which are within the range of reported serum E2/P4 levels (Stricker et al. 2006). The concentrations of 
MPA used (100 nM) represents the upper levels detected in the serum of DMPA users (Hapgood et al. 
2018). 
 
While MPA and P4 act via the PR, MPA also binds to the GR with high affinity (Africander et al. 
2011b) and thus can control the expression of GR-regulated genes. Since the GR is a key mediator of 
the immune system and inflammatory responses, MPA-induced changes in GR-regulated gene 
expression could have important consequences for immune function and therefore susceptibility to 
infection in the FRT. The present author’s laboratory has shown that MPA, like the GC Dex but 
unlike NET or P4, at physiologically relevant concentrations (excluding during pregnancy), changes 
the expression of key immunomodulatory genes in a GR-dependent manner, in both cell lines and 
primary cells (Koubovec et al. 2004, Verhoog 2010, Africander et al. 2011a, Verhoog et al. 2011, 
Govender 2014, Govender et al. 2014, Hapgood et al. 2014b, Louw-du Toit et al. 2014, Ray 2015). 
These important GR-regulated immunomodulatory genes include the transactivation gene, GILZ, and 
the transrepression gene, IL-6. GILZ is an anti-inflammatory protein that plays an important role in 
mediating the effects of GCs (Ronchetti et al. 2015). GILZ expression is induced by GCs and its GR-
mediated regulation occurs through by direct GR binding to multiple GREs in its promoter (Wang et 
al. 2004, Ayroldi and Riccardi 2009). IL-6 is one of the pro-inflammatory cytokines that drive 
inflammatory responses (Feghali and Wright 1997, Ershler and Keller 2000). IL-6 expression is 
activated by the transcription factors NFκB and AP-1 and therefore GR-mediated repression of IL-6 is 
believed to occur via GR tethering to subunits of NFκB and inhibiting its activity (Heck et al. 1997, 
De Bosscher et al. 2000, Nissen and Yamamoto 2000, Tao et al. 2001, De Bosscher et al. 2003). 
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However both PR and GR recognize similar DNA target sequences (such as GRE/PREs) and both 
inhibit the activity of NFκB (Kalkhoven et al. 1996, Davies et al. 2004, Hardy et al. 2006). Following 
this, it is possible that PR could regulate GR-mediated gene expression in some contexts, depending 
on relative receptor levels. GR is ubiquitously expressed whereas PR is expressed in some tissues, 
including reproductive tissues, and is dependent on regulation by E2, which fluctuates with the 
menstrual cycle. Therefore in the FRT there are likely to be states in which the relative levels of GR 
and PR change in response to endogenous and exogenous sex hormones. The consequences of 
changing GR/PR levels on immune function and HIV-1 susceptibility have not been studied. The 
second central hypothesis of this study is therefore that changing the relative levels of GR/PR 
can influence HIV-1 infection and the regulation of immunomodulatory genes.  
 
In order to investigate this hypothesis, human cervical cell line models were used to represent the FRT 
and conditions of changing GR/PR levels. These cell lines, which express high levels of endogenous 
GR, were the End1/E6E7 immortalized endocervical epithelial cells, HeLa cervical carcinoma cells 
and TZM-bl cervical carcinoma cells, which are modified HeLa cells. In these cells, the relative levels 
of GR/PR were changed by using siRNA to knock down the endogenous GR, with or without the 
simultaneous over-expression of PR-B, the more transcriptionally active PR isoform. While other cell 
line strategies of GR/PR over-expression and endogenous expression were also investigated, 
End1/E6E7, HeLa and TZM-bl cells were chosen for this study as models for investigating the effects 
of changing GR/PR levels in cervical cells. HeLa and End1/E6E7 cells have been shown by the 
present author’s laboratory to have robust GR-mediated regulation of GILZ and IL-6 (Verhoog 2010, 
Govender 2014). While cell line studies have limitations, molecular techniques such as transfection 
used to change GR/PR levels were already established in the present author’s laboratory and are 
generally more robust and reproducible than in primary cells. HIV-1 infection was assessed in TZM-
bl cells using the R5-tropic IMC HIV-1BaL_Renilla and luciferase reporter assays. Secretion of IL-6 was 
investigated as a possible soluble mediator that enhances infection. Previous in vitro work has 
demonstrated that exogenous IL-6 stimulation induces HIV-1 reverse transcriptase or LTR activity in 
monocyte-derived macrophages (MDMs) and promonocyte U1 cells (Poli et al. 1990, Kinter et al. 
2001) and enhances infection of MDMs (Zaitseva et al. 2000). Some clinical studies have shown 
correlations between increased IL-6 levels and higher HIV-1 RNA levels or viral load (Spear et al. 
2008, Roberts et al. 2012, Masson et al. 2014). Therefore the effect of changing relative GR/PR levels 
on IL-6 expression and the effect of IL-6 and/or other soluble mediators on HIV-1 infection was also 
investigated. 
 
Transcriptional activity can be modulated by cross talk between steroid receptors (Bagamasbad and 
Denver 2011). There are multiple lines of evidence of cross talk between the GR-ER and the PR-ER, 
including direct interactions between the proteins. Therefore it is likely that mechanisms of cross-talk 
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exist between GR and PR. While both GR and PR can regulate the same promoters, such as MMTV, 
whether GR and PR associate together is not established. The final hypothesis of the current study 
is that GR and PR reciprocally modulate each other’s activity through a possible interaction. 
 
In order to investigate this hypothesis, cells expressing very low levels of endogenous GR and no PR 
(COS1 monkey fibroblast and U2OS human osteosarcoma cells) were used in assays where GR/PR 
were transiently over-expressed. Alternatively cells expressing high endogenous levels of both GR 
and PR (MCF-7 human breast cancer cells) were used. Co-immunoprecipitation assays in COS1 and 
MCF-7 cells were used to indicate a potential association between GR and PR in response to the 
GR/PR agonist MPA. In addition, the nucleocytoplasmic distribution of the GR and PR in COS1 cells 
over-expressing GR and PR was measured using immunofluorescence with confocal microscopy. 
Quantitative co-localization analysis was used to suggest close physical proximity of the GR and PR, 
using both confocal microscopy and structured illumination super-resolution microscopy. The ligand-
dependency of this potential association was investigated by comparing equimolar concentrations 
(100 nM) of the GR-specific agonist Dex, the PR-specific agonist R5020 and MPA. Specific research 
questions are outlined in more detail at the start of each results chapter. 
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Chapter 2 
Materials and Methods 
 
All work in this thesis was carried out by the present author, with technical assistance for the 
following: fixed cells prepared by the candidate were analyzed for flow cytometry by Dr Michele 
Tomasicchio at the Lung Infection and Immunity Unit (University of Cape Town), and 
immunofluorescence slides prepared by the candidate were analyzed together with Mrs Susan Cooper 
at the Confocal and Light Microscope Unit (University of Cape Town) and Dr John Woodland at the 
Central Analytical Facility Fluorescence Microscopy Unit (Stellenbosch University). 
 
 
2.1 Ethics and biosafety 
 
This research formed part of a sub-study of HREC 210/2011, which was approved by the Human 
Research Ethics Committee at the University of Cape Town for use of human peripheral blood 
mononuclear cells from the Western Province Blood Transfusion Services and cervical explant tissue 
from Groote Schuur and Tygerberg Hospitals. Donors provided written informed consent. 
 
This study, for a doctoral degree, was approved by the Human Research Ethics Committee at the 
University of Cape Town with reference number 076/2017. 
 
All work was carried out according to the biosafety procedures established by the Health and Safety 
Committee of the Department of Molecular and Cell Biology at the University of Cape Town. 
 
 
2.2 Compounds and antibodies 
 
The following compounds were purchased from Sigma Aldrich, South Africa: (11b,16a)-9-fluoro-
11,17,21- trihydroxy-16-methylpregna-1,4-diene-3,20-dione (dexamethasone, Dex); 6α-methyl-17α-
hydroxy-progesterone acetate (medroxyprogesterone acetate; MPA); 4-pregnene-3,20-dione 
(progesterone; P4); 17α-ethynyl-19-nortestosterone (norethisterone; NET); 17β-estradiol (E2); 13β-
ethyl-17α-ethynyl-17β-hydroxygon-4-en-3-one (levonorgestrel; LNG); 11β-(4-
dimethylamino)phenyl-17β-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one (Mifepristone; RU486); and 
17,21-dimethyl-19-norpregna-4,9-dien-3,20-dione (Promegestone, R5020). All hormones were 
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prepared in absolute ethanol (EtOH), and added to cells such that final [EtOH] was 0.1% (v/v). 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was also obtained from Sigma 
Aldrich, South Africa. IL-2 was obtained from the AIDS Research and Reference Reagent Program, 
Division of AIDS, NIAID, NIH. 
 
For western blotting, antibodies against human GAPDH (0411; sc-47724) and GR (H-300; sc-8992) 
were obtained from Santa Cruz Biotechnology, USA, while anti-HA (12CA5) was from Roche 
Applied Science, South Africa, and anti-PR (NCL-LPGR-312) was obtained from Leica Biosystems 
(Novacastra, UK). Horseradish peroxidise-conjugated secondary antibodies, anti-mouse (sc-2005) and 
anti-rabbit (sc-2313), were purchased from Santa Cruz Biotechnology, USA. 
 
For flow cytometry, antibodies against human CD4 phycoerythrin (PE)-Dazzle 594 (357412), anti-
CD8 PE/Cy5 (300910), anti-CD69 PE/Cy7 (310912), anti-CCR5 PE (359106), anti-CD14 APC 
(325608), anti-CD3 fluorescein isothiocyanate (FITC) (300306) and the ZOMBIE Violet Fixable 
Viability Kit (423113) were purchased from Biolegend, USA. The isotype controls, anti-mouse IgG 
(APC, 555751) and anti-rat IgG (PE, 12-4321) were purchased from Becton Dickinson (BD) 
Sciences, USA. The anti-rabbit AlexaFluor488 (#A21206) antibody was purchased from Invitrogen, 
USA, while the donkey anti-mouse Cy3 (#715-166-150) and the donkey anti-rabbit Cy5 (#711-175-
152) antibodies were obtained from Jackson ImmunoResearch, USA. 
 
 
2.3 Plasmids 
 
The luciferase reporter gene plasmid, pTAT-GRE-E1b-LUC (TAT-GRE-LUC), containing two 
glucocorticoid response elements (GREs) from the rat tyrosine amino transferase (TAT) gene under 
the control of the E1b promoter was a gift from G. Jenster (Erasmus University of Rotterdam, 
Rotterdam, Netherlands) (Sui et al. 1999). The empty vector, pcDNA3.1, containing a CMV promoter 
and no downstream DNA sequence, was obtained from Invitrogen, UK. The steroid receptor plasmid 
for the GR, pcDNA3-hGR, containing full-length untagged human GRα cloned into the pcDNA3 
vector, was a gift from D. W. Ray (University of Manchester, UK) (Ray et al. 1999). The steroid 
receptor plasmid for the PR isoform PR-B, pMT-hPRB, containing full length untagged human PR-B 
cloned into the pMT vector, was a gift from S. Okret (Karolinska Institute, Sweden) (Cairns et al. 
1993).The steroid receptor plasmid for PR-A, pSG5-hPRA, was a gift from F. Claessens (University 
of Leuven, Leuven, Belgium) (Kastner et al. 1990). The plasmid for HA-tagged GR-Interacting 
Protein 1 (GRIP-1), pHA-GRIP1 was a gift from M. R. Stallcup (University of Southern California, 
Los Angeles, CA). 
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2.3.1 Plasmid transformation and purification 
 
Plasmids were transformed into Escherichia coli DH5α cells using heat shock as previously described 
(Sambrook and Russell 2006). Competent DH5α cells (100 μL) were incubated with 10 ng plasmid 
DNA on ice for 30 min, then at 42°C for 2 min and on ice for 2 min. Cells were subsequently mixed 
into 900 μL Luria broth (LB, 1% (w/v) tryptone, 0.5% (w/v) yeast extract, 0.5% (w/v) NaCl) and 
incubated at 37°C for 1 h with shaking. Transformed cells were then plated onto LB-agar plates (1% 
(w/v) tryptone, 0.5% yeast extract, 1% NaCl, 1.5% agar) containing 100 μg/mL final concentration of 
the antibiotic ampicillin (Sigma Aldrich, South Africa) and incubated overnight at 37°C. Day cultures 
of 5 mL LB containing 100 μg/mL ampicillin were inoculated with single colonies and incubated at 
37°C for 8 h with shaking. Plasmid glycerol stocks were prepared by mixing 500 μL 70% (v/v) 
glycerol with 500 μL transformed cell suspension and storage at -80°C. Overnight cultures of 200 mL 
LB containing 100 μg/mL ampicillin were inoculated with 200 μL day culture cell suspension and 
incubated at 37°C for 16 h with shaking. Plasmid DNA was subsequently purified using the PureYield 
plasmid maxi-prep kit (Promega, Madison, WI, USA), according to the manufacturer’s instructions. 
The purity and yield of the plasmid preparation were assessed using a Nanodrop ND-1000 
spectrophotometer (NanoDrop Technologies). 
 
 
2.3.2 Restriction enzyme digestion 
 
The supercoiled conformation of plasmid DNA was assessed by agarose gel electrophoresis by 
comparison with the linearized plasmid after restriction enzyme digestion. Reactions of 300 ng DNA, 
1 unit (U)/μL restriction enzyme (or equivalent volume of water for the undigested control) and 1 X 
FastDigest universal buffer containing sample application dye (Fermentas, Thermo Scientific, USA) 
were incubated for 10 min at 37°C. Digested and undigested samples were separated by 
electrophoresis on a 0.8% (w/v) 1 X Tris-Acetate-EDTA (TAE) agarose gel containing 10 μg/mL 
ethidium bromide (Sigma Aldrich, South Africa). Samples were subsequently visualized under 
ultraviolet light on a Syngene, G:Box (Vacutec, England) and images acquired using GeneSnap 
version 7.08 (SynGene, England). The identity of the plasmids was assessed by restriction enzyme 
digestion pattern. 
 
 
2.4 Mammalian cell culture 
 
Immortalized or cancerous human and simian cell lines, and human PBMCs and cervical tissue were 
used as model systems in this study. 
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2.4.1 Cell lines 
 
The African green monkey kidney fibroblast (COS1), human osteosarcoma (U2OS) and human 
embryonic kidney (HEK293T) cell lines were purchased from the America Type Culture Collection 
(ATCC, USA). The human endocervical epithelial cell line immortalized with HPV-16 E6E7 
(End1/E6E7) was received from Dr R Fichorova (Brigham & Women’s Hospital, Boston, USA) 
(Fichorova et al. 1997). The breast carcinoma cell line, MCF-7 (Soule et al. 1973), was a gift from Dr 
S Prince (Human Biology, University of Cape Town), and the T47D breast carcinoma cell line 
(Keydar et al. 1979) was from Prof M I Parker (ICGEB, University of Cape Town). The human 
cervical carcinoma cell lines, HeLa and TZM-bl, were obtained from the NIH AIDS Reagent 
Program, Division of AIDS, NIAID, NIH from Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme 
Inc. (ARP, NIH, USA). TZM-bl cells are modified HeLa cells stably expressing CD4, CXCR4 and 
CCR5 (Platt et al. 1998) and the luciferase and β-galactosidase reporter genes controlled by the HIV-1 
LTR promoter (Wei et al. 2002). 
 
Cells were cultured in humidified 37°C incubators containing 5% CO2 in the P2 Mammalian Tissue 
Culture Facility in the Department of Molecular & Cell Biology at the University of Cape Town. All 
cell lines were maintained in 75 cm
2
 flasks (Greiner Bio-one International, Austria) in Dulbecco’s 
modified Eagle’s medium (DMEM, Sigma Aldrich, South Africa) supplemented with 1 mM sodium 
pyruvate (Sigma Aldrich, South Africa), 44 mM sodium bicarbonate (Sigma Aldrich, South Africa), 
10% (v/v) foetal calf serum (FCS, Thermo Scientific, South Africa) and 100 IU/mL penicillin and 100 
mg/mL streptomycin (Gibco, Invitrogen, UK), except for End1/E6E7 cells which were maintained in 
Keratinocyte Serum-free media (Gibco, Invitrogen, UK) supplemented with bovine pituitary extract 
(BPE) and 100 IU/mL penicillin and 100 mg/mL streptomycin (Gibco, Invitrogen, UK).  
 
Transfections and stimulations were carried out in serum-free (SF) media and HIV-1 infection assays 
in TZM-bl cells were carried out in phenol red-free DMEM (Sigma Aldrich, South Africa) 
supplemented with 10% (v/v) charcoal-stripped FCS (cs-FCS, Thermo Scientific, South Africa) and 
100 IU/mL penicillin and 100 mg/mL streptomycin (Gibco, Invitrogen, UK). For sub-culturing, cells 
were washed with warm 1 X phosphate-buffered saline (PBS, Sigma Aldrich, South Africa) and 
incubated at 37°C with 2 mL 0.25% trypsin/0.1% EDTA in PBS (Highveld Biological, South Africa) 
for 5 min. Trypsin was neutralized by the addition of full DMEM containing 10% FCS. 
 
Cells were routinely checked for mycoplasma contamination by Hoescht staining (Freshney 1987) 
and fluorescence microscopy (Department of Molecular and Cell Biology, University of Cape Town), 
and only mycoplasma-negative cells were used for experiments. 
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2.4.2 PBMCs 
 
All PBMCs were from female donors only and were isolated from whole blood as previously 
described (Tomasicchio et al. 2013). Buffy packs from healthy female HIV-negative donors, of 
unknown menstrual cycle phase, were obtained from the Western Province Blood Transfusion 
Services (Pinelands, South Africa). PBMCs were isolated by Histopaque (H1077 Hybri-Max, Sigma-
Aldrich) density centrifugation using Leucosep tubes (Greiner Bio-One International, Austria). 
Briefly, 15 mL Histopaque was centrifuged in Leucosep tubes at 2500 rpm for 1 min at room 
temperature using the Heraeus Megafuge 40 centrifuge (Thermo Scientific, South Africa), while 
whole blood was diluted in unsupplemented Roswell Park Memorial Institute (RPMI) 1640 (Lonza, 
Switzerland) and PBS at a ratio of 2:1:1. The diluted blood (40 mL) was loaded onto the Leucosep 
tube and centrifuged for 15 min at 2500 rpm with lowest deceleration. PBMCs that had separated 
from red blood cells and serum into a white buffy coat were collected with a 1 mL pipette and washed 
twice with 1 X PBS containing 1% (v/v) cs-FCS by centrifugation at 1200 rpm for 5 min. Cell number 
and viability was determined by diluting the PBS-suspended PBMCs 1:10 with trypan blue (Lonza, 
Switzerland) and counting on a haemocytometer. 
 
PBMCs were maintained in high-glucose (4.5 g/mL) RPMI medium (Lonza, Switzerland) containing 
10% (v/v) cs-FCS (Thermo Scientific, South Africa), 2 mM L-glutamine (Sigma Aldrich, South 
Africa), 0.1 mg/mL sodium pyruvate (Sigma Aldrich, South Africa), 100 IU/mL penicillin and 100 
mg/mL streptomycin (Sigma-Aldrich, South Africa) and 30 U/mL final concentration IL-2 at 37°C in 
a humidified incubator containing 5% CO2 at the P2+ Mammalian Tissue Culture Facility in the 
Department of Molecular & Cell Biology at the University of Cape Town.  
 
 
2.4.3 Cervical explants 
 
Cervical epithelial explant tissue was obtained after informed consent from HIV-negative, normal Pap 
smear, pre- and postmenopausal women undergoing hysterectomies for benign reasons, at either 
Groote Schuur or Tygerberg hospitals. After pathologist inspection to exclude abnormal or cancerous 
tissue, the sample was transported to the P2 Mammalian Tissue Culture Facility at the Department of 
Molecular and Cell Biology, where the explant was washed in warm 1 X PBS and processed by 
removal of stroma and fatty connective tissue and separation of endo- and ectocervix if necessary and 
if available. Cervical explants were then cut into small pieces and transferred into round-bottom 96-
well plates (Greiner Bio-One International, Austria) containing full RPMI supplemented with 10% 
(v/v) charcoal-stripped foetal calf serum (c-s FCS) (Thermo Scientific, USA), 2 mM L-glutamine 
(Sigma Aldrich, South Africa), 10 μg/mL Fungizone (Sigma Aldrich, South Africa), 100 IU/mL 
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penicillin and 100 mg/mL streptomycin (Sigma Aldrich, South Africa). Thereafter, cervical explants 
were stimulated and cultured in the P2+ facility, in a 37°C humidified incubator containing 5% CO2. 
Blood samples collected from hysterectomy donors were tested for HSV-1 and HSV-2 status and for 
the endogenous levels of LH, FSH, E2 and P4 at the National Health Laboratory Services (NHLS, 
Groote Schuur Hospital, South Africa). Menstrual cycle phase was determined from these four 
hormones, based on the NHLS guideline hormone ranges (Appendix D, Table D2).  
 
 
2.5 Transfections 
 
Transient transfection of steroid receptor expression constructs and luciferase reporter vectors was 
carried out using XtremeGENE-9 transfection reagent (Roche Applied Science, South Africa), 
according to the manufacturer’s protocol at a ratio of 2:1 (XtremeGENE-9: DNA). Transfection mixes 
containing DNA and XtremeGENE-9 were incubated in SF-KSF (End1/E6E7 cells) or SF-DMEM 
(all other cells) at room temperature for 30 min before dropwise addition to the cells. For over-
expression of PR-B, HeLa/TZM-bl (1 X 10
5
 cells/well) and End1/E6E7 (1.5 X 10
5
 cells/well) cells 
were seeded in 12-well plates (Greiner Bio-One International, Austria) for 24 h, and transfected with 
250 ng (End1/E6E7) or 500 ng (HeLa/TZM-bl) pMT-hPRB or equivalent pcDNA3 for 24 h before 
stimulation with the indicated ligands for a further 24 h prior to harvesting for RNA, protein or 
supernatant media. Positive controls for western blots were prepared by transfecting 1 X 10
5
 cells/well 
COS1 cells with 1 μg pcDNA3-hGR, pMT-hPRB or pSG5-PRA for 24 h prior to harvesting.  
 
 
2.5.1 Promoter-reporter assays 
 
Promoter-reporter assays using the luciferase reporter gene were carried out as described previously 
(Africander et al. 2011a) with a few modifications. Cells were seeded as indicated in the figure 
legends and allowed to adhere overnight in 24-well plates. Transfection mixtures containing 47 ng 
pTAT-GRE-LUC and either 125 ng or 250 ng steroid receptor expression vector (GR or PR-A or PR-
B) or empty vector (pcDNA3.1) were prepared using XtremeGENE-9 transfection reagent (Roche 
Applied Science, South Africa) and added dropwise onto cells. After 24 h, cells were stimulated in 
SF-media with the indicated ligands for a further 24 h, after which cells were washed in cold 1 X PBS 
and harvested by shaking in 50 μL 1 X reporter lysis buffer (Promega, Madison, WI, USA) with a 
freeze-thaw step. Luciferase activity was assessed using the Luciferase Assay System (Promega, 
Madison, WI, USA) by measuring relative light units (RLU) in 10 μL cell lysate after addition of 50 
μL luciferin substrate in a Modulus microplate luminometer (Turner Biosystems, Sunnyvale, CA, 
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USA). Luciferase activity was calculated as RLU relative to total protein content per well as measured 
spectrophotometrically using the Bradford assay (Bradford 1976). 
 
 
2.5.2 Small interfering RNA (siRNA) transfections 
 
Transfection with siRNA was carried out as previously described (Govender et al. 2014, Louw-du 
Toit et al. 2014) with a few modifications. Cells were seeded as indicated in the figure legends and 
allowed to adhere overnight in 12 well plates. Cells were transfected with 10 nM final concentration 
either validated GR HS_NR3C1_5 (GR5, referred to in this study as siGR) (catalogue no. 
SI02654757, Qiagen, South Africa) siRNA targeting the human GR or validated non-silencing control 
(NSC) scrambled sequence siRNA (catalogue no. 1027310, Qiagen, South Africa) using 3.5 μL 
HiPerfect transfection reagent (Qiagen, South Africa) in 46 μL OptiMEM medium with GlutaMAXTM 
(Gibco-BRL Life Technologies) in a dropwise manner after incubation at room temperature for 15 
min. Cells were incubated with the siRNA transfection mixtures for 48 h before stimulation with the 
indicated ligands for a further 24 h prior to harvesting for RNA, protein or supernatant media. GR 
protein knock down was confirmed by western blotting. 
 
 
2.6 Protein assays 
 
2.6.1 Protein isolation 
 
2.6.1.1 Cell lines 
 
At the end of the experiment (transfection, knockdown, stimulation, etc.), cells seeded in 12 well 
plates were washed in ice cold 1 X PBS. Total protein was then harvested by scraping in 50 μL 2 X 
SDS sample buffer (5 X SDS sample buffer: 100 mM TRIS-HCl pH 6.8, 5% (w/v) SDS, 20% (v/v) 
glycerol, 2% β-mercaptoethanol, 0.1% (w/v) bromophenol blue). After transfer to microfuge tubes, 
samples were boiled for 10 min at 100°C then stored at -20°C. Secreted protein was harvested by 
collecting growth media supernatants from adhered End1/E6E7 or HeLa cells in cryovials, which 
were stored at -80°C. 
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2.6.1.2 PBMCs 
 
At the end of the experiment, PBMCs were pelleted by centrifugation at 1200 rpm for 5 min using the 
Heraeus Megafuge 40 centrifuge (Thermo Scientific, South Africa), transferred to microfuge tubes 
and washed in ice cold 1 X PBS. Dry pellets were stored at -80°C until protein was harvested using 
N-[Tris(hydroxymethyl)-methyl]-3-aminopropanesulfonic acid (TAPS) buffer [0.1 M TAPS, pH 9.5, 
supplemented with 1 mM final concentration phenylmethylsulfonyl fluoride (PMSF), 2 μg/mL 
Aprotinin (Roche Applied Science, South Africa), 5 μg/mL Leupeptin (Roche Applied Science, South 
Africa) and 1 X Complete Mini protease inhibitor tablet (1 tablet/ 10 mL buffer; Roche Applied 
Science, South Africa)]. Samples were incubated on ice and vortexed every 10 min for 1 h prior to 
centrifugation at 12000 x g at 4°C for 15 min. Supernatants were transferred to new microfuge tubes 
in which 5 X SDS sample buffer was added to a final volume of 1 X (v/v). Samples were then boiled 
for 7 min at 100°C and stored at -20°C. 
 
 
2.6.1.3 Cervical explants 
 
On the day of surgery, individual pieces of cervical explant tissue (approximately 3mm
3
) were placed 
in cryovials containing about 200 μL All-Protect® (Qiagen, Netherlands) and were stored at -80°C 
until use. Explants were thawed at room temperature and excess All-Protect® was removed by wiping 
on tissue paper using sterile forceps. Explants were then transferred to 2 mL microfuge tubes 
containing two 7 mm stainless steel beads (Qiagen, Netherlands) and 100 μL radio-
immunoprecipitation (RIPA) buffer (50 mM TRIS-HCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% 
sodium deoxycholate and 0.1% SDS) containing 1 mM final concentration PMSF and 1 X Complete 
Mini protease inhibitor tablet (1 tablet/ 10 mL buffer; Roche Applied Science, South Africa). Total 
protein was harvested mechanically using the TissueLyser LT (Qiagen, Netherlands) at 50 Hz in 4 x 1 
min steps, cooling on ice in between steps. Samples were centrifuged for 20 min at 12000 x g at 4°C, 
then transferred to new microfuge tubes. Total protein was quantified using the BCA protein assay kit 
according to the manufacturer’s instructions (Pierce, Rockford, IL, USA) and 5 X SDS sample buffer 
was added to a final volume of 1 X (v/v) to the remaining sample. Samples were boiled at 100°C for 7 
min and stored at -20°C. 
 
 
 
 
 
 
47 
 
2.6.2 Western blotting 
 
Western blotting was carried out as previously described (Avenant et al. 2010a). Equal amounts of 
cell lysate (a minimum of 40 μg protein for explant samples) were loaded onto 8% SDS-
polyacrylamide gels and separated by electrophoresis at 75 V for 20 min then 120 V for 1 h in 1 X 
running buffer (25 mM TRIS-HCl, 250 mM glycine and 0.1% (v/v) SDS pH 8.4) using a Bio-Rad 
Mini Protean II electrophoresis system (Bio-Rad, South Africa). Proteins were then blotted onto 
Hybond-ECL nitrocellulose membrane (AEC-Amersham, South Africa) for 1 h at 180 mA in cold 1 X 
transfer buffer (25 mM TRIS, 200 mM glycine, 20% (v/v) methanol). Membranes were subsequently 
blocked for 1 h at room temperature by shaking in 4% (w/v) ECL advance blocking powder (AEC-
Amersham, South Africa) in 1 X TRIS-buffered saline (50 mM TRIS, 150 mM NaCl; TBS) 
containing 0.1% (v/v) Tween (TBS-Tween; TBST). Primary antibodies were diluted in 4% ECL-
TBST (Table 2.1) and incubated on membranes overnight with shaking at 4°C. Membranes were then 
washed three times in 1 X TBST for 5 min and incubated with secondary antibodies diluted in 5% 
(w/v) skim milk powder in 1 X TBST (Table 2.1) for 1 h at room temperature with shaking. After 
three 5 min washes in 1 X TBST, membranes were placed in 1 X TBS prior to 1 min incubation with 
Pierce ECL-chemiluminescent western blotting substrate (Thermo Scientific, USA). Proteins were 
visualized by autoradiography using Amersham Hyperfilm™ MP high performance autoradiography 
film (AEC-Amersham, South Africa). Densitometric quantification of film was carried out using 
AlphaEaseFC™ Software, version 3.1.2 (Alpha Innotech, USA). 
 
 
Table 2.6.2 Antibodies used in Western blotting procedure 
 
Primary 
Antibody 
Size 
(kDa) 
 
Dilution Secondary Antibody 
 
GR⍺ 95 1: 4000 (cell lines) 
1: 2000 (primary cells) 
Rabbit (1: 10 000) 
PR-B/PR-A 114/94 1: 1000 (cell lines) 
1: 500 (primary cells) 
Mouse (1: 4000) (cell lines) 
(1:2000) (primary cells) 
GAPDH 37 1:15 000 Mouse (1: 4000) 
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2.6.3 Co-immunoprecipitation (Co-IP) assay 
 
The Co-IP assay was carried out as previously described (Avenant et al. 2010a) with a few 
modifications. COS1 cells were seeded at a density of 1.5 X 10
6
 in 10 cm dishes for 24 h and were 
subsequently transfected with 3 μg of pMT-hPR-B and 3 μg of either pcDNA3.1 or pcDNA3-hGR 
using XtremeGene-9 transfection reagent (Roche Applied Science, South Africa) for a further 24 h. 
MCF-7 cells were seeded as for COS1 cells and were incubated for 48 h without transfection. Cells 
were then stimulated with 1 μM MPA or vehicle in SF-DMEM for 1 h, washed once with cold 1 X 
PBS and lysed by scraping in 500 μL CytoBusterTM protein extraction reagent (Novagen®) containing 
protease inhibitors (1 X Complete Mini protease inhibitor tablet [Roche, South Africa] per 10 mL). 
Cellular debris was pelleted by centrifugation at 16000 x g for 5 min at 4°C and 9 μL of supernatant 
were collected for inputs. From the supernatants of MPA-treated and vehicle control samples, equal 
volumes (200 μL each) were combined and incubated with 1.6 μg of donkey anti-rabbit IgG antibody 
(sc-2313, Santa Cruz Biotechnology) at 4°C overnight with rotation. The remaining supernatants were 
incubated with 1.6 μg anti-GR (H300, Santa Cruz Biotechnology) at 4°C overnight with rotation. 
Antibody-bound protein complexes were precipitated the following day by the addition of 20 μL pre-
blocked PureProteome
TM
 Protein A/G magnetic beads (LSKMAGG02, Millipore, Merck, South 
Africa) for 2 h with rotation at 4°C. The complexes were washed twice with 1 X PBS by 
centrifugation at 2000 x g for 1 min at 4°C. GR-bound proteins were then released from the beads by 
boiling in 25 μL 2 X SDS sample buffer for 5 min, then were separated using 6% SDS-PAGE and 
western blotting as described in 2.6.2. Samples were run on duplicate blots which were probed with 
anti-GR (H300, Santa Cruz Biotechnology) or anti-PR (NCL-LPGR-312, Leica Biosystems) 
antibodies. 
 
 
2.6.4 IL-6 ELISA 
 
The human IL-6 high sensitivity ELISA kit was purchased from eBioscience and followed according 
to the manufacturer’s instructions (BMS213HS, San Diego, USA), except that supernatants from 
End1/E6E7 and HeLa experiments were diluted 1:40 in the sample diluent prior to the assay.  
 
 
2.6.5 Flow cytometry 
 
Fluorescence-activated cell sorting (FACS) was carried out as previously described (Tomasicchio et 
al. 2013) with a few modifications. PBMCs seeded at 4 X 10
6
 in 5 mL Falcon tubes (Becton Dickson 
Scientific, South Africa) were stimulated with the indicated ligands for 7 days in full RPMI in an 
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incubator at 37℃. Cells were subsequently stained with anti-CD3 FITC, anti-CD4 PE-DAZZLE 594, 
anti-CD8 PE/Cy5, anti-CD14 APC, anti-CCR5 PE, anti-CD69 PE/Cy7 and the viability dye, 
ZOMBIE NIR (Biolegend, USA), for 15 min in the dark at room temperature. Fluorescence minus 
one (MFO) controls for CD14, CD69 and CCR5 were also prepared, including all the antibodies 
except CD14, CD69 and CCR5, respectively. Cells were washed with 1 X PBS then resuspended in 1 
X Cell Fix solution (Becton-Dickinson, USA) and taken for analysis at the Lung Infection and 
Immunity Unit, Department of Medicine, University of Cape Town, using a BLSRII Becton-
Dickinson flow cytometer (Becton-Dickinson, USA). Samples were analyzed from 50 000 cells using 
FlowJo software version 10.1 (Treestar Inc., Ashland, Ore). Lymphocytes were chosen from forward 
and side scatter plots and single cells were selected (Appendix C). Dead cells were excluded by 
selecting for ZOMBIE-negative cells (Appendix C). Negative gates were set using first the CD14 
MFO control, then CCR5 and CD69 (Appendix C). Results were plotted as frequency, that is, a 
percentage of total, or expression, as median fluorescence intensity (MFI) per number of double-
positive cells. Fold change was calculated relative to the vehicle control (EtOH) set to 1.  
 
 
2.7 Gene expression assays 
 
2.7.1 RNA isolation 
 
RNA was isolated from both cell lines and PBMCs using Tri-Reagent® (T9429, Sigma-Aldrich, 
South Africa). PBMCs that were pelleted by centrifugation or adherent cells seeded in 12-well plates 
were incubated with 400 μL Tri-Reagent® for 5 min at room temperature. Lysed cells were 
transferred from the 12 well plates into microfuge tubes. After the addition of 80 μL chloroform, tubes 
were vortexed vigorously for 15 s then centrifuged at 20 000 x g at 4°C for 15 min. The aqueous 
phase was removed carefully by pipetting and transferred into a new microfuge tube, into which 200 
μL isopropanol (Merck, South Africa) was then added. Samples were mixed by gentle inversion and 
incubated for 10 min at room temperature. RNA was pelleted by centrifugation at 4°C for 10 min at 
20 000 x g. The supernatants were discarded and the RNA pellet was washed twice in 75 % (v/v) 
EtOH in diethyl pyrocarbonate (DEPC)-treated water (1:1000). Samples were air dried and RNA 
pellets were resuspended in 12 μL DEPC-treated water. RNA was precipitated by the addition of 24 
μL 100% (v/v) EtOH and 1.2 μL 3M sodium acetate pH 5.5 followed by storage at -80°C for 30 min. 
RNA was then pelleted by centrifugation at 20 000 x g for 15 min at 4°C, washed in 75 % (v/v) EtOH 
in DEPC-treated water, air dried and resuspended in 12 μL DEPC-treated water. Following the clean-
up procedure, RNA was quantified by spectrophotometry (NanoDrop Technologies) and integrity was 
measured by denaturing formaldehyde agarose gel electrophoresis (Sambrook and Russell 2006). 
Briefly, 500 ng RNA was mixed with sample loading buffer [12% (v/v) DEPC-treated water, 5% (v/v) 
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bromophenol blue, 7% (v/v) glycerol, 10% (v/v) 10X MOPS buffer (0.2 M MOPS in DEPC-treated 
water, 0.05 M sodium acetate, 0.01 M EDTA), 17% (v/v) 12.3 M formaldehyde and 49% (v/v) 
formamide] and 20 μg/mL EtBr. Samples were then electrophoresed on a 1% formaldehyde agarose 
gel [70% (v/v) DEPC-treated water, 10% (v/v) 10 x MOPS buffer, 20% (v/v) formaldehyde] in 1 X 
MOPS buffer (40 mM MOPS; 10 mM sodium acetate; 1 mM EDTA, pH 8.00) at 65V for 40 min. 
Samples were visualized under ultraviolet light on a Syngene, G:Box (Vacutec, England) and images 
acquired using GeneSnap version 7.08 (SynGene, England). RNA was stored at -80°C. 
 
 
2.7.2 cDNA synthesis 
 
cDNA was synthesized from 250 ng RNA using the Transciptor First Strand Synthesis cDNA kit 
(Roche Applied Science, South Africa) according to the manufacturer’s instructions. This reverse 
transcription method is based on anchored oligo d(T) priming. Samples were stored at -20°C. 
 
 
2.7.3 Quantitative real-time RT-PCR (qRT-PCR or qPCR) 
 
Relative gene expression was determined by qPCR using 1 X SensiMix
TM
 SYBR® no ROX master 
mix (QT650-05, Bioline, USA), forward and reverse primers (sequences and concentrations used are 
shown in Table 2.7.3) and 1 μL cDNA template in a 20 μL reaction. Samples were analysed on a 
RotorGene 3000 qPCR machine (Qiagen, Netherlands). Cycling conditions included an initial 
denaturation step at 95°C for 5 min, followed by 40 cycles of denaturation at 95°C for 8 s, annealing 
(primer-specific annealing temperatures are indicated in Table 2.7.3) for 10 s and elongation for 8 sec 
at 72°C. Melting curve analysis and Ct determination were carried out by the RotorGene software 
(version 1.7). qPCR product samples were analysed by 2% agarose gel electrophoresis in 1 X TAE at 
70 V for 1 h. The primer efficiency was determined by standard curves. mRNA transcript levels 
normalized to the housekeeping gene GAPDH were calculated using the Pfaffl method (Pfaffl 2001). 
Fold change was calculated relative to the vehicle control (EtOH) set to 1. 
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Table 2.7.3 Primers used for qPCR reactions, primer sequences, concentrations, annealing 
temperatures and product sizes  
 
Primer Sequence Final 
conc. 
Ta 
(°C) 
Product 
size (bp) 
Reference 
GAPDH F: 5’- TGAACGGGAAGCTCACTGG-3’ 
R: 5’-TGTCAGTTGATAAAACCGCTGCC-3’ 
 
200 nM 60 307 (Ishibashi et 
al. 2003) 
GILZ Quantitect Primer QT00091035 
 
1 X 60 69 Qiagen, 
Netherlands 
IL-6 F: 5’ - TCTCCACAAGCGCCTTCG - 3’ 
R: 5’ - CTCAGGGCTGAGATGCCG - 3’ 
250 nM 60 193 (Wolf et al. 
2002) 
 
IL-8 F: 5’ - TGCCAAGGAGTGCTAAAG - 3’ 
R: 5’ - CTCCACAACCCTCTGCAC - 3’ 
 
250 nM 60 197 (Wolf et al. 
2002) 
RANTES F: 5’ - TACCATGAAGGTCTCCGC - 3’ 
R: 5’ - GACAAAGACGACTGCTGG - 3’ 
 
250 nM 60 199 (Wolf et al. 
2002) 
IL-10 F: 5’-AAAGGCATCTACAAAGCCA-3’ 
R: 5’-TTGTCATGTAGGCTTCTATGTAGT-
3’ 
 
500 nM 55 67 (Louw-du 
Toit et al. 
2014) 
IL-12p35 F: 5’-TGATGAGCTGATGCAGGC-3’ 
R: 5’-ATCCGGTTCTTCAAGGGAG-3’ 
 
500 nM 56 73 (Louw-du 
Toit et al. 
2014) 
IL-12p40 F: 5’-CCACATTCCTACTTCTCCC-3’ 
R: 5’-CTTGTCCGTGAAGACTCTAT-3’ 
 
500 nM 51 87 (Louw-du 
Toit et al. 
2014) 
MKP1 F: 5’-AGTACCCCACTCTACGATCAGG-3’ 
R: 5’-TGATGGAGTCTATGAAGTCAATGG-
3’ 
 
250 nM 55 250 (Rauhala et 
al. 2005) 
CCR5 F: 5’ TGGACCAAGCTATGCAGGTG 3' 
R: 5' CGTGTCACAAGCCCACAGAT 3' 
 
500 nM 55 240 M. Maritz, 
unpublished 
CD4 F: 5'-GGGGATACAGTGGAACTGACC-3' 
R: 5'-TCCCAAAGGCTTCTTCTTGAG-3' 
 
500 nM 55 164 (Eszterhas et 
al. 2011) 
CXCR4 F: 5'GAAATGGGCTCAGGGGACTAT 3'  
R: 5' TTCAGCCAACAGCTTCCTTGG 3 
 
500 nM 60 417 M. Maritz, 
unpublished 
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2.8 HIV-1 infection assays 
 
The R5 infectious molecular clone used in this study, HIV-1BaL_Renilla, was a gift from Dr Christina 
Ochsenbauer (Edmonds et al. 2010). This virus was created by insertion of a luciferase gene next to 
env in the HIV-1 NL4-3 backbone, NL-LucR.T2A-BaL.ecto (Edmonds et al. 2010). 
 
 
2.8.1 Preparation of virus and determination of viral titres 
 
Viral stocks were prepared by transfection in HEK293T cells as previously described (Pear et al. 
1993), with a few modifications. HEK293T cells were seeded at 4 X 10
6
 cells per 10 cm dish in full 
DMEM supplemented with 25 mM HEPES buffer (Lonza, Germany) for 24 h. Cells were then 
transfected with 12 μg HIV-1BaL-Renilla or DMEM as a negative no-virus control, for 48h, using 
XtremeGENE-9 transfection reagent (Roche Applied Science, South Africa). The media was collected 
and passed through a 0.22 μM filter, after which cs-FCS (Thermo Scientific, USA) was added to a 
final concentration of 12.5%. Aliquots of the viral stock and no-virus control were stored at -80°C.  
 
The viral titres were determined in TZM-bl cells as previously described (Edmonds et al. 2010). 
Briefly, TZM-bl cells were seeded at 2.5 X 10
4
 cells/well in a 96-well plate in full DMEM for 24 h. 
The virus was serially diluted 1:5 in full phenol red-free DMEM (Sigma Aldrich, South Africa) for 8 
dilutions in a separate 96-well plate. The media was removed from the TZM-bl cells and the diluted 
virus, or the no-virus control, was then added in quadruplicate wells. After 72 h the cells were 
harvested in 70 μL/well Bright-Glo luciferase lysis buffer (Promega, USA) in the dark for 5 min. 
Samples were transferred into a white 96-well plate (Greiner, Germany) and fluorescence in RLU was 
measured on a luminometer (Modulus microplate, Promega, USA). The viral titre was calculated as 
log infectious units (IU)/mL using the Reed and Muench method (Reed and Muench 1938). The 
typical viral titre ranged from 1 X 10
4
-4 X 10
5
 IU/mL.  
 
 
2.8.2 PBMC infection assay 
 
Owing to the wide inter-individual variability in HIV-1 infection observed in PBMC donors, PBMCs 
were pre-screened for infectability prior to hormone plus infection assays. PBMCs were seeded 
immediately after isolation (as described in 2.4.2) at 2 X 10
5
 cells/well in U-bottom 96-well plates. 
Aliquots of PBMCs were frozen at -80°C in full RPMI containing 5% cs-FCS until infectability was 
determined using the Reed and Muench method (Reed and Muench 1938).  
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The following day, the virus was serially diluted as for the TZM-bl assay described above. The media 
was removed from pelleted PBMCs and the diluted virus was then added in quadruplicate wells. 
Control cells (no-virus control) underwent mock infection by incubation with diluted media collected 
from mock-transfected HEK293T cells. After infection for 2 h at 37°C, the cells were washed three 
times in 1 X PBS containing 1% cs-FCS, resuspended in full RPMI containing IL-2 and incubated for 
a further 5 days. PBMCs were pelleted by centrifugation at 1200 rpm for 5 min then harvested for 
Renilla luciferase expression (infection) using Renilla luciferin according to the manufacturer’s 
specifications (Promega, USA) with a few modifications. Briefly, PBMCs were resuspended in 70 
μL/well 1 X reporter lysis buffer with Renilla luciferin after incubation for 10 min in the dark at room 
temperature. Lysed cells were transferred into a white 96-well plate (Greiner, Germany) and 
fluorescence in RLU was measured on a luminometer (Modulus microplate, Promega, USA). 
Infection was determined using the Reed and Muench method (Reed and Muench 1938). 
 
For experiments, infectable PBMCs were thawed from frozen stock, seeded at 4 X 10
6
 in 5 mL FACS 
tubes and stimulated with the indicated ligands for 2 or 7 days. PBMCs were infected with 10 IU/mL 
HIV-1BaL-Renilla or the equivalent volume of no-virus control for 2 h at 37°C, followed by three washes 
in 1 X PBS containing 1% cs-FCS. Cells were then resuspended in full RPMI containing IL-2. Five 
days post-infection, cells were seeded into two U-bottom 96-well plates in quadruplicate wells. Cells 
on the first plate were pelleted by centrifugation at 1200 rpm for 5 min then harvested for Renilla 
luciferase expression as described above. Cells on the second plate were analysed for cell viability 
using the MTT assay. Briefly, cells were incubated with MTT solution (5 mg/mL MTT in PBS, filter 
sterilized) to a final concentration of 0.5 mg/mL for 2 h in an incubator at 37°C. Cells were pelleted 
by centrifugation at 1200 rpm for 5 min then resuspended in 70 μL/well Solubilisation solution (0.1 N 
HCl in isopropanol) and transferred into a new 96-well plate. Absorbance was measured at 595 nm on 
a spectrophotometer (Thermo Scientific, USA). Infection was calculated as RLU of each 
quadruplicate divided by the average absorbance at 595 nm of the four quadruplicate wells 
(RLU/MTT). Relative infection was determined by setting the vehicle control (EtOH) in the presence 
of virus to 100% or as indicated in the figure legend. 
 
 
2.8.3 TZM-bl infection assay  
 
TZM-bl cells were seeded in quadruplicate wells at 2.5 X 10
4
 cells/well in two 96-well plates and 
allowed to adhere overnight. Cells were then stimulated with the indicated ligands in phenol red-free 
SF-DMEM for 48 h at 37°C in an incubator. The media was removed and cells were incubated with 
10 IU/mL HIV-1BaL-Renilla or the equivalent volume of no-virus control (prepared as in 2.8.1) in phenol 
red-free RPMI. After 72 h the cells on one plate were harvested in Bright-Glo luciferase lysis buffer 
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as described in 2.8.1 and cells on the other plate were harvested for cell viability using the MTT assay 
as described in 2.8.2. Infection as RLU/MTT was calculated as for PBMCs (2.8.2). Relative infection 
was determined by setting the vehicle control (EtOH) in the presence of virus to 100% or as indicated 
in the figure legend. 
 
 
2.8.4 Media add-back onto TZM-bl cells infection assay 
 
The effect of soluble factors secreted into growth media from cervical cell lines on HIV-1 infectivity 
in indicator TZM-bl cells was measured in a media add-back assay based on a previous protocol 
(Patel et al. 2014). TZM-bl cells were seeded at 2.5 X 10
4
 cells/well in two 96-well plates for 24 h. 
Supernatants from knockdown and over-expression experiments in End1/E6E7 and HeLa cells were 
collected at the time of harvest and stored at -80°C. These supernatants were diluted 1:20 in phenol-
free DMEM prior to use. Half of the diluted supernatants (100 μL) was incubated on the TZM-bl cells 
for 1 h at 37°C, while the other half of diluted supernatants was incubated with 10 IU/mL HIV-1BaL-
Renilla or the equivalent volume of no-virus control in phenol red-free DMEM for 1 h at 37°C. After 
this incubation, the control/virus-supernatant mixture was added to TZM-bl cells in the corresponding 
wells. After 72 h the cells on one plate were harvested in Bright-Glo luciferase lysis buffer as 
described in 2.8.1 and cells on the other plate were harvested for cell viability using the MTT assay as 
described in 2.8.2. Infection as RLU/MTT was calculated as for PBMCs (2.8.2). Relative infection 
was determined by setting the vehicle control (EtOH) in the presence of virus to 100% or as indicated 
in the figure legend. 
 
 
2.9 Immunofluorescence 
 
2.9.1 Slide preparation 
 
COS1 cells were seeded onto sterilized, acid-washed coverslips at 1.4 X 10
5
 cells/well in 6-well plates 
and allowed to adhere for 24 h. Cells were then transfected with 125 ng each pcDNA3.1-hGR, pSG5-
hPR-A and pMT-hPR-B using XtremeGENE-9 transfection reagent for 24 h, then stimulated with the 
indicated ligands for a further 24 h in SF-DMEM. Cells were then washed with ice cold 1 X PBS and 
fixed with ice cold methanol at -20°C for 10 min. After fixing, cells were washed again three times 
with cold 1 X PBS for 5 min, then blocked with 5% (w/v) BSA in PBS for 1 h at room temperature. 
Cells were then incubated with 1:250 anti-GR (H300, Santa Cruz Biotechnology), and 1:1000 anti-PR 
(NCL-LPGR-312, Leica Biosystems) antibodies diluted in 5% (w/v) BSA-PBS in a humidified 
chamber for 1 h at room temperature, followed by three washes in 1 X PBS for 5 min each. The 
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highest dilutions of antibodies that generated suitable fluorescent signals were established during pilot 
experiments. Cells were then incubated with 1:500 Alexa488-labelled anti-rabbit (to detect GR) and 
1:1000 Cy 3-labelled anti-mouse (to detect PR) antibodies in 5% (w/v) BSA-PBS in a humidified 
chamber in the dark for 1h at room temperature. Cells were washed three times in 1% (w/v) BSA-PBS 
for 5 min each, followed by staining with Hoechst in PBS (100 μg/mL) for 5 min. Coverslips were 
subsequently mounted onto glass slides with 45 μL mowiol (Calbiochem, Merck, South Africa) and 
dried overnight in the dark at room temperature. Slides were stored in the dark at 4°C prior to 
fluorescence visualization. 
 
 
2.9.2 Confocal microscopy 
 
Slides of COS1 cells from 3 independent experiments prepared in 2.9.1 were imaged at the Confocal 
and Light Microscope Unit, Department of Human Biology, University of Cape Town, using a Zeiss 
Axiovert 200M LSM 510 Meta NLO Confocal Microscope. Six to eight representative fields of view 
per condition (Vehicle, Dex, R5020, MPA) were captured, with approximately 1-30 cells per field of 
view. These images were analyzed for co-localization using Carl Zeiss ZEN software (Version 2009), 
and Manders correlation and overlap coefficients were recorded (Manders et al. 1993). The data 
represent the mean and SEM of all the transfected cells from all fields of view from the 3 independent 
experiments. 
 
 
2.9.3 Super-resolution structured illumination microscopy (SR-SIM) 
 
Slides of COS1 cells from 3 independent experiments prepared in 2.9.1 were re-imaged at the Central 
Analytical Facility Fluorescence Microscopy Unit at the University of Stellenbosch using a Zeiss 
LSM 780 ELYRA S1 microscope. Two to four representative high-resolution fields of view per 
condition (Vehicle, Dex, R5020, MPA) and 8-20 z-stacks (0.1 μm) per field of view were captured. 
Channel alignment was carried out using fluorescent beads #1783-455 (Tool for Calibration Multip 
Spek, Carl Zeiss Microscopy Gmbh) in order to ensure accurate analysis of co-localization. Images 
were recreated using a structured-illumination algorithm in ZEN 2011 (Carl Zeiss Microscopy 
Gmbh). Single channel images captured using ZEN 2011 were converted to .tiff files for a 
representative z-stack per image and these files were then processed into 8-bit format using ImageJ. 
Co-localization analysis was carried out using the Just Another Co-localization Plug-in (JACoP) tool 
in ImageJ (Bolte and Cordelieres 2006). The data represent the mean and SEM of all the fields of 
view per condition, per independent experiment. 
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2.10 Statistical analysis 
 
All statistical tests were performed using GraphPad Prism software (version 7) and are indicated, as 
well as n values indicating number of independent experiments, in the figure legends,. All data were 
first analysed for normal distribution using a D’Agostino and Pearson normality test for experiments 
with n values of 8 or more, or a Shapiro Wilk normality test for experiments with n values less than 8. 
Normally distributed data were analyzed using either one-way ANOVA with either Dunnett’s 
(compared to control sample) or Tukey’s (compared to every other sample) post tests for multiple 
comparisons or unpaired t tests for comparisons between two samples. Non-normally distributed data 
was analysed using a non-parametric Kruskal-Wallis test (non-parametric one-way ANOVA) with 
Dunn’s post-test (compared to control sample) for multiple comparisons or a Wilcoxon signed-rank 
test for comparisons between two samples. For some molecular data such as western blot 
densitometry and pilot experiments (Appendix B), less stringent tests (unpaired t tests or Wilcoxon 
signed-rank tests) were used. All grouped data sets, that is where each condition was in triplicate or 
quadruplicate, were analyzed using two-way ANOVA with either Dunnett’s or Tukey’s post tests for 
multiple comparisons, since this version of GraphPad Prism does not offer a non-parametric two-way 
ANOVA. Graphs are plotted as mean ± SEM and the variation between independent experiments is 
represented by the spread of the black dots, indicating individual experiments. 
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Chapter 3 
Both MPA used in injectable contraception and exogenous hormones 
mimicking different phases of the menstrual cycle increase HIV-1 infection, 
but via potentially different mechanisms 
 
 
3.1 Background and aims 
 
Since MPA is derived from P4 and was designed to imitate the biological actions of P4, MPA prevents 
pregnancy by mimicking the high-P4 state of the luteal phase of the menstrual cycle. Both MPA and 
the luteal phase have been linked to increased susceptibility to HIV-1 infection. However, there is 
limited research directly comparing the effects of both menstrual cycle hormones and MPA on HIV-1 
infection. 
 
Therefore, the aims of this section were to answer the following research questions: 
(i) Do exogenous hormones mimicking the menstrual cycle phases or contraception with MPA 
increase HIV-1 infection? 
(ii) Do hormones mimicking the menstrual cycle phases or contraception with MPA affect 
regulation of biomarkers likely relevant to HIV-1 infection and immune function? 
 Do menstrual cycle hormones and MPA differentially regulate  
o immune cell populations and their activation? 
o  co-receptor expression? 
o immunomodulatory gene expression? 
(iii) Are the effects on HIV-1 infection between menstrual cycle hormones and MPA mediated by 
the GR? 
 Do hormones mimicking the menstrual cycle phases or contraception with MPA 
change GR levels, thereby increasing HIV-1 infection? 
To answer these questions, human PBMCs were used as a model for the circulatory system and TZM-
bl human as a model of infectable cervical cells. These cells were stimulated with exogenous hormone 
combinations of E2 and P4 to mimic the phases of the menstrual cycle – referred to hereafter as “luteal 
phase E2/P4” (10 nM P4 + 400 pM E2), or “follicular phase E2/P4” (1 nM P4 + 400 pM E2), – or with 100 
nM MPA to represent near-peak serum levels of contraception with the injectable DMPA. Cells were 
infected with the R-tropic HIV-1 infectious molecular clone, HIV-1BaL_Renilla using luciferase assays as 
a proxy for HIV-1 infection. 
 
58 
 
 
 
3.2 Luteal phase E2/P4 and MPA increase HIV-1 infection in PBMCs 
 
In order to assess the effect of menstrual cycle hormones or MPA on systemic HIV-1 infectivity, 
PBMCs from female donors stimulated with exogenous E2/P4 mimicking the luteal phase or follicular 
phase or with exogenous MPA for 2 or 7 days were infected with HIV-1BaL_Renilla. A significant 3-fold 
increase in HIV-1 infection was observed comparing the absence (no-virus control) to the presence of 
virus (HIV-1BaL_Renilla) (Appendix B, Fig. B1.1). Since there were no differences in relative luciferase 
activity between the no-virus control for each stimulation condition at either day (Appendix B, Fig. 
B1.1), only the vehicle control from Day 2 is shown as a representative in Fig. 3.2.1.  
 
Stimulation with luteal phase E2/P4 significantly increased HIV-1 infection at 7 days (5.3-fold, Fig 
3.2.1). Stimulation with MPA significantly increased HIV-1 infection at both 2 (12.3-fold) and 7 days 
(7.4-fold), with a greater fold increase than for the menstrual cycle phases (at 2 days: 5.4-fold greater 
than luteal phase, 5-fold greater than follicular phase; at 7 days: 1.4-fold greater than luteal phase, 12-
fold greater than follicular phase; Fig. 3.2.1). HIV-1 infection for the vehicle control at 7 days was 
significantly greater than the vehicle control at 2 days, thereby indicating productive infection was 
achieved (Appendix B, Fig. B1.2). 
 
The large variability in relative infection in PBMCs was not due to changes in cell viability but 
appears to reflect inherent biological variation in infection between experiments (Appendix B, Table 
B1). 
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Figure 3.2.1. HIV-1 infection in PBMCs increases in response to luteal phase E2/P4 and MPA. 
PBMCs were seeded at 4 X 10
6
 in FACS tubes and stimulated for 2 or 7 days with hormones representing the 
luteal phase (10 nM P4 + 400 pM E2), follicular phase (1 nM P4 + 400 pM E2) or peak levels of the injectable 
contraceptive MPA (100 nM). PBMCs were subsequently infected with 10 IU/mL HIV-1BaL_Renilla (HIV-BaL) or 
equivalent volume of no-virus control (labelled as Virus control) for 2 h, washed and re-suspended in ligand-
free full RPMI for 5 days. Cells were re-seeded in round-bottom 96 well plates in quadruplicate wells per 
condition at 2 X 10
5
 cells/well and harvested for Renilla luciferase (infection) and for cell viability (MTT). The 
results show pooled data from at least 3 independent experiments, with 2-3 PBMC donors each, for a total of 7 
independent donors. Relative infection was calculated as Renilla luciferase (RLU) divided by average 
absorbance at 595nm (MTT) for the quadruplicate wells. Infection was plotted relative to each day’s vehicle 
control in the presence of virus set to 100%. Statistical comparisons were carried out using a two-way ANOVA 
with Dunnett’s multiple comparisons post test. Stars above bars indicate significance compared to own vehicle 
control in the presence of virus, with **** indicating p<0.0001. 
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3.3 Menstrual cycle phase hormones and MPA differentially regulate markers likely 
relevant to HIV-1 infection and immune function 
 
Since both luteal phase E2/P4 and MPA significantly increased HIV-1 infection in PBMCs, with MPA 
increasing HIV-1 infection to a greater extent, the potential mechanisms of infection were further 
investigated in PBMCs and TZM-bl cells. Owing to their established or suggested roles in HIV-1 
infection, the variables investigated were (i) the frequency of HIV-1 target immune cell populations in 
PBMCs, (ii) the expression of the CD4 receptor and co-receptors CCR5 and CXCR4, (iii) a marker 
for early immune activation, CD69, and (iv) the expression of the pro-inflammatory cytokine IL-6. 
 
 
3.3.1 Menstrual cycle phase hormones and MPA differentially regulate the frequency of 
immune cell populations and their activation in PBMCs 
 
The frequency of CD3+, CD4+ and CD8+ T-lymphocytes and CD14+ monocytes and the density i.e.  
expression of these receptors was assessed by flow cytometry in PBMCs stimulated for 7 days with 
MPA or luteal/follicular phase E2/P4. Additionally the frequency and expression of the activation 
marker CD69 was investigated within these immune cell populations. The ratio of CD4+ to CD8+ cell 
frequency was calculated for total cells, CD69+ and CCR5+ cells. The combined raw data (mean, 
SEM) for the frequency of cells expressing CD3, CD4, CD8, CD14, CD69, CCR5 and CD4/CD8 
ratio, and expression of CD3/4/8/14, CD69 and CCR5 on T cells and monocytes are shown in Table 
3.3.1.1 and 3.3.1.2, respectively. 
 
Stimulation with MPA, unlike luteal or follicular phase E2/P4, significantly increased the frequency of 
CD4+ T-lymphocytes 1.1-fold and decreased the frequency of CD8+ T-lymphocytes 1.35-fold (Fig. 
3.3.1.1a). However none of the hormone combinations changed the frequency of CD3+ or CD14+ 
cells (Fig. 3.3.1.1a, Table 3.3.1.1) nor the frequency of CD69-expressing T-cells, but MPA 
significantly decreased the frequency of activated CD69+CD14+ monocytes (Fig. 3.3.1.1b, Table 
3.3.1.1). MPA, but not luteal/follicular phase E2/P4, significantly increased the CD4/CD8 ratio 1.5-
fold in CD3+ cells (Fig. 3.3.1.1c) and CD69+CD3+ cells (Fig. 3.3.1.1d). 
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Figure 3.3.1.1. MPA, unlike luteal or follicular phase E2/P4, increases the frequency of CD4+ T 
cells, decreases the frequency of total  CD8+ T cells and activated CD14+CD69+ monocytes in 
PBMCs, and increases the CD4/CD8 ratio in total and CD69+ cells, while follicular phase E2/P4 
decreases the frequency of activated CD8+CD69+ T cells. PBMCs were seeded at 4 X 106 in FACS 
tubes and stimulated for 7 days with hormones representing the luteal phase (10 nM P4 + 400 pM E2), follicular 
phase (1 nM P4 + 400 pM E2) or peak levels of the injectable contraceptive MPA (100 nM). PBMCs were 
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subsequently stained with conjugated antibodies specific for the relevant markers, fixed and then sorted by flow 
cytometry. Samples were gated as shown in Appendix C to exclude dead cells and separating cell populations 
using Fluorescence Minus One (MFO) controls for CD14, CCR5 and CD69. The results are pooled from 2 
independent experiments, with 4 donors each, for a total of 8 independent donors. Data are plotted as frequency 
of cell populations (a), frequency of CD69+ cell populations (b), or relative ratio of CD4+ to CD8+ cell 
frequency for total (c) or CD69+ (d) cells, and are plotted relative to the vehicle control set to 1. Statistical 
comparisons were carried out using a parametric one-way ANOVA with Dunnett’s multiple comparisons post 
test (a: CD3, CD8, CD14; b: CD3, CD14; c; d) or a non-parametric Kruskal-Wallis test with Dunn’s multiple 
comparisons post test (a: CD4; b: CD4, CD8). Stars above bars indicate significance compared to own vehicle 
control, with ****, ***, ** and * indicating p<0.0001, p<0.001, p<0.01 and p<0.05 respectively. 
 
 
Whereas the frequency looks at the percentage of cells expressing at least one of the above markers, 
expression levels account for the number (or density) of markers expressed between the immune cell 
populations. The expression of these same markers was calculated from the median fluorescent 
intensity score per number of cells expressing the relevant markers, generated by FlowJo software. 
 
MPA, unlike the menstrual cycle hormones, significantly decreased the expression of CD3, CD4 and 
CD8, while no change was observed for CD14 (Fig. 3.3.1.2a). For the activation marker CD69, no 
differences were observed with luteal or follicular phase E2/P4, but stimulation with MPA 
significantly increased the expression of CD69 in CD4+ T-lymphocytes 1.14 fold (Fig. 3.3.1.2b). 
 
Together these results suggest that increased HIV-1 infection with MPA could be due to increased 
frequency of CD3+CD4+ T-cells and decreased frequency of CD3+CD8+ T-cells (that is, increased 
CD4/CD8 ratio) and increased activation of CD4+ T cells through CD69 expression, thereby 
enhancing their potential for infection.  
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Figure 3.3.1.2. MPA, unlike luteal or follicular phase E2/P4, decreases CD3, CD4 and CD8 
expression, but increases the expression of CD69 in activated CD4+CD69+ T-lymphocytes in 
PBMCs. PBMCs were seeded at 4 X 106 in FACS tubes and stimulated for 7 days with hormones representing 
the luteal phase (10 nM P4 + 400 pM E2), follicular phase (1 nM P4 + 400 pM E2) or peak levels of the injectable 
contraceptive MPA (100 nM). PBMCs were subsequently stained, fixed and then sorted by flow cytometry. 
Samples were gated and analyzed as per Appendix C. The results are pooled from 2 independent experiments, 
with 4 donors each, for a total of 8 independent donors. CD3, 4, 8 or 14 (a) or CD69 (b) expression (MFI) was 
plotted relative to the vehicle control set to 1. Statistical comparisons were carried out using a parametric one-
way ANOVA with Dunnett’s multiple comparisons post test (a: CD4, CD8; b: CD3, CD4, CD14) or a non-
parametric Kruskal-Wallis test with Dunn’s multiple comparisons post test (a: CD3, CD14; b: CD8). Stars 
above bars indicate significance compared to own vehicle control, with ***, ** and * indicating p<0.001, 
p<0.01 and p<0.05 respectively. 
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3.3.2  Menstrual cycle phase hormones and MPA differentially regulate CCR5 co-receptor 
expression in PBMCs and TZM-bl cells 
 
The frequency of CD3+, CD4+ and CD8+ T-lymphocytes and CD14+ monocytes expressing the 
HIV-1 co-receptor CCR5, and expression levels of CCR5 on these cells were also assessed by flow 
cytometry in PBMCs stimulated for 7 days with luteal or follicular phase E2/P4 or MPA. 
 
Stimulation with MPA, unlike luteal or follicular phase E2/P4, showed a 2-fold numerical increase in 
the frequency of CCR5-expressing CD3+ and CD4+ cells that did not reach statistical significance 
(Fig. 3.3.2.1a). The CD4/CD8 frequency ratio in CCR5+ cells was not significantly different between 
the hormone stimulations and the vehicle control (Fig. 3.3.2.1b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.2.1. MPA, unlike luteal or follicular phase E2/P4, appears to increase the frequency of 
CCR5+ cells in PBMCs. PBMCs were seeded at 4 X 106 in FACS tubes and stimulated for 7 days with 
hormones representing the luteal phase (10 nM P4 + 400 pM E2), follicular phase (1 nM P4 + 400 pM E2) or 
peak levels of the injectable contraceptive MPA (100 nM). PBMCs were subsequently stained, fixed and then 
sorted by flow cytometry. Samples were gated and analyzed as per Appendix C. The results are pooled from 2 
independent experiments, with 4 donors each, for a total of 8 independent donors. Frequency of CCR5+ cell 
populations (a) and relative ratio of CD4+ to CD8+ cell frequency for CCR5+ cells (b) was plotted relative to 
the vehicle control set to 1. Statistical comparisons were carried out using a non-parametric Kruskal-Wallis test 
with Dunn’s multiple comparisons post test. No significant differences were observed, but p values above bars 
indicate a comparison to each vehicle control.  
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Stimulation with MPA, unlike luteal or follicular phase E2/P4, significantly increased the expression 
of the HIV-1 co-receptor CCR5 in CD4+ (1.32-fold) and CD3+ T-lymphocytes (1.44-fold, Fig. 
3.3.2.2). Although not significant, there appeared to be a trend for increased CCR5 expression in 
CD8+ T-lymphocytes (2 donors reaching 2-fold) (Fig. 3.3.2.2). CCR5 expression was not altered in 
CD14+ monocytes (Fig. 3.3.2.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.2.2. MPA, unlike luteal or follicular phase E2/P4, increases the expression of CCR5 in 
CD3+, CD4+ and CD8+ T-lymphocytes in PBMCs. PBMCs were seeded at 4 X 106 in FACS tubes and 
stimulated for 7 days with hormones representing the luteal phase (10 nM P4 + 400 pM E2), follicular phase (1 
nM P4 + 400 pM E2) or peak levels of the injectable contraceptive MPA (100 nM). PBMCs were subsequently 
stained, fixed and then sorted by flow cytometry. Samples were gated and analyzed as per Appendix C. The 
results are pooled from 2 independent experiments, with 4 donors each, for a total of 8 independent donors. 
CCR5 expression (MFI) was plotted relative to the vehicle control set to 1. Statistical comparisons were carried 
out using a parametric one-way ANOVA with Dunnett’s multiple comparisons post test (CD3, CD4, CD14) or 
non-parametric Kruskal-Wallis test with Dunn’s multiple comparisons post test (CD8). Stars above bars indicate 
significance compared to own vehicle control, with **** and *** indicating p<0.0001 and p<0.001, 
respectively.  
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Table 3.3.1.1. Frequencies of total, CD69+ and CCR5+ cells expressing the markers CD3, CD4, 
CD8 (T-lymphocytes) or CD14 (monocytes).  
 
Immune cell phenotype: 
Frequency 
Vehicle Luteal Follicular MPA 
Mean SEM Mean SEM Mean SEM Mean SEM 
CD3+ (% total) 79.70 3.57 79.98 3.10 76.71 3.75 73.13 3.90 
CD3+CD69+ 5.63 0.96 5.73 1.07 5.05 0.88 6.16 0.53 
CD3+CCR5+ 23.44 5.23 24.66 5.61 23.36 4.81 32.24 4.06 
CD4+ (% total) 63.43 4.63 63.84 4.75 62.06 4.57 67.43 4.13 
CD4+CD69+ 6.84 0.92 6.98 0.92 6.16 0.52 9.44 1.32 
CD4+CCR5+ 21.03 4.47 22.68 5.27 21.71 4.32 28.98 3.55 
CD8+ (% total) 27.35 4.03 27.13 4.29 26.83 4.38 21.37 4.37 
CD8+CD69+ 6.38 0.97 5.98 1.03 5.31 0.78 6.33 0.82 
CD8+CCR5+ 47.55 8.44 48.91 8.64 47.24 8.12 53.15 6.57 
CD14+ (% total) 36.81 13.52 34.14 12.43 35.38 12.98 35.05 13.19 
CD14+CD69+ 29.98 1.73 33.11 1.32 31.71 2.79 19.19** 1.81 
CD14+CCR5+ 72.06 8.93 72.91 7.75 75.05 7.4 79.60 5.14 
CD4/CD8 ratio (total) 3.16 0.94 3.23 0.93 3.18 0.90 4.84 1.28 
CD4/CD8 ratio: CD69+ 1.33 0.35 1.41 0.33 1.41 0.30 1.65 0.24 
CD4/CD8 ratio: CCR5+ 0.43 0.05 0.44 0.07 0.47 0.08 0.58 0.11 
 
 
Mean and SEM are shown as percentages, not normalized to fold change, and were calculated from 8 
independent donors. CD69+ and CCR5+ cells are frequencies of the cells expressing CD3, CD4, CD8 or CD14. 
Statistical comparisons were carried out using either a parametric one-way ANOVA with Dunnett’s post test 
(CD3+CD69+, CD3+CCR5+, CD4+, CD8+, CD8+CD69+, CD8+CCR5+, CD14+CD69+) or a non-parametric 
Kruskal-Wallis test with Dunn’s post test (CD3+, CD4+CD69+, CD4+CCR5+, CD14+, CD14+CCR5+, 
CD4/CD8-total, CD4/CD8-CD69, CD4/CD8-CCR5). Stars next to values indicate significance compared to 
own vehicle control, with ** indicating p<0.01. Where the fold changes (relative to vehicle) were significantly 
different, as shown in Fig. 3.3.1.1 and 3.3.2.1, the values in the table are in bold. ** p<0.01. 
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Table 3.3.1.2. Expression of CD69 and CCR5 in cells expressing the markers CD3, CD4, CD8 
(T-lymphocytes) or CD14 (monocytes).  
 
Immune cell 
phenotype:  
Expression 
Vehicle Luteal Follicular MPA 
Mean SEM Mean SEM Mean SEM Mean SEM 
CD3 9039.00 476.50 8915.00 461.30 8535.00 602.20 6946.00* 422.90 
CD3+CD69+ 4178.00 431.60 4056.88 451.60 4028.75 444.60 4023.50 340.00 
CD3+CCR5+ 2609.25 142.70 2579.63 128.50 2621.75 140.40 3551.38** 245.00 
CD4 8333.00 596.90 8241.00 659.40 8098.00 690.00 6659.00 358.90 
CD4+CD69+ 2170.75 234.00 2206.63 219.00 2196.00 242.00 2328.38 240.20 
CD4+CCR5+ 2496.38 104.00 2516.50 149.60 2539.25 140.30 3533.63** 278.50 
CD8 44095.00 8157.00 43658.00 8328.00 42219.00 8429.00 32038.00 5220.00 
CD8+CD69+ 4972.75 550.60 4770.13 524.00 5032.38 590.60 4499.50 318.60 
CD8+CCR5+ 1193.38 146.90 1197.50 141.60 1170.75 116.80 1650.50 263.50 
CD14 2354.00 274.60 2432.00 339.90 2336.00 287.40 2221.00 309.20 
CD14+CD69+ 4202.75 122.00 4163.75 217.70 4069.50 302.20 3725.00 403.20 
CD14+CCR5+ 5203.88 1223.00 5345.88 1333.00 4970.75 1107.00 4803.25 1012.00 
 
 
Mean and SEM represent the median fluorescent intensities, not normalized to fold change, of either CD69 or 
CCR5 expressed on double-positive cells and were calculated from 8 independent donors. Statistical 
comparisons were carried out using either a parametric one-way ANOVA with Dunnett’s post test (CD3, 
CD3+CCR5+, CD4, CD4+CD69+, CD4+CCR5+, CD8, CD14+CD69+) or a non-parametric Kruskal-Wallis test 
with Dunn’s post test (CD3+CD69+, CD8+CD69+, CD8+CCR5+, CD14, CD14+CCR5+). Stars next to values 
indicate significance compared to own vehicle control, with ** and * indicating p<0.01 and p<0.05 respectively. 
Where the fold changes (relative to vehicle) were significantly different, as shown in Fig. 3.3.1.2 and 3.3.2.2, 
the values in the table are in bold. ** p<0.01, * p<0.05. 
 
 
 
Using the modified cervical carcinoma cell line, TZM-bl, as a model in which to study the biological 
mechanisms of infection, gene expression of the host receptor/co-receptors involved in HIV-1 
infection, CD4, CXCR4 and CCR5 was assessed. This was carried out using real-time qPCR in 
response to hormones mimicking the luteal or follicular phases of the menstrual cycle or 
contraception with the injectable MPA for 2 days. 
 
TZM-bl cells stimulated with MPA but not luteal or follicular phase E2/P4 significantly up-regulated 
CCR5 mRNA levels 1.5-fold (Fig. 3.3.2.3a) and significantly increased CD4 mRNA levels 1.6-fold 
(Fig. 3.3.2.3b). Interestingly, MPA but not luteal or follicular phase E2/P4 appeared to down-regulate 
expression of CXCR4 (Fig. 3.3.2.3c), the co-receptor utilized during infection with X-tropic viruses, 
although this was not significant. 
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Figure 3.3.2.3. MPA, unlike luteal or follicular phase E2/P4, up-regulates the total mRNA 
expression of CCR5 and CD4 but down-regulates the expression of CXCR4 in TZM-bl cells. 
TZM-bl cells were seeded at 1 X 10
5
 cells/well in 12 well plates and allowed to adhere overnight. Cells were 
then stimulated with hormones representing the luteal phase (10 nM P4 + 400 pM E2), follicular phase (1 nM P4 
+ 400 pM E2) or peak levels of the injectable contraceptive MPA (100 nM) in SF-DMEM for 48 h. Cells were 
washed and RNA was extracted. cDNA was synthesized from 500 ng RNA then used in quantitative RT real-
time qPCR. Relative mRNA levels of CCR5 (a), CD4 (b) and CXCR4 (c) were normalized to GAPDH mRNA 
levels. Relative expression was determined by normalizing to the vehicle control set to 1. The results are pooled 
from 3 independent experiments. Statistical comparisons were carried out using a parametric one-way ANOVA 
with Dunnett’s multiple comparisons post test. Stars above bars indicate significance compared to own vehicle 
control, with *** and ** indicating p<0.001 and p<0.01 respectively. 
 
 
Together, these results suggest that contraception with MPA, unlike the P4-dominant luteal phase of 
the menstrual cycle, may increase HIV-1 infection through up-regulating the frequency of HIV-1 
target CD4+ T cells, and down-regulating the frequency of cytotoxic CD8+ T cells. The consequent 
increase in the CD4/CD8 ratio implies that enhanced infection can occur through increased 
proportions of cells being infected with HIV-1 relative to cells that can fight HIV-1 infection. 
Furthermore, MPA, unlike menstrual cycle hormones, may increase HIV-1 infection by increasing 
expression of CD69 on activated CD4+ T-lymphocytes in PBMCs, and increasing expression of the 
HIV-1 co-receptor CCR5 in both PBMCs and TZM-bl cells. 
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3.3.3 Menstrual cycle phase hormones and MPA differentially regulate pro-inflammatory IL-
6 gene expression in PBMCs and TZM-bl cells 
 
Although it is not established whether DMPA use is associated with increased or decreased levels of 
inflammatory markers, most studies in cell lines suggest that MPA is immunosuppressive (see section 
1.4.3). In order to explore this further using the pro-inflammatory cytokine IL-6 as a marker for 
inflammation, IL-6 mRNA levels in response to MPA and menstrual cycle phase hormones were 
investigated in PBMCs and TZM-b cells. 
 
In PBMCs, stimulation with MPA but not luteal or follicular phase E2/P4 for 2 days significantly 
decreased IL-6 mRNA levels 2.6-fold (Fig. 3.3.3.1a). A similar decrease of 1.8-fold was observed at 7 
days, although this was not significant (Fig. 3.3.3.1a). Like PBMCs, TZM-bl cells stimulated with 
MPA but not luteal or follicular phase E2/P4 for 2 days also significantly decreased IL-6 mRNA levels 
3.5-fold (Fig. 3.3.3.1b). In both PBMCs and TZM-bl cells, the repression of IL-6 by MPA was also 
significantly different to luteal phase E2/P4 (Fig. 3.3.3.1). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.3.1. MPA, unlike luteal or follicular phase E2/P4, represses the expression of IL-6 in 
PBMCs and TZM-bl cells. PBMCs (a) were seeded at 4 X 106 in FACS tubes and stimulated for 2 or 7 days 
in full RPMI, while TZM-bl cells (b) were seeded at 1 X 10
5
 cells/well in 12 well plates and stimulated for 2 
days in SF-DMEM. Hormones represent the luteal phase (10 nM P4 + 400 pM E2), follicular phase (1 nM P4 + 
400 pM E2) or peak levels of the injectable contraceptive MPA (100 nM). Upon harvesting, PBMCs (a) were 
pelleted by centrifugation. PBMCs and TZM-bl cells were washed, RNA was extracted and cDNA was 
synthesized from 500 ng RNA then used in quantitative RT real-time qPCR. Relative mRNA levels of IL-6 
were normalized to GAPDH mRNA levels. Relative expression was determined by normalizing to the vehicle 
control set to 1. The results are pooled from 3 (TZM-bl and PBMCs Day 7) or 4 (PBMCs Day 0-2) independent 
experiments. Statistical comparisons were carried out using a parametric one-way ANOVA with Tukey’s 
multiple comparisons post test. Stars above bars indicate significance compared to each vehicle control unless 
otherwise indicated by lines, with *** and ** indicating p<0.001 and p<0.01 respectively.  
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Together these results suggest that contraception with MPA, unlike the P4-dominant luteal phase of 
the menstrual cycle, may promote an anti-inflammatory response in both PBMCs and TZM-bl cells. 
 
 
3.4 The GR is required for the increased HIV-1 infection in response to MPA, but not 
menstrual cycle phase hormones  
 
The GR is a major regulator of the immune system and inflammatory processes. It has been 
established that both MPA and P4 bind to the GR, with MPA having a much higher relative binding 
affinity than P4 (see section 1.4.1). In order to investigate whether GR is required for enhanced HIV-1 
infection observed for both luteal phase E2/P4 and MPA, GR protein levels and the effects of GR 
antagonism on HIV-1 infection in PBMCs were assessed.  
 
 
3.4.1 Increased HIV-1 infection in response to stimulation with MPA but not luteal or 
follicular phase E2/P4 is mediated via the GR 
 
The role of the active GR in changing HIV-1 infection in response to luteal or follicular phase E2/P4 or 
MPA was assessed by co-stimulating PBMCs with the GR/PR antagonist, RU486. Since PBMCs only 
express the GR but not the PR [Appendix A, Fig. A1.1, and (Tomasicchio et al. 2013)], the effects of 
RU486 in these experiments are likely to represent the antagonism of GR only. 
 
Similar to earlier data (Fig. 3.2.1), stimulation with luteal phase E2/P4 (1.5-fold) and MPA (2.7-fold) 
for 7 days significantly increased HIV-1 infection in PBMCs, while the apparent increase (1.4-fold) 
observed with follicular phase E2/P4 was not significant (Fig. 3.4.1.1).  
 
In the absence of exogenous hormones, co-stimulation with RU486 significantly increased HIV-1 
infection 5.6-fold (Fig. 3.4.1.1a), suggesting that RU486 is a partial agonist for infection.  
Furthermore, the increased HIV-1 infection observed with MPA, but not luteal phase E2/P4, was 
significantly repressed 2-fold when co-stimulated with RU486 (Fig. 3.4.1.1b). This effect was also 
observed when HIV-1 infection was plotted from only the PBMC donors showing increased infection 
with MPA (“MPA responders”, Appendix B, Fig. B1.3). Together, these data suggest that MPA-
induced HIV-1 infection requires the active GR, but that unliganded GR protects against infection in 
the absence of exogenous hormones. 
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Figure 3.4.1.1. The GR antagonist RU486 represses the MPA- but not luteal phase E2/P4-
induced increase in HIV-1 infection in PBMCs. PBMCs were seeded at 4 X 106 in FACS tubes and 
stimulated for 7 days with hormones representing the luteal phase (10 nM P4 + 400 pM E2), follicular phase (1 
nM P4 + 400 pM E2) or peak levels of the injectable contraceptive MPA (100 nM). PBMCs were subsequently 
infected with 10 IU/ml HIV-1BaL_Renilla (HIV-BaL) or equivalent volume of no-virus control (labelled as Virus 
control) for 2 h, washed and re-suspended in ligand-free full RPMI for 5 days. Cells were re-seeded in round-
bottom 96 well plates in quadruplicate wells per condition at 2 X 10
5
 cells/well and harvested for Renilla 
luciferase (infection) and for cell viability. The results show pooled data from at least 4 independent 
experiments, with 2-3 PBMC donors each, for a total of 11 independent donors for both – and + RU486. 
Additionally, the HIV-1 infection data for 7 days’ stimulation from Fig. 3.2.1 was included in the –RU486 data 
set in (a) (n=18). Relative infection was calculated as Renilla luciferase (RLU) divided by average absorbance at 
595nm (MTT) for the quadruplicate wells. Infection was plotted relative to the vehicle control in the presence of 
virus but the absence of RU486 (-RU486) set to 100% in (a) and both vehicle controls (±RU486) in the presence 
of virus set to 100% in (b). Statistical comparisons were carried out using a two-way ANOVA with Dunnett’s 
(a) or Tukey’s (b) multiple comparisons post test, indicated by stars (*), or a Wilcoxon test, indicated by letters 
(a-d). Stars above bars indicate significance compared to the vehicle control in the presence of virus but absence 
of RU486, unless otherwise indicated by lines. Letters above bars indicate significance for the comparison 
indicated by lines, with ****/a, ***/b, **/c and */d indicating p<0.0001, p<0.001, p<0.01 and p<0.05 
respectively. 
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3.4.2 GR protein levels are decreased in response to MPA but not menstrual cycle phase 
hormones in PBMCs 
 
It has previously been demonstrated that the agonist ligand-activated GR undergoes ligand-dependent 
turnover (Hoeck et al. 1989, Bellingham et al. 1992, Oakley and Cidlowski 1993). Since previous 
research from the present author’s laboratory has shown that MPA acts like a glucocorticoid 
(Koubovec et al. 2004, Avenant et al. 2010b, Tomasicchio et al. 2013, Govender et al. 2014, Hapgood 
et al. 2014b), it would be expected that, as a proof of GR involvement, MPA would promote a 
decrease in GR protein levels. Therefore the levels of GR protein in PBMCs were assessed in 
response to stimulation with luteal or follicular phase E2/P4 or MPA. 
 
Total protein was harvested from matched samples during PBMC infection assays (Fig. 3.2.1) and 
was probed for GR protein levels by western blotting (Fig. 3.4.2.1a, b). The representative western 
blot indicates that GR protein levels were lower when stimulated with MPA but not luteal or follicular 
phase E2/P4. However when the western blots from all donors were pooled together and analyzed by 
densitometry, the large variability between experiments suggests the differences in GR protein levels 
are not significant (Fig. 3.4.2.1b).  
 
In order to confirm that the effects with MPA were via the GR only, it was assessed whether PR 
protein was possibly up-regulated in PBMCs. Following reports that PR protein has been detected in 
PBMCs (Asin et al. 2008, Cabrera-Munoz et al. 2012) and the knowledge that PR expression is 
regulated by E2 (Kastner et al. 1990), it was attempted to promote PR protein expression in PBMCs 
by stimulation with the exogenous luteal phase E2/P4 for 7 days. However, as shown by the 
representative western blot, this combination of E2 and P4 did not up-regulate the endogenous PR 
(Fig. 3.4.2.1c).  
 
The above results suggest that in response to MPA, HIV-1 infection increases in PBMCs, in a manner 
involving the active GR, since GR protein levels appeared to be decreased with MPA stimulation. In 
contrast, luteal phase E2/P4 increases HIV-1 infection in PBMCs, but this appears to not be mediated 
by the GR, and GR protein levels were unaffected. The results further imply that MPA, but not 
menstrual cycle hormones, promotes an anti-inflammatory response by repressing expression of IL-6. 
In combination with the other data showing that MPA increases the CD4/CD8 ratio in total and 
CD69+ cells, CCR5 expression and the frequency of activated CD4+CD69+ T cells, the results from 
this chapter imply that MPA and the luteal phase increase HIV-1 infection via different mechanisms. 
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Figure 3.4.2.1. GR protein levels appear to decrease in PBMCs stimulated with MPA but not 
luteal or follicular phase E2/P4. (a, b) PBMCs were seeded at 4 X 10
6
 in FACS tubes and stimulated with 
hormone combinations representing the luteal phase (10 nM P4 + 400 pM E2), follicular phase (1 nM P4 + 400 
pM E2) or peak levels of the injectable contraceptive MPA (100 nM). From matched samples at Day 0, 2, 7 and 
12, 8 million PBMCs were pelleted and harvested for total protein using TAPS buffer. Total protein lysates were 
analyzed for GR protein levels by western blotting using GAPDH as a loading control. Blots were scanned and 
quantified for relative GR levels by calculating integrated density values. (a) Representative western blot from 
donor #9937. Apparent very differences in GR band sizes may be due to pH effects of the TAPS buffer from 
protein isolation or limited differential proteolysis. If this effect is due to different degrees of GR protein 
degradation, use of proteasomal inhibitors such as MG-132 may reverse the effect in future work.  (b) 
Densitometry indicating GR protein relative to GAPDH protein, pooled from 7 independent donors. GR levels 
are plotted relative to the vehicle control at Day 2 set to 100 %. (c) PBMCs (8 million) from 3 independent 
donors (#5209, #6591, #7186) were stimulated with hormone combinations representing the luteal phase (10 nM 
P4 + 400 pM E2) for 0, 2 or 7 days then pelleted and harvested for total protein using TAPS buffer. Lysates were 
analyzed for PR protein levels by western blotting using GAPDH as a loading control. (b) Statistical 
comparisons were carried out using a non-parametric Kruskal-Wallis test with Dunn’s multiple comparisons 
post test. No significant differences were observed, but p values above bars indicate a comparison to each day’s 
vehicle control. 
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Chapter 4 
MPA-induced and basal HIV-1 infection and immunomodulatory gene 
expression change when the relative levels of GR and PR are altered 
 
 
4.1 Background and aims 
 
It has previously been shown that of the steroid receptors, only GR is detectable in PBMCs (Appendix 
A, Fig. A1.1) while GR and AR are detectable in TZM-bl cells (Appendix A, Fig. A2.1). However, 
tissues at the site of infection in the FRT express other steroid receptors; importantly the PR. 
Expression of PR is under the control of the fluctuating levels of E2 during the menstrual cycle. Since 
both GR and PR are activated by MPA, this raises the question whether these receptors can be 
activated at the same time in the FRT of DMPA users, and whether HIV-1 infection in the FRT is 
modulated by the levels of these receptors.  
 
Expression of both GR and PR protein in ectocervical explant tissue from premenopausal women in 
the luteal and follicular phase was confirmed by western blotting (Appendix B, Fig. B2.1, Appendix 
D, Table D1). In the samples with high detectable levels of total protein, as shown by GAPDH levels, 
there appeared to be some differences in GR/PR levels between the luteal and follicular phases 
(Appendix B, Fig. B2.1, Appendix D, Table D1). However, a pattern was difficult to deduce. This 
variation in protein levels could reflect biological inter-individual differences in protein levels, 
differences in relative composition of cell types, different durations of sample storage (Appendix D, 
Table D1) and/or differences in protein degradation during sample processing. Nevertheless, other 
research from the present author’s laboratory (Ray 2015) observed higher levels of PR in ectocervical 
explants from the follicular phase compared to the luteal phase (Appendix A, Fig. A3.1), suggesting 
that the relative levels of GR/PR change during the menstrual cycle.  
 
Furthermore, in cervical explants from postmenopausal women, in which endogenous E2/P4 levels are 
both much lower than in premenopausal women (Appendix D, Table D1), both GR and PR protein 
were detectable by western blotting in both endo- and ectocervix (Appendix B, Fig. B2.2), Despite 
high inter-individual variation in protein expression, greater PR levels were detectable in the 
endocervix than ectocervix samples (Appendix B, Fig. B2.2), suggesting that the relative GR/PR 
levels change depending on the cervical compartment, at least in postmenopausal samples.  
 
Together these results imply that the relative GR/PR levels in cervical tissue ex vivo vary depending 
on the menstrual cycle and menopausal status. However the consequences of changing GR/PR levels 
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on immune function and HIV-1 susceptibility have not been studied. Therefore a molecular 
manipulation of GR/PR levels by siRNA knockdown and over-expression strategies was established 
in human cell lines in order to investigate the consequences of changing relative GR/PR levels on 
MPA-induced immunomodulatory gene expression and HIV-1 infection. 
 
The aims of this section were therefore to answer the following research questions: 
(i) Does changing the relative levels of GR and PR modify MPA-induced HIV-1 infection? 
 Does the increase in HIV-1 infection with luteal phase E2/P4 and MPA change with 
relative GR/PR levels? 
 Does HIV-1 infection in the absence of MPA and luteal phase E2/P4 change with relative 
GR/PR levels?  
(ii) Does changing the relative levels of GR and PR modify MPA-induced and/or basal 
expression of genes relevant to HIV-1 infection and immune function, specifically the 
following? 
 HIV-1 receptor and co-receptor expression 
 Immunomodulatory gene expression 
(iii) Is a difference in HIV-1 infection between relative levels of GR and PR due to a possible 
change in expression of soluble mediators? 
 
In order to answer these questions, several cervical cell lines were used to model cells in the female 
reproductive tract, the site of heterosexual HIV-1 infection. These included End1/E6E7 immortalized 
endocervical epithelial cells; HeLa cervical carcinoma cells and TZM-bl cells, which are modified 
HeLa cells that are infectable with HIV-1. While TZM-bl cells endogenously express GR and AR 
(Appendix A, Fig. A2.1) and End1/E6E7 cells express GR, AR and ERα (Appendix A, Fig. A2.2), 
HeLa cells only express GR (Appendix A, Fig. A2.1). The expression of GR in these three cell lines 
renders them suitable for studying GR-mediated HIV-1 infection and immunomodulatory gene 
expression. The relative levels of GR/PR were changed by using siRNA to decrease expression of the 
endogenous GR (siGR), as compared to non-silencing control (NSC) siRNA, with or without the 
simultaneous over-expression of PR-B. This leads to four conditions: NSC-PR-B, siGR-PR-B, 
NSC+PR-B and siGR+PR-B, also referred to throughout this chapter as “high GR/no PR”, “low 
GR/no PR”, “high GR/high PR” and “low GR/high PR”, respectively. Pilot experiments to confirm 
decreased GR expression, PR-B over-expression and GR- or PR-mediated gene expression were 
performed in these cell lines (Appendix B, Fig. B3.1, 3.2, 4.1, 4.2, 4.3).  
 
Over-expression of GR/PR in U2OS cells, which express very low levels of endogenous GR, was 
further explored as a strategy in which to study the effects of changing the relative levels of GR/PR on 
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endogenous immunomodulatory gene expression. However, despite predictable Dex-induced, GR-
mediated responses on the transactivation gene GILZ, robust and reproducible repression of IL-6 by 
Dex was not observed (not shown, reported in Appendix B5). Furthermore the breast cancer cell lines, 
MCF-7 and T47D, in which GR and PR are endogenously expressed (Appendix B, Fig. B6.1), were 
investigated in parallel for their suitability to study changing GR/PR. However, despite functional 
GR/PR activity on the TAT-GRE-LUC reporter gene in MCF-7 cells (Appendix B, Fig. B6.2a, b), 
reproducible GR-mediated transcriptional responses on endogenous genes were not observed 
(Appendix B, Fig. B6.3a, b). GR-mediated responses in T47D cells were not achieved on the TAT-
GRE-LUC reporter gene (Appendix B, Fig. B6.2d) nor endogenous genes (Appendix B, Fig. B6.3c, d) 
and attempts to over-express GR in T47D cells were unsuccessful (Appendix B, Fig. B6.4). In 
contrast, End1/E6E7 and HeLa cells have been shown to exhibit transactivation and transrepression of 
endogenous genes such as GILZ and IL-6, mediated by the endogenous GR [(Govender 2014) and 
Appendix B, Fig. B3.1-2]. In addition, PR-B could be successfully over-expressed in these cells, 
making End1/E6E7 and HeLa cells suitable model cell lines in which to investigate GR/PR-mediated 
gene expression (reported in Chapter 4), while U2OS/COS1 and MCF-7 cells were used in assays 
other than gene expression studies (Chapter 5). 
 
 
4.2 MPA-induced HIV-1 infection changes when the relative levels of GR/PR are altered in 
TZM-bl cells 
 
Since increased HIV-1 infection with luteal phase E2/P4 and MPA was shown in PBMCs, HIV-1 
infection was assessed in response to luteal phase E2/P4 and MPA in TZM-bl cells in which the 
relative levels of GR/PR were changed by siRNA and over-expression strategies. 
 
 
4.2.1 The increase in HIV-1 infection with MPA, but not luteal phase E2/P4, depends on GR 
but not PR-B levels 
 
Stimulation with MPA significantly increased HIV-1 infection 1.5-fold in TZM-bl cells (Fig. 
4.2.1.1a). While HIV-1 infection appeared to increase 1.3-fold in response to luteal phase E2/P4, this 
was not significant (Fig. 4.2.1.1a). The large variability in relative infection in TZM-bl cells was not 
due to changes in cell viability but appears to reflect inherent biological variation in infection between 
experiments (Appendix B, Table B1). 
 
The increase in HIV-1 infection with MPA (NSC) was lost when GR expression was decreased using 
siRNA targeting the GR (siGR) (Fig. 4.2.1.1a). This effect occurred both in the presence and absence 
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of over-expressed PR-B. Although high GR/high PR (NSC+PR-B) appeared to further increase MPA-
induced HIV-1 infection (1.7-fold) compared to high GR/no PR (NSC-PR-B),  this effect was not 
significant (p=0.4456). Decreased GR levels by about 40% (Fig. 4.2.1.1c) and PR-B over-expression 
by 1.5-2-fold (Fig. 4.2.1.1d) were confirmed by western blotting on parallel samples (Fig. 4.2.1.1b). 
Taken together, these results show that MPA increases HIV-1 infection in a GR-mediated, PR-B-
independent manner.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2.1.1. MPA-induced HIV-1 infection is mediated by the GR in TZM-bl cells. TZM-bl 
cells were seeded at 1 X 10
5
 cells/well in 12 well plates and left to adhere overnight. Cells were subsequently 
transfected with 10 nM non-silencing control (NSC) or siRNA targeting the human GR (siGR) for 24 h, then 
transiently transfected with 500 ng/well empty vector pcDNA3 or pMT-hPR-B for 24 h. (a) Cells were re-
seeded at 2.5 X 10
4
 cells/well into 96-well plates in quadruplicate wells for another 24 h, followed by 
stimulation for 24 h with hormone combinations representing the luteal phase (10 nM P4 + 400 pM E2) or peak 
levels of the injectable contraceptive MPA (100 nM). Media was removed and replaced with phenol red-free 
DMEM containing 10 IU/mL HIV-1BaL_Renilla (HIV-BaL) or equivalent volume of no-virus control (labelled as 
Virus control). Cells were harvested 72 h later for luciferase (infection) and for cell viability. The results are 
pooled from 3 independent experiments where each point was in quadruplicate. Relative infection was 
calculated as luciferase (RLU) divided by average absorbance at 595nm (MTT) for the quadruplicate wells. 
V
e
h
ic
le
 
L
u
te
a
l
M
P
A
V
e
h
ic
le
 
L
u
te
a
l
M
P
A
V
e
h
ic
le
 
L
u
te
a
l
M
P
A
V
e
h
ic
le
 
L
u
te
a
l
M
P
A
V
e
h
ic
le
 
L
u
te
a
l
M
P
A
V
e
h
ic
le
 
L
u
te
a
l
M
P
A
V
e
h
ic
le
 
L
u
te
a
l
M
P
A
V
e
h
ic
le
 
L
u
te
a
l
M
P
A
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
T Z M -b l
H IV -1  in fe c tio n
n = 3
R
e
la
ti
v
e
 R
e
p
li
c
a
ti
o
n
(L
u
c
if
e
r
a
s
e
/A
v
e
 M
T
T
)
E
a
c
h
 +
H
IV
-B
a
L
 V
e
h
ic
le
 s
e
t 
to
 1
0
0
%
N S C siG R N S C siG R
* * *
V iru s  c o n tro l H IV -B a L V iru s  c o n tro l H IV -B a LV iru s  c o n tro l H IV -B a LV iru s  c o n tro l H IV -B a L
* * * * * *
* *
-P R -B + P R -B
* * * *
p = 0 .0 8
* * * * * * * * * * * *
U
n
tr
a
n
s
fe
c
te
d
N
S
C
s
iG
R
N
S
C
s
iG
R
0
2 5
5 0
7 5
1 0 0
1 2 5
T Z M -b l
G R  p ro te in  le v e ls
n = 3
R
e
la
ti
v
e
 I
n
te
g
r
a
te
d
 D
e
n
s
it
y
 V
a
lu
e
(G
R
/G
A
P
D
H
)
U
n
tr
a
n
s
fe
c
te
d
 s
e
t 
to
 1
0
0
%
* *
-P R -B + P R -B
**
U
n
tr
a
n
s
fe
c
te
d
N
S
C
s
iG
R
N
S
C
s
iG
R
0
1
2
3
T Z M -b l
P R -B  p ro te in  le v e ls
n = 3
R
e
la
ti
v
e
 I
n
te
g
r
a
te
d
 D
e
n
s
it
y
 V
a
lu
e
(P
R
-B
/G
A
P
D
H
)
U
n
tr
a
n
s
fe
c
te
d
 s
e
t 
to
 1 p = 0 .1 4
p = 0 .6 2
-P R -B + P R -B
a) 
b) c) d) 
78 
 
Infection was plotted relative to the vehicle control for NSC-PR-B in the presence of virus set to 100%. (b) Cells 
seeded and transfected in parallel were harvested in SDS sample buffer and lysates were analyzed for GR and 
PR-B levels by western blotting using GAPDH as a loading control. A representative blot is shown. Blots were 
probed first for GR then stripped and re-probed for PR-B. (c, d) Western blots were scanned and quantified for 
relative GR (c) or PR-B (d) levels by calculating integrated density values. Data are pooled from 3 independent 
experiments. GR levels are plotted relative to the untransfected control set to 100% (c), while PR-B levels are 
plotted relative to the untransfected control set to 1 (d). Statistical comparisons were carried out using a two-
way ANOVA with Tukey’s (a) or Dunnett’s (c, d) multiple comparisons post test. Stars above bars indicate 
significance compared to each vehicle in the presence of virus (a) or to the untransfected control (c, d), unless 
otherwise indicated by lines, with *** and ** indicating p<0.001 and p<0.01 respectively. 
 
 
4.2.2 HIV-1 infection in the absence of exogenous hormones changes when the relative levels 
of GR/PR are altered 
Since antagonism of the GR in the absence of exogenous hormones increased HIV-1 infection in 
PBMCs (Fig. 3.4.1.1), it was hypothesized that decreasing GR levels using siRNA in TZM-bl cells 
would also increase HIV-1 infection. Therefore the effect of directly changing the relative GR/PR 
levels on HIV-1 infection in the absence of exogenous MPA or luteal phase E2/P4 in TZM-bl cells was 
assessed. 
 
HIV-1 infection was significantly higher when GR levels were decreased (siGR) compared to basal 
GR levels (NSC), both in the presence (3.1-fold, siGR+PR-B) and absence (2.9-fold, siGR-PR-B) of 
PR-B (Fig. 4.2.2.1a). With high GR/high PR (NSC+PR-B), HIV-1 infection was significantly 
increased 1.7-fold, compared to high GR/low PR (Fig. 4.2.2.1a). However the highest HIV-1 infection 
was observed for low GR/high PR (3.1-fold, siGR+PR-B, Fig. 4.2.2.1a), although this was not an 
additive effect. This same pattern was observed in the previous figure (Fig. 4.2.1.1) when vehicle 
controls were plotted relative to NSC-PR-B (not shown). 
 
Decreased GR levels by about 50% (Fig. 4.2.2.1c) and PR-B over-expression by about 10-20-fold 
(Fig. 4.2.2.1d) were confirmed by western blotting on parallel samples (Fig. 4.2.2.1b). The low 
GR/high PR combination appeared to express lower PR-B protein levels on the western blot than the 
high GR/high PR combination, despite equal amounts of PR-B expression vector transfected (Fig. 
4.2.2.1b). However, when pooled samples were analyzed densitometrically, this difference was not 
significant (Fig. 4.2.2.1d). Nevertheless, this suggests that the siRNA targeting the GR may also 
silence the expression of PR-B or another factor required for PR-B expression. 
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Figure 4.2.2.1 Basal HIV-1 infection in the absence of exogenous hormones in TZM-bl cells 
increases with low GR/high PR. TZM-bl cells were seeded at 1 X 105 cells/well in 12 well plates and left to 
adhere overnight. Cells were subsequently transfected with 10 nM NSC or siGR for 24 h, then transiently 
transfected with 500 ng/well empty vector pcDNA3 or pMT-hPR-B for 24 h. (a) Cells were re-seeded at 2.5 X 
10
4
 cells/well into 96-well plates in quadruplicate wells for another 24 h, then infected with 10 IU/mL HIV-
1BaL_Renilla (HIV-BaL) or equivalent volume of no-virus control (labelled as Virus control) by addition to the 
wells. Cells were harvested 72 h later for luciferase (infection) and for cell viability. The results are pooled from 
5 independent experiments where each point was in quadruplicate. Relative infection was calculated as 
luciferase (RLU) divided by average absorbance at 595nm (MTT) for the quadruplicate wells. Infection was 
plotted relative to NSC-PR-B in the presence of virus set to 100%. (b) Cells seeded and transfected in parallel 
were harvested in SDS sample buffer and lysates were analyzed for GR and PR-B levels by western blotting 
using GAPDH as a loading control. (c, d). A representative blot is shown. Western blots were scanned and 
quantified for relative GR (c) or PR-B (d) levels by calculating integrated density values. Data are pooled from 5 
independent experiments.GR levels are plotted relative to the untransfected control set to 100% (c), while PR-B 
levels are plotted relative to the untransfected control set to 1 (d). Statistical comparisons were carried out using 
a two-way ANOVA with Tukey’s (a) or Dunnett’s (c, d) multiple comparisons post test. Stars above bars 
indicate significance compared to NSC-PR-B in the presence of virus (a) or to the untransfected control (c, d), 
unless otherwise indicated by lines, with ****, ***, ** and * indicating p<0.0001, p<0.001, p<0.01 and p<0.05 
respectively. 
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Together these results suggest that in the absence of MPA, unliganded basal levels of GR seem to 
protect against HIV-1 infection, while PR seems to increase HIV-1 infection; and in the presence of 
MPA, the MPA-induced HIV-1 infection is mediated by the GR only, while PR has no significant 
effect. 
 
 
4.3 Altering the relative levels of GR/PR modifies the MPA-induced expression of genes 
relevant to HIV-1 infection and immune function in TZM-bl cells 
 
The previous section showed that HIV-1 infection in TZM-bl cells increased in the presence of MPA, 
in a manner dependent on GR levels, and furthermore that HIV-1 infection in the absence of 
exogenous hormones increased with low GR/no PR, high GR/high PR and low GR/high PR compared 
to high GR/no PR. In order to investigate possible mechanisms of infection, the effect of changing 
relative GR/PR levels on expression of genes relevant to HIV-1 infection and immune function was 
assessed.   
 
 
4.3.1 Basal HIV-1 CD4 receptor, but not CCR5 or CXCR4 co-receptor, expression changes 
when GR/PR levels are altered in TZM-bl cells in the absence of exogenous hormones 
 
TZM-bl cells stably express high levels of the CD4 receptor and the HIV-1 co-receptors CXCR4 and 
CCR5 (Platt et al. 1998). The previous chapter showed that MPA increased the expression of CCR5 in 
CD3+ and CD3+CD4+ T-cells in PBMCs (Fig. 3.3.2.2) and increased CCR5 mRNA levels in TZM-bl 
cells (Fig. 3.3.2.3a). Furthermore, CCR5 is the co-receptor used by the R5-tropic infectious molecular 
clone used in our experiments, HIV-1 BaL_Renilla. 
 
Interestingly, CCR5 mRNA levels were not modified by altering the relative levels of GR/PR in 
TZM-bl cells, in the absence of exogenous hormones (Fig. 4.3.1.1a). In contrast, CD4 mRNA levels 
were significantly increased 1.35-fold with low GR/no PR (siGR-PR-B), but unaffected by PR-B 
over-expression (Fig. 4.3.1.1b). CXCR4 mRNA levels were not significantly changed compared to 
high GR/no PR (Fig. 4.3.1.1c). Decreased GR levels by about 40% (Fig. 4.2.1.1c) and PR-B over-
expression by 1.5-2-fold (Fig. 4.2.1.1d) were confirmed by western blotting on parallel samples (Fig. 
4.2.1.1b). 
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Figure 4.3.1.1. Basal CD4 but not CCR5 or CXCR4 expression is increased with low GR/no PR. 
TZM-bl cells were seeded at 1 X 10
5
 cells/well in 12 well plates and left to adhere overnight. Cells were 
subsequently transfected with 10 nM NSC or siGR for 24 h, then transiently transfected with 500 ng/well empty 
vector pcDNA3 or pMT-hPR-B for 24 h. Media was changed to SF-DMEM for a further 24 h, then cells were 
washed. RNA was extracted and cDNA was synthesized from 500 ng RNA then used in quantitative RT real-
time qPCR. Relative mRNA levels of CCR5 (a), CD4 (b) and CXCR4 (c) were normalized to GAPDH mRNA 
levels. Relative expression was determined by normalizing to NSC-PR-B set to 1. Decreased GR expression and 
PR-B over-expression were confirmed by western blotting in parallel samples (Fig. 4.2.1.1b-d). The results are 
pooled from 3 independent experiments. Statistical comparisons were carried out using a two-way ANOVA 
with Dunnett’s multiple comparisons post test. Stars above bars indicate significance compared to NSC-PR-B, 
with. ** indicating p<0.01. 
 
 
These results suggest that changing GR levels does not influence basal CCR5 or CXCR4 mRNA 
levels in TZM-bl cells, but there is an increase in the basal levels of the CD4 receptor when GR 
expression is decreased. Furthermore these results show that over-expression of PR-B did not change 
expression of CCR5, CD4 or CXCR4. 
 
 
4.3.2 MPA-induced immunomodulatory gene expression changes when GR/PR levels are 
altered in End1/E6E7 and HeLa cells 
 
Given the knowledge that GR regulates immunomodulatory genes and that MPA activates both the 
GR and the PR, the effect of altering the relative GR/PR levels on immunomodulatory gene 
expression in response to GR- (Dex), PR- (R5020) or GR/PR-specific (MPA) ligands was next 
investigated. This was carried out using the more physiologically relevant endocervical epithelial cell 
line, End1/E6E7, and the cervical carcinoma cell line, HeLa, both expressing endogenous GR and in 
which PR-B protein could be over-expressed (Appendix B, Fig. 3.1c, 3.2c, 4.1b, 4.2b). In order to 
interpret these results, the data were plotted relative to each vehicle control, where comparisons 
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between vehicle and ligands within the same transfection condition and between ligands from 
different transfection conditions (NSC vs siGR) were made. 
 
In End1/E6E7 cells, the model transactivation gene, GILZ (Fig. 4.3.2.1a), was significantly induced 
4-fold by Dex in a typical GR-mediated response (NSC) that was reduced to 2-fold when GR 
expression was decreased (siGR), in both the absence and presence of PR-B, although this reduction 
was not significant (Fig. 4.3.2.1a). MPA also appeared to increase the transactivation of GILZ, but to 
a lower extent than Dex, and this also appeared to occur in a GR-dependent manner (Fig. 4.3.2.1a). 
The numerical fold reduction for MPA between NSC (high GR) and siGR (low GR) conditions 
appeared to be greater in the presence (0.5-fold) than the absence (0.3-fold) of PR-B (Fig. 4.3.2.1a). 
MPA-induced GILZ up-regulation appeared to increase with high GR/high PR (1.9-fold) compared to 
high GR/no PR (1.5-fold), although this was not significant (Fig. 4.3.2.1a). These results suggest that 
the presence of PR-B may alter the GR-mediated regulation of GILZ in response to MPA but not Dex, 
although not conclusively. 
 
With high GR/no PR, the model transrepression gene, IL-6 (Fig. 4.3.2.1b), was significantly repressed 
by Dex (4.9-fold), in a GR-dependent manner, since decreasing GR expression lifted this repression 
(low GR/no PR, Fig. 4.3.2.1b). Dex appeared to repress IL-6 with high GR/high PR (2.8-fold), 
suggesting that Dex repression may be PR-B-independent (Fig. 4.3.2.1b). In the absence of PR-B, 
MPA appeared to repress IL-6 in a GR-dependent manner (Fig. 4.3.2.1b). In the presence of PR-B, 
however, MPA no longer repressed IL-6 either with high GR/high PR (NSC+PR-B) or low GR/high 
PR (siGR+PR-B, Fig. 4.3.2.1b). This suggests that the presence of PR-B changes MPA-induced IL-6 
expression to no longer be anti-inflammatory, unlike the result for Dex.  
 
In response to R5020, both GILZ and IL-6 mRNA fluctuated around basal levels (Fig. 4.3.2.1a, b), 
suggesting that no PR-specific response was observed on these genes. 
 
Decreased GR levels by about 50% (Fig. 4.3.2.1d) and PR-B over-expression by about 2-fold (Fig. 
4.3.2.1e) were confirmed by western blotting on parallel samples (Fig. 4.3.2.1c). Similar to TZM-bl 
cells, PR-B protein levels were lower in the presence of siGR than NSC siRNA oligonucleotides, 
although this difference was not statistically significant (Fig. 4.3.2.1e). 
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Figure 4.3.2.1. The presence of PR-B alters the GR-mediated transcriptional responses to MPA 
on GILZ and IL-6 in End1/E6E7 cells. Continued on next page. 
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Figure 4.3.2.1. The presence of PR-B alters the GR-mediated transcriptional responses to MPA 
on GILZ and IL-6 in End1/E6E7 cells. Cells were seeded at 1.5 X 105 cells/well in 12 well plates and 
allowed to adhere overnight. Cells were subsequently transfected with 10 nM NSC or siGR for 24 h, then 
transiently transfected with 250 ng/well empty vector pcDNA3 or pMT-hPR-B for 24 h. Cells were stimulated 
with 100 nM final concentration of the indicated ligands in SF-KSFM for a further 24 h, then cells were washed. 
RNA was extracted and cDNA was synthesized from 500 ng RNA then used in quantitative RT real-time qPCR. 
Relative mRNA levels of GILZ (a) and IL-6 (b) were normalized to GAPDH mRNA levels. Relative expression 
was determined either by normalizing to each vehicle control set to 1. The results are pooled from 6 independent 
experiments. (c) Cells seeded and transfected in parallel were harvested in SDS sample buffer and lysates were 
analyzed for GR and PR-B levels by western blotting using GAPDH as a loading control. A representative blot 
is shown. Blots were probed first for GR then stripped and re-probed for PR-B. Western blots were scanned and 
quantified for relative GR (d) or PR-B (e) levels by calculating integrated density values. Data are pooled from 4 
(PR-B) or 6 (GR) independent experiments, since PR-B protein was not detectable in every experiment. GR 
levels are plotted relative to the untransfected control set to 100% (d), while PR-B levels are plotted relative to 
the untransfected control set to 1 (e). Statistical comparisons were carried out using a two-way ANOVA with 
Tukey’s (a, b) or Dunnett’s (d, e) post test. Stars above bars indicate significance compared to each vehicle 
control (a, b) or to the untransfected control (d, e), unless otherwise indicated by lines, with ***, ** and * 
indicating p<0.001, p<0.01 and p<0.05 respectively.  
 
 
 
 
 
The same experiment was carried out in HeLa cells, in which greater amounts of PR-B expression 
vector DNA could be transfected for PR-B over-expression without noticeable effects on cell 
proliferation and/or viability, unlike End1/E6E7 cells (Appendix B4).  
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Similar to End1/E6E7 cells, GILZ mRNA was significantly induced 6.7-fold by Dex in the presence 
of endogenous GR (NSC) and this was reduced to 2.9-fold when GR expression was decreased 
(siGR), both in the absence (significantly) and presence (near-significantly) of PR-B (Fig. 4.3.2.2a). 
Similarly, MPA also induced GILZ expression, to a lesser extent than Dex, and this induction was 
greater with high GR/high PR (4.2-fold, NSC+PR-B, significant) than high GR/no PR (2.5-fold, NSC-
PR-B, not significant, Fig. 4.3.2.2a). The numerical fold reduction for MPA between NSC (high GR) 
and siGR (low GR) conditions was greater in the presence (2.3-fold) than the absence (0.5-fold) of 
PR-B, although these changes did not reach statistical significance (Fig. 4.3.2.2a). Similar to 
End1/E6E7 cells, these results in HeLa cells suggest that Dex regulation of GILZ is PR-B-
independent, but PR-B alters the response to MPA. 
 
Also similar to results for End1/E6E7 cells with high GR/no PR, in HeLa cells IL-6 mRNA was 
significantly repressed by Dex (2.8-fold), in a GR-dependent manner, since this repression was lifted 
back to basal levels when GR expression was decreased (low GR/no PR, Fig. 4.3.2.2b). In the 
presence of PR-B, Dex near-significantly repressed IL-6 (2.3-fold), in a GR-dependent manner (Fig. 
4.3.2.2b). MPA appeared to repress IL-6 with high GR/no PR and high GR/high PR (Fig 4.3.2.2b). 
However, while this apparent repression was lifted to basal levels with low GR/no PR, MPA 
continued to repress IL-6 by 1.5-fold with low GR/high PR (siGR+PR-B), although not significantly 
(Fig. 4.3.2.2b). This suggests that the presence of PR-B promotes MPA repression of IL-6 
independent of GR levels in HeLa cells, unlike in End1/E6E7 cells. 
 
Decreased GR levels by about 25% (Fig. 4.3.2.2d) and PR-B over-expression by about 7-fold (Fig. 
4.3.2.2e) were confirmed by western blotting on parallel samples (Fig. 4.3.2.2c). Similar to results for 
End1/E6E7 and TZM-bl cells, in HeLa cells PR-B protein levels were lower in the presence of siGR 
than NSC siRNA oligonucleotides, although this was not statistically significant (Fig. 4.3.2.2c). 
 
Two additional interesting observations were made when the mRNA levels were plotted relative to 
the NSC-PR-B vehicle control (Appendix B4). Firstly, in End1/E6E7 cells with high GR/high PR, the 
Dex-induced increase of GILZ was not as high as expected, or as high as observed with high GR/no 
PR, although this effect was not significantly different (Appendix B, Fig. B4.4a). A similar trend was 
observed for the transactivation gene MKP1 in these cells (not shown). This dampening of the GR-
mediated Dex response on GILZ was not observed for MPA in End1/E6E7 cells (Appendix B, Fig. 
B4.4a), nor for Dex or MPA in HeLa cells (Appendix B, Fig. B4.5a), suggesting that the presence of 
PR-B can change GR-mediated transcriptional regulation in a ligand- and cell-specific manner. 
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Figure 4.3.2.2. The presence of PR-B alters the GR-mediated transcriptional responses to MPA 
on GILZ and IL-6 in HeLa cells. Continued on next page. 
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Figure 4.3.2.2. The presence of PR-B alters the GR-mediated transcriptional responses to MPA 
on GILZ and IL-6 in HeLa cells. Cells were seeded at 1 X 105 cells/well in 12 well plates and allowed to 
adhere overnight. Cells were subsequently transfected with 10 nM NSC or siGR for 24 h, then transiently 
transfected with 500 ng/well empty vector pcDNA3 or pMT-hPR-B for 24 h. Cells were stimulated with 100 
nM final concentration of the indicated ligands in SF-DMEM for a further 24 h, then cells were washed. RNA 
was extracted and cDNA was synthesized from 500 ng RNA then used in real-time qPCR. Relative mRNA 
levels of GILZ (a) and IL-6 (b) were normalized to GAPDH mRNA levels. Relative expression was determined 
by normalizing to each vehicle control set to 1 (a, b). The results are pooled from 3 independent experiments. 
(c) Cells seeded and transfected in parallel were harvested in SDS sample buffer and lysates were analyzed for 
GR and PR-B levels by western blotting using GAPDH as a loading control. A representative blot is shown. 
Blots were probed first for GR then stripped and re-probed for PR-B. Western blots were scanned and quantified 
for relative GR (d) or PR-B (e) levels by calculating integrated density values.GR levels are plotted relative to 
the untransfected control set to 100% (d), while PR-B levels are plotted relative to the untransfected control set 
to 1 (e). Statistical comparisons were carried out using a two-way ANOVA with Tukey’s (a, b) or Dunnett’s (d, 
e) multiple comparisons post test. Stars above bars indicate significance compared to each vehicle control (a, b) 
or to the untransfected control (d, e), unless otherwise indicated by lines, with ****, ***, ** and * indicating 
p<0.0001, p<0.001, p<0.01 and p<0.05 respectively. 
 
 
Secondly, in End1/E6E7 cells in the presence of over-expressed PR-B (high GR/high PR), the basal 
levels of GILZ decreased (Appendix B, Fig. B4.4a) while IL-6 increased (Appendix B, Fig. B4.4b) 
compared to high GR/no PR. Increased basal IL-6 mRNA levels were observed with decreased GR 
protein levels (Appendix B, Fig. B4.4b), which has been observed previously in these cells (Verhoog 
et al. 2011). Furthermore with low GR/high PR, basal IL-6 mRNA levels were further increased, 
although not significantly (Appendix B, Fig. B4.4b). In HeLa cells, basal IL-6 levels significantly 
increased about 4-fold with high GR/high PR and low GR/high PR compared to high GR/no PR 
(Appendix B, Fig. B4.5b). Together these results indicate that the relative GR/PR levels can also 
regulate immune function gene expression in a ligand-independent manner. 
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Following the above results indicating that responses to MPA appear to change when the relative 
levels of GR/PR were altered, the effect of only MPA, without the GR/PR-specific ligands, on 
immunomodulatory gene regulation was investigated. The same RNA samples were re-analyzed 
together with additional independent experiments for MPA-induced GILZ and IL-6 gene expression 
in End1/E6E7 (2, to make n=8) and HeLa (1, to make n=4) cells (Fig 4.3.2.3). GR and PR-B protein 
levels were confirmed previously (Fig. 4.3.2.1c, Fig. 4.3.2.2c). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.2.3. MPA-induced, GR-mediated regulation IL-6 in End1/E6E7 and HeLa cells 
changes in the presence of PR-B. Cells were seeded at 1.5 X 105 cells/well (End1/E6E7, a, b) or 1 X 105 
cells/well (HeLa, c, d) in 12 well plates and allowed to adhere overnight. Cells were subsequently transfected 
with 10 nM NSC or siGR for 24 h, then transiently transfected with 250 ng/well (End1/E6E7, a, b) or 500 
ng/well (HeLa, c, d) empty vector pcDNA3 or pMT-hPR-B for 24 h. Cells were stimulated with 100 nM final 
concentration of the indicated ligands in SF-KSFM (End1/E6E7, a, b) or SF-DMEM (HeLa, c, d) for a further 
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24 h, then cells were washed. RNA was extracted and cDNA was synthesized from 500 ng RNA then used in 
quantitative RT real-time qPCR. Relative mRNA levels of GILZ (a, c) and IL-6 (b, d) were normalized to 
GAPDH mRNA levels. Relative expression was determined either by normalizing to NSC-PR-B set to 1. The 
results are pooled from 8 (End1/E6E7, a, b) or 4 (HeLa, c, d) independent experiments. Statistical comparisons 
were carried out using a two-way ANOVA with Tukey’s multiple comparisons post test. Stars above bars 
indicate significance compared to each vehicle control unless otherwise indicated by lines, with ** and * 
indicating p<0.001 and p<0.05 respectively. Decreased GR expression and PR-B over-expression were 
confirmed previously by western blotting in parallel samples (Fig. 4.3.2.1c-e; Fig. 4.3.2.2c-e). 
 
 
Two main comparisons were made upon interpretation of these results: GR-mediated responses 
(comparing NSC vs siGR) and the effect of PR-B over-expression on GR-mediated responses (-PR-B 
vs +PR-B). 
 
Analysis of GR-mediated responses showed that MPA induction of GILZ in End1/E6E7 cells required 
the GR, independent of PR-B levels (Fig. 4.3.2.3a). MPA induction of GILZ in HeLa cells did not 
change when GR levels were decreased (Fig. 4.3.2.3c). In the absence of PR-B, repression of IL-6 in 
End1/E6E7 (Fig. 4.3.2.3b) and HeLa (Fig. 4.3.2.3d) cells showed a trend of a GR-mediated response.  
 
Analysis of the presence of PR-B on GR-mediated responses showed that repression of IL-6 by MPA 
(high GR/high PR) was not elevated when GR levels were decreased (low GR/high PR, siGR+PR-B) 
in either End1/E6E7 (Fig. 4.3.2.3b) or HeLa (Fig. 4.3.2.3d) cells. This may suggest that PR-B blocks 
GR-mediated repression of IL-6 in response to MPA. Interestingly, in HeLa cells, a GR-mediated 
effect on GILZ was only observed in the presence of PR-B, although not significant (Fig. 4.3.2.3c). 
 
When comparing high GR/no PR (NSC-PR-B) to high GR/high PR (NSC+PR-B), or comparing low 
GR/no PR (siGR-PR-B) to low GR/high PR (siGR+PR-B), there were no significant differences in 
GILZ expression in End1/E6E7 cells (Fig. 4.3.2.3a). Similarly, the presence of PR-B had no 
significant effects on IL-6 expression in End1/E6E7 cells (Fig. 4.3.2.3b) or GILZ in HeLa cells (Fig. 
4.3.2.3c). However, IL-6 expression significantly increased in the presence of PR-B in HeLa cells, 
both when comparing high GR/high PR to high GR/no PR, and comparing low GR/high PR to low 
GR/no PR (Fig. 4.3.2.3d). 
 
Taken together, these results suggest that the effects of changing GR/PR on MPA-induced responses 
are gene- and cell type-specific. Furthermore this implies that the balance of pro-inflammatory versus 
anti-inflammatory responses to MPA depend on the relative levels of GR/PR. These findings are 
summarized in Table 6.3 in the Discussion. 
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4.3.3 Basal immunomodulatory gene expression changes when GR/PR levels are altered in 
End1/E6E7 and HeLa cells 
In the absence of exogenous ligands, basal changes in immunomodulatory gene expression were also 
observed when the relative levels of GR/PR were altered (Fig. 4.3.2.3, Appendix B, Fig. B4.4 and 
B4.5). In order to further characterize basal changes in gene expression, the same RNA samples were 
re-analyzed for GILZ and IL-6 mRNA levels in End1/E6E7 and HeLa cells, and for a selection of 
additional immunomodulatory genes in HeLa cells. GR and PR-B protein levels were confirmed 
previously (Fig. 4.3.2.1c, Fig. 4.3.2.2c). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.3.1. The basal expression of IL-6 in End1/E6E7 and HeLa cells, and GILZ in 
End1/E6E7 cells, changes when the relative levels of GR/PR are altered. Cells were seeded at 1.5 X 
10
5
 cells/well (End1/E6E7, a, b) or 1 X 10
5
 cells/well (HeLa, c, d) in 12 well plates and allowed to adhere 
overnight. Cells were subsequently transfected with 10 nM NSC or siGR for 24 h, then transiently transfected 
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with 250 ng/well (End1/E6E7, a, b) or 500 ng/well (HeLa, c, d) empty vector pcDNA3 or pMT-hPR-B for 24 h. 
Cells were stimulated with 100 nM final concentration of the indicated ligands in SF-KSFM (End1/E6E7, a, b) 
or SF-DMEM (HeLa, c, d) for a further 24 h, then cells were washed. RNA was extracted and cDNA was 
synthesized from 500 ng RNA then used in quantitative RT real-time qPCR. Relative mRNA levels of GILZ (a, 
c) and IL-6 (b, d) were normalized to GAPDH mRNA levels. Relative expression was determined either by 
normalizing to NSC-PR-B set to 1. The results are pooled from 8 (End1/E6E7, a, b) or 4 (HeLa, c, d) 
independent experiments. Statistical comparisons were carried out using a two-way ANOVA with Dunnett’s 
multiple comparisons post test. Stars above bars indicate significance compared to NSC-PR-B, with ***, ** and 
* indicating p<0.001, p<0.01 and p<0.05 respectively. Decreased GR expression and PR-B over-expression 
were confirmed previously by western blotting in parallel samples (Fig. 4.3.2.1c-e; Fig. 4.3.2.2c-e). 
 
 
In End1/E6E7 cells, basal GILZ mRNA levels were significantly reduced with high GR/high PR (1.8-
fold) and with low GR/high PR (1.9-fold), compared to high GR/no PR (Fig. 4.3.3.1a). Basal IL-6 
mRNA levels significantly increased with low GR/high PR (3.6-fold, Fig. 4.3.3.1b). 
 
In HeLa cells, contrary to End1/E6E7 cells, basal GILZ mRNA levels appeared to increase 1.4-fold 
with low GR/high PR compared to high GR/no PR (Fig. 4.3.3.1c). Basal IL-6 mRNA levels, however, 
were significantly increased with high GR/high PR (4-fold) and, like for End1/E6E7 cells, with low 
GR/high PR (5-fold, Fig. 4.3.3.1d). Taken together, these results suggest that the basal expression of 
GILZ and IL-6 are regulated in a PR-B-dependent, GR-dependent manner in End1/E6E7 cells and in 
a PR-B-dependent, GR-independent manner in HeLa cells.  
 
To further assess gene-specific effects, additional immunomodulatory genes, including the pro-
inflammatory chemokines RANTES and IL-8, the anti-inflammatory cytokine IL-10 and the pro-
inflammatory cytokine IL-12, were assessed by qPCR for changing expression in response to altered 
GR/PR levels in HeLa cells. 
 
RANTES mRNA levels were near-significantly increased 12-fold with low GR/high PR compared to 
high GR/no PR (Fig. 4.3.3.2a). No statistically significant changes were observed for IL-8 (Fig 
4.3.3.2b), IL-12p35 (Fig. 4.3.3.2c), IL-10 (Fig. 4.3.3.2d) or IL-12p40 (Fig. 4.3.3.2e) mRNA levels. 
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Figure 4.3.3.2. The basal expression of some but not other immunomodulatory genes appears to 
change when the relative levels of GR/PR are altered in HeLa cells. Cells were seeded at 1 X 105 
cells/well in 12 well plates and allowed to adhere overnight. Cells were subsequently transfected with 10 nM 
NSC or siGR for 24 h, then transiently transfected with 500 ng/well empty vector pcDNA3 or pMT-hPR-B for 
24 h. Cells were incubated in SF-DMEM for a further 24 h, then washed. RNA was extracted and cDNA was 
synthesized from 500 ng RNA then used in quantitative RT real-time qPCR. Relative mRNA levels of RANTES 
(a), IL-8 (b), IL-12p35 (c), IL-10 (d) and IL-12p40 (e) were normalized to GAPDH mRNA levels. Relative 
expression was determined either by normalizing to NSC-PR-B set to 1 (b, d, f). The results are pooled from 4 
independent experiments. Statistical comparisons were carried out using a two-way ANOVA with Dunnett’s 
multiple comparisons post test. No significant differences were observed, but p values above bars indicate a 
comparison to NSC-PR-B. Decreased GR expression and PR-B over-expression were confirmed previously by 
western blotting in parallel samples (Fig. 4.3.2.2c-e). 
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These results suggest that the effects of changing the relative levels of GR/PR are different for 
different genes. Changing GR/PR in HeLa cells to low GR/high PR could increase expression of the 
immunomodulatory genes RANTES and possibly IL-8, in the absence of exogenous ligands, similar 
to IL-6 expression in both End1/E6E7 and HeLa cells. This increase in pro-inflammatory gene 
expression could subsequently alter the inflammatory response depending on the relative levels of GR 
and PR, in the FRT of women using either no hormonal contraceptives or with very low levels of 
MPA. These findings are summarized in Table 6.4 in the Discussion. 
 
 
 
4.4 Differences in HIV-1 infection with changing GR/PR levels is mediated by soluble 
factors, but likely not IL-6 
Previous results in this chapter showed that in the absence of exogenous ligands, changing the relative 
levels of GR/PR, particularly with low GR/high PR, resulted in a change in basal mRNA expression 
of some key cytokines and chemokines (Fig. 4.3.3.1, Fig. 4.3.3.2). Secreted soluble cytokines and/or 
chemokines are likely to play a role in modulating HIV-1 susceptibility in the FRT. In order to assess 
the effect of these soluble mediators on HIV-1 infection, growth media (supernatants) containing 
secreted modulators were collected from End1/E6E7 and HeLa cells in which GR/PR levels had been 
altered. Decreased GR expression and PR-B protein over-expression in End1/E6E7 (Fig. 4.3.2.1c-e) 
and HeLa (Fig. 4.3.2.2c-e) cells was confirmed by western blotting in previous samples. These 
supernatants were subsequently cultured together with HIV-1BaL_Renilla (HIV-BaL) onto TZM-bl cells 
in a conditioned media add-back assay.   
 
HIV-1 infection was significantly increased in TZM-bl cells cultured with End1/E6E7 supernatants in 
which the GR expression was decreased, both in the absence (1.7-fold, siGR-PR-B) and presence 
(1.5-fold, siGR+PR-B) of PR-B (Fig. 4.4.1a). In TZM-bl cells cultured with HeLa supernatants, 
however, HIV-1 infection only appeared to increase after exposure to supernatants from low GR/high 
PR (siGR+PR-B) HeLa cells (1.9-fold, Fig. 4.4.1b). 
 
These results suggest that decreasing GR expression in End1/E6E7 cells, with or without the 
simultaneous over-expression of PR-B, causes, either directly or indirectly, changes the secretion of 
soluble mediators into the surrounding growth media that increase HIV-1 infection in TZM-bl cells. 
In HeLa cells, however, only low GR/high PR influences the secretion of soluble mediators that 
increase HIV-1 infection in TZM-bl cells, suggesting that in this system susceptibility to HIV-1 only 
increases with low GR/high PR. This would suggest a role for the GR in protecting against HIV-1 
infection and for PR-B to increase susceptibility to HIV-1. 
94 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.1. Low GR/high PR in the absence of exogenous hormones causes changes in soluble 
mediators from End1/E6E7 and HeLa cells that increase HIV-1 infection when cultured with 
TZM-bl cells. Growth media supernatants from End1/E6E7 (a) and HeLa (b) cells in which the relative levels 
of GR/PR were directly changed by decreased GR expression and PR-B over-expression were collected during 
previous experiments and stored at -80°C (Fig. 4.3.2.1, 4.3.2.2). TZM-bl cells were seeded in quadruplicate 
wells at 2.5 X 10
4
 cells/well in 96-well plates and left to adhere overnight. Supernatants were thawed, diluted 
1:20 with phenol red-free DMEM and half was incubated with 10 IU/mL HIV-1BaL_Renilla (HIV-BaL) or 
equivalent volume of no-virus control (labelled as Virus control) for 1 h at 37°C, while the other half was added 
to the TZM-bl cells for 1 h at 37°C. The supernatant-virus/control mix was subsequently added onto the TZM-bl 
cells which were incubated for 72 h after which cells were harvested for luciferase (infection) and for cell 
viability (MTT). The results are pooled from 7 (End1/E6E7) or 5 (HeLa) independent experiments. Relative 
infection was calculated as luciferase (RLU) divided by average absorbance at 595nm (MTT) for the 
quadruplicate wells. Infection was plotted relative to NSC-PR-B in the presence of virus set to 100%. Statistical 
comparisons were carried out using a two-way ANOVA with Tukey’s multiple comparisons post test (a) or an 
unpaired t test (b). Stars above bars indicate significance compared to NSC-PR-B in the presence of virus unless 
otherwise indicated by lines, with ****, ***, ** and * indicating p<0.0001, p<0.001, p<0.01 and p<0.05 
respectively. 
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A possible candidate secreted factor that may play a role in HIV-1 infection following add-back onto 
TZM-bl cells is the cytokine IL-6, although it is not established that the change in IL6 levels affects 
HIV-1 infection. Basal IL-6 mRNA levels were shown to be up-regulated with low GR/high PR in 
End1/E6E7 and HeLa cells (Fig. 4.3.3.1b, d). Following this observation, IL-6 protein levels were 
determined by ELISA in the growth media collected from these cells. 
 
IL-6 protein levels ranged from 100-400 pg/mL and were significantly increased 3.4-fold in 
supernatants collected from HeLa cells in which low GR/high PR were expressed, relative to high 
GR/no PR (NSC-PR-B, Fig. 4.4.2a). This mirrors the pattern observed for IL-6 mRNA in HeLa cells 
(Fig. 4.3.3.1d). In End1/E6E7 cells, however, IL-6 protein levels were 10 pg/mL or lower and 
appeared to be decreased with low GR/no PR and low GR/high PR (Fig. 4.4.2b). This could be 
because less IL-6 protein is expressed in End1/E6E7 than HeLa cells. Alternatively, there could be 
sample degradation in End1/E6E7 supernatants due to storage in SF-KSFM, which may be less 
cryoprotective than SF-DMEM in which HeLa supernatants were stored. However, this was not 
directly tested. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.2. Secreted IL-6 protein increases when GR is knocked down and PR-B is over-
expressed in HeLa but not End1/E6E7 cells. Growth media supernatants from End1/E6E7 (a) and HeLa 
(b) cells in which the relative levels of GR/PR were directly changed by decreased GR expression and PR-B 
over-expression were collected during previous experiments and stored at -80°C (Fig. 4.3.2.1, 4.5). Supernatants 
were diluted 1:20 and analysed for absolute IL-6 protein expression using the Human IL-6 High Sensitivity 
ELISA. Statistical comparisons were carried out using a two-way ANOVA with Dunnett’s multiple 
comparisons post test. Stars above bars indicate significance compared to NSC-PR-B, with * indicating p<0.05. 
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Low GR/high PR was previously shown to up-regulate IL-6 mRNA (Fig. 4.3.3.1d) and IL-6 protein 
(Fig. 4.4.2a) in HeLa cells and cause changes in soluble factors from both End1/E6E7 and HeLa cells 
that increased HIV-1 infection in TZM-bl cells (Fig. 4.4.1a, b). These observations led to the 
consideration that IL-6 may be the soluble factor that increases HIV-1 infection. In order to test this 
hypothesis, TZM-bl cells were stimulated with increasing doses of exogenous recombinant IL-6 
protein at the same time as infection with HIV-1BaL_Renilla (HIV-BaL) using the same protocol as for 
the supernatant add-back assays. Since IL-6 concentrations in HeLa cells ranged from 100-400 
pg/mL, TZM-bl cells were incubated with increasing doses of exogenous IL-6 ranging from 0-200 
pg/mL. As shown in Figure 4.4.3, however, increasing doses of exogenous IL-6 used in the same 
manner as the supernatants did not increase HIV-1 infection in TZM-bl cells. This would suggest that 
IL-6 alone, within these concentrations, does not increase HIV-1 infection in this mode system. Thus 
it is likely that it is a combination of secreted factors, perhaps including RANTES and/or IL-8 (Fig. 
4.3.3.2) that increase HIV-1 infection in TZM-bl cells exposed to End1/E6E7 or HeLa supernatants.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.3. Exogenous IL-6 does not dose-dependently increase HIV-1 infection in TZM-bl 
cells. TZM-bl cells were seeded in quadruplicate wells at 2.5 X 104 cells/well in 96-well plates and left to 
adhere overnight. Recombinant IL-6 was diluted to the indicated concentration in phenol red-free DMEM and 
half was incubated with 10 IU/mL HIV-1BaL_Renilla (HIV-BaL) or equivalent volume of no-virus control for 1 h at 
37°C, while the other half was added to the TZM-bl cells for 1 h at 37°C. The IL-6-virus/control mix was 
subsequently added onto the TZM-bl cells which were incubated for 72 h after which cells were harvested for 
luciferase (infection) and for cell viability (MTT). The results are pooled from 4 independent experiments where 
each point was in quadruplicate. Relative infection was calculated as luciferase (RLU) divided by average 
absorbance at 595nm (MTT) for the quadruplicate wells. Infection was plotted relative to 0 pg/mL IL-6 in the 
presence of virus set to 100%. Statistical comparisons were carried out using a two-way ANOVA with Tukey’s 
multiple comparisons post-test. Stars above bars indicate significance comparing each concentration to its own 
control in the absence of virus, with **** indicating p<0.0001. 
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Taken together, the results from this chapter show that MPA-induced HIV infection requires the GR 
in TZM-bl cells, and the unliganded GR plays an important role in protecting against HIV-1 infection 
in TZM-bl cells. In general, the presence of PR-B appears to increase susceptibility to HIV-1 infection 
in TZM-bl cells and alters the GR-regulated MPA-induced and ligand-independent expression of 
some key immunomodulatory genes such as IL-6, in End1/E6E7 and/or HeLa cells. Secreted soluble 
mediators change in response to changing relative GR/PR levels in End1/E6E7 and TZM-bl cells. A 
combination of these soluble mediators, but likely not IL-6 alone, appear to mediate increased HIV-1 
infection in TZM-bl cells.  
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Chapter 5 
Modulation of GR activity by PR potentially occurs via GR-PR association 
and co-localization 
 
 
5.1 Background and aims 
 
The previous research chapter established that the relative levels of GR/PR influence HIV-1 infection 
and expression of genes relevant to immune function in the absence of exogenous ligand, with PR 
generally increasing infection and GR generally protecting against infection. In addition, some 
experiments revealed that the presence of PR-B may decrease the transcriptional activity of the 
liganded GR. For example, the presence of PR-B inhibited the GR-mediated immunosuppressive 
effect of MPA on IL-6 in both End1/E6E7 (Fig. 4.3.2.1b) and HeLa cells (Fig. 4.3.2.2b). Furthermore 
there are hints that GR may modulate PR activity. For example, in the presence of PR-B, basal IL-6 
mRNA in HeLa cells increased when GR levels were decreased (Fig. 4.3.2.3d, Fig. 4.3.3.1d) which 
might suggests that PR regulation of IL-6 might only occur with low GR. 
 
In light of this apparent co-regulation of HIV-1 infection and immunomodulatory gene expression by 
GR and PR-B, the question arose as to whether GR and PR regulate the same gene/s at the same time 
and whether the GR and PR reciprocally modulate each other’s activity. Within the scope of this 
study, the effect of PR-B on GR activity and the crude physical proximity of GR and PR were chosen 
as a starting point from which to investigate these broader issues. In addition it was investigated 
whether the presence of the less transcriptionally active PR isoform, PR-A, influenced the effects of 
PR-B on GR-mediated reporter gene regulation. 
 
The aims of this section were therefore to answer the following specific research questions: 
a) Does the PR-A/B inhibit the GR’s activity? 
b) Do GR and PR-B associate together? 
c) Are transiently expressed GR and PR-B co-expressed within the same cells? 
d) Do GR and P-BR co-localize in response to different ligands? 
 
In order to answer these questions, over-expressed (in COS1 or U2OS cells) or endogenously 
expressed (in MCF-7 cells) GR and/or PR were assessed for ligand-dependent regulation of the 
GR/PR-responsive TAT-GRE-LUC reporter gene, ligand-dependent co-immunoprecipitation of GR 
and PR, and ligand-dependent cellular co-localization of the GR and PR by confocal and super-
resolution microscopy. Dex and R5020 were used as GR- and PR-specific ligands, respectively, while 
MPA was used as a GR/PR agonist. 
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5.2 PR-A and PR-B individually repress GR-mediated activity on the TAT-GRE-LUC 
reporter gene in COS1 and U2OS cells over-expressing GR and/or PR 
 
PR-A has been shown to act as a transdominant repressor of transcriptional activity of PR-B in CV-1 
monkey kidney fibroblasts (Vegeto et al. 1993). This was confirmed in U2OS cells over-expressing 
PR-A and/or PR-B (Appendix B Fig. B5). Furthermore PR-A was demonstrated to inhibit the 
transcriptional activity of the GR in vitro (Vegeto et al. 1993). Interestingly some results from this 
study – such as PR-B altering GR-mediated anti-inflammatory regulation of IL-6 (Fig. 4.3.2.1b, Fig. 
4.3.2.2b) - point towards PR-B as a potential inhibitor of GR activity. 
 
In order to further test the effect of PR-B on GR-mediated activity, monkey fibroblast COS1 cells 
over-expressing GR and PR-A and/or PR-B were assessed for their ligand-dependent activation of the 
TAT-GRE-LUC reporter gene. 
 
In the absence of over-expressed GR, the TAT-GRE-LUC reporter gene was significantly induced 
3.7-fold by Dex, most likely mediated by the low levels of endogenous GR in COS1 cells (Fig. 
5.2.1a). In the presence of over-expressed GR this Dex induction increased considerably to a 
significant 171-fold (Fig. 5.2.1a). In the presence of PR-A or PR-B alone, this Dex-induced reporter 
gene activity was significantly reduced to 117-fold or 94-fold, respectively, but when both PR-A and 
PR-B were over-expressed together, the repression of the Dex-induced response was lifted back to 
193-fold induction (Fig. 5.2.1a). 
 
For simplification, only the Dex-induced statistical differences are shown in Figure 5.2.1a, but other 
significant differences were also observed with R5020 and MPA. MPA significantly induced the 
TAT-GRE-LUC reporter gene in the presence of GR alone (48-fold), GR with PR-B (110-fold) and 
GR with both PR-A and PR-B (83-fold), but not GR with PR-A (21.5-fold, p=0.589, Fig. 5.2.1a). 
Similarly, R5020 significantly induced TAT-GRE-LUC in the presence of GR with PR-B (210-fold) 
and GR with both PR-A and PR-B (67-fold, Fig. 5.2.1a). As expected, the R5020-induced response 
was significantly greater in the presence of PR-B (210-fold) than PR-A (6.2-fold, Fig. 5.2.1a), since 
PR-B is more transcriptionally active than PR-A. Furthermore, consistent with the repressive function 
of PR-A on PR-B, R5020-induced activation of TAT-GRE-LUC was significantly lower when both 
PR-A and PR-B were present (67-fold) compared to PR-B only (210-fold, Fig. 5.2.1a).  Over-
expression of GR and PR was confirmed by western blotting (Fig. 5.2.1b) and densitometric analysis 
(Fig. 5.2.1c-e). 
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Figure 5.2.1. PR-A and PR-B individually, but not together, repress Dex-induced activation of 
the TAT-GRE-LUC reporter gene by GR in COS1 cells. (a) Cells were seeded at 7 X 104/well in 24-
well plates and allowed to adhere overnight. Cells were subsequently transfected with 125 ng pcDNA3-hGR 
and/or pSG5-hPR-A and/or pMT-hPR-B and/or pcDNA3.1 and 47 ng pTAT-GRE-E1b-LUC for 24 h. Cells 
were stimulated in triplicate wells with 100 nM final concentration of the indicated ligands in SF-DMEM for 24 
h, then washed and harvested in Reporter Lysis Buffer. Luciferase activity and total protein were measured. 
Luciferase activity was normalized to average protein concentration in mg/mL. Fold change was determined 
relative to each vehicle control set to 1. Data are pooled from 4 independent experiments where each point was 
in triplicate. (b) The remaining cell lysates were harvested in SDS sample buffer and analyzed for GR and PR-
A/B levels by western blotting using GAPDH as a loading control. Blots were probed first for PR then stripped 
and re-probed for GR. A representative western blot is shown (b). Western blots were scanned and quantified 
for relative GR (c), PR-A (d) or PR-B (e) levels by calculating integrated density values. Protein levels are 
plotted relative to the pcDNA3 empty vector control set to 1. Statistical comparisons were carried out using a 
two-way ANOVA with Tukey’s multiple comparisons post test (a) or a non-parametric Mann-Whitney t-test (c, 
-GR vs +GR) or a parametric unpaired t-test (c- e). Stars above bars indicate significant differences compared to 
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each vehicle control (a) or empty vector (-GR/PR-A/PR-B) control (c-e) unless otherwise indicated by lines, 
where ****, *** and * indicate p<0.0001, p<0.001 and p<0.05 respectively. 
 
In order to test whether these observations were reproducible in a different cell line, human U2OS 
cells over-expressing GR and PR-A and/or PR-B were assessed for their ligand-dependent activation 
of the TAT-GRE-LUC reporter gene using the same protocol as for COS1 cells. 
 
In U2OS cells, the TAT-GRE-LUC reporter gene was not induced by Dex in the absence of over-
expressed GR and PR (Fig. 5.2.2a). However, in the presence of over-expressed GR, Dex 
significantly increased reporter gene expression by 117-fold (Fig. 5.2.2a). Similar to COS1 cells, in 
the presence of PR-A or PR-B alone, Dex-induced reporter gene activity was significantly reduced to 
91-fold or 58-fold, respectively, but when both PR-A and PR-B were over-expressed together, the 
repression of the Dex-induced response was lifted back to 119-fold induction (Fig. 5.2.2a). This 
observation in both COS1 and U2OS cells is consistent with the apparent dampening of endogenous 
GR-mediated transcriptional regulation by Dex of endogenous GILZ in the presence of over-
expressed PR-B in End1/E6E7 cells (Appendix B, Fig. B4.4a). 
 
As for COS1 cells, only the Dex-induced statistical differences are shown in Figure 5.2.2a for U2OS 
cells, but R5020- and MPA-induced significant differences were also observed. The TAT-GRE-LUC 
reporter gene was significantly induced by MPA with GR alone (47-fold), GR with PR-B (75-fold) 
and GR with both PR-A and PR-B (28-fold), but not GR with PR-A (8-fold, p=0.6577, Fig. 5.2.2a). 
TAT-GRE-LUC was also significantly induced by R5020 in the presence of GR with PR-B (158-fold) 
and GR with both PR-A and PR-B (49-fold).  
 
In addition, as for COS1 cells, the R5020-induced response was significantly greater in the presence 
of PR-B (158-fold) than PR-A (5.8-fold, Fig. 5.2.2a) for U2OS cells, although the difference was 
greater for COS1 cells. Also like COS1 cells, R5020-induced activation of TAT-GRE-LUC was 
significantly lower when both PR-A and PR-B were present (49-fold) compared to PR-B only (158-
fold, Fig. 5.2.2a).  Over-expression of GR and PR was confirmed by western blotting (Fig. 5.2.2b) 
and densitometric analysis (Fig. 5.2.2c-e). The differences in absolute fold changes between COS1 
and U2OS cells may be attributed to different levels of endogenous GR (Appendix B, Fig. B6.1), 
different transfection efficiencies and/or other biological differences arising between cell lines from 
different species. Taken together, these data suggest that PR-B inhibits the GR-mediated activity on a 
reporter gene in both cell lines. 
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Figure 5.2.2. PR-A and PR-B individually, but not together, repress Dex-mediated activation of 
the TAT-GRE-LUC reporter gene by GR in U2OS cells. (a) Cells were seeded at 7 X 104/well in 24-
well plates and allowed to adhere overnight. Cells were subsequently transfected, stimulated and harvested as 
described for COS1 cells (Fig. 5.2.1).  Luciferase activity was normalized to average protein concentration in 
mg/mL. Fold change was determined relative to each vehicle control set to 1. Data are pooled from 3 
independent experiments where each point was in triplicate. (b) The remaining cell lysates were harvested in 
SDS sample buffer and analyzed for GR and PR-A/B levels by western blotting using GAPDH as a loading 
control. Blots were probed first for PR then stripped and re-probed for GR. A representative western blot is 
shown (b). Western blots were scanned and quantified for relative GR (c), PR-A (d) or PR-B (e) levels by 
calculating integrated density values. Protein levels are plotted relative to the pcDNA3 empty vector control set 
to 1. Statistical comparisons were carried out using a two-way ANOVA with Tukey’s multiple comparisons post 
0
2
4
6
U 2 O S
G R  p ro te in  le v e ls
n = 3
R
e
la
ti
v
e
 I
n
te
g
r
a
te
d
 D
e
n
s
it
y
 V
a
lu
e
(G
R
/G
A
P
D
H
)
E
m
p
ty
 v
e
c
to
r
 c
o
n
tr
o
l 
s
e
t 
to
 1
G R
P R -A
P R -B
-
-
-
+
-
-
+
+
-
+
-
+
+
+
+
p = 0 .0 7
p = 0 .0 7
p = 0 .1 3
p = 0 .0 9
0
2 0
4 0
6 0
8 0
U 2 O S
P R -A  p ro te in  le v e ls
n = 4
R
e
la
t
iv
e
 I
n
te
g
r
a
t
e
d
 D
e
n
s
it
y
 V
a
lu
e
(
P
R
-
A
/G
A
P
D
H
)
E
m
p
t
y
 v
e
c
t
o
r
 c
o
n
t
r
o
l 
s
e
t
 t
o
 1
G R
P R -A
P R -B
-
-
-
+
-
-
+
+
-
+
-
+
+
+
+
*
p = 0 .1
0
2
4
6
8
U 2 O S
P R -B  p ro te in  le v e ls
n = 3
R
e
la
ti
v
e
 I
n
te
g
r
a
te
d
 D
e
n
s
it
y
 V
a
lu
e
(P
R
-B
/G
A
P
D
H
)
E
m
p
ty
 v
e
c
to
r
 c
o
n
tr
o
l 
s
e
t 
to
 1
G R
P R -A
P R -B
-
-
-
+
-
-
+
+
-
+
-
+
+
+
+
* p = 0 .1 2
V
e
h
ic
le
 
D
e
x
R
5
0
2
0
M
P
A
V
e
h
ic
le
 
D
e
x
R
5
0
2
0
M
P
A
V
e
h
ic
le
 
D
e
x
R
5
0
2
0
M
P
A
V
e
h
ic
le
 
D
e
x
R
5
0
2
0
M
P
A
V
e
h
ic
le
 
D
e
x
R
5
0
2
0
M
P
A
0
5
1 0
1 5
5 0
1 0 0
1 5 0
2 0 0
2 5 0
3 0 0
3 5 0
4 0 0
U 2 O S
T A T -G R E -L U C
n = 3
L
u
c
if
e
r
a
s
e
 a
c
ti
v
it
y
 (
R
L
U
/[
m
g
/m
L
])
E
a
c
h
 V
e
h
ic
le
 s
e
t 
to
 1
G R
P R -A
P R -B
-
-
-
+
-
-
+
+
-
+
-
+
+
+
+
* * * *
* * * *
* * * *
* * * *
* * * *
* * * *
* * * *
* * * *
* * * *
a) 
b) 
c) d) e) 
103 
 
test (a) or a parametric unpaired t-test (c-e). Stars above bars indicate significant differences compared to each 
vehicle control (a) or empty vector (-GR/PR-A/PR-B) control (c-e) unless otherwise indicated by lines, where 
**** and * indicate p<0.0001 and p<0.05 respectively. 
 
 
5.3 GR and PR associate in the same protein complex 
 
In order to test the hypothesis that the presence of PR modulates the activity of GR by the receptors 
associating with each other, the ability of GR and PR to co-immunoprecipitate was investigated in 
COS1 cells over-expressing GR and PR-B. These cells were chosen as they express very low levels of 
endogenous GR and are readily transfected in order to over-express GR and PR. 
 
PR-B was co-immunoprecipitated with anti-GR antibody, both in the absence and presence of MPA, 
although there was greater co-immunoprecipitation with MPA in the indicated western blot (Fig. 
5.3.1a) and in total for three out of five experiments (Fig. 5.3.1b). When experiments were pooled 
together (n=5) however, the 2.4-fold greater PR-B co-immunoprecipitation in response to MPA 
compared to the vehicle control was not statistically significant (Fig. 5.3.1b). Therefore it cannot be 
concluded that PR-B co-immunoprecipitation with GR is a ligand-dependent interaction. In all 
experiments, PR protein was not detected in the input samples (Fig. 5.3.1a, b), which may be due to 
low levels of PR below the limit of detection by western blot. As expected, GR was 
immunoprecipitated with anti-GR antibody in the presence compared to the absence of over-
expressed GR (Fig. 5.3.1a, c). A faint GR band is visible in the control lane (-GR), which most likely 
indicates the low levels of endogenous GR in COS1 cells (Fig. 5.3.1a). GR protein was only detected 
in the input samples in which GR was over-expressed (Fig. 5.3.1a, c). 
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Figure 5.3.1. PR-B is co-immunoprecipitated with anti-GR antibody in COS1 cells over-
expressing GR and PR. COS-1 cells were seeded at 1.5 X 106/dish in 10 cm dishes and allowed to adhere 
overnight. Cells were then transiently transfected with 3 μg pMT-hPR-B and 3 μg pcDNA3.1 or pcDNA3-hGR 
for 24 h and stimulated with 1 μM MPA, using EtOH as the vehicle control, for 1 h. Cells were lysed and an 
aliquot was analysed by western blotting for input levels of GR and PR-B. The remaining cell lysate was 
immunoprecipitated with anti-GR antibody and magnetic protein A/G beads. Co-immunoprecipitated proteins 
were analysed by western blotting on separate blots for GR and PR-B to ensure no cross-reaction between anti-
GR or –PR antibodies. A western blot showing the biggest differences is shown (a). GR (95 kDa) and PR-B 
(114 kDa) were identified by size relative to the protein molecular weight marker. Western blots were scanned 
and quantified for relative PR-B (b) and GR (c) levels by calculating integrated density values. Protein levels are 
plotted relative to the vehicle control for both IP and input. The data are pooled from 5 independent 
experiments. Statistical comparisons were carried out using parametric unpaired t-tests (b, c) or a non-
parametric Wilcoxon t-test (c, input Vehicle vs MPA). Stars above bars indicate significant differences 
compared to each vehicle control (b, c) unless otherwise indicated by lines, where ** and * indicate p<0.01 and 
p<0.05 respectively. 
 
 
In order to eliminate any confounding factors introduced by transient transfection, the potential 
association of GR and PR was also investigated by co-IP in MCF-7 cells. These cells were chosen as 
they express detectable levels of both endogenous GR and PR. 
 
In MCF-7 cells, PR was co-immunoprecipitated with anti-GR antibody, both in the absence and 
presence of MPA (Fig. 5.3.2a, b). No significant difference between the vehicle control and MPA 
stimulation was observed, suggesting that the GR-PR association does not depend on MPA (Fig. 
5.3.2b). As expected, GR was immunoprecipitated independent of stimulation with ligand (Fig. 
5.3.2a, c). The lack of signal in the IgG control lane (sample incubated with anti-rabbit secondary 
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antibody) confirmed that PR and GR pull-down were specific (Fig. 5.3.2b, c). Equal GR and PR 
levels in the input samples were also observed (Fig. 5.4b, c), although PR-A protein levels appeared 
to be greater than PR-B (Fig. 5.3.2a). While both PR-A and PR-B were distinguishable in the input 
lanes, due to over-exposure of the western blot, the isoform that predominantly co-
immunoprecipitates with GR cannot be conclusively identified (Fig. 5.3.2a), but is labelled as PR-B 
for densitometric analysis (Fig. 5.3.2b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.2. PR is co-immunoprecipitated with anti-GR antibody in both the absence and 
presence of MPA in MCF-7 cells endogenously expressing both GR and PR. MCF-7 cells were 
seeded at 1.5 X 10
6
/dish in 10 cm dishes and allowed to adhere for 48 h. Cells were then stimulated with 1 μM 
MPA, using EtOH as the vehicle control, for 1 h. Cells were lysed and an aliquot was analysed by western 
blotting for input levels of GR and PR. The remaining cell lysate was immunoprecipitated with anti-GR 
antibody (Vehicle, MPA) and magnetic protein A/G beads. As a control, a mixture of equal volumes of Vehicle 
and MPA-stimulated cell lysates was incubated with anti-rabbit secondary antibody (IgG). Co-
immunoprecipitated proteins were analysed by western blotting on separate blots for GR and PR-B to ensure no 
cross-reaction between anti-GR or –PR antibodies. A western blot showing the biggest differences is shown (a). 
GR (95 kDa), PR-A (95 kDa) and PR-B (114 kDa) were identified by size relative to the protein molecular 
weight marker. Western blots were scanned and quantified for relative PR-B (b) and GR (c) levels by 
calculating integrated density values. Protein levels are plotted relative to the vehicle control for both IP and 
input. The data are pooled from 3 independent experiments. Statistical comparisons were carried out using 
parametric unpaired t tests. Stars above bars indicate significant differences compared to each vehicle control (b, 
c) unless otherwise indicated by lines, where *** and * indicate p<0.001 and p<0.05 respectively. 
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In order to determine whether GR could also co-immunoprecipitate with PR, the reciprocal pull-down 
assay was carried out in MCF-7 cells. While PR was immunoprecipitated with anti-PR antibody, and 
GR protein was detectable in the input samples, there was insufficient GR protein co-
immunoprecipitated with anti-PR for detection by western blotting (data not shown). This avenue 
warrants further investigation, since GR-PR association should be confirmed by a reciprocal co-IP 
assay. Nevertheless, taken together, these results suggest that GR and PR associate, within the same 
protein complex in a ligand-independent manner, both in COS1 cells over-expressing GR/PR and in 
MCF-7 cells expressing endogenous GR/PR. 
 
 
5.4 GR and PR are co-expressed within the same cells 
 
Crucial to the interpretation of reporter gene results in COS1 cells over-expressing GR and PR is the 
confirmation that GR and PR are co-expressed within the same cells. This would ensure the overall 
result is not a reflection of populations of cells expressing only GR or only PR. In order to test that 
GR and PR are expressed together in the same cells, COS1 cells were transfected and stimulated with 
Dex, R5020 or MPA using the same protocol used in the reporter assay (Fig. 5.2.1) and analyzed 
visually for transfected cells by immunofluorescence using confocal microscopy. 
 
Overall only 17% of cells were successfully transfected. However, of those cells that were transfected, 
80% expressed both GR and PR together (Fig. 5.4a). A small percentage of cells expressed only PR 
(12%) or only GR (8%, Fig. 5.4a). When further divided according to ligand stimulation or vehicle 
control, 70-90% of transfected cells expressed both GR and PR together (Fig. 5.4.1b). 
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Figure 5.4. GR and PR are co-expressed within the same cells, in COS1 cells over-expressing 
GR and PR. COS1 cells were seeded at 1 X 105 cells/well in 6 well plates containing sterilized coverslips and 
allowed to adhere overnight. Cells were transiently transfected with 125 ng each pcDNA3-hGR, pMT-hPR-B 
and pSG5-hPR-A for 24 h, then stimulated with 100 nM final concentration of Dex, R5020 or MPA in SF-
DMEM for 24 h, with 0.1% (v/v) EtOH as the vehicle control. Coverslips were washed, stained with anti-GR 
and anti-PR primary antibodies, fluorophore-conjugated secondary antibodies and Hoechst for nuclear staining. 
Coverslips were then mounted onto glass slides prior to immunofluorescence visualization using a confocal 
microscope. Images captured were counted manually for the number of transfected cells expressing GR and/or 
PR. The data shown are pooled from 3 independent experiments, containing 4-7 fields of view captured per slide 
and 1-30 cells per field of view. (a) percentages of combined transfected cells expressing GR only, PR only or 
both GR and PR. (b) percentages of transfected cells classified by ligand expressing GR only, PR only or both 
GR and PR. The total number of transfected cells analysed is indicated by the n value under each ligand. 
 
 
These results confirm that GR and PR are co-expressed within the same cells, in COS1 cells 
transiently transfected with GR and PR and stimulated with GR- and/or PR-specific ligands.  
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5.5 PR is mostly nuclear while GR is located in both the cytoplasm and nucleus 
 
The cellular distribution (i.e. nuclear or cytoplasmic localization) of GR and PR in response to Dex, 
R5020 or MPA in the COS1 cells over-expressing both GR and PR was also assessed by 
immunofluorescence. The localization was determined by visual examination of the fluorescent 
images and estimated to be nuclear when the fluorescent signal of the PR (red) or GR (green) channel 
overlapped with the blue signal of the nuclear stain (Hoechst, Fig. 5.6.1). 
 
While PR is expected to be localized in the nucleus in the absence and presence of PR ligands, GR is 
expected to translocate from the cytoplasm into the nucleus upon activation by GR ligands. Consistent 
with this, PR was entirely nuclear in response to R5020 and MPA (Fig. 5.5a). For Dex and the vehicle 
control, about 25% of cells showed PR localization in both the cytoplasm and nucleus, with PR being 
entirely nuclear in the remaining cells (Fig. 5.5a). No PR was localized to the cytoplasm only in any 
of the conditions (Fig. 5.5a). 
 
In the absence of ligands, GR was localized to the cytoplasm only in 35% of cells and to both the 
cytoplasm and nucleus in 62% of cells (Fig. 5.5b), suggesting that not all GR resides in the cytoplasm 
in the absence of ligands. Upon stimulation with any of the ligands, no GR was localized to the 
cytoplasm only (Fig. 5.5b). With Dex stimulation, GR was localized to the nucleus only in 28% of 
cells, and localized to the cytoplasm and nucleus in the remaining 72% of cells (Fig. 5.5b). In 
response to MPA, GR was entirely nuclear in 78% of cells, and localized to both the cytoplasm and 
nucleus in 28% of cells (Fig. 5.5b). Surprisingly, GR was entirely nuclear in 74% of cells stimulated 
with R5020, and both cytoplasmic and nuclear in the remaining 22% of cells (Fig. 5.5b). This 
suggests that GR can translocate into the nucleus in response to R5020, supposedly a PR-specific 
ligand (Fig. 5.5b).  
 
Taken together, these results show that the PR is mostly localized to the nucleus ligand-
independently, while the GR is both cytoplasmic and nuclear in the absence of ligands but is mostly 
nuclear in response to GR- and PR-specific ligands. This suggests that in COS1 cells expressing both 
GR and PR, there is overlapping GR/PR localization in the nucleus in both the presence and absence 
of ligands. 
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Figure 5.5. Increased nuclear versus cytoplasmic localization of GR and PR is observed in 
response to R5020 and MPA compared to the vehicle control in COS1 cells over-expressing both 
GR and PR. COS1 cells were prepared on glass slides as for Fig. 5.4 and visualized using a confocal 
microscope. Images captured were counted manually for the number of cells containing GR and PR localized to 
the nucleus and/or cytoplasm. Images shown are representative of 3 independent experiments, containing 4-7 
fields of view captured per slide and 1-30 cells per field of view.  Data shown are percentage of PR (a) or GR 
(b) expressed in the cytoplasm only, nucleus only or both cytoplasm and nucleus. The total number of 
transfected cells analysed is indicated by the n value under each ligand in Fig. 5.4b. 
 
 
 
5.6 GR and PR co-localize in the nucleus in response to GR- and/or PR-specific ligands 
 
Following the observation that GR and PR are expressed within the same COS1 cells and they both 
localize to the nucleus in the absence and presence of ligands, nuclear co-localization of GR and PR 
was quantified by immunofluorescence in the absence and presence of ligands. Whether or not GR 
and PR co-localize was determined here by whether signals within one fluorescent channel co-localize 
with signals in the other fluorescent channel. The extent of co-localization was quantified using a 
variety of parameters: the Manders co-localization coefficients, M1 and M2, which represent the 
proportion of GR signals overlapping with PR signals (M1) and the proportion of PR signals 
overlapping with GR signals (M2); and the Manders-derived overlap coefficient (O) which represents 
the degree of overlap between the two channels (Manders et al. 1993, Bolte and Cordelieres 2006). 
With M1/M2, co-localization is inferred with values between 0.5 and 1, for both channels; whereas no 
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co-localization is indicated when values are between 0 and 0.5. For the overlap coefficient O, co-
localization is inferred by values between 0.6 and 1, and no co-localization indicated by values 
between 0 to 0.6 (Bolte and Cordelieres 2006). However, it should be noted that co-localization, as 
determined by this method, can only be used to suggest close spatial co-occurrence or a possible GR-
PR association, given that co-localization cannot prove that the two receptors inhabit the same space, 
due to resolution limitations. 
 
The white regions of the representative merged overlay images (Fig. 5.6.1) suggest that the detectable 
signals for GR and PR overlap in the nucleus in response to the ligands Dex, R5020 and MPA, but not 
the vehicle control, where GR was mostly cytoplasmic and PR was mostly found in the nucleus. 
Quantification of co-localization for all pooled experiments confirmed that GR and PR do not appear 
to co-localize in the absence of ligands (Table 5.6.1).  
 
In the presence of the GR-specific agonist Dex, 83% of GR significantly co-localized with PR (M1) 
and 76% of PR significantly co-localized with GR (M2, Table 5.6.1), suggesting GR and PR co-
localize in response to Dex. In the presence of the PR-specific agonist R5020, 84% of GR 
significantly co-localized with PR (M1) but only 61% of PR co-localized with GR (not significant, 
M2, Table 5.6.1). For the GR/PR agonist MPA, 74% of GR near-significantly co-localized with PR 
(M1) and 77% of PR significantly co-localized with GR (M2, Table 5.6.1), suggesting that GR and 
PR co-localize in response to MPA, similar to R5020. Consistent with the above M1/M2 values, the 
overlap coefficients (O) indicate significant GR/PR nuclear co-localization occurs in response to Dex, 
R5020 and MPA (Table 5.6.1). 
 
 
Table 5.6.1. Quantification of co-localization of GR and PR in COS1 cells in response to Dex, 
R5020 and MPA using confocal microscopy.  
 
 GR co-localized with 
PR (M1) 
PR co-localized 
with GR (M2) 
Overlap (O) 
 
 
n Mean SEM Mean SEM Mean SEM 
Vehicle 22 0.483 0.074 0.39 0.078 0.666 0.044 
Dex 46 0.83
*
 0.041 0.76
**
 0.05 0.866
****
 0.023 
R5020 
29 
0.84
***
 0.061 0.61 0.072 0.821
***
 0.017 
MPA 
31 
0.741
p=0.0561
 0.063 0.765
***
 0.062 0.857
****
 0.016 
Data are shown for 3 independent experiments. Number of GR/PR-expressing cells evaluated is indicated by n 
value for each condition. Statistical comparisons were carried out comparing ligands to the vehicle control using 
a non-parametric Kruskal-Wallis ANOVA with Dunn’s post-test (M1, M2) or a parametric one-way ANOVA 
with Dunnett’s post-test (O). Stars next to the mean values indicate significance compared to the vehicle control, 
with ****, ***, ** and * indicating p<0.0001, p<0.001, p<0.01 and p<0.05 respectively. 
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Figure 5.6.1. GR and PR co-localize in the nucleus in response to Dex, R5020 and MPA in COS1 
cells over-expressing both GR and PR. COS1 cells were prepared on glass slides as for Fig. 5.4 and 
visualized using a confocal microscope. Images shown are representative of 3 independent experiments, 
containing 4-7 fields of view captured per slide and 1-30 cells per field of view. The green channel indicates 
detection of GR, the red channel indicates detection of PR and the blue channel indicates the nuclei by Hoechst 
staining. The merge panel indicates overlay of the red, green and blue channels. Quantification of co-
localization was carried out on the merged images using ZEN software, generating the co-localization panel. 
Yellow regions in the merge panel and white regions in the co-localization panel indicate overlap of the red and 
green channels. The control panel represents the secondary antibody-only control slide. Co-localization was 
quantified using Manders coefficients (Table 5.6.1). M: Manders co-localization coefficient; indicates the mean 
coefficient across the double positive transfected cells showing the degree of red (PR) in the green (GR) channel 
and the degree of green (GR) in the red (PR) channel. O: Overlap coefficient; indicates the mean overlap 
coefficient across the double positive transfected cells showing the degree of overlap of the two channels. The 
scale bar (red) indicates 20 μm. 
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The observation that GR translocated into the nucleus in response to R5020, led to the concern that 
R5020 was perhaps activating the GR. In order to test this idea, the activation of over-expressed GR 
on the reporter gene TAT-GRE-LUC in response to increasing doses (1 pM-1 μM final concentration) 
of Dex, MPA, P4 and R5020 was assessed (Fig. 5.6.2). GR over-expression was confirmed by western 
blotting (Fig. 5.6.2b).  
 
 
 
 
 
 
 
 
 
 Dex MPA P4 R5020 
Efficacy (% ± SEM) 97.15 ± 3.863 95.22 ± 4.278 28.42 ± 4.026 4.141 ± 6.06 
Potency/ EC50 (M) 3.937 e-009 1.170 e-008 3.189 e-006 N/A 
 
 
Figure 5.6.2. The PR agonist R5020, like P4, does not transactivate the TAT-GRE-LUC reporter 
gene in COS1 cells over-expressing GR. COS1 cells were seeded in 10 cm dishes at 1 X 106/dish and 
allowed to adhere overnight. Cells were subsequently transfected with 10 μg pcDNA3-hGR and 3 μg pTAT-
GRE-E1b-LUC for 24 h. Cells were re-seeded at 2.5 X 10
4
 cells/well in 96-well plates and allowed to adhere for 
24 h. Ligands were prepared by serial dilutions in 100% ethanol from a 10 mM ligand stock. Cells were 
stimulated in triplicate wells with ligands at the indicated final concentrations (10 pM - 10 μM) in SF-DMEM 
for 24 h, then washed and harvested in Reporter Lysis Buffer. (a) Luciferase activity and total protein were 
measured, with luciferase activity normalized to average protein concentration in mg/mL. For the dose response 
curve, data were analysed with the maximal response (10 μM Dex) set to 100%. A non-linear regression model 
was carried out by plotting log agonist versus response with the Hill slope set to 1. (b) Cells seeded and 
transfected in parallel were harvested in SDS sample buffer and lysates were analyzed for GR levels by western 
blotting using GAPDH as a loading control. A representative western blot is shown. (c) Efficacy and potency for 
each ligand were calculated using GraphPad Prism 5. The results are pooled from 3 (R5020) or 4 (Dex, MPA, 
P4) independent experiments where each point was in triplicate.  
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With Dex as the reference full GR agonist, dose response curves were plotted in order to determine 
the relative efficacy (maximal response) and potency (effective concentration required for 50% of 
maximal response) of each ligand (Fig. 5.6.2c). MPA reached a similar maximal response to Dex, 
however the efficacies for the highest concentration (10 μM) of P4 and R5020 were only 28% and 4%, 
respectively, relative to Dex (Fig. 5.6.2a, c). The order of ligands in terms of potency was Dex > MPA 
> P4 (Fig. 5.6.2c). These results suggest that the concentration of R5020 used in the gene expression 
studies (100 nM) is unlikely to activate the GR (Fig. 4.3.2.1-4.3.2.2). However the nuclear 
translocation of GR in response to R5020 warrants further investigation. 
 
In order to obtain greater confidence in the co-localization results obtained with confocal microscopy, 
and to further indicate the close physical proximity of the GR and PR, nuclear co-localization was 
further investigated using super-resolution structured illumination microscopy (SR-SIM). This 
technique improves resolution by about 2-fold. Slides of COS1 cells used for the confocal microscopy 
were re-analyzed using SR-SIM (Fig. 5.6.3) and nuclear co-localization of GR and PR was quantified 
(Table 5.6.2). Channel alignment with commercial fluorescent beads was set up prior to imaging to 
calibrate the microscope.  
 
In addition to the Manders co-localization coefficients, M1 and M2, and the Manders derivative 
overlap coefficient, O, the Pearson’s correlation coefficient (P) was calculated using SR-SIM. P 
represents the correlation between the channels’ distributions of intensity and is considered the 
simplest co-localization coefficient. Co-localization is indicated by a P value of 0.5 to 1, with no co-
localization indicated by a value of -1 to 0.5. 
 
Consistent with the confocal microscopy data, representative SR-SIM images indicate that GR and PR 
co-localized in the nucleus in response to Dex, R5020 and MPA, while GR was mostly cytoplasmic 
and PR appeared to be entirely nuclear for the vehicle control (Fig. 5.6.3). 
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Figure 5.6.3. GR and PR co-localize in the nucleus in response to Dex, R5020 and MPA, unlike 
the vehicle control, in COS1 cells over-expressing both GR and PR. COS1 cells were prepared on 
glass slides as for Fig. 5.4 and visualized using super-resolution SIM. Images were captured and pre-processed 
and co-localization was quantified on two z-stacks per image (Table 5.6.2). Images shown are representative of 
3 independent experiments, with 3-4 fields of view captured per slide and 1-3 cells per field of view. The scale 
bar (red) indicates 10 μm. 
 
Co-localization was implied when both Manders coefficients (M1 and M2) were between 0.5 and 1. 
Based on this criteria, no co-localization between GR (M1: 0.437) and PR (M2: 0.792) was indicated 
in the absence of ligands (Table 5.6.2). Following ligand stimulation, however, the Manders 
coefficients indicated GR-PR co-localization in response to Dex (M1: 0.708, M2: 0.831), R5020 (M1: 
0.629, M2; 0.836) and MPA (M1: 0.696, M2: 0.831, Table 5.6.2). However only M1 coefficients for 
Dex and MPA were statistically significant (Table 5.6.2). Interestingly, the Manders co-localization 
coefficients obtained here (M1, M2 and O) were lower than those determined by confocal microscopy 
(Table 5.6.1), suggesting that the extent to which GR and PR co-localize may be over-estimated by 
confocal microscopy. 
Vehicle
Dex
R5020
MPA
10 μm10 μm 10 μm 10 μm
10 μm 10 μm 10 μm10 μm
MergeHoechstPRGR
10 μm
10 μm
10 μm 10 μm
10 μm10 μm 10 μm 10 μm
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The finding that both the Manders overlap coefficient (O) and the Pearson’s correlation coefficient (P) 
were less than 0.5 indicated that no co-localization between GR and PR was observed in the absence 
of ligands (Table 5.6.2). In contrast, in the presence of ligands, O and P indicated significant GR-PR 
nuclear co-localization occurs in response to Dex, R5020 and MPA (Table 5.6.2). 
 
Taken together, these co-localization parameters are consistent with a ligand-dependent nuclear co-
localization between GR and PR, which suggests that GR and PR are likely to be within close 
physical proximity of each other in the nucleus of COS1 cells stimulated with Dex, R5020 or MPA. 
 
 
Table 5.6.2. Quantification of co-localization of GR and PR in COS1 cells in response to Dex, 
R5020 and MPA using super-resolution microscopy. 
 
  
GR co-localized with 
PR (M1) 
 
PR co-localized with 
GR (M2) 
 
Overlap coefficient 
(O) 
 
Pearson's coefficient 
(P) 
 
  Mean SEM Mean SEM Mean SEM Mean SEM 
Vehicle 
(n=8) 0.437 0.087 0.792 0.0297 0.375 0.049 0.322 0.050 
Dex  
(n=8) 0.708* 0.069 0.831 0.049 0.748*** 0.072 0.734**** 0.077 
R5020 
(n=8) 0.629 0.049 0.836 0.049 0.619* 0.054 0.604** 0.057 
MPA 
(n=7) 0.696* 0.077 0.831 0.047 0.681** 0.041 0.667** 0.043 
 
Co-localization coefficients were calculated using JACoP in ImageJ. The data are from 3 independent 
experiments, where 2-4 images were captured for each condition and a single z-stack was quantified per image. 
The n value indicates the number of GR/PR-expressing cells evaluated. Statistical comparisons were carried out 
using a parametric one-way ANOVA with Dunnett’s post-test. Stars next to the mean value indicate significance 
compared to the vehicle control, with ****, ***, ** and * indicating p<0.0001, p<0.001, p<0.01 and p<0.05 
respectively. 
 
 
Upon closer examination of the enlarged images, there appeared to be regions within the nucleus that 
expressed only GR (green), only PR (red) or both together (yellow), and that these regions were 
expressed adjacent to each other throughout the nucleus (Fig. 5.6.4). The yellow regions were more 
evident with the ligand stimulations compared to the vehicle control (Fig. 5.6.4) but varied in 
frequency depending on the position of the z-stack (not shown). Furthermore there were pockets of 
the nucleus where only blue stain was observed, which most likely indicates regions of DNA 
inaccessible to transcription factors (Fig. 5.6.4).  
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These results suggest that although there are regions in the nucleus that contain only the GR or only 
the PR, there are indeed areas throughout the nucleus where GR and PR do co-localize in the presence 
of ligands. Taken together, the results in this chapter support the previous findings that PR-B 
modulates the activity of the GR, and that this potentially occurs through GR-PR association and co-
localization in some regions of the nucleus, in a ligand-dependent manner. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6.4. Super-resolution microscopy indicates GR- and PR-specific regions, as well as co-
localized regions, within the nucleus of COS1 cells over-expressing GR and PR. COS1 cells were 
prepared on glass slides as for Fig. 5.4.1 and visualized using SR-SIM. Representative image of a COS1 cell 
(left) with enhanced zoom (right). Arrows indicate a representative GR-specific region (green), PR-specific 
region (red), co-localized region (yellow) and condensed DNA (white). The scale bar (red) indicates 10 μm. 
a) 
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Chapter 6 
Discussion 
 
 
 
Many women of reproductive age in Sub-Saharan Africa who are at the highest risk for HIV-1 
acquisition also use the progestin-only injectable contraceptive DMPA (Butler et al. 2013). It is 
therefore crucial to understand whether, and how, MPA increases HIV-1 infection in HIV-1 target 
cells, in order to enable women at high HIV-1 risk to make informed contraceptive choices. 
 
The lower FRT is the primary site for heterosexual HIV-1 transmission and provides a protective 
physical and immunological barrier to infection. The FRT has its own immune system compared to 
the circulatory blood system (Givan et al. 1997, Haynes and Shattock 2008, Wira and Fahey 2008, 
Jespers et al. 2010, Hafner et al. 2013, Nguyen et al. 2014, Wira et al. 2015). The immune cells 
predominantly targeted for HIV-1 infection are CD4+ T cells (Pope and Haase 2003), which represent 
a portion of the immune cells within both the circulating peripheral blood and the cervix (Prakash et 
al. 2001, Nguyen et al. 2014, Trifonova et al. 2014, Lee et al. 2015).  
 
The present study used both primary cells and a cell line (PBMCs and TZM-bls) as models to 
investigate HIV-1 infection and mechanisms thereof between the P4-high luteal phase of the menstrual 
cycle, the P4-low follicular phase and contraception with the injectable MPA. Since MPA has been 
shown to activate the GR and the PR, the present study also expanded on the role of the GR and 
changing GR/PR levels on HIV-1 infection and regulation of genes relevant to HIV-1 infection. To 
this end, this study used HeLa and End1/E6E7 cells to investigate the effects of changing GR/PR 
levels on immunomodulatory gene expression, and COS1, U2OS and MCF-7 cells to explore the 
possible modulation of GR activity by the PR through protein association and nuclear co-localization.  
 
 
6.1 MPA and luteal phase hormones both increase HIV-1 infection, but via potentially 
different mechanisms 
 
Data from the present study show that while both MPA and luteal phase E2/P4 increase HIV-1 
infection in PBMCs, MPA but not luteal phase E2/P4 changes the frequency of immune cell 
populations and expression of other markers relevant to HIV-1 infection. This suggests that MPA-
induced HIV-1 infection may occur through different mechanisms to luteal phase E2/P4, unlike 
follicular phase E2/P4 which does not significantly alter HIV-1 infection in these models. 
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6.1.1 MPA and luteal phase E2/P4 increase HIV-1 infection 
 
The present study showed that stimulation with near-peak concentrations of the contraceptive 
progestin MPA (100 nM) increased HIV-1 infection in both PBMCs and TZM-bl cervical cells. 
Specifically, MPA significantly increased HIV-1 infection in PBMCs after both 2 and 7 days’ 
stimulation (Fig. 3.2.1, Fig 3.4.1.1a) and in TZM-bls after 2 days’ stimulation (Fig. 4.2.1.1a). 
 
The observation that MPA enhanced HIV-1 infection is consistent with other in vitro studies. For 
example, exogenous stimulation with MPA increased HIV-1 infection in activated PBMCs at 1 μM 
(Huijbregts et al. 2013) or 100 nM (Ray 2015), and non-activated PBMCs and ectocervical explants at 
10 nM (Ray et al. 2017). Another study showed that 1-12.5 nM MPA increased single-cycle 
replication of HIV-1 pseudovirus (Sampah et al. 2015). One study showed that exogenous MPA did 
not increase productive HIV-1 replication, but did increase the uptake of HIV-1 in primary genital 
epithelial cells (GECs) (Ferreira et al. 2015). The same study showed that growth media supernatants 
from MPA-treated GECs increased HIV-1 replication in indicator TZM-bl cells (Ferreira et al. 2015). 
Similarly, supernatants from MPA-treated Vk2/E6E7 vaginal cells increased HIV-1 replication in 
indicator U1 cells (Irvin and Herold 2015).  
 
Furthermore, this study is in line with non-human primate models showing that MPA increases 
SIV/SHIV in rhesus and pigtail macaques (Trunova et al. 2006, Smith et al. 2015, Butler et al. 2016). 
These molecular data are also in agreement with the latest clinical studies showing increased HIV-1 
acquisition in predominantly DMPA users (Byrne et al. 2016, Tasker et al. 2017) as well as the most 
recent epidemiological observational meta-analyses showing a 40% increased HIV-1 acquisition risk 
in DMPA users compared to women using no hormone (Morrison et al. 2015, Ralph et al. 2015, Polis 
et al. 2016).  
 
The observation that MPA increases infection in animal, clinical and both local (FRT) and systemic 
(PBMCs) models in vitro/ex vivo strongly implies that MPA can increase susceptibility to infection in 
multiple settings, independent of differences in species, cell populations, immune activation status, 
hormonal microenvironment and donor. This research is thus highly relevant to women in high-risk 
areas such as Kwa-Zulu Natal in South Africa, where DMPA is the most commonly used 
contraceptive.  
 
A major concern with cell culture studies is whether the concentrations of MPA used truly represents 
physiological doses in DMPA users in vivo. Comparing the published serum MPA levels after the first 
1-3 weeks post-administration showed there is a wide inter-individual and inter-study range of MPA 
serum levels (Fig. 1.4.1.1). The average detected peak MPA serum levels are about 5-40 nM and the 
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maximum levels reported reach up to 65-100 nM (Kirton and Cornette 1974, Koetsawang 1977, 
Hapgood et al. 2018). After about 1 month, MPA serum levels plateau at around 2.6 nM for 3 months 
(Mishell 1996). Therefore the MPA concentration used in the present study (100 nM) is still within 
the physiological range and represents the upper range of peak serum DMPA-IM levels detected 
shortly after injection. It should also be noted that MPA concentrations in different tissues are 
unknown and may be different to serum levels. 
 
Additional evidence in support of MPA increasing HIV-1 infection at physiologically relevant doses 
comes from in vitro dose response experiments from the present author’s laboratory. In these studies, 
MPA as low as 50 nM in PBMCs and 10 nM in ecto- and endocervical explants still significantly 
increases HIV-1 replication [(Ray et al. 2017) and unpublished]. These findings are consistent with a 
report showing that low concentrations of MPA (1-12.5 nM) increased HIV-1 pseudovirus infection 
in non-activated PBMCs (Sampah et al. 2015). Another study indicated that MPA increased HIV-1 
replication in activated PBMCs at higher (1 μM) but not lower (10 nM) concentrations (Huijbregts et 
al. 2013). The discrepancy between the latter studies is likely to be influenced by the activation status 
of the PBMCs. Activated cells are already primed to produce T cell responses and are more 
susceptible to infection. The study by Sampah et al (2015) found that prior activation of PBMCs 
minimized the effect of MPA on HIV-1 infection. Additional differences between these studies, such 
as time of MPA incubation (18 versus 24 h), donor-specific effects, and relative immune cell 
populations between donors may explain the differences in HIV-1 replication. 
 
While no studies have yet investigated HIV-1 acquisition risk in DMPA-SC users (Polis et al. 2017, 
Hapgood et al. 2018), the peak serum concentrations are in the range of 1.6-4.4 nM (Jain et al. 2004, 
Toh et al. 2004). This appears to be lower than peak DMPA-IM levels, but to date no studies have 
directly compared maximal peak levels for DMPA-IM and DMPA-SC in the same study. Thus it is 
difficult to predict whether or not DMPA-SC use would change biological responses relevant to HIV-
1 susceptibility (Polis et al. 2017). 
 
Collectively, the evidence from this study and others showing that MPA increases HIV-1 infection in 
PBMCs at both the middle and upper ranges of physiological MPA serum levels suggests that DMPA 
users are at risk of increased HIV-1 acquisition shortly after DMPA administration.  
 
The present study also showed that hormones mimicking the luteal phase of the menstrual cycle, 
unlike the follicular phase hormones, enhanced HIV-1 infection in both PBMCs and TZM-bl cervical 
cells. Specifically, luteal phase E2/P4 significantly increased HIV-1 infection in PBMCs after 7 days’ 
stimulation (Fig. 3.2.1, Fig. 3.4.1.1), while a non-significant increase was shown in TZM-bls after 2 
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days’ stimulation (Fig. 4.2.1.1a). In PBMCs, the extent of HIV-1 infection with luteal phase E2/P4 was 
1.4-5.4-fold lower than that with MPA (Fig. 3.2.1, Fig. 3.4.1.1).  
 
Higher HIV-1 infection with luteal phase hormones in PBMCs in this study is in agreement with non-
human primate models showing increased SIV/SHIV infection during the luteal phase in naturally 
cycling macaques (Sodora et al. 1998, Vishwanathan et al. 2011, Kersh et al. 2014, McNicholl et al. 
2014, Radzio et al. 2014) or macaques treated with P4 that reached serum levels similar to the luteal 
phase (Marx et al. 1996). This finding is also consistent with a report using cervical explants ex vivo 
from naturally cycling women in the luteal phase (Saba et al. 2013). There are not many studies using 
exogenous combinations of E2/P4 to assess HIV-1 infection in vitro. One study in activated PBMCs 
showed that exogenous stimulation with follicular phase hormones (100 pM E2/1 nM P4) increased 
HIV-1 infection in PBMCs, while luteal phase hormones (1 nM E2/100 nM P4) decreased infection 
(Asin et al. 2008). However their result could reflect donor-specific differences since only one donor 
was used, as well as differences in incubation period (4 days prior to infection), concentrations of 
E2/P4 used and activation state (Asin et al. 2008). Another study indicated that a combination of 20 
nM E2/500 pM P4 had no effect on HIV-1 p24 or RNA levels in a T cell line, CEMss (Ragupathy et 
al. 2016). However, since different experimental protocols were used for these studies, the effect of 
exogenous E2/P4 on HIV-1 infection may critically depend on the donor/s used, frequency of immune 
cell types, differential activation states, order of hormone and virus incubation, type of virus used 
(IMC or pseudovirus, R5- or X4-tropic), duration of hormone stimulation and infection, and 
concentrations of E2/P4 used. 
 
Follicular phase E2/P4 (400 pM E2/1 nM P4) did not significantly increase HIV-1 infection in PBMCs 
(Fig. 3.2.1, Fig. 3.4.1.1), in contrast to luteal phase E2/P4. This is in agreement with non-human 
primate studies showing that SIV/SHIV infection was higher during the luteal phase than the 
follicular phase (Marx et al. 1996, Sodora et al. 1998, Vishwanathan et al. 2011, Kersh et al. 2014). 
Limited information is available on exogenous follicular phase hormones and HIV-1 infection in 
vitro. One study showed follicular phase hormones (100 pM E2/1 nM P4) increased HIV-1 replication 
in activated PBMCs (Asin et al. 2008). However several experimental differences exist between their 
study and the present one, including but not limited to, different E2 concentrations used, different 
hormone and virus incubation times and prior activation of the PBMCs in their study.  
 
The concentrations of E2/P4 used in the present study to represent menstrual cycle phases are 
comparable to physiological E2/P4 levels in naturally cycling women. This study used 400 pM E2 plus 
10 nM P4 to mimic the luteal phase of the menstrual cycle, but other studies have used different 
concentrations of E2/P4 to represent the luteal phase in vitro in other model systems. For example, 1 
nM E2/100 nM P4 in PBMCs (Asin et al. 2008), 10 nM E2/1 μM P4 in primary endometrial stromal 
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cells (Ancelin et al. 2002), 1 nM E2/100 nM P4 in activated PBMCs (Huijbregts et al. 2013), 10 nM 
E2/100 nM P4 in immortalized endometrial stromal cells (Schutte and Taylor 2012), and 10 nM E2/100 
nM ORG2058, as a more stable progestogen than P4, in primary endometrial stromal cells 
(Salamonsen et al. 1997). While the concentrations of luteal phase E2/P4 used in this study are lower 
than those used in the above studies, especially that of P4, the concentrations nevertheless still fall 
within the physiological range of reference values in another report (Stricker et al. 2006), where P4 
levels range between 0.95-71.87 nM and the range for E2 is 51.75-1163.02 pM across the luteal phase 
of the menstrual cycle (see section 1.3.1). Nevertheless it is possible that higher P4 concentrations 
such as 100 nM may have shown more pronounced or different effects. 
 
The effects of P4 alone (that is, without E2) on HIV-1 infection have been reported in some studies. 
For example, 500 pM P4 increased HIV-1 infection as measured by p24 levels in both a T cell line and 
PBMCs, and reduced antiviral efficacy in the T cell line (Ragupathy et al. 2016). In another study, 10 
nM P4 did not increase X4 or R5-tropic HIV-1 replication in activated PBMCs, whereas 1 μM P4 
increased replication of an X4- but not R5-tropic virus (Huijbregts et al. 2013). Previous work in the 
present author’s laboratory using available T cell lines, including Jurkat cells, showed that these cell 
lines appeared to be non-physiological due to the absence of active GR (data not shown). 
 
While high P4 has been linked to increased HIV-1 susceptibility, there is also some evidence to 
suggest exogenous E2 is protective against HIV-1 infection. For example, 10 nM E2 significantly 
decreased HIV-1 p24 levels in CD4+ T cells and macrophages (Rodriguez-Garcia et al. 2013a), while 
in other studies, topical E2 protected against SIV in animal models (Smith et al. 2000b, Smith et al. 
2004). In the present study, the combined stimulation of E2 and P4 makes it impossible to distinguish 
potential protective effects conferred by E2. The concentration of E2 used (400 pM) may also be too 
low to counteract the effects of P4, but was used in order to more accurately represent the two main 
menstrual cycle phases. However, since the E2 concentration is the same for both luteal and follicular 
phase in this study, the effects observed on HIV-1 infection and expression of immune markers are 
likely due to P4.  
 
In the present study, TZM-bl cells were used as a model of infectable cervical cells, since they express 
high levels of CD4 and CCR5 (Platt et al. 1998). Infection in TZM-bl cells measures the steps up to 
transcription of the LTR, including fusion, entry, reverse transcription, nuclear translocation and LTR 
transcription. Therefore any changes in HIV-1 infection in response to MPA in these cells suggest that 
the mechanism is not via downstream events in the HIV life cycle. TZM-bl cells thus provide a useful 
opportunity to gain insight into biological mechanisms of infection involving any of the 
abovementioned steps. Importantly, TZM-bl cells do not undergo activation like T cells and therefore 
lack the receptors and T cell-specific signalling pathways that occur in PBMCs. Therefore this model 
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provides additional insight into biological mechanisms that are independent of activation and T cell 
specific functions. However, the evidence from this study showing similar effects (that is, increased 
CCR5 levels) for both PBMCs and TZM-bl cells gives additional insight into biological mechanisms 
that are likely applicable to target cells expressing CD4 and CCR5. These target cells include many 
cell types in the FRT such as CD4+ T cells, macrophages and DCs. 
   
Large variability in HIV-1 infection was observed between biological repeat experiments in both 
PBMCs and TZM-bls, although the inter-donor variability was greater for PBMCs. This variability in 
PBMC infection was typically observed in all PBMC assays in the present author’s laboratory and is 
consistent with the literature (Sampah et al. 2015). Therefore PBMCs from each donor were pre-
screened for infectability prior to infection assays (see section 2.8.2). However the large variability 
observed in TZM-bl cells was somewhat surprising, as a cell line is expected to be relatively 
homogeneous. The source of variation between experiments was not from the virus used, since these 
assays used aliquots from the same virus stock, nor was it from changes in cell viability in the 
presence of virus, since MTT assay results showed no major changes (Appendix B. Table B1.1). 
Therefore the cause for the differences in infection is most likely the biological variation in viral 
infection between independent biological assays for TZM-bls as well as PBMCs, in which inter-donor 
variability between responses is an additional source of variability.  
 
Collectively the results from this study show, despite large variations in HIV-1 infection between 
PBMC donors, that exogenous stimulation with luteal phase hormones and MPA, but not follicular 
phase hormones, at levels within the physiological range, increases HIV-1 infection in PBMCs and/or 
TZM-bl cells. These findings may have major significance for susceptibility to HIV-1 infection in 
both naturally cycling women during the luteal phase and DMPA users during the first few weeks 
shortly after injection. These findings also suggest that the effects observed in clinical studies are 
likely due to direct effects on HIV-1 target cells expressing CD4 and co-receptors and offer 
opportunities to further investigate the mechanisms behind infection. 
 
 
6.1.2 MPA- induced HIV-1 infection most likely occurs through increased frequency of CD4+ 
T cells, increased CD4/CD8 ratios and increased CCR5 and CD69 on CD4+ T cells, 
while luteal phase E2/P4 increases HIV-1 infection via a different, unidentified 
mechanism 
 
Multiple plausible biological mechanisms have been suggested to explain how the injectable 
contraceptive MPA can increase HIV-1 infection in the FRT and in peripheral blood (see section 
1.4.3). Important mechanisms most likely relevant to the present study are changes in adaptive 
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immunity (frequency of key immune cell types and their activation status) and increased levels of the 
CCR5 co-receptor, which would facilitate R5-tropic viral entry. 
 
The present study showed that in PBMCs, MPA but not luteal phase E2/P4 significantly increased the 
frequency of CD4+ T cells (Fig. 3.3.1.1a), the primary target cells for HIV-1 infection, and 
furthermore increased the density of the activation marker CD69 on CD4+ T cells (Fig. 3.3.1.2b). 
Increased T cell activation correlates with increased T cell infection reported in some studies 
(Stevenson et al. 1990, Haase 2005, Meditz et al. 2011). The activation status of immune cells has 
been shown to render them more susceptible to HIV-1 infection (Greenhead et al. 2000, McKinnon et 
al. 2011, McKinnon and Kaul 2012). Together with higher levels of the CD4 receptor on the surface 
of host target cells, increased levels of the co-receptor CCR5 could facilitate HIV-1 entry into target 
cells. The present study showed that MPA but not luteal phase hormones increased the density of 
CCR5 on target CD4+ and CD3+ T cells (Fig. 3.3.2.2), without changing the frequency of CCR5-
expressing cells (Fig. 3.3.2.1a). These results agree with some studies in PBMCs from DMPA users. 
A recent report showed a trend for increased activation and CCR5 density in CD4+ T cells from 
women at 1 or 3 months after DMPA injection, compared to before injection (Tasker et al. 2017). In 
the same study, PBMC infection increased from month 1 to month 3 in DMPA users (Tasker et al. 
2017). Another study observed increased CCR5 expression in CD4+ and CD8+ T cells, without a 
concomitant increase in frequency in CCR5-expressing CD4+ or CD8+ T cells in DMPA users 
compared to women not using hormonal contraception (Sciaranghella et al. 2015). A third study 
showed higher CCR5 expression and frequency of CCR5-expressing T cells in the cervix but not 
matched PBMCs of injectable contraceptive (predominantly DMPA) users compared to women not 
using long-term contraceptives (Byrne et al. 2016). In this study, injectable contraceptive users were 
at a higher risk of HIV-1 acquisition compared to naturally cycling women (Byrne et al. 2016). In 
contrast, another study did not observe a difference in cervical CD4+CCR5+ T cell proportion in 
DMPA users compared to women not using hormonal contraception (Smith-McCune et al. 2017). In 
an ex vivo study, 1 μM but not 100 nM MPA prevented CXCR4 and CCR5 down-regulation in T cells 
from activated PBMCs (Huijbregts et al. 2013), which is not inconsistent with MPA increasing CCR5 
density in T cells from the present study. 
 
The finding that MPA but not luteal phase E2/P4 significantly increased CD4 and CCR5 mRNA levels 
in cervical TZM-bl cells (Fig. 3.3.2.3) further supports the PBMC results. Multiple studies with MPA 
in different FRT compartments are broadly consistent with the increased activation of CD4+ T cells in 
PBMCs and higher CCR5 levels in PBMCs and TZM-bls from this study. For example, a recent 
report in injectable contraceptive (predominantly DMPA) users showed higher frequency of activated 
cervical CD4+CCR5+ T cells compared to women not using a long-term contraceptive (Byrne et al. 
2016), while another report in DMPA users showed higher frequency of activated endometrial T cells, 
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without an increase in CCR5 density on CD4+ T cells (Smith-McCune et al. 2017). The latter study 
also showed increased expression of the activation marker HLA-DR in endometrial CD4+ and CD8+ 
T cells (Smith-McCune et al. 2017). Higher numbers of cells expressing CD3, CD8, CCR5 and the 
activation marker HLA-DR were observed in vaginal biopsies from DMPA users compared to women 
in the follicular phase (Chandra et al. 2013). In line with these studies, a recent study has shown that 
HIV-1 preferentially targets cervical CD4+ T cells that also express increased CCR5, CD69 and 
mucosal integrins (Joag et al. 2016). In addition, DMPA-treated rhesus macaques exhibited a higher 
frequency of CCR5+CD4+ cells in vaginal tissue than E2-treated macaques, although this effect was 
not statistically significant (Goode et al. 2014). In contrast to the above reports, one study showed 
decreased frequency of vaginal CD3+ and CCR5+CD3+ T cells in DMPA users (Mitchell et al. 
2014), while another reported no change in vaginal CD4+ or CD8+ T cells in DMPA users (Michel et 
al. 2015). A report in primary DCs ex vivo showed that MPA at different doses did not change 
expression of the activation marker HLA-DR (Quispe Calla et al. 2015). Furthermore, a study using 
non-activated PBMCs stimulated ex vivo with exogenous MPA (1-12.5 nM) did not observe an effect 
on the frequency of CD4+ T cells expressing CCR5, CXCR4 or the activation markers CD25, CD69, 
HLA-DR and CD38 (Sampah et al. 2015). 
 
Collectively these results suggest that increased CD4+ T cell activation and CCR5 levels are 
sometimes but not always detectable in peripheral blood and the FRT. The detectable effects of MPA 
may therefore depend on multiple variables, including but not limited to time of sampling post-
injection, populations of other immune cells and their activation status, levels of other endogenous 
hormones in vivo, concentration of MPA used and duration of stimulation in vitro. This may in part 
translate to variable responses in vivo due to inter-individual differences, for example in immune 
activation status and serum levels, which is a possible reason for varying results over 40 years in HIV-
1 acquisition studies. 
 
Importantly, the present study showed that MPA but not luteal phase hormones simultaneously 
decreased the frequency of CD8+ T cells while increasing the frequency of CD4+ T cells (Fig. 
3.3.1.1). Therefore the ratio of CD4/CD8 was significantly increased by 1.5-fold in both MPA-treated 
total CD3+ lymphocytes (Fig. 3.3.1.1c) and in cells expressing the activation marker CD69 (Fig. 
3.3.1.1d). A higher CD4/CD8 ratio is consistent with other studies in PBMCs where CD4 cells 
outnumber CD8 cells (Byrne et al. 2016, Iyer et al. 2017). In addition, higher CD4/CD8 ratios have 
been observed in PBMCs of DMPA users (Sridama et al. 1992) and postmenopausal women using 
NET for HRT (Dogan et al. 2005) but not women using COCs (Prakash et al. 2002). Taken together 
with the increase in CD69 density on activated CD4+ T cells, these results suggest that MPA 
enhances HIV-1 infection in target cells by increasing the frequency of infectable cells (CD4+), while 
concomitantly decreasing the frequency of cytotoxic cells capable of combating infection (CD8+). 
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Decreased frequency of CD8+ T cells in response to MPA is consistent with a study showing 
decreased CD8+ T cell effector function (production of IFNγ and TNF) in murine trigeminal ganglia 
stimulated with 100 pM MPA ex vivo or from mice treated with MPA-containing pellets (Cherpes et 
al. 2008a).  
 
The present study showed that MPA but not menstrual cycle hormones significantly decreased the 
frequency of activated CD69+CD14+ monocytes (Fig. 3.3.1.1b), although CD69 density (Fig. 
3.3.1.2b), CCR5 density (Fig. 3.3.2.2) and frequency of CCR5-expressing cells (Fig. 3.3.2.1a) were 
not changed. Monocytes play an important role in activating CD4+ T cells by producing soluble 
mediators. In line with this, a study in non-activated PBMCs showed that HIV-1 replication in CD3+ 
cells and whole PBMCs was lower when CD14+ monocytes were depleted (Sampah et al. 2015). The 
results from this study could therefore suggest decreased monocyte function in response to MPA, but 
further investigation is needed. 
 
Furthermore MPA has been shown to repress mRNA expression of the ligand for CCR5, RANTES, in 
PBMCs, Ect1/E6E7 and End1/E6E7 cells (Africander et al. 2011a, Govender et al. 2014, Hapgood et 
al. 2014b), which is in agreement with the literature that RANTES decreases HIV-1 infection through 
competition for CCR5 (Cocchi et al. 1995, Alfano and Poli 2005).  
 
Several clinical, ex vivo and animal studies suggest that high P4 levels, like those observed during the 
luteal phase, are associated with increased susceptibility to infection and/or increased CCR5 levels in 
the FRT (see section 1.3.2). This would suggest that there are common overlapping potential 
mechanisms for enhanced HIV-1 infection between DMPA usage and the luteal phase. However, the 
results from this study in PBMCs indicate that luteal phase hormones, unlike MPA, do not increase 
the frequency of CD3+, CD4+, CD8+ T cells or CD14+ monocytes (Fig. 3.3.1.1a), or frequency of 
activated CD69-expressing cells (Fig. 3.3.1.1b), or expression of CD69 (Fig. 3.3.1.2b), or frequency 
of CCR5-expressing cells (Fig. 3.3.2.1), or expression of CCR5 (Fig. 3.3.2.2, Fig. 3.3.2.3a). Limited 
studies are available comparing menstrual cycle phases to the injectable contraceptive MPA in the 
same study. One of these is a recent study in a cohort of South African women showing that the 
frequency of cervical CCR5+CD4+ T cells was about 4 times higher in injectable contraceptive 
(predominantly DMPA) users than naturally cycling women in the luteal phase (Byrne et al. 2016). 
Another study showed that IgG and IgA levels in CVL samples were increased in DMPA users but 
decreased in naturally cycling women post-ovulation (luteal phase) (Francis et al. 2016). However it 
is difficult to compare across in vitro and clinical studies due to methodological and biological 
differences. These results are likely to be influenced by time of sampling, immune cell frequencies, 
concentrations of endogenous hormones and/or MPA, how the menstrual cycle phases were classified, 
duration of contraceptive use and/or other variables. Taken together, the results from this study and 
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limited clinical studies support the conclusion that MPA and luteal phase E2/P4 increase HIV-1 
infection via potentially different mechanisms.  
 
The pro-inflammatory cytokine IL-6 was used in this study as a marker for inflammation. While a link 
for inflammation and enhanced HIV-1 susceptibility has been established, whether DMPA use is 
associated with increased or decreased inflammation has yielded conflicting results. Some clinical 
studies have reported an increase (Deese et al. 2015, Francis et al. 2016), decrease (Walong et al. 
2016) or no change (Morrison et al. 2014, Ngcapu et al. 2015) in IL-6 protein levels from CVLs in 
DMPA users. In the present study, MPA but not luteal phase E2/P4 repressed IL-6 mRNA expression 
in both PBMCs and TZM-bl cells (Fig. 3.3.3.1). This finding is consistent with the 
immunosuppressive function of MPA on IL-6 mRNA or protein shown in PBMCs (Huijbregts et al. 
2013, Hapgood et al. 2014b, Huijbregts et al. 2014, Michel et al. 2015), CD14+ monocytes (Hapgood 
et al. 2014b), primary endocervical fluid (Smith-McCune et al. 2017), primary ectocervical explants 
(Ray 2015), immortalized endocervical cells (Govender et al. 2014), and mouse fibroblast cells 
(Koubovec et al. 2004). Furthermore, previous research from the present author’s laboratory has 
shown that 100 nM MPA gives different effects on select genes involved in immune function 
compared to 100 nM or 1 μM P4 (Koubovec et al. 2004, Govender et al. 2014, Hapgood et al. 2014b). 
In addition, some of this work also shows that the repression of IL-6 and other pro-inflammatory 
genes by MPA requires the GR in immortalized endocervical cells and PBMCs (Govender et al. 2014, 
Hapgood et al. 2014b). In general, P4 inhibits inflammatory responses and promotes an anti-
inflammatory state in vitro (Hall and Klein 2017). Limited research on exogenous P4 include one 
study showing that 10 nM or 1 μM P4 did not change IL-6 protein levels in activated PBMCs 
(Huijbregts et al. 2013), in agreement with the present study. Other studies have shown that 1 μM P4 
represses LPS-induced IL-6 expression in primary uterine fibroblasts (Fukuyama et al. 2012, Kim et 
al. 2012), but increases TNFα-induced IL-6 mRNA expression in Vk1/E6E7 and Ect1/E6E7 cells in 
vitro (Africander et al. 2011a). The differences between studies are likely to reflect multiple 
differences in experimental design, such as cell type, activating compound and concentration of 
hormone used.  
 
The present study showing enhanced HIV-1 infection in PBMCs in response to MPA may have 
significance for disease progression to AIDS in DMPA users. However, the available albeit 
limited studies from large populations suggest MPA and other hormonal contraceptives have no 
effects on disease progression (Heffron et al. 2013, Phillips et al. 2013, Phillips et al. 2016). This 
conclusion does not exclude the possibility that the effects of MPA may be relevant for some 
individual women and may depend on time post-injection, number of years using MPA and/or 
individual MPA pharmacokinetics. 
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Taken together, the present data suggests that MPA but not luteal phase E2/P4 increase HIV-1 
infection in target cells through different potential mechanisms, with MPA increasing activated CD4+ 
T cells and CCR5 expression, while luteal phase hormones increase HIV-1 infection via an 
unidentified mechanism. This study appears to be the first to directly compare a combination of E2/P4 
representing menstrual cycle phase hormones and MPA in terms of HIV-1 infection in PBMCs and 
TZM-bls and molecular mechanisms of infection. Collectively the results from PBMCs and TZM-bl 
cells provide insight into biological mechanisms by which MPA can increase HIV-1 infection in any 
target cells which express CD4 and the CCR5 co-receptor. The increase in CCR5 levels in both of 
these cell models suggests that there is a common mechanism that is likely to be clinically relevant to 
CCR5-expressing cells in both the peripheral blood and the FRT. 
 
 
6.1.3 MPA- but not luteal phase E2/P4-induced HIV-1 infection is mediated by the GR 
 
The present study showed that HIV-1 infection induced by MPA, but not luteal phase E2/P4, is 
mediated by the GR in PBMCs (Fig. 3.4.1.1b) and TZM-bl cells (Fig. 4.2.1.1a), using the GR/PR 
antagonist, RU486 and GR siRNA, respectively.  
 
The levels of endogenous steroid hormone receptors were measured in representative female PBMC 
donors in this study. Since GR but not PR was detected (Fig. 3.4.2.1, Appendix A, Fig. A1.1), the 
effect of MPA on HIV-1 infection is most likely via the endogenous GR. The lack of detectable PR in 
PBMC samples is consistent with some (Neifeld et al. 1977, Kontula et al. 1983, Tabibzadeh and 
Satyaswaroop 1989, Mansour et al. 1994, Schust et al. 1996, D'Amore et al. 2013) but not other 
(Szekeres-Bartho et al. 1989, Asin et al. 2008, Cabrera-Munoz et al. 2012, Tan et al. 2015) reports. 
These differences could be due to multiple factors, such as donor gender, methods of detection, choice 
of antibody, menstrual cycle status (if female donors) and/or other variables. Although studies in 
MCF-7 breast cancer cells showed that stimulation with 1 nM E2 up-regulated PR mRNA levels (Cho 
et al. 1994), attempts by the present author to up-regulate expression of the endogenous PR by 
prolonged incubation with low levels of E2 (400 pM for up to 14 days) were not successful (data not 
shown). The presence of over-expressed PR-B in TZM-bl cells did not have a significant effect on 
MPA-induced HIV-1 infection (Fig. 4.2.1.1a). This supports the idea that MPA-induced HIV-1 
infection in TZM-bl cells, like in PBMCs, is mediated by the GR. While no significant increase in 
HIV-1 infection was observed with luteal phase E2/P4 in TZM-bl cells, this was also not altered upon 
PR-B over-expression (Fig. 4.2.1.1a), further suggesting that PR-B is not involved in luteal phase 
hormone-associated HIV-1 infection.   
 
128 
 
Possible roles of SRs other than GR and PR in MPA-induced effects were considered. The 
representative female PBMC donors expressed ERα mRNA but not protein (Appendix A, Fig. A1.1). 
Other studies have shown ERα mRNA or protein expression in PBMCs (Cohen et al. 1983, Phiel et al. 
2005, Asin et al. 2008, Pierdominici et al. 2010, D'Amore et al. 2013). Thus the effects of exogenous 
E2 upon stimulation with luteal or follicular phase hormones are likely to be mediated by endogenous 
ER in PBMCs. However, MPA does not bind to the ER (Africander et al. 2011b, Stanczyk et al. 
2013), and therefore the actions of MPA are most likely to not be mediated by the ER in PBMCs. 
While MR mRNA was detected in both PBMCs (Appendix A, Fig. A1.1) and TZM-bl cells 
(Appendix A, Fig. A2.1), MR protein levels were not detectable due to the non-specific nature of the 
available anti-MR antibody. The equilibrium dissociation constant (Ki, an indication of the ligand 
concentration at which 50% of receptors are occupied) for P4 binding to the MR is 1.7 nM and P4 has 
potent anti-mineralocorticoid activity (Wambach and Higgins 1978, Fagart et al. 1998, Africander et 
al. 2011b, Africander et al. 2013, Stanczyk et al. 2013). MPA binds MR with lower affinity than P4 
and a Ki of 197 nM (Africander et al. 2013). It is therefore possible that if MR protein was expressed, 
P4 but not MPA would be expected to antagonize the MR at the concentrations used in this study. 
While neither AR mRNA nor protein was detected in representative PBMCs (Appendix A, Fig. A1.1), 
TZM-bl cells express both GR and AR protein (Appendix A, Fig. A2.1). Given that the Ki values for 
P4 and MPA binding to the AR are 36.6 nM and 19.4 nM, respectively (Africander et al. 2014), some 
binding to the AR would be expected to occur using the concentrations of P4 and MPA in TZM-bl 
cells in this study. However, since no AR was detected in PBMCs, the effects of MPA on HIV-1 
infection observed in PBMCs are likely to be mediated by the GR only. 
 
In the present study, co-stimulation with the GR/PR antagonist RU486 in PBMCs did not change 
luteal phase E2/P4-induced HIV-1 infection in PBMCs (Fig. 3.4.1.1b), and decreasing GR levels using 
siRNA did not change luteal phase E2/P4-induced HIV-1 infection in TZM-bl cells (Fig. 4.2.1.1). This 
suggests that the increase in HIV-1 infection in PBMCs with luteal phase hormones is not mediated 
by the GR. In line with this observation is binding affinity research showing that the Ki for P4 binding 
to the GR (215 nM) is much higher than the Ki for MPA (10. 8 nM) (Koubovec et al. 2005), 
suggesting that the concentrations of P4 used in the present study to mimic the luteal phase (10 nM) or 
the follicular phase (1 nM) are most likely too low to activate a significant percentage of the GR, 
unlike MPA. Further supporting this conclusion is the dose response assay from the present study, 
where P4 activated GR-mediated reporter gene activity in COS1 cells over-expressing GR only at 1-
10 μM (Fig. 5.6.2a). P4 binding to the GR may therefore only be relevant at higher P4 concentrations 
(Jones et al. 2008, Guo et al. 2012, Lei et al. 2012, Engler et al. 2017), such as pregnancy where P4 
serum levels reach 400-636 nM (Kuhl 1990, Sheffield et al. 2009) and P4 is immunosuppressive in 
order to promote foetal tolerance (Piccinni et al. 1995, Chien et al. 2009, Tan et al. 2015). 
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Following the results showing that MPA-induced HIV-1 infection in PBMCs is mediated by the GR, 
it was of interest to measure GR protein levels in these cells. The present study showed that GR 
protein levels, in matched samples from the HIV-1 infection assay, appeared to be lower in MPA- but 
not luteal phase E2/P4-stimulated PBMCs compared to the vehicle control (Fig. 3.4.2.1a). While GR 
protein levels appeared to be decreased after 2, 7 and 12 days’ exposure to MPA, the levels were only 
significantly lower after 7 days (Fig. 3.4.2.1b). This observation suggests that MPA requires the active 
GR for increased HIV-1 infection, but may also increase ligand-dependent GR turnover. This agrees 
with other work from the present author’s laboratory showing MPA decreased GR protein levels in a 
time-dependent manner in PBMCs (Ray 2015), End1/E6E7 cells (Govender et al. 2014) and COS1 
cells (Avenant et al. 2010b). Decreased GR protein is consistent with the glucocorticoid-like 
properties of MPA and the established observation that glucocorticoids like Dex induce GR turnover 
(Dong et al. 1988, Hoeck et al. 1989, Webster et al. 1997, Wallace and Cidlowski 2001, Deroo et al. 
2002, Avenant et al. 2010a, Avenant et al. 2010b).  
 
Taken together, these data support a role for GR, but not other steroid receptors, in mediating HIV-1 
infection in response to MPA but not luteal phase E2/P4 at the concentrations used in this study. 
 
 
6.2 HIV-1 infection in the absence of exogenous MPA or E2/P4 increases with low GR/high 
PR and may involve the regulation of soluble factors  
 
The present study showed that in the absence of exogenous MPA or E2/P4, HIV-1 infection 
significantly increased when GR levels were decreased by siRNA in TZM-bl cells (Fig. 4.2.2.1a). 
Consistent with this, HIV-1 infection in PBMCs significantly increased upon stimulation with the 
GR/PR antagonist RU486 in the vehicle control condition (Fig. 3.4.1.1a). GR protein levels were not 
changed by PR-B over-expression (Fig. 4.2.2.1b, c). These results suggest that HIV-1 infection in the 
absence of exogenous MPA or E2/P4 is sensitive to changes in GR levels, with unliganded GR 
protecting against infection. However, due to the fluctuating levels of multiple endogenous hormones, 
there is unlikely to be a state of no hormones in vivo, at least for E2/P4. This suggests that GR and PR 
are unlikely to be truly unliganded. Nevertheless these data provide some insight into molecular 
mechanisms of cross talk between the GR and PR.  
 
A potential mechanism for increased HIV-1 infection when GR levels were decreased in the absence 
of exogenous MPA or E2/P4 could be via a preferential increase in CD4 expression, since CD4 mRNA 
levels were significantly increased when GR levels were decreased, unlike CCR5 or CXCR4 (Fig. 
4.3.1.1) mRNA levels which were unchanged. However the direct effects of GR on CD4 levels 
remain to be determined.  
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This potential mechanism of higher CD4 levels could also be applicable in the presence of MPA in 
TZM-bl cells, since CD4 mRNA levels were increased (Fig. 3.3.2.3b). In PBMCs, however, while 
MPA increased the frequency of CD4+ T cells (Fig. 3.3.1.1a), the densities of CD3, CD4 and CD8 on 
the surface of lymphocytes were significantly decreased (Fig. 3.3.1.2a). Usually the CD4 receptor is 
down-regulated during HIV-1 infection and cell differentiation (Paillard et al. 1990, Butera et al. 
1991, Pimentel-Muinos et al. 1992, Geleziunas et al. 1994, Levesque et al. 2004). The results from the 
present study could indicate that despite the decrease in CD4 density, the increase in the number of 
CD4+ T cells in combination with the simultaneous increase in CCR5 levels on CD4+ T cells (Fig. 
3.3.2.2), is sufficient to promote infection in the presence of MPA. Again, however, a direct effect for 
MPA on CD4 was not established in this study. 
 
Together these data suggest that there may be different effects on HIV-1 infection and expression of 
markers relevant to infection depending on different levels of GR, and whether the GR is unliganded 
or bound to MPA. There is evidence from the literature to suggest a role for the GR and GR levels in 
HIV-1 pathogenesis, although this research has mostly focussed on the liganded GR, usually bound to 
Dex. Clinically, AIDS patients have been shown to develop GC hypersensitivity and reduced 
immunity, possibly through GC-induced repression of cytokines (Mirani et al. 2002, Kino et al. 2003, 
Hapgood and Tomasicchio 2010). In addition, skin samples from AIDS-associated Kaposi’s sarcoma 
(AIDS-KS) patients have higher GR protein levels than healthy control donors (Guo et al. 1996). 
Using shRNA targeting the GR in the THP1 monocyte cell line, it was shown that ligand-activated 
GR was required for proviral integration (Wiegers et al. 2008). Thus changes in GR levels are likely 
to have physiological implications in HIV-infected individuals, as well as people exposed to high 
amounts of the endogenous GC cortisol during periods of chronic stress. 
 
In addition, the present study suggests that HIV-1 infection in the absence of exogenous MPA or 
E2/P4 is sensitive to changes in PR levels. In TZM-bl cells, HIV-1 infection was significantly 
increased with both high GR/high PR and low GR/high PR (Fig. 4.2.2.1a). This increase in HIV-1 
infection with high levels of unliganded PR-B occurs through an unknown mechanism, since there 
was no change in CD4, CCR5 or CXCR4 mRNA levels with over-expressed PR-B in TZM-bl cells 
(Fig. 4.3.1.1). There appears to be no evidence in the literature directly implicating a role for 
unliganded PR-B in HIV-1 infection. The effect of unliganded PR may be relevant to HIV-1 infection 
in the FRT, where PR protein is expressed in cervical stromal fibroblast cells and sometimes in the 
epithelium (Ayehunie et al. 2015). The PR detected in pre- and postmenopausal ecto- and 
endocervical explants in this study could therefore represent PR expression in stromal but not 
epithelial cells (Appendix B, Fig. B2.1, B2.2). Interestingly, a recent study showed that co-culture of 
endometrial stromal fibroblasts with PBMCs enhanced HIV-1 infection of CD4+ T cells, in the 
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absence of exogenous E2/P4 mimicking the luteal phase (Neidleman et al. 2017). This suggests that 
adjacent cells expressing PR can mediate HIV-1 infection of other cells. 
 
An interesting observation from the present study was that, in the absence of exogenous MPA or 
E2/P4, HIV-1 infection in TZM-bl cells could be changed when co-cultured with supernatants from 
End1/E6E7 or HeLa cells in which GR/PR levels were altered from high GR/no PR to low GR/high 
PR (Fig. 4.4.1). This indirect effect is consistent with the result in TZM-bl cells in which GR/PR 
levels were directly changed (Fig. 4.2.2.1a). Supernatants from End1/E6E7 cells with low GR/no PR 
also increased HIV-1 infection in TZM-bl cells (Fig. 4.4.1a). These results suggest a role for secreted 
soluble mediators in HIV-1 infection in the absence of exogenous MPA or E2/P4 in TZM-bl cells. 
These soluble mediators could be the result of paracrine signalling from adjacent cells or autocrine 
signalling from the TZM-bl cells themselves. Whether or not the soluble factors are regulated directly 
or indirectly by changing GR/PR remains unanswered.   
 
The present study aimed to investigate the role of the pro-inflammatory cytokine IL-6 as a soluble 
factor that could be mediating increased HIV-1 infection in the absence of exogenous MPA or E2/P4 
in TZM-bl cells. IL-6 was an attractive candidate for two reasons. Firstly, some studies have shown a 
potential association between increased IL-6 levels and HIV-1 infection (see section 1.6). Secondly, 
IL-6 expression is regulated by the transcription factor NFκB, whose subunits have been shown to 
bind to and are inhibited by both GR and PR (see section 1.6). This puts forward IL-6 as a potential 
link between the secretion of soluble mediators, HIV-1 infection and changing GR/PR levels 
 
The present study showed that basal IL-6 mRNA levels were significantly increased with low 
GR/high PR in both End1/E6E7 cells and HeLa cells (Fig. 4.3.3.1). IL-6 protein levels in HeLa cells 
followed the same pattern; with higher IL-6 protein levels of about 400 pg/ml with low GR/high PR 
compared to about 100 pg/ml with high GR/no PR (Fig. 4.4.2a). These levels are much lower than the 
20 ng/ml IL-6 secreted from endocervical cells in one study (Fahey et al. 2005). Together these results 
suggest that IL-6 mRNA and/or protein levels are sensitive to changes in GR/PR levels, where GR 
favours an anti-inflammatory response and PR-B promotes a pro-inflammatory response.  
 
The attempt to link GR/PR levels, increased IL-6 levels and HIV-1 infection in TZM-bl cells 
disappointingly did not show increased HIV-1 infection with increasing concentrations (0-200 pg/ml) 
of exogenous recombinant IL-6 (Fig. 4.4.3). This experiment did not have a positive control, which 
would in retrospect have been useful for the interpretation of the result. However, obtaining a positive 
control for the efficacy of recombinant IL-6 is not straight-forward and would have required finding a 
cell line system responsive to IL-6, that expresses an IL-6 receptor and generates a quantifiable IL-6 
response. Such a system was not available at the time but might be worth considering in future work. 
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Nevertheless, there are some in vitro studies suggesting that exogenous IL-6 increases HIV-1 
infection in different models. For example, stimulation with exogenous IL-6 (20 ng/ml) together with 
IFNγ increased susceptibility of MDMs to X4-tropic infection (Zaitseva et al. 2000). Another report 
showed that IL-6 (100 units/ml) increased HIV-1 replication in MDMs (Poli et al. 1990). However 
another study observed that recombinant IL-6 (40-1000 pg/ml) dose-dependently decreased HIV-BaL 
reverse transcriptase activity in macrophages (Rogez-Kreuz et al. 2005). Together these studies imply 
that the mechanism for IL-6 increasing HIV-1 infection is not clear. The differences between these 
studies and the present study could be attributed to multiple variables, including but not limited to 
different cell type, different concentrations of exogenous IL-6, duration of incubation, degradation of 
IL-6, and order of stimulation and infection. There appears to be no evidence in the literature on 
exogenous IL-6 and increased infection in T cells. However, the results from the present study do not 
exclude the possibility that, in line with the studies above, the increase in IL-6 mRNA/protein could 
be a potential mechanism for the observed increase in HIV-1 infection in TZM-bl cells, with low 
GR/high PR. 
Taken together, the results from this study in the absence of exogenous MPA or E2/P4 support a role 
for changes in relative GR/PR levels, from high GR/no PR to low GR and/or high PR-B levels, in 
increasing HIV-1 infection in TZM-bl cells, and that this occurs through mediating changes in 
unidentified secreted factors. 
 
 
6.3 GR-mediated gene regulation in response to MPA is altered in the presence of PR-B  
 
GILZ and IL-6 were used in this study as model genes for GR-mediated transactivation and 
transrepression, respectively (see section 1.6). Consistent with results from the present study 
(summarized in Table 6.3), robust GR-mediated transcriptional responses to GILZ and IL-6 in 
response to Dex and/or MPA have previously been reported in other cell types (Ronacher et al. 2009, 
Verhoog 2010, Africander et al. 2011a, Verhoog et al. 2011, Govender 2014, Govender et al. 2014, 
Hapgood et al. 2014b, Ray 2015).  
 
The cell type- and gene-specific differences between End1/E6E7 and HeLa cells may be due to 
variations in GR knockdown efficiency, with End1/E6E7 cells showing a 50% decreased in GR levels 
(Fig. 4.3.2.1c, d) and HeLa cells only having 25% decrease in GR levels (Fig. 4.3.2.2c, d). The GR 
levels in HeLa cells after GR knockdown may therefore still be sufficient to induce GILZ mRNA in 
response to MPA, while IL-6 repression still occurs in a GR-dependent manner possibly because IL-6 
transrepression is more sensitive to GR levels.  
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The data from the present study suggest that the presence of PR-B changes the GR-mediated 
responses to MPA. This effect was observed for the endogenous gene IL-6 in both End1/E6E7 and 
HeLa cells, whereas no effect was observed for GILZ or in response to Dex (Fig. 4.3.2.1-3, Table 
6.3). Thus the effect of PR-B on GR-mediated transcriptional responses appears to be gene- and 
ligand-specific. 
 
It could be hypothesized that with high GR/high PR, MPA molecules are divided between GR and 
PR-B such that the GR is not sufficiently activated and does not repress IL-6 expression. Then, with 
low GR/high PR in End1/E6E7 cells, MPA binds to the more available PR-B and the lower numbers 
of GR-MPA cannot repress IL-6. In contrast in HeLa cells which have a slightly higher GR:PR ratio 
even in the low GR/high PR condition, the levels of GR are sufficiently high enough to be activated 
by MPA to repress IL-6. Together this suggests that MPA regulation of IL-6 is anti-inflammatory via 
the GR and either anti-inflammatory or not changed (i.e. no longer anti-inflammatory) via the PR, 
depending on the cell type and relative GR levels. These findings could have important implications 
for the inflammatory environment in the FRT of DMPA users, where the relative levels of GR/PR 
change in response to the menstrual cycle and in different FRT compartments (see section 1.5.4). 
 
 
Table 6.3. Summary of Dex- and MPA-induced effects on GILZ and IL-6 transcriptional 
responses in End1/E6E7 and HeLa cells when the relative levels of GR/PR are altered. 
 
  
High GR 
No PR 
 
 
Low GR 
No PR 
 
 
High GR 
High PR 
 
 
Low GR 
High PR 
 
    
Ligand Gene Cell line NSC siGR NSC siGR 
-PR-B +PR-B 
Dex GILZ End1/E6E7 ++++ ++ ++++ ++ 
HeLa ++++ ++ ++++ ++ 
IL-6 End1/E6E7 ++++ + ++++ ++ 
HeLa ++++ + ++++ + 
MPA GILZ End1/E6E7 ++ - ++ - 
HeLa ++ ++ +++ ++ 
IL-6 End1/E6E7 ++ - - - 
HeLa + - - + 
Number of + signs indicates the degree of induction for GILZ and repression for IL-6, - indicates no change 
relative to the vehicle control. Results are summarized from Figures 4.3.2.1, 4.3.2.2 and 4.3.2.3.  
 
GR
GR
GR
GR
GR GR GR
GR
GR
GR
PRPR GR GR PR PR
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GR/PR protein levels relative to GAPDH were determined by western blotting in End1/E6E7, HeLa 
and TZM-bl cells. In all three cell lines, PR-B over-expression in the low GR condition was slightly 
but not significantly lower than in the non-silencing control (Fig. 4.2.1.1b, d, Fig. 4.2.2.1b, d, Fig. 
4.3.2.1c, e, Fig. 4.3.2.2c, e). This might suggest that the siRNA oligonucleotides targeting the GR can 
also target the PR for knockdown. Therefore the results with PR-B over-expression should be 
interpreted with caution. Additionally, both GR and PR undergo ligand-dependent turnover (Dong et 
al. 1988, Hoeck et al. 1989, Webster et al. 1997, Lange et al. 2000) and therefore the relative levels of 
GR and PR would also be expected to be lower in response to their ligands, adding further complexity 
to the interpretation of these results. Furthermore, differences in PR-B over-expression between the 
cell lines are likely due to variations in transfection efficiency. This was also observed between 
experiments in the same cell line (Fig. 4.2.1.1b, d, Fig. 4.2.2.1b, d). However, transfection efficiency 
using a β-galactosidase expression vector was not used since previous work suggests its expression is 
regulated by steroid hormones in the cell line models used in the present author’s laboratory.  
 
This study also suggests that liganded PR-B can decrease liganded GR transcriptional activity on a 
reporter gene (Fig. 5.2.1a, Fig. 5.2.2a). In addition, unliganded PR-A repressed GR-mediated activity 
in response to Dex as well as PR-B-mediated activity in response to R5020 (Fig. 5.2.1a, Fig. 5.2.2a, 
Appendix B, Fig. B5), which is in line with previous studies (Vegeto et al. 1993, Pieber et al. 2001, 
Maruo et al. 2010). However, when both PR-A and PR-B were over-expressed, Dex induction of 
TAT-GRE-LUC was similar to that in the absence of either PR isoform (Fig. 5.2.1a, Fig. 5.2.2a). This 
could mean that when PR-A and PR-B are co-expressed in the presence of GR, PR-A preferentially 
represses PR-B-mediated activity such that neither PR-A nor PR-B can inhibit GR-mediated activity 
and therefore a higher Dex induction is observed. These results therefore suggest that the relative ratio 
of PR-A/PR-B could influence GR-mediated gene regulation, which may change the pro- or anti-
inflammatory response. In line with this, a study showed that liganded PR-A increases pro-
inflammatory responses while PR-B promotes anti-inflammatory responses on some 
cytokine/chemokine genes (IL-1β, IL-8) in immortalized myometrial cells expressing inducible PR 
isoforms (Tan et al. 2012).  
 
Interestingly, while MPA induced TAT-GRE-LUC 48-fold in the presence of GR, this induction was 
further increased to 110-fold in the presence of GR and PR-B (Fig. 5.2.1a, Fig. 5.2.2a). This suggests 
that both GR and PR-B mediate up-regulation of TAT-GRE-LUC at the same time in response to 
MPA. Following the hypothesis from the earlier data on endogenous IL-6 that PR-B modulates GR-
mediated activity in response to MPA, it is possible that MPA-bound PR-B inhibits the activity of 
MPA-bound GR. However this effect cannot be distinguished since MPA-bound PR-B also mediates 
135 
 
induction of TAT-GRE-LUC. Alternatively, perhaps only the unliganded PR is able to modulate GR 
activity, in the presence of Dex which does not bind PR. 
 
PR-specific gene regulation was not fully explored in this study, for a number of reasons. Firstly, the 
study aimed to investigate expression of endogenous genes, which are likely to be more 
physiologically relevant than promoters such as MMTV which contain 4 GRE/PREs. Another 
criterion for candidate genes in this study was their relevance to immune function. It was therefore 
challenging to find a PR-regulated immune function gene that is not already regulated by the GR. It is 
likely that other transactivation and/or transrepression immune function genes are regulated by the PR 
only; however a thorough search for such genes was not conducted. For the purposes of this study it 
was decided that robust GR-mediated responses on GILZ and IL-6 would be sufficient for the current 
investigation into immune function in the FRT. 
 
Secondly, results from this study suggest that over-expressed PR-B was not functional on endogenous 
genes, based on the observation that over-expressed PR-B regulated progestin induction of the 
reporter gene TAT-GRE-LUC but not the GR/PR-regulated endogenous gene MKP1 in both 
End1/E6E7 and HeLa cells (Appendix B, Fig. B4.3). This observation is consistent with a previous 
report that newly synthesized PR, unlike constitutively expressed PR, cannot activate the MMTV 
promoter in NIH 3T3-derived cells (Smith et al. 1993, Smith et al. 2000a). The same authors showed 
that deficient PR activity on an endogenous MMTV promoter was due to the inability of the PR to 
initiate the chromatin remodelling required for gene activation (Smith et al. 1997). In retrospect, a 
more suitable cell line model would have been the derivative HeLa cells stably over-expressing each 
of the PR isoforms (Richer et al. 1998). There are additional reasons why PR-B would be functional 
on a reporter gene but not an endogenous gene. For example, the high copy number of over-expressed 
promoter-reporter expression vectors, and the absence of adjacent condensed regions of chromatin 
could enable greater access for PR-B to the DNA and therefore could explain high PR-B activity on 
the TAT-GRE-LUC reporter gene but not the endogenous gene. 
 
Thirdly, while characterizing the function of endogenous GR and PR in MCF-7 and T47D cell lines, it 
was found that PR was functional on the TAT-GRE-LUC reporter gene (Appendix B, Fig. B6.2a, c), 
but GR was only weakly functional on endogenous transactivation models (Appendix B, Fig. B6.2b, 
d, Fig. B6.3a, c) and not functional on endogenous transrepression models (Appendix B, Fig. B6.3b, 
d). It is tempting to speculate that the high levels of PR in T47D cells could be inhibiting endogenous 
GR activity. One study found that the absolute levels of GR protein were about 60-fold lower than PR 
in T47D cells (Horwitz et al. 1978), which could suggest preferential use of the more-available PR 
than GR, at least for ligands that can bind both receptors. Consistent with the present study, other 
studies have also reported a non-functional GR in T47D cells (Cato et al. 1986, Cato et al. 1988, 
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Chalepakis et al. 1988, Wu and Pfahl 1988, Nordeen et al. 1989). A T47D derivative cell line stably 
expressing comparable amounts of GR to those of PR, T47D-A(1-2), has been described (Nordeen et 
al. 1989). This cell line would also perhaps have been a better choice for investigating GR/PR 
reciprocal modulation on endogenous genes. However, attempts to transiently over-express increasing 
amounts of GR expression vector in T47D cells in this study were unsuccessful (Appendix B, Fig. 
B6.4). Interestingly, in T47D-A(1-2) cells the stably integrated MMTV promoter was found to be 
more inducible by GC than progestin (Archer et al. 1994a, Archer et al. 1994b), suggesting that when 
GR/PR levels are equivalent, a GR-mediated response is favoured. In line with this, a recent study in 
T47D-A(1-2) cells showed that GR knockdown restored PR-mediated gene regulation in response to 
R5020, suggesting that GR can modulate PR activity in this model (Ogara et al. 2015). It is tempting 
to speculate that stably expressed GR inhibits PR activity in these cells. 
 
While the results of the present study suggest that PR-B can modulate the activity of liganded GR on 
some genes in some cells, other studies suggest that the presence of GR can inhibit PR activity. 
Collectively these observations suggest that GR and PR can reciprocally modulate each other’s 
activity. These findings suggest that the relative levels of GR/PR may play an important role in 
determining the inflammatory and immune responses in the FRT of DMPA users. 
 
 
6.4 Unliganded GR-mediated gene regulation is altered in the presence of unliganded PR-B 
 
This study also provides some evidence that changing the relative levels of GR/PR alters the basal 
transcription of some but not other immunomodulatory genes in the absence of MPA (Fig. 4.3.3.1-2). 
These findings are summarized in Table 6.4. These results suggest that in the absence of MPA, 
changing GR/PR levels from high GR/no PR to low GR/high PR modulates the basal expression of 
some immunomodulatory genes, in a gene- and cell-specific manner. 
 
While the genes investigated in this study (Table 6.4) are known to be regulated by the GR, their 
regulation by the PR is not well established. The exception is IL-8, for which ligand-mediated 
repression via both GR and PR has been demonstrated. IL-8 repression by GR and PR occurs through 
different mechanisms, where PR inhibits the recruitment of Pol II to the transcription initiation site 
and GR bound to SRC-2 inhibits the transcription elongation factor b complex (Rogatsky et al. 2002, 
Kobayashi et al. 2010). Interestingly, one study in immortalized myometrial cells with inducible PR 
isoforms showed that in the absence of ligands, PR-B-dominant cells expressed higher levels of IL-1β 
and IL-8 than the PR-A-dominant cells (Tan et al. 2012). Together the data on IL-6, IL-8, RANTES 
and GILZ in the present study could suggest that the unliganded GR generally favours an anti-
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inflammatory state while the unliganded PR-B generally favours a pro-inflammatory state in cervical 
cells.   
 
It is difficult to say whether or not unliganded GR modulates the activity of unliganded PR-B based 
on the results from this study. In HeLa cells over-expressing PR-B, basal IL-6 mRNA levels increased 
when GR levels were decreased (Fig. 4.3.3.1d, Table 6.3). In addition, in End1/E6E7 cells over-
expressing PR-B, basal GILZ mRNA levels increased when GR levels were decreased (Fig. 4.3.3.1a, 
Table 6.3). It could be that PR-mediated regulation of these genes can only occur with low GR levels, 
but the effects appear to be gene- and cell type-specific. Further investigation is therefore needed, 
using genes shown to be directly regulated by the PR. 
 
Table 6.4. Summary of basal transcriptional responses in End1/E6E7 and HeLa cells when the 
relative levels of GR/PR are altered 
 
  
High GR 
No PR 
 
 
Low GR 
No PR 
 
High GR 
High PR 
 
Low GR 
High PR 
    
Ligand Gene Cell line NSC siGR NSC siGR 
-PR-B +PR-B 
None 
(basal) 
GILZ End1/E6E7 +++ ++ + + 
HeLa - - - + 
IL-6 End1/E6E7 - + - + 
HeLa - + +++ ++++ 
IL-8 HeLa - - - + 
RANTES HeLa - - - + 
IL-10 HeLa - + (?) + (?) - 
IL12-p35 HeLa - - - - 
IL12-p40 HeLa - + (?) - + (?) 
Number of + signs indicates degree of induction for GILZ and IL-10, and repression for IL-6, IL-8, IL-12 and 
RANTES. - indicates no change relative to NSC-PR-B. (?) indicates a non-statistically significant effect. Results 
are summarized from Figures 4.3.3.1 and 4.3.3.2. 
 
It is possible that the effects on immunomodulatory gene expression in this study from high GR/no 
PR to low GR/high PR are solely due to changes in GR levels (Gougat et al. 2002). Higher levels of 
unliganded GR can dimerize and regulate expression of GILZ in COS1 cells over-expressing GR 
(Robertson et al. 2013b). In addition, a portion of unliganded GR is localized to the nucleus and can 
activate transcription in the absence of hormone ligands, and in the presence of other signalling 
factors such as TNFα (Hapgood et al. 2016).  
 
GR
GR
GR
GR
GR GR GR
GR
GR
GR
PRPR GR GR PR PR
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Alternatively, it could be that unliganded GR and unliganded PR-B modulate each other’s activity 
through various mechanisms including changing chromatin remodelling in key regulatory regions. 
There are many studies using liganded receptors that support this hypothesis. For example, progestin-
bound PR can activate transiently expressed but not stably integrated MMTV that has acquired an 
ordered chromatin formation, unlike glucocorticoid-bound GR (Archer et al. 1994a, Archer et al. 
1994b, Smith et al. 1997). Another study showed that RU486-bound PR inhibited GR activation of 
the MMTV promoter by preventing GR’s ability to promote assembly of a transcription initiation 
complex (Fryer et al. 1998). In line with this, the unliganded PR in breast cancer cells was shown to 
silence basal expression of target genes by recruiting a multi-protein repressor complex that was 
displaced upon hormone binding (Vicent et al. 2013). Additionally, R5020-activated PR has been 
shown to inhibit glucocorticoid-induced activation of β-casein by physically binding to the promoter 
and blocking GR binding (Buser et al. 2011). However, the chromatin remodelling capabilities, 
interacting partners and context-dependence of GR and PR are more complex than indicated here and 
have been reviewed by others (Kagoshima et al. 2001, Trotter and Archer 2007, Grontved and Hager 
2012, King et al. 2012, Burd and Archer 2013, Ceballos-Chavez et al. 2015). Taken together, PR-B 
could repress GR activity by modifying the chromatin architecture and/or physically preventing GR 
binding to promoters. 
 
The differential effects observed with changing GR/PR levels could also be a result of competition for 
available co-factors (co-activators, co-repressors and co-modulators). Hundred of co-regulators 
interact with the GR (Weikum et al. 2017b). Levels of exogenously expressed co-repressors NCoR 
and SMRT differentially affected the potency of agonists bound to GR versus PR (Song et al. 2001). 
Furthermore, PR and GR both interact with steroid receptor coactivator (SRC)-1 and SRC-2, but have 
different preferences, that is, PR preferentially recruits SRC-1, while GR prefers SRC-2 (Li et al. 
2003). Co-activator expression and function also vary in a cell- and tissue-specific manner (Molenda 
et al. 2003, Lonard et al. 2007, York and O'Malley 2010, Stashi et al. 2014) and could therefore 
influence the ligand-independent transcriptional responses to changing GR/PR. 
 
Taken together, over-expressed PR-B appears to modulate the GR-mediated regulation of some key 
immunomodulatory genes, but not others, in the absence of MPA, which may involve a number of 
mechanisms not further explored in this thesis. This provides useful insight into reciprocal modulation 
of GR- and PR-mediated transcriptional activity. These results could have implications for the 
baseline inflammatory and immune responses in naturally cycling women not using contraceptives, 
where relative levels of GR/PR change in the FRT across the menstrual cycle.  
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6.5 GR and PR may associate within the same protein complexes within the nucleus 
 
Following the data above suggesting that GR and PR may reciprocally modulate each other’s activity 
in regulation of some immunomodulatory genes, it was hypothesized that the mechanism of reciprocal 
modulation could be through physical association of the receptors. Using co-IP to infer an interaction 
(which could be either direct or indirect), PR appeared to be pulled down with anti-GR antibody, in 
both COS1 cells over-expressing GR/PR-B and MCF-7 cells expressing endogenous GR/PR (Fig. 
5.3.1-2). There appeared to be greater PR pulled down in the presence of MPA in COS1 cells in some 
but not all experimental repeats (Fig. 5.3.1), suggesting that the GR-PR interaction may be ligand-
dependent. However this was not clear in MCF-7 cells. Further investigation is therefore required to 
determine the ligand-dependency of this association. 
 
Consistent with this, another study using reciprocal co-IP assays showed that PR-A interacts with GR 
in mouse lung cells, although they did not investigate whether GR interacts with PR-B (Shao et al. 
2006). Furthermore a recent study in T47D cells showed that fluorescent tagged mCherryGR and 
eGFP-PR formed a complex in the presence of R5020 or Dex but not in the absence of ligand (Ogara 
et al. 2015). The same study showed using ChIP-seq in T47D-A(1-2) cells that 74% of Dex-bound 
GR mapped to the same binding regions as R5020-bound PR, and conversely that 48% of PR-bound 
regions were also bound by GR (Ogara et al. 2015). This supports the hypothesis that GR and PR can 
bind to the same target regulatory DNA regions as a possible heterodimer.  
 
Following the indication of a potential association, the cellular localization of over-expressed GR and 
PR in COS1 cells was investigated using immunofluorescence with confocal microscopy (Fig. 5.5). 
GR and PR were shown to be mostly co-expressed within the same cells (Fig. 5.4). In addition, 
quantification of nuclear co-localization showed that GR and PR co-localized (that is, spatially co-
occurred) in the nucleus in response to the ligands Dex, R5020 and MPA but not the vehicle control 
(Fig 5.6.1, Table 5.6.1). This finding was further supported using SR-SIM, which has about a 2-fold 
higher resolution than confocal microscopy (Fig. 5.6.3, Table 5.6.2). Further inspection of SR-SIM 
images indicated that ligand-dependent GR-PR co-localization occurred within some regions of the 
nucleus, but that there were regions expressing GR-only or PR-only (Fig. 5.6.4). 
 
These results are consistent with other work showing that PR is mostly localized to the nucleus 
(Perrot-Applanat et al. 1985, Renoir et al. 1990, Guiochon-Mantel et al. 1991) and that GR 
translocates to the nucleus in a ligand-dependent manner (Picard and Yamamoto 1987, Vicent et al. 
2002). It has also been shown that GR nuclear translocation can be increased by increasing GR levels 
(Robertson et al. 2013a). A previous report using immunohistochemistry showed that PR-A and GR 
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co-localize in the nucleus in mouse lung alveolar but not bronchial epithelium, although this is likely 
influenced by the low levels of endogenous corticosterone (Shao et al. 2006).  
 
The nuclear translocation of GR in response to R5020 has to the present author’s knowledge not been 
previously shown. R5020 is generally used in relative binding affinity studies as the reference ligand 
with 100% binding to the PR. There are limited reports suggesting that R5020 can bind to the GR 
with low affinity (Nordeen et al. 1981, Stromstedt et al. 1990), so this finding is perhaps unsurprising. 
The dose response assay in this study indicated that R5020 at 100 nM did not activate GR-mediated 
TAT-GRE-LUC reporter gene activity (Fig. 5.6.2). This suggests that while R5020 could induce GR 
nuclear translocation, R5020-bound GR may not be transcriptionally active. These results support the 
idea that R5020 is a poor PR-specific agonist, and future studies should perhaps focus on a PR agonist 
with no GR cross-reactivity, such as NET (Ronacher et al. 2009). 
 
In light of the work showing that PR can physically block GR binding to a target promoter (Buser et 
al. 2011), there is likely a dynamic and temporal interplay where the GR and PR move on and off the 
same target promoters. This leads to interesting unanswered questions such as whether GR and PR 
bind to the same sites like promoters and/or regulatory regions of immunomodulatory genes, in a 
ligand-dependent or –independent manner. However, as mentioned above, this may depend on 
chromatin context, co-factor expression, promoter-specific effects and/or other factors. 
 
Together the results from the co-IP assays suggest that GR and PR associate in a ligand-independent 
manner, while the immunofluorescence results suggest that GR and PR co-localize in a ligand-
dependent manner. It is possible that a GR-PR association in the same complex in the nucleus 
modulates the ligand-dependent effects of different GR/PR ligands, while other non-genomic 
mechanisms may operate for ligand-independent effects. These non-genomic mechanisms could 
include modulation of chromatin remodelling and activation of signalling cascades. Non-genomic 
signalling pathways have been described for both the GR and PR (Ehring et al. 1998, Edwards et al. 
2002, Leonhardt et al. 2003, Stellato 2004, Vallejo et al. 2005, Chien et al. 2006, Lowenberg et al. 
2008, Gellersen et al. 2009, Ordonez-Moran and Munoz 2009). It is also possible that the GR-PR 
association in the absence of MPA observed by co-IP occurs with a very small percentage of GR/PR 
such that these effects are not observed with immunofluorescence. This effect would especially not be 
observed if this association occurs in the cytoplasm, since SR molecules are more spread out than in 
the nucleus. Taken together, the results from this study support the hypothesis that GR and PR 
associate with each other. This closer physical proximity may be a mechanism by which GR and PR 
reciprocally modulate each other’s activities. This may be relevant in the FRT where GR/PR ligands 
induce the nuclear co-localization and association of GR and PR, in addition to possible non-genomic 
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effects in the cytoplasm, which may have important consequences on GR- and PR-mediated 
immunomodulatory gene regulation and/or HIV-1 infection. 
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Chapter 7 
Conclusions and Future Perspectives 
 
 
 
7.1 Conclusions 
 
The results in PBMCs and TZM-bl cells support the first central hypothesis in this study, which was 
that MPA, at a concentration representing the upper range of serum levels in DMPA users, and E2/P4, 
mimicking the luteal phase of the menstrual cycle, increase HIV-1 infection, and that this may occur 
through potentially different biological mechanisms. These mechanisms of enhanced infection in 
PBMCs with MPA, unlike luteal phase E2/P4, are most likely through an increased CD4/CD8 ratio, 
increased expression of CCR5 co-receptor on the surface of CD4+ T cells, and increased expression 
of the activation marker CD69 on CD4+ T cells. The results in cervical TZM-bl cells showing that 
MPA increases HIV-1 infection and mRNA levels of both the CD4 receptor and the CCR5 co-
receptor strongly support the PBMC results. The results in both PBMCs and TZM-bl cells also 
provide evidence of a role for the GR and GR levels in modulating HIV-1 infection in the presence of 
MPA. The results also support other studies suggesting that DMPA users and women in the luteal 
phase of the menstrual cycle are at higher risk of HIV-1 acquisition than women in the follicular 
phase.  
 
While the TZM-bl cervical cell model does not fully represent the FRT, it provides a useful 
opportunity to study HIV-1 infection, particularly viral entry, and provides insight into biological 
mechanisms relevant to HIV-1 target cells. While there are known differences in immune cells (such 
as frequency of T cells) in the FRT compared to PBMCs, the results from the two models used in this 
study combined (PBMCs and TZM-bls) suggest that these mechanisms are likely relevant to any 
HIV-1 target cells in the body. These HIV-1 target cells include many cell types in the FRT that 
express CD4 and the CCR5 co-receptor, such as CD4+ T cells and macrophages. This thesis therefore 
provides important evidence for the proof of concept for biological mechanisms of infection. 
Currently the biomarkers for infectability have not been defined (Hapgood et al. 2018). However the 
results from this study suggest that CCR5 levels may be a useful biomarker. Furthermore the finding 
that luteal phase hormones increase HIV-1 infection via a different mechanism to MPA suggests that 
the effects are not due to P4 but rather to activation of the GR by MPA. 
 
The present author is aware that there are limitations translating ex vivo research to in vivo effects. 
However this study aimed to find evidence of biological mechanisms for MPA and HIV-1 infection, 
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which cannot be done in vivo. Another limitation of the current study is that the cell models used were 
non-FRT target cells, so the immune system of the FRT was not fully represented. Furthermore the 
concentrations of exogenous hormones used ex vivo in this study were possibly too high for MPA and 
too low for P4 representing the luteal phase. Nevertheless the molecular mechanisms and insights 
provided by these data are consistent with many clinical observations, and provide strong support for 
a role of increased CCR5 levels as a key biological mechanism by which MPA can increase HIV-1 
infection in any HIV-1 target cells that express CD4 and CCR5, in both peripheral blood and the local 
FRT. 
 
In line with the growing body of epidemiological and molecular evidence that MPA increases 
susceptibility to HIV-1 infection, the WHO has recently changed the medical eligibility criteria for 
MPA and other injectables from Category 1 (no restriction) to Category 2 (where the benefits of using 
this method “generally outweigh the theoretical or proven risks”) (World Health Organization 2017). 
Identifying progestin contraceptives with no effects on HIV-1 infection, such as NET-EN or LNG, 
that may be more suitable alternatives to DMPA in high HIV-1 risk areas, is a subject of ongoing 
research (Hapgood 2013). 
 
The results of this thesis also provide proof of concept in support of the second central hypothesis of 
this study, which was that changing the relative levels of GR/PR can influence HIV-1 infection and 
the regulation of immunomodulatory genes in the FRT. This is relevant to DMPA users in vivo since 
MPA activates both the GR and the PR. Together the results in cervical cell lines suggest that MPA 
acting via the GR increases HIV-1 infection and promotes immunosuppressive regulation of key GR-
mediated immunomodulatory genes. Furthermore the presence of PR-B increases HIV-1 infection in 
the absence of MPA and modulates GR-mediated immunomodulatory gene regulation in both the 
absence and presence of MPA. However the effect of PR-B on immunomodulatory gene expression 
appeared to be gene-, ligand- and cell type-specific, which suggests that in these models the main 
contribution to increased HIV-1 infection is not via different expression of immunomodulatory genes. 
This appears to be consistent with the current clinical studies suggesting that overall MPA may have 
no effect on immunomodulatory gene expression. Nevertheless the in vitro evidence of 
immunosuppressive effects of MPA via the GR suggest that other progestin-based contraceptives that 
do not act via the GR, such as NET (Ronacher et al. 2009), administered as the injectable Nur-isterate, 
may be more suitable contraceptives to use in high HIV-1 risk areas (Hapgood 2013). The use of NET 
instead of MPA may thus be less likely to enhance sexual HIV-1 transmission in these high-risk areas. 
 
The third central hypothesis of the current study, stating that GR and PR reciprocally modulate each 
other’s activity through a possible interaction, was supported by the results suggesting that PR-B may 
modulate the activity of GR in some contexts and that there is a ligand-dependent association between 
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GR and PR in the nucleus. Although cell lines and not primary FRT cells were used, the results 
supporting the second and third hypotheses are likely to have important physiological relevance to 
changing relative GR/PR levels in FRT tissues in vivo. This may be particularly relevant for immune 
function and susceptibility to HIV-1 acquisition in the ectocervix, where both GR and PR are 
expressed. PR expression in the ectocervix has been shown to be higher during the luteal phase, which 
would result in conditions of either high GR/high PR or low GR/high PR in vivo. This would depend 
on GR levels which also fluctuate in response to circadian and chronic stress-induced variations in 
endogenous GCs like cortisol (Cohen et al. 2012, Patterson et al. 2013, Contoreggi 2015, Cain and 
Cidlowski 2017). However, the high inter-donor variability in GR and PR protein expression in 
cervical samples ex vivo suggests that the effects of changing relative GR/PR levels on HIV-1 
infection and immunomodulatory gene regulation may be more pronounced in some women than 
others.  
 
Based on the results from this study, it could be hypothesized that HIV-1 infection increases in the 
presence of MPA as a result of two concurrent biological mechanisms, which are represented 
schematically in Figure 7.1. The main mechanism is that MPA increases CCR5 levels on the surface 
of target cells and increases activation of CD4+ T cells while simultaneously increasing the ratio of 
CD4/CD8 T cell frequency (Fig. 7.1: 1). This effect is likely to be relevant to all HIV-1 target cells in 
the body, including the FRT. The second mechanism is that MPA activates the GR which regulates 
GR-dependent transactivation of GILZ and transrepression of IL-6 (Fig. 7.1: 2, 3). GR-mediated 
regulation of immunomodulatory genes creates a more anti-inflammatory, immunosuppressive state 
which could promote HIV-1 infection by suppressing the adaptive immune responses in the local FRT 
(Fig. 7.1: 2). The presence of PR-B, however, does not affect HIV-1 infection but modulates GR-
mediated regulation of key immunomodulatory genes, such as increasing expression of IL-6, via a 
GR-PR association (Fig. 7.1: 4, 5). Therefore the presence of PR-B promotes a more pro-
inflammatory state. However the balance of pro- or anti-inflammatory effects depends on the relative 
levels of GR/PR, which are likely to vary in the FRT from different women in vivo.  
 
In conclusion, the results from this thesis provide insight into likely biological mechanisms for MPA-
induced HIV-1 infection in target cells expressing CD4 and CCR5. In addition, the results from this 
study suggest that HIV-1 infection critically depends on GR but not PR-B levels, while regulation of 
immunomodulatory genes depends on changing GR/PR levels. Taken together, it is likely that DMPA 
use may increase HIV-1 infection in some but not other individuals, depending on multiple factors 
such as CCR5 levels on target cells, CD4+ T cell frequency, varying GR/PR levels, metabolism, 
serum concentrations, immune activation status and endogenous hormone levels. The complexity of 
these factors may be a molecular explanation for why so much variability has been observed in 
clinical studies of MPA and HIV-1 acquisition. 
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Figure 7.1. Model representing possible biological mechanisms by which MPA increases HIV-1 
infection in target cells and the effects of changing GR/PR levels on HIV-1 infection and 
immunomodulatory gene regulation in the presence of MPA. MPA is lipophilic and diffuses 
across the cell membrane. (1) MPA increases CCR5 levels on the surface of target cells, increases 
activation of CD4+ T cells and increases the frequency of CD4+ T cells while simultaneously 
decreasing the frequency of CD8+ T cells. These biological mechanisms combined result in increased 
HIV-1 infection in target cells. (2) With high GR/no PR, MPA induces GR-mediated transactivation 
of GILZ and transrepression of IL-6. In addition, MPA increases HIV-1 infection, most likely via the 
biological mechanisms indicated in (1). (3) With low GR/no PR, the GR-mediated regulation of GILZ 
and IL-6 is lost. Furthermore HIV-1 infection with low GR/no PR is abolished compared to high 
GR/no PR, suggesting that high GR levels are required for MPA-induced HIV-1 infection. (4) With 
high GR/high PR and (5) low GR/high PR, MPA induces IL-6 mRNA expression, suggesting that PR 
modulates GR-mediated activity. This occurs via a ligand-dependent GR-PR association, indicated by 
the line joining GR and PR. The presence of PR-B does not change MPA-induced HIV-1 infection, 
suggesting that infection depends on GR but not PR levels. For simplification, GR and PR are 
represented as monomers that directly bind to target gene DNA and regulate transactivation of GILZ 
or transrepression of IL-6, IL-8 and RANTES. Figure layout adapted from (Hapgood et al. 2016). 
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7.2 Future perspectives 
 
The results from this thesis led to several interesting unanswered questions that could be explored 
further. A few of these are discussed below. 
 
Importantly, this study provides in vitro proof of concept of relevant biological mechanisms by which 
MPA can increase HIV-1 infection. Whether these biological mechanisms are clinically relevant in 
vivo remains to be determined. Therefore important future work could test whether some or more of 
these mechanisms are also observed using PBMC and FRT samples from women on MPA compared 
to women using no hormonal contraceptives and either in the luteal or the follicular phase of the 
menstrual cycle.  
 
The PBMCs used in the present study were from female donors at unknown phases of the menstrual 
cycle. It remains unanswered whether or not the endogenous E2/P4 levels in the serum of these 
women, who may already be in either the luteal or follicular phase, could be masking the effects of 
exogenous E2/P4 in this study. Future work could therefore include quantifying endogenous E2/P4 
serum levels, thereby categorizing the PBMC donors as in the luteal or follicular phase, prior to HIV-
1 infection assays. This study also did not investigate whether more pronounced or different effects on 
HIV-1 infection and regulation of markers relevant to infection would be observed using exogenous 
P4 at higher concentrations. Peak levels of P4 in the luteal phase as high as 71-200 nM have been 
reported (Goebelsmann 1986, Vassiliadou et al. 1999, Stricker et al. 2006). Therefore another 
approach for in vitro PBMC experiments would be to use different combinations of E2/P4 with higher 
P4 concentrations, in order to better mimic the early, mid- and late luteal and follicular phases. Co-
stimulation with exogenous LH and FSH could also be used to mimic the natural cycle more closely. 
 
It could be that different responses might be observed if E2 was co-stimulated with MPA. Therefore, 
in order to more closely mimic the hormonal environment in the serum of DMPA users, future PBMC 
experiments could use exogenous stimulation of MPA together with E2/P4 at concentrations observed 
in DMPA users. Whether the effects on HIV-1 infection with MPA are also observed at lower 
physiological doses of exogenous MPA is a subject of ongoing study in the present author’s 
laboratory. These experiments also use ex vivo cervical explant models to gain insight into 
mechanisms of HIV-1 infection in the FRT. Infection assays from the current study used an R5-tropic 
IMC where infection was indicated by LTR-driven expression of Renilla luciferase. However, since 
the findings from this study are in the context of the laboratory-adapted strain HIV-1BaL_Renilla, and 
since different strains of HIV-1 behave differently, some of this data may change if other strains were 
to be tested. Whether this infection model is physiologically relevant could be tested using clinical 
isolates of R5- and X4-tropic viruses. It remains unanswered whether the GR plays a direct role in the 
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regulation of CCR5 expression. This is also a subject of ongoing research in the present author’s 
laboratory. 
 
The question also remains whether GR/PR levels change in tissues from the FRT in vivo. Future work 
could therefore investigate GR/PR levels in FRT samples from women using MPA and women during 
different stages of the menstrual cycle. An approach for measuring relative GR/PR levels in primary 
FRT cells could be immunohistochemistry analysis of archived sections taken from these women. 
 
Another unanswered question is whether endogenous or stably expressed PR could have different 
effects on immunomodulatory gene expression in vitro compared to transiently over-expressed PR, as 
used in this study. Further research could employ the use of other cell line models expressing both GR 
and PR, for example, the HeLa derivative stably expressing PR-B (Richer et al 1998, Mori et al 2009), 
the MDA-MB-231 breast cancer cell lines stably expressing each of the PR isoforms and the 
T47D(A1-2) breast cancer cell line which expresses high levels of endogenous PR and equivalent 
levels of stably expressed GR (Nordeen et al. 1989).  In these cell line models, the relative levels of 
GR/PR could be altered using siRNA knockdown only, thereby eliminating the confounding effects of 
variable PR over-expression. In addition to these cell lines, another approach to investigate changing 
GR/PR levels in a primary cell model could be to use nucleofection to over-express PR in PBMCs. 
 
It is unclear whether the GR and PR may be in close enough physical proximity to interact and form a 
heterodimer. The work of this study showing ligand-dependent GR/PR nuclear co-localization and 
protein association, and of Ogara et al (2015), enticingly suggest that GR and PR may interact in a 
ligand-dependent manner to form a heterodimer. This would be interesting to follow up using Forster 
Resonance Energy Transfer (FRET) in MPA-treated cells, in order to suggest close physical 
proximity. FRET and GR/PR co-localization in response to MPA could also be investigated in other 
cell line models expressing both GR and PR, such as the cell lines stably expressing PR derived from 
HeLa and MDA-MB-231 cells and the T47D(A1-2) breast cancer cell line.  
 
One of the unanswered questions from the present study is whether there is a causative link between 
one or more of the immunomodulatory genes regulated by GR/PR and increased HIV-1 infection. It is 
tempting to speculate that IL-6, showing higher mRNA and/or protein levels with low GR/high PR, 
could increase HIV-1 infection in TZM-bl cells. However, this link was not established in this study. 
Future work could therefore investigate different combinations of soluble factors, such as IL-6 and 
other cytokines, on mediating HIV-1 infection indirectly in TZM-bl cells. However there are likely to 
be complex combinations of soluble factors involved, making it difficult to identify in vitro. Therefore 
another experiment for future consideration is the high-throughput screening for genes relevant to 
immune function that are differentially expressed with changing GR/PR levels, for example using 
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RNA-Seq. If a candidate(s) is identified and exogenous stimulation of its product can enhance HIV-1 
infection in vitro, the causal link can be demonstrated if co-incubation with an antibody specific to 
this factor abolishes HIV-1 infection. A candidate gene for further investigation could be the 
chemokine IL-8. Previous work has shown that repression of NFκB-driven IL-8 expression is 
regulated by both GR and PR (Kunsch and Rosen 1993, Mukaida et al. 1994, Nissen and Yamamoto 
2000, Horie et al. 2005, Tsaprouni et al. 2007). There is also some conflicting evidence linking IL-8 
and HIV-1 infection (Denis and Ghadirian 1994, Meddows-Taylor et al. 1998, Tiemessen et al. 2000, 
Lane et al. 2001, Promadej-Lanier et al. 2010, Mamik and Ghorpade 2014), further suggesting that 
IL-8 could be a promising GR/PR-regulated gene involved in HIV-1 infection. Whether GR and PR 
occupy the same promoter(s), such as IL-8, at the same time, in a ligand-dependent manner, could be 
tested in vitro using chromatin immunoprecipitation assays. Regarding the choice of receptor-specific 
agonists, there are some hints from this thesis suggesting that R5020 may be a poor PR-specific 
agonist. Therefore future assays could instead use NET or other progestins which do not bind to the 
GR. 
 
The mechanism by which unliganded PR-B increased HIV-1 infection in TZM-bl cells was not 
identified in this study. Interestingly, there is evidence that the HIV-1 long terminal repeat (LTR) 
promoter contains binding sites for the GR (Mitra et al. 1995, Hapgood and Tomasicchio 2010). 
Owing to their ability to recognise and bind to similar DNA target sequences, the PR may also bind to 
these sites in the LTR promoter. It would therefore be interesting to determine whether PR-B could 
also modulate HIV-1 infection via regulating LTR promoter activity. However there are conflicting 
reports in the literature (Hapgood and Tomasicchio 2010) showing that liganded GR can mediate 
either increased (Furth et al. 1990, Wiegers et al. 2008) or decreased (Laurence et al. 1989, Mitra et 
al. 1995, Kino et al. 2000, Hanley and Viglianti 2011) HIV-1 LTR transcription. Thus investigating a 
role for GR/PR and changing relative GR/PR levels on LTR-mediated transcription could be an 
avenue for further research. 
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Appendix A 
Supporting data from other researchers in the Hapgood laboratory 
 
 
Previous research from former PhD students in the Hapgood laboratory has established the basal 
steroid receptor mRNA and/or protein levels in the model cell systems used within this study.  
 
A1. PBMCs: 
PBMCs from two representative female donors express only detectable GR protein (Fig. A1.1b), but 
also express ERα, GR and MR mRNA (Fig. A1.1a). In this experiment, the same anti-PR antibody 
was used as for the present study, while MR was excluded due to the non-specific property of the 
available anti-MR antibody. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1.1. Basal steroid receptor mRNA (a) and protein (b) levels in two representative 
female PBMC donors (R. Ray, PhD thesis 2015, pg 74). (a) Steroid receptor mRNA levels were 
determined using conventional PCR with cDNA from two PBMC donors (#1 and #2) and receptor-specific 
primers (Tomasicchio et al. 2013), using GAPDH as a control for mRNA levels. Positive controls (+ctrl) for the 
steroid receptors were created by PCR amplification of the relevant plasmid DNA. PR (PRAB) has two positive 
controls, with PR-B loaded first, then PR-A. NTC denotes the no template control (negative control). PCR 
products were analyzed by gel electrophoresis. (b) Total protein isolated from two PBMC donors using TAPS 
b) a) 
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buffer was electrophoresed on an 8% SDS-PAGE gel followed by western blotting using antibodies specific to 
each steroid receptor. Positive controls (+) were created using COS1 cells, and were visualized using shorter 
exposure times on the same blots (Ray 2015). This figure also appears in (Tomasicchio et al. 2013). 
 
 
A2. Cell Lines 
 
HeLa cervical carcinoma cells express only detectable GR protein (Fig. A2.1b), but also express GR, 
AR and MR mRNA (Fig. A2.1a). The modified HeLa cell line, TZMBL, expresses GR and AR 
protein (Fig. A2.1b), and GR, AR and MR mRNA (Fig. A2.1a). The antibody against MR used here 
appears to be non-specific, but since MR mRNA is expressed, it may be possible that MR protein is 
expressed in HeLa and TZMBL cells at levels below the western blot detection limit.  
 
 
 
 
Figure A2.1. Basal steroid receptor mRNA (a) and protein (b) levels in HeLa and TZMBL cells 
(Y. Govender, PhD thesis 2014, pg 73). HeLa (1.5 X 105) and TZMBL (1 X 105) cells were seeded in 12 
well plates and incubated overnight. Cells were washed with cold 1 x PBS and harvested with TRI Reagent for 
total RNA (a) or with SDS sample buffer for total protein (b). Steroid receptor gene expression (a) was 
measured using real-time qPCR with receptor-specific primers (Tomasicchio et al. 2013) and primers for the 
housekeeping gene GAPDH as a loading control. PCR products were confirmed by gel electrophoresis. Controls 
were created by PCR amplification of the relevant steroid receptor expression vector (pcDNA3-hGR, pMT-PR-
B, pSV-hAR, pRS-hMR and pSG5-hER) plasmid DNA (+CTRL) or empty vector pcDNA3 plasmid DNA (-
CTRL). Steroid receptor protein levels (b) were confirmed by SDS-PAGE with equal volumes of cell lysate and 
western blotting using specific antibodies, including anti-MR (H-300, sc-11412), anti-AR (441, sc-7305), anti-
PR (C-20, sc-539) anti-ERα (MC-20, sc-542, all from Santa Cruz Biotechnology) and GAPDH as the loading 
control. Controls were created in COS1 cells by transient transfection for 24 h with empty vector pcDNA3 (-
CTRL) or with steroid receptor expression vectors (+CTRL), followed by harvesting in SDS sample buffer 
(Govender 2014). This figure also appears in (Govender et al. 2014). 
 
H
e
L
a
T
Z
M
B
L
-
C
T
R
L
+
 C
T
R
L
H
e
L
a
T
Z
M
B
L
-
C
T
R
L
+
 C
T
R
La) b) 
151 
 
 
End1/E6E7 immortalized endocervical epithelial cells express GR, ERα and low levels of AR but not 
MR or PR-B protein (Fig. A2.2). The same non-specific antibody against MR was also used here. 
Both Fig. A2.1 and A2.2 used different anti-PR antibodies to what was used in the present study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A2.2. Basal steroid receptor protein levels in End1/E6E7 cells (N. Verhoog, PhD thesis 
2010, pg 62). Equal volumes of whole cell lysates from End1/E6E7 cells, untransfected COS1 cells (-ve 
control) or COS1 cells transiently transfected with steroid receptor expression vectors (pSG5hPR-B, pCMV-
HA-hGR, pSVhARo, and pRShMR) (+ve control) were analyzed by western blotting using antibodies against 
(a) ERα, (b) GR, (c) PR (B-30, sc-811, Santa Cruz Biotechnology), (d) MR and (e) AR, using β-actin (#4967, 
Cell Signaling, South Africa) as the loading control. Other antibodies used were the same as for Fig. A1b. For 
ERα (a), the positive control was an ER-expressing HeLa cell lysate (Verhoog 2010). 
 
 
A3. Cervical explants 
 
Ectocervical explants from normally cycling premenopausal women express detectable protein levels 
of GR, PR-A, PR-B, ERα and AR, in both the luteal (n=6) and follicular (n=6) phases of the 
menstrual cycle, with high inter-individual variability in protein levels (Fig. A3.1). In this experiment, 
the same anti-PR antibody was used as for the present study, while MR was excluded due to the non-
specific property of the available anti-MR antibody. A slightly different method of protein isolation 
from cervical explant tissue (TissueRuptor probe homogenizer) was used compared to the present 
study (TissueLyser). 
 
d) 
e) 
a) b) 
c) 
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Figure A3.1. Basal steroid receptor protein levels in ectocervical explants from premenopausal 
women in the luteal or follicular phase of the menstrual cycle (R. Ray, PhD thesis 2015, pg 114). 
Cervical explants were homogenized in 800 μl Buffer RLT (Qiagen) with a probe homogenizer (TissueRuptor, 
Qiagen) and total protein was quantified using the Bradford assay. Western blots were carried out using 20 μg 
total protein loaded onto 8% SDS-PAGE gels and western blotting using antibodies specific to each steroid 
receptor. Positive controls (+) were created using COS1 cells, and were visualized using shorter exposure times 
on the same blots (Ray 2015).  
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Appendix B 
Supporting data from the present author 
 
 
Pilot assays for HIV-1 infection and the establishment of model cell line systems in which to study 
changing GR/PR, carried out by the present author, are presented as supplementary data in this 
appendix.  
 
B1.  Confirmation of HIV-1 infection in PBMCs 
 
The ability of exogenous MPA or hormones mimicking the menstrual cycle phases to activate the 
HIV-1 LTR in the absence of HIV-1BaL_Renilla (that is, the no-virus control) was measured in PBMCs. 
No significant differences were observed for any of the stimulation conditions (Fig. B1.1), suggesting 
that the exogenous hormones do not regulate the HIV-1 LTR. The presence of HIV-1BaL_Renilla 
significantly increased the relative HIV-1 infection of the vehicle control, after both 2 and 7 days’ 
stimulation with ligands (Fig. B1.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B1.1 Stimulation with MPA or hormones mimicking the menstrual cycle phases does not 
change basal HIV-1 LTR activity. PBMCs were stimulated and infected as described in Fig. 3.2.1. The 
results show pooled data from at least 3 independent experiments, with 2-3 PBMC donors each, for a total of 7 
independent donors. Relative infection was calculated as Renilla luciferase (RLU) divided by average 
absorbance at 595nm (MTT) for the quadruplicate wells. Infection was plotted relative to each day’s vehicle 
control plus virus set to 100%. Statistical comparisons were carried out using a two-way ANOVA with Tukey’s 
multiple comparisons post test. Significance is indicated by lines between samples with **** indicating 
p<0.0001.  
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For the same experiment, absolute HIV-1 infection was significantly higher in the vehicle control 
after 7 days, compared to the vehicle control plus virus after 2 days (Fig. B1.2), implying that the 
PBMCs were productively infected. These results are supplementary figures from the experiment 
reported in Fig. 3.2.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B1.2. HIV-1 infection increases between 2 and 7 days of stimulation with exogenous 
hormones mimicking the menstrual cycle phases or contraception with MPA. PBMCs were 
stimulated and infected as described in Fig. 3.2.1. The results show pooled data from at least 3 independent 
experiments, with 2-3 PBMC donors each, for a total of 7 independent donors. Relative infection was calculated 
as Renilla luciferase (RLU) divided by average absorbance at 595nm (MTT) for the quadruplicate wells. 
Infection was plotted relative to each day’s vehicle control plus virus set to 100%. Statistical comparisons were 
carried out using a two-way ANOVA with Dunnett’s multiple comparisons post test. Stars above bars indicate 
significant differences compared to the Day 2 Vehicle control plus HIV-BaL, where **** indicates p<0.0001. 
 
 
 
The effect of the GR antagonist RU486 on MPA-induced HIV-1 infection was measured in PBMCs 
(Fig. 3.4.1.1b). When the PBMC donors in which MPA increased HIV-1 infection relative to the 
vehicle control (that is, the MPA-responders) were plotted separately, the same decrease in MPA-
induced HIV-1 infection in the presence of RU486 observed for all donors pooled together (Fig. 
3.4.1.1b) was also shown. These results imply that the MPA-induced increase in HIV-1 infection is 
mediated by the GR. 
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In order to depict the biological variation in HIV-1 infection but not cell viability in response to HIV-
1 infection, raw luciferase and MTT values are shown for two representative experiments for both 
PBMCs and TZM-bls (Table B1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B1.3. MPA-induced HIV-1 infection is mediated by the GR in MPA-responder PBMC 
donors. PBMCs were stimulated and infected as described in Fig. 3.4.1.1. The results show pooled data from 4 
PBMC donors. Relative infection was calculated as Renilla luciferase (RLU) divided by average absorbance at 
595nm (MTT) for the quadruplicate wells. Infection was plotted relative to both vehicle controls plus virus set 
to 100%. Statistical comparisons were carried out using a two-way ANOVA with Tukey’s multiple comparisons 
post test. Significance is indicated by lines between samples with **** indicating p<0.0001.  
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Table B1. Variation in HIV-1 infection in PBMCs and TZM-bls arises from biological 
variability in luciferase and not cell viability between replicate wells.  
   
PBMCs 
Experiment Infection Stimulation Raw LUC (RLU) Raw MTT (A595) 
#2058  
(Day 7) 
No-virus 
control 
Vehicle 60.0002 56.0002 76.0003 62.0002 0.098 0.106 0.099 0.101 
Luteal 60.0002 62.0002 64.0002 76.0003 0.073 0.1 0.078 0.088 
Follicular 74.0003 44.0001 58.0002 62.0002 0.084 0.09 0.077 0.093 
MPA 62.0002 66.0002 48.0001 70.0002 0.082 0.096 0.083 0.093 
HIV-BaL 
Vehicle 282.004 208.002 366.007 136.001 0.073 0.068 0.074 0.088 
Luteal 238.003 1290.08 182.002 102.001 0.078 0.069 0.076 0.081 
Follicular 148.001 182.002 106.001 198.002 0.075 0.077 0.073 0.092 
MPA 968.046 984.048 1416.1 898.04 0.066 0.062 0.066 0.068 
#9922  
(Day 7) 
No-virus 
control 
Vehicle 90.0004 62.0002 66.0002 82.0003 0.071 0.09 0.074 0.086 
Luteal 66.0002 76.0003 54.0001 64.0002 0.056 0.07 0.062 0.077 
Follicular 70.0002 70.0002 80.0003 86.0004 0.055 0.067 0.065 0.07 
MPA 94.0004 90.0004 70.0002 68.0002 0.055 0.067 0.066 0.077 
HIV-BaL 
Vehicle 82.0003 56.0002 66.0002 64.0002 0.054 0.07 0.061 0.075 
Luteal 2214.24 500.012 2532.31 1628.13 0.055 0.066 0.061 0.073 
Follicular 160.001 86.0004 172.001 132.001 0.054 0.063 0.06 0.059 
MPA 2232.24 2234.24 1600.13 1890.18 0.059 0.062 0.053 0.07 
   
TZM-bls 
Experiment Infection Transfection Raw LUC (RLU) Raw MTT (A595) 
#2 
No-virus 
control 
NSC-PR-B 28854.7 30140.4 31326 29787.4 0.532 0.558 0.694 0.694 
NSC+PR-B 29235.8 33011.3 32957.1 29693.1 0.459 0.469 0.531 0.595 
siGR-PR-B 20965.5 25756.5 24260.8 21238.1 0.226 0.239 0.308 0.283 
siGR+PR-B 23150.2 25622.1 20801.2 22107.9 0.365 0.271 0.336 0.293 
HIV-BaL 
NSC-PR-B 586966 205754 329188 380737 0.493 0.669 0.602 0.43 
NSC+PR-B 733567 512358 515511 723883 0.531 0.466 0.587 0.542 
siGR-PR-B 354830 719678 483164 671821 0.324 0.322 0.327 0.351 
siGR+PR-B 498183 643268 568996 621761 0.354 0.194 0.3 0.226 
#3 
No-virus 
control 
NSC-PR-B 42713.2 54350.4 52681.6 51455.4 0.29 0.396 0.372 0.235 
NSC+PR-B 33517 48806.4 55134.6 51294.6 0.308 0.328 0.264 0.367 
siGR-PR-B 22126 36854.4 41237.2 38821.7 0.372 0.248 0.316 0.353 
siGR+PR-B 18717.2 32925 33878.1 33930.3 0.218 0.309 0.372 0.344 
HIV-BaL 
NSC-PR-B 711256 905192 933196 816823 0.319 0.49 0.42 0.479 
NSC+PR-B 761815 1085240 887348 664797 0.274 0.322 0.407 0.401 
siGR-PR-B 436981 535677 554797 623917 0.333 0.33 0.33 0.284 
siGR+PR-B 437437 554517 480423 747691 0.294 0.199 0.176 0.16 
 
Raw values for Renilla luciferase (HIV-1 infection/LTR activation) and cell viability (MTT assay) are shown 
for two representative experiments each for PBMCs and TZM-bls. Each condition was measured in 
quadruplicate wells. 
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B2. GR and PR are expressed in pre- and post-menopausal cervical explant tissue 
 
In order to replicate the pattern of PR-A, PR-B and GR protein expression between the luteal and 
follicular phase of the menstrual cycle shown previously (Appendix A, Fig. A3.1), total protein was 
extracted from additional ectocervical explants from normally cycling premenopausal donors and was 
probed for GR and PR protein levels by western blotting (Fig. B2.1). Donor information such as age 
and levels of endogenous reproductive hormones are shown in Appendix D. While no clear pattern 
between the luteal and follicular phase was observed for these samples due to the high variability in 
protein detection, both GR and PR were detectable in both phases of the menstrual cycle (Fig. B2.1). 
 
 
 
 
 
 
 
 
 
 
 
Figure B2.1. Both GR and PR are detectable in ectocervical explants from women in the luteal 
and follicular phase of the menstrual cycle. Cervical explants of about 3 x 3 mm were thawed from 
samples archived on the day of surgery. Explants were homogenized in RIPA Buffer using the TissueLyser. 
Total protein was quantified using the BCA assay. Western blots were carried out using antibodies specific to 
GR, PR or the loading control GAPDH. Luteal phase donors n=7; Follicular phase donors n=9. 
 
 
In addition to premenopausal cervical explants, samples from postmenopausal donors were screened 
for endogenous GR/PR protein expression by western blotting in matched endocervical and 
ectocervical lysates from the same donors. Both GR and PR were detectable in cervical explants from 
postmenopausal donors, with GR levels appearing to be greater in the ectocervix while PR levels were 
greater in the endocervix (Fig. B2.2). 
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Figure B2.2. Both GR and PR are detectable in endo- and ectocervical explants from 
postmenopausal women (n=4). Cervical explants of about 3 x 3 mm were thawed from samples archived on 
the day of surgery. Explants were homogenized in RIPA Buffer using the TissueLyser. Total protein was 
quantified using the BCA assay. Western blots were carried out using antibodies specific to GR, PR or the 
loading control GAPDH. Positive controls were created using COS1 cells transiently transfected with 1 μg GR/1 
X 10
5
 cells and T47D breast cancer cells expressing endogenous PR-A and PR-B.  
 
B3. Establishing GR knockdown and immune function gene regulation by the GR in 
End1/E6E7 and HeLa cells 
 
An important aspect of investigating the effects of changing the relative ratios of GR/PR on 
transcriptional responses in cervical cells was to establish independent GR- and PR-mediated gene 
regulation. Known for their robust responses to GCs, the anti-inflammatory mediator GILZ and the 
pro-inflammatory cytokine IL-6 were chosen as a model gene for GR-mediated transactivation and 
transrepression, respectively.  
 
In pilot experiments in End1/E6E7 cells, GILZ mRNA was induced 7.4-fold by Dex but not MPA, 
and this up-regulation was reduced to 2.7-fold when GR levels were decreased by siRNA targeting 
the human GR (Fig. B3.1a). IL-6 mRNA was repressed by Dex 5.3-fold and MPA 2.4-fold, and when 
GR levels were decreased, this repression was lifted back to basal levels (Fig. B3.1b). However these 
differences were not significant as only two independent repeats were analyzed. Decreased GR 
protein levels after 72 h post-transfection with siRNA were confirmed by western blotting (Fig. 
B3.1c). 
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Figure B3.1. The effects of Dex and/or MPA on GILZ and IL-6 gene expression is mediated by 
the GR in End1/E6E7 cells. Cells were seeded at 1.5 X 105 cells/well in 12 well plates and allowed to 
adhere overnight. Cells were subsequently transfected with 10 nM NSC or siGR for 48 h. Cells were stimulated 
with 100 nM final concentration of the indicated ligands in SF-KSFM for a further 24 h, then cells were washed 
and RNA was extracted. cDNA was synthesized from 500 ng RNA then used in quantitative RT real-time 
qPCR. Relative mRNA levels of GILZ (a) and IL-6 (b) were normalized to GAPDH mRNA levels. Relative 
expression was determined by normalizing to the vehicle control set to 1. The results are pooled from 2 
independent experiments. (c) Cells seeded and transfected in parallel were harvested in SDS sample buffer and 
lysates were analyzed for GR levels by western blotting using GAPDH as a loading control. Lysates from COS1 
cells over-expressing 1 μg pcDNA3-hGR were used as a positive control.  A representative blot is shown. 
 
 
In pilot experiments in HeLa cells, GILZ mRNA was induced by both Dex (4.6-fold) and MPA (3.9-
fold); however when GR levels were decreased, GILZ was only reduced by 1.5/1.3-fold (Dex/MPA) 
(Fig. B3.2a), which was much less than the 2.8-fold difference observed in End1/E6E7 cells (Fig. 
B3a). IL-6 mRNA was repressed only by Dex (2.7-fold) but not MPA; this repression was lifted when 
GR levels were decreased (Fig. B3.2b). Decreased GR protein levels after 72 h post-transfection with 
siRNA were confirmed by western blotting (Fig. B3.2c).  
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Figure B3.2. The effects of Dex and/or MPA on GILZ and IL-6 gene expression is mediated by 
the GR in HeLa cells. Cells were seeded at 1 X 105 cells/well in 12 well plates and allowed to adhere 
overnight. Cells were subsequently transfected with 10 nM NSC or siGR for 48 h. Cells were stimulated with 
100 nM final concentration of the indicated ligands in SF-DMEM for a further 24 h, then cells were washed and 
RNA was extracted. cDNA was synthesized from 500 ng RNA then used in quantitative RT real-time qPCR. 
Relative mRNA levels of GILZ (a) and IL-6 (b) were normalized to GAPDH mRNA levels. Relative expression 
was determined by normalizing to the vehicle control set to 1. The results are pooled from 2 independent 
experiments. (c) Cells seeded and transfected in parallel were harvested in SDS sample buffer and lysates were 
analyzed for GR levels by western blotting using GAPDH as a loading control. Lysates from COS1 cells over-
expressing 1 μg pcDNA3-hGR were used as a positive control. A representative blot is shown. 
 
 
These results suggest that Dex-induced GILZ and IL-6 responses are regulated via the GR in both 
End1/E6E7 and HeLa cells, and that MPA-induced GILZ expression in HeLa cells and IL-6 
expression in End1/E6E7 cells are regulated via the GR. The discrepancy between End1/E6E7 and 
HeLa cells may in part be due to different endogenous GR levels (Fig. B6.1) or other cell- and/or 
promoter-specific differences. 
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B4. Establishing PR-B over-expression and TAT-GRE-LUC reporter gene regulation by the 
PR-B in End1/E6E7 and HeLa cells 
 
Over-expression of PR-B was achieved in End1/E6E7 and HeLa cells by transient transfection of 
different amounts of the pMT-hPR-B expression vector. 
 
End1/E6E7 cells appeared to be sensitive to transfection with PR-B, as observed by less cell growth 
or perhaps cell death seen under the microscope when amounts greater than 250 ng/1.5 X 10
5
 cells 
were transfected (not shown). In a pilot assay, transfection of 250 ng PR-B/1.5 X 10
5
 cells showed a 
460-fold PR-B response on TAT-GRE-LUC (not shown). By looking at the total protein levels, an 
indication of cell number, only a small, acceptable reduction in cell number was observed (not 
shown). Therefore 250 ng PR-B was used in all subsequent experiments in End1/E6E7 cells. 
 
PR-B was successfully over-expressed without changing endogenous GR levels in both End1/E6E7 
(Fig. B4.1b) and HeLa (Fig. B4.2b) cells. A greater amount of pMT-hPR-B expression vector could 
be transfected into HeLa cells (500 ng/ 1 X 10
5
 cells, Fig. B4.3b). In western blots, relative PR-B 
signal strength from over-expressed samples was not greater than those from samples expressing 
endogenous PR (data not shown), suggesting that over-expressed PR levels were within the 
physiological range. In End1/E6E7 cells, transactivation of the PR-responsive TAT-GRE-LUC 
reporter gene by the progestins R5020 (75-fold), LNG (149-fold) and MPA (61-fold) was observed 
only in the presence of over-expressed PR-B (Fig. B4.1a). While the fold increase only tended 
towards statistical significance for R5020, LNG- and MPA-induced fold increase was significant (Fig. 
B4.1a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B4.1. Over-expressed PR-B mediates progestin responses on the TAT-GRE-LUC 
reporter gene in End1/E6E7 cells. (a) End1/E6E7 cells were seeded at 8 X 104/well in 24-well plates and 
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allowed to adhere overnight. Cells were subsequently transfected with 125 ng pcDNA3 or pMT-hPR-B and 47 
ng pTAT-GRE-E1b-LUC for 24 h. Cells were stimulated in triplicate wells with 100 nM final concentration of 
the indicated ligands in SF-KSFM for 24 h, then washed and harvested in Reporter Lysis Buffer. Lysates were 
analyzed for luciferase activity and total protein. Luciferase activity was normalized to average protein 
concentration in mg/mL. Fold change was determined relative to the –PR-B vehicle control. The results are 
pooled from 3 independent experiments where each point was in triplicate. Statistical comparisons were carried 
out using a two-way ANOVA with Tukey’s multiple comparisons post-test (+PR-B Vehicle vs LNG), or an 
unpaired t-test (+PR-B Vehicle vs R5020/MPA). Stars above bars indicate significant differences compared to 
the +PR-B vehicle control, where * indicates p<0.05. (b) Cells seeded in 12-well plates and transfected in 
parallel were harvested in SDS sample buffer and lysates were analyzed for GR and PR-B levels by western 
blotting using GAPDH as a loading control. Blots were probed first for PR-B then stripped and re-probed for 
GR. Lysates from T47D cells expressing endogenous PR-A/PR-B or COS1 cells over-expressing 1 μg pcDNA3-
hGR were used as positive controls. A representative blot is shown. 
 
In HeLa cells, the GR/PR-agonist MPA activated TAT-GRE-LUC only 2.5-fold in the absence of PR-
B, presumably via the endogenous GR, but a massive and significant 492-fold response was observed 
in the presence of PR-B (Fig. B4.2a). The progestin R5020 only significantly activated TAT-GRE-
LUC in the presence of PR-B (553-fold, Fig. B4.2a).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B4.2. Over-expressed PR-B mediates progestin responses on the TAT-GRE-LUC 
reporter gene in HeLa cells. (a) HeLa cells were seeded at 5 X 104/well in 24-well plates and allowed to 
adhere overnight. Cells were subsequently transfected with 250 ng pcDNA3 or pMT-hPR-B and 47 ng pTAT-
GRE-E1b-LUC for 24 h. Cells were stimulated in triplicate wells with 100 nM final concentration of the 
indicated ligands in SF-DMEM for 24 h, then washed and harvested in Reporter Lysis Buffer. Lysates were 
analyzed for luciferase activity and total protein. Luciferase activity was normalized to average protein 
concentration in mg/mL. Fold change was determined relative to the –PR-B vehicle control. The results are 
pooled from 2 independent experiments where each point was in triplicate. Statistical comparisons were carried 
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out using a two-way ANOVA with Tukey’s multiple comparisons post-test. Stars above bars indicate significant 
differences compared to the +PR-B vehicle control, where **** indicates p<0.0001. (b) Cells seeded in 12-well 
plates and transfected with 250 or 500 ng pMT-hPR-B in parallel were harvested in SDS sample buffer and 
lysates were analyzed for GR and PR-B levels by western blotting using GAPDH as a loading control. Blots 
were probed first for PR-B then stripped and re-probed for GR. Lysates from T47D cells expressing endogenous 
PR-A/PR-B or COS1 cells over-expressing 1 μg pcDNA3-hGR or pMT-hPR-B were used as positive controls. 
A representative blot is shown. 
 
Over-expressed PR-B was assessed for transcriptional activity on the endogenous transactivation 
gene, MKP1, reported to be regulated by the PR (Gizard et al. 2005, Chen et al. 2011). R5020 and/or 
LNG were used as PR-specific agonists in order to determine PR-specific effects, since the PR agonist 
MPA is also an agonist for the GR.  
 
In End1/E6E7 cells, Dex up-regulated MKP1 5-fold, presumably via the endogenous GR (Fig. B4.3a), 
which is consistent with previous reports that glucocorticoids increase MKP1 expression (Kassel et al. 
2001, Chen et al. 2002, Lasa et al. 2002, Clark 2003). This shows that endogenous GR is still active in 
the presence of over-expressed PR-B, which is also consistent with PR-B over-expression not 
changing GR protein levels (Fig. B4.1b). MKP1 expression did not increase in response to the 
progestins R5020 or LNG in the presence of over-expressed PR-B but increased 2-fold in response to 
MPA (Fig. 4.3a). The absence of progestin-induced up-regulation suggests that MPA-induced MKP1 
up-regulation was most likely via the endogenous GR.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B4.3. PR-B-mediated responses were not observed on endogenous MKP1 in End1/E6E7 
and HeLa cells. Cells were seeded at 1.5 X 105 cells/well (a, End1/E6E7) or 1 X 105 cells/well (b, HeLa) in 
12 well plates and allowed to adhere overnight. Cells were subsequently transfected with 250 ng  (End1/E6E7) 
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or 500 ng (HeLa) pMT-hPR-B or equivalent pcDNA3.1 for 24 h. Cells were stimulated with 100 nM final 
concentration of the indicated ligands in SF-KSFM (End1/E6E7) or SF-DMEM (HeLa) for a further 24 h, then 
cells were washed and RNA was extracted. cDNA was synthesized from 500 ng RNA then used in quantitative 
RT real-time qPCR. Relative mRNA levels of MKP1 were normalized to GAPDH mRNA levels. Relative 
expression was determined by normalizing to the vehicle control set to 1. The results are pooled from 2 
(End1/E6E7) or 1-3 (HeLa) independent experiments.  
 
 
In HeLa cells, both Dex and MPA up-regulated MKP1 (Fig. B4.3b) in both the presence and absence 
of PR-B, with Dex-induced up-regulation greater than for MPA and the up-regulation appearing to be 
greater in the presence of PR-B. R5020 had no effect on MKP1 gene expression in either the absence 
or presence of PR-B. These results suggest that PR-mediated regulation of endogenous MKP1 does 
not occur via over-expressed PR-B in End1/E6E7 or HeLa cells. Since GR-mediated transcriptional 
responses on immunomodulatory genes were a primary focus of this project, further investigations 
into endogenous PR-mediated gene regulation were not continued. Subsequently, the effects of 
detectable levels of over-expressed PR-B protein on GR-mediated gene regulation were investigated. 
 
Since the relative GR/PR levels change in vivo within different compartments of the FRT and in 
response to fluctuating menstrual cycle hormones, the molecular strategies of decreased GR levels 
and PR-B over-expression were combined in End1/E6E7, HeLa and TZM-bl cells order to represent 
changing GR/PR levels in an in vitro model of the FRT. Decreased GR protein levels using siRNA 
and transient transfection of PR-B resulted in four combinations: high GR/no PR, low GR/no PR, high 
GR/high PR and low GR/high PR. The consequences of changing relative GR/PR levels on HIV-1 
infection (Fig. 4.2.1.1-4.2.2.1), HIV-1 CD4 receptor and CCR5/CXCR4 co-receptor expression (Fig. 
4.3.1.1) and immunomodulatory gene regulation (Fig 4.3.2.1-4.3.3.2) were investigated in Chapter 4. 
 
The gene expression results in Fig. 4.3.2.1 (End1/E6E7 cells) and Fig. 4.3.2.2 (HeLa cells) suggest 
that the presence of PR-B alters the GR-mediated transcriptional responses to MPA on GILZ and IL-
6, when analysing the fold change relative to the vehicle control. Supplementary to these figures, 
these data were plotted relative to the NSC-PR-B (high GR/no PR) vehicle control in order to assess 
the effect of PR-B over-expression on GILZ and IL-6 gene regulation (Fig. B4.4-B4.5).  
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Figure B4.4. The presence of PR-B alters basal GILZ and IL-6 expression, and potentially 
dampens the GR-mediated transcriptional response to Dex on GILZ in End1/E6E7 cells. Cells 
were seeded at 1 X 10
5
 cells/well in 12 well plates and allowed to adhere overnight. Cells were subsequently 
transfected with 10 nM NSC or siGR for 24 h, then transiently transfected with 250 ng/well empty vector 
pcDNA3 or pMT-hPR-B for 24 h. Cells were stimulated with 100 nM final concentration of the indicated 
ligands in SF-KSFM for a further 24 h, then cells were washed. RNA was extracted and cDNA was synthesized 
from 500 ng RNA then used in real-time qPCR. Relative mRNA levels of GILZ (a) and IL-6 (b) were 
normalized to GAPDH mRNA levels. Relative expression was determined by normalizing to the NSC-PR-B 
vehicle control set to 1. The results are pooled from 6 independent experiments.  Statistical comparisons were 
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carried out using a two-way ANOVA (a, b) with Tukey’s multiple comparisons post test (a) or unpaired t tests 
(b). Stars above bars indicate significant differences compared to the NSC-PR-B vehicle control unless 
otherwise indicated by lines, where *** indicates p<0.001. Decreased GR expression and PR-B over-expression 
were confirmed previously by western blotting in parallel samples (Fig. 4.3.2.1c-e). 
 
 
The results in End1/E6E7 cells show that Dex-induced up-regulation of GILZ mRNA was mediated 
by the GR, since the induction was lost with low GR/no PR (significantly) and low GR/high PR (near-
significantly, Fig. B4.5a). Despite this, GILZ induction by Dex was not as elevated with high GR/high 
PR (2.6-fold) compared to high GR/no PR (4.1-fold, Fig. B4.4a). Although this was not significant, 
this may suggest a possible dampening of the Dex-induced, GR-mediated response by the presence of 
PR-B. However, this effect was not observed in HeLa cells (Fig. B4.5a), suggesting that the effect is 
cell type-specific. Furthermore no such observation was made for MPA on GILZ in either End1/E6E7 
(Fig. B4.4a) or HeLa (Fig. B4.5a) cells, suggesting that the dampening effect is also ligand-specific. 
 
These results also revealed that the basal levels (in the absence of ligands) of GILZ and/or IL-6 
mRNA changed when the relative levels of GR/PR were altered. Although not significant, basal GILZ 
levels in End1/E6E7 cells decreased with high GR/high PR and low GR/high PR compared to high 
GR/no PR (Fig. B4.4a). Conversely, basal IL-6 levels appeared to increase with low GR/no PR and 
low GR/high PR compared to high GR/no PR in End1/E6E7 cells (Fig. B4.4b). No change was 
observed for basal GILZ levels in HeLa cells (Fig. B4.5a), but basal IL-6 levels significantly 
increased with high GR/high PR and low GR/high PR, compared to high GR/no PR (Fig. B4.5b). 
These initial experiments led to the further investigation of MPA-induced and basal responses to 
changing relative GR/PR levels in End1/E6E7 and HeLa cells. 
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Figure B4.5. The presence of PR-B alters basal IL-6 but not GILZ expression in HeLa cells. 
Cells were seeded at 1 X 10
5
 cells/well in 12 well plates and allowed to adhere overnight. Cells were 
subsequently transfected with 10 nM NSC or siGR for 24 h, then transiently transfected with 500 ng/well empty 
vector pcDNA3 or pMT-hPR-B for 24 h. Cells were stimulated with 100 nM final concentration of the indicated 
ligands in SF-DMEM for a further 24 h, then cells were washed. RNA was extracted and cDNA was 
synthesized from 500 ng RNA then used in real-time qPCR. Relative mRNA levels of GILZ (a) and IL-6 (b) 
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were normalized to GAPDH mRNA levels. Relative expression was determined by normalizing to the NSC-PR-
B vehicle control set to 1. The results are pooled from 6 independent experiments.  Statistical comparisons were 
carried out using a two-way ANOVA with Tukey’s multiple comparisons post test. Stars above bars indicate 
significant differences compared to the NSC-PR-B vehicle control unless otherwise indicated by lines, where 
*** and ** indicate p<0.001 and p<0.01 respectively. Decreased GR expression and PR-B over-expression were 
confirmed previously by western blotting in parallel samples (Fig. 4.3.2.2c-e). 
 
 
B5.  Over-expression strategies in U2OS cells do not generate good GR-mediated responses 
 
In parallel to using cells expressing endogenous GR in which PR-B can be over-expressed 
(End1/E6E7, HeLa) as physiologically relevant models of the FRT, another strategy to investigate the 
transcriptional effects of changing the relative levels of GR/PR was the use of receptor-negative cell 
lines in which both GR and PR could be over-expressed. U2OS human osteosarcoma cells were 
chosen due to their low endogenous expression of GR. The initial approach was to investigate the 
effects of over-expressed GR- and PR-regulated immunomodulatory gene expression individually, 
then to combine over-expressed GR and PR-B in different ratios (GR>PR, GR=PR, GR<PR) in order 
to assess whether there was a preference for GR- or PR-mediated transcriptional responses when 
stimulated with the GR/PR ligand, MPA. However, this strategy did not reach that far.  
 
U2OS cells could successfully over-express PR-A and PR-B (Fig. B5b). Using the PR agonist R5020 
to activate PR-mediated regulation of the TAT-GRE-LUC reporter gene, it was confirmed in U2OS 
cells that PR-B is more transcriptionally active than PR-A since the response to R5020 was greater for 
cells over-expressing PR-B (79-fold) than PR-A (5.6-fold, Fig. B5a). Furthermore, it was established 
that R5020-induced activation of the TAT-GRE-LUC reporter gene by PR-B could be reduced by 1.5-
fold (from 79-fold to 53-fold), although not significantly, by co-expression of PR-A (Fig. B5a). This 
observation is consistent with previous reports that PR-A acts as a transdominant repressor of PR-B 
(Vegeto et al. 1993). 
 
U2OS cells could also successfully over-express GR (Fig. 5.2.2). However, while a GR-mediated 
response to Dex was observed for the transactivation model gene GILZ, from 1.5-fold in the absence 
to 4.8-fold in the presence of GR, the GR did not significantly repress the model transrepression gene 
IL-6 (only 1.4-fold) and did not significantly repress TNFα-regulated induction of IL-6 (not shown). 
Since the classical regulation of IL-6 by the GR was not shown in U2OS cells, it was decided that 
U2OS cells were not a suitable model for GR-mediated gene regulation. 
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Figure B5. PR-A represses the R5020-induced activity of PR-B on the TAT-GRE-LUC reporter 
gene in U2OS cells. (a) U2OS cells were seeded at 7 X 104/well in 24-well plates and allowed to adhere 
overnight. Cells were subsequently transfected with 125 ng pcDNA3, pSG5-hPR-A and/or pMT-hPR-B and 47 
ng pTAT-GRE-E1b-LUC for 24 h. Cells were stimulated in triplicate wells with 100 nM final concentration 
R5020 in SF-DMEM for 24 h, then washed and harvested in Reporter Lysis Buffer. Lysates were analyzed for 
luciferase activity and total protein. Luciferase activity was normalized to average protein concentration in 
mg/mL. Fold change was determined relative to each vehicle control. The results are pooled from 4 independent 
experiments where each point was in triplicate. Statistical comparisons were carried out using unpaired t-
tests.Stars above bars indicate significant differences compared to each vehicle control unless otherwise 
indicated by lines, where *** and * indicate p<0.001 and p<0.05 respectively. (b) Cells seeded in 12-well plates 
and transfected in parallel with 125 ng pSG5-hPR-A or pMT-hPR-B for 48 h were harvested in SDS sample 
buffer and lysates were analyzed for PR levels by western blotting using GAPDH as a loading control. Lysates 
from COS1 cells over-expressing 1 μg pSG5-hPR-A or pMT-hPR-B were used as positive controls. A 
representative blot is shown. 
 
 
 
B6. Endogenously GR- and PR-expressing cell lines, MCF-7 and T47D, do not generate 
good GR responses 
 
In parallel to receptor-negative cell lines in which GR and PR could be over-expressed, a third 
strategy in which to study GR/PR levels was to investigate GR- and PR-mediated responses in 
endogenous GR- and PR-positive cell lines. Although not directly relevant to the site of HIV-1 
transmission in the FRT, the breast cancer cell lines MCF-7 and T47D were promising candidates 
since both GR and PR were detectable by western blot (Fig. B6.1). This would eliminate any 
confounding effects arising from transient transfections of GR/PR expression vectors or siRNA. GR 
protein levels were highest in End1/E6E7 and HeLa cells, but were greater in MCF-7 and T47D cells 
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than in the “receptor-negative” COS1 and U2OS cells (Fig. B6.1a). While MCF-7 and T47D cells 
were the only cell lines to express endogenous PR (Fig. B6.1b), T47D cells expressed more 
endogenous PR than MCF-7 cells (Fig. B6.1b). 
 
 
 
 
 
 
 
 
 
 
 
Figure B6.1. End1/E6E7, HeLa, MCF-7, T47D, COS1 and U2OS cells express detectable GR 
protein but only MCF-7 and T47D express endogenous PR. Cells from the indicated cell lines were 
seeded at varied densities in 12 well plates and allowed to grow until ~80% confluent. Cells were washed and 
total protein was harvested in SDS sample buffer and analyzed for GR and PR levels by western blotting using 
GAPDH as a loading control. Lysates from COS1 cells over-expressing 1 μg pcDNA3-hGR, pSG5-hPR-A or 
pMT-hPR-B were used as positive controls.   
 
Functional activity of the endogenous GR and PR was assessed in MCF-7 and T47D cells by their 
ability to activate the TAT-GRE-LUC reporter gene, which is recognized and activated by both GR 
and PR.  
 
Over-expression of PR-B activated the TAT-GRE-LUC reporter gene in response to the PR-specific 
agonist R5020 in both MCF-7 (significantly, 169-fold, Fig. B6.2a) and T47D (40-fold, Fig. B6.2c) 
cells, although in the absence of PR-B there was still an increase in R5020-induced TAT-GRE-LUC 
reporter gene activation in both MCF-7 (significantly, 20-fold, Fig. B6.2a) and T47D (64-fold, Fig. 
B6.2c) cells.  
 
Over-expression of GR activated the TAT-GRE-LUC reporter gene in response to the GR-specific 
agonist Dex in both MCF-7 (significantly, 4989-fold, Fig. B6.2b) and T47D (575-fold, Fig. B6.2d) 
cells. In the absence of over-expressed GR there was a significant increase in Dex-induced TAT-
a) 
b) 
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GRE-LUC reporter gene activation in only MCF-7 (3.2-fold, Fig. B6.2b) but not T47D (1.12-fold, 
Fig. B6.2d) cells. These results suggest that both endogenous GR and PR are functional on the TAT-
GRE-LUC reporter gene in MCF-7 cells, but only endogenous PR is functional on the TAT-GRE-
LUC reporter gene in T47D cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B6.2. Endogenous GR and PR are functional on the TAT-GRE-LUC reporter gene in 
MCF-7 cells, while only endogenous PR is functional on the TAT-GRE-LUC reporter gene in 
T47D cells. MCF-7 (a, b) or T47D (c, d) cells were seeded at 7 X 104/well in 24-well plates and allowed to 
adhere overnight. Cells were subsequently transfected with 125 ng pcDNA3, pMT-hPR-B or pcDNA3-hGR and 
47 ng pTAT-GRE-E1b-LUC for 24 h. Cells were stimulated in triplicate wells with 100 nM final concentration 
Dex or R5020 in SF-DMEM for 24 h, then washed and harvested in Reporter Lysis Buffer. Lysates were 
analyzed for luciferase activity and total protein. Luciferase activity was normalized to average protein 
concentration in mg/mL. Fold change was determined relative to each vehicle control in the absence of GR/PR-
B. The results are pooled from 3 (MCF-7) or 1 (T47D) independent experiments where each point was in 
triplicate. Statistical comparisons were carried out using a one-way ANOVA with Tukey’s multiple 
comparisons post test (a, b). Stars above bars indicate significant differences compared to the –PR-B vehicle 
control unless otherwise indicated by lines, where *** indicates p<0.001. 
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Further investigation into endogenous GR/PR activity was carried out by assessment of endogenous 
gene expression. The up-regulation of the model transactivation genes GILZ, MKP1, TAT and IκB 
was measured in response to Dex in MCF-7 cells. Surprisingly, only GILZ was up-regulated 1.5-fold 
in response to Dex, while MKP1 expression did not change (Fig. B6.3a). Selected model 
transrepression genes were assessed for their ability to be repressed by Dex in both the absence and 
presence of TNFα. However, Dex did not significantly repress IL-6, IL-8 or RANTES via the 
endogenous GR in MCF-7 cells, in either the absence or presence of TNFα (Fig. B6.3b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B6.3. Endogenous GR does not regulate Dex-induced transrepression genes in MCF-7 or 
T47D cells. MCF-7 (a, b) or T47D (c, d) cells were seeded at 1 X 105 cells/well in 12 well plates and 
allowed to adhere overnight. Cells were stimulated with 100 nM final concentration of the indicated ligands 
and/or 20 ng/mL TNFα (b) in SF-DMEM for a further 24 h, then cells were washed and RNA was extracted. 
cDNA was synthesized from 500 ng RNA then used in quantitative RT real-time qPCR. Relative mRNA levels 
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of GILZ (a, c), IL-6 (b, d), MKP1 (a), IL-8 (b) and RANTES (b) were normalized to GAPDH mRNA levels. 
Relative expression was determined by normalizing to the vehicle control set to 1. The results are pooled from 2 
(a, c, d) or 3 (b) independent experiments. Statistical comparisons were carried out using an unpaired t-test (b). 
Stars above bars indicate significant differences compared to each gene’s vehicle control (b) unless otherwise 
indicated by lines, where * indicates p<0.05. 
 
In T47D cells, the expression of only one transactivation (GILZ) and transrepression (IL-6) gene was 
investigated. The endogenous GR appeared to up-regulate GILZ in response to Dex 7.6-fold, and 
surprisingly GILZ was up-regulated in response to the progestins R5020 (12.6-fold), LNG (4.7-fold) 
and MPA (16.7-fold, Fig. B6.3c). IL-6 mRNA was marginally repressed 1.15-fold in response to Dex, 
via the endogenous GR, and presumably via the endogenous PR, R5020 but not LNG or MPA up-
regulated IL-6 by 3.8-fold (Fig. B6.3d). 
 
These results suggest that both MCF-7 and T47D cells, although expressing detectable GR protein, do 
not exhibit robust GR-mediated responses that would be required to establish GR/PR-mediated effects 
on immunomodulatory genes. 
 
This observation of a non-functional GR in T47D cells is consistent with other reports (Cato et al. 
1986, Cato et al. 1988, Chalepakis et al. 1988, Wu and Pfahl 1988, Nordeen et al. 1989). Therefore 
attempts were made to over-express GR in T47D cells by transient transfection: this would be an 
attractive model in which to study GR/PR levels, given that T47D cells already express large amounts 
of endogenous PR which could be knocked down using siRNA (not shown). However, transient 
transfection of increasing amounts of GR expression vector did not translate into greater levels of GR 
protein (Fig. B6.4). 
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Figure B6.4. GR protein cannot be over-expressed in T47D cells. Cells were seeded at 1 X 105 
cells/well in 12 well plates and allowed to adhere overnight. Cells were subsequently transfected with increasing 
amounts of pcDNA3-hGR for 48 h. Cells were washed and total protein was harvested in SDS sample buffer 
and analyzed for GR and PR levels by western blotting using GAPDH as a loading control. Western blots were 
scanned and quantified for relative GR (b) or PR-A/B (d) levels by calculating integrated density values. 
 
 
Since the hypotheses of this study required robust GR-mediated responses, especially via 
transrepression mechanisms on immune function genes, for the same reasons as U2OS cells, the 
endogenous GR/PR-expressing model cell strategy was left in favour of the GR-positive cervical 
End1/E6E7 and HeLa cell lines in which the relative levels of GR/PR could be altered by knockdown 
and over-expression approaches.  
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Appendix C 
Gating strategy used for flow cytometry 
 
The selection of live, single cell populations and gating strategy using MFO controls for CD14, CCR5 
and CD69 are indicated in the figures below. A representative PBMC donor (#2864) is shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CD14 CD3 
CD4 
Single cell populations were identified from the lymphocyte population, from which live (ZOMBIE-) 
cells were selected. 
CD14+ monocytes were identified from the live single cells using the CD14 MFO control. CD3+ 
lymphocytes were selected from the CD14- cells. 
 
CD4+ and CD8+ lymphocytes were identified from 
the CD3+ lymphocyte population. 
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The CD14 MFO gating was applied to all samples. Next, the CCR5 MFO control was used to identify 
CCR5+ populations (CD14+CCR5+, CD3+CCR5+, CD4+CCR5+, CD8+CCR5+) and this gate was 
applied to all samples.  
 
 
Finally, the CD69 MFO control was used to identify CD69 populations (CD14+CD69+, 
CD3+CD69+, CD4+CD69+, CD8+CD69+) and this gate was applied to all samples. 
 
The gates for frequencies of double-positive cell populations (CD3/4/8/14+ with CD69+/CCR5+) for 
each stimulation (Vehicle, Luteal, Follicular, MPA) are shown for a representative PBMC donor 
(#2684) below. 
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Appendix D 
Cervical explant donor information 
 
Table D1: Endogenous reproductive hormone levels, age and HSV status of the pre- and 
postmenopausal donors of cervical explant tissue 
 
Patient no. Date of 
collection 
 
LH 
(IU/L) 
FSH 
(IU/L) 
E2 
(pM) 
P4 
(nM) 
Age Menstrual 
cycle phase 
HSV-
1 
HSV-
2 
LUTEAL PHASE 
 
PROG0027 10-Feb-14 2.4 2.8 341.7 7.3 36 Luteal + - 
PROG0039 9-Jun-14 3.8 2.8 408.6 12 49 Luteal + - 
PROG0051 15-Dec-14 0.6 3.3 212.4 0.5 41 Late luteal + + 
PROG0083 6-Jan-16 5.1 2.8 390 7.2 45 Luteal * * 
PROT001 30-Jul-13 0.6 1.9 370.5 32.1 43 Luteal – day 30 + + 
PROT0011 26-Jun-15 6.9 14.7 395.2 16.5 41 Early luteal  + 
PROT0058 12-Jul-16 3.4 2.9 260 16 40 Luteal + + 
FOLLICULAR PHASE 
 
PROG0028 10-Feb-14 5.3 4 1186 0.2 45 Follicular + - 
PROG0040 10-Jul-14 3.1 7.2 125.9 0.3 43 Follicular + - 
PROG0042 18-Sept-14 10.4 6.1 230.4 1.6 44 Follicular + + 
PROG0044 9-Oct-14 9 6 2629 0.9 48 Follicular + - 
PROG0049 5-Nov-14 3 5.9 84.2 0.5 44 Follicular + - 
PROG0050 2-Dec-14 5.6 6.3 476.3 0.9 38 Follicular - - 
PROT003 3-Dec-13 5.5 8.7 83.7 9.1 51 Follicular – day 7 + + 
PROT007 17-Apr-15 9.3 17.5 99.9 <0.7 46 Follicular – day 5 * + 
POSTMENOPAUSAL 
 
PROG0082 6-Jan-16 35.2 92.9 <19 1.4 69 Postmenopausal + - 
PROG0085 14-Jan-16 37.2 77.5 43 0.6 51 Postmenopausal + + 
PROT0015 25-Jan-16 * * * * 58 Postmenopausal * + 
PROT0017 28-Jan-16 * * * * 72 Postmenopausal + + 
PROG: Groote Schuur Hospital; PROT: Tygerberg Hospital. *: information unavailable. All 
laboratory tests were carried out at the NHLS. Menstrual cycle status was classified according to the 
NHLS guidelines (Table D2), by considering the levels of all hormones (LH, FSH, E2, P4). 
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Table D2: NHLS guideline reference ranges of endogenous sex hormone levels by menstrual 
cycle phase 
 
 
 
  
 Reference ranges 
 LH (IU/l) FSH (IU/l) E2 (pM) P4 (nM) 
Follicular phase 2.4-12.6 3.5-12.5 46-608 0.6-4.7 
Ovulatory phase 14.0-95.6 4.7-21.5 315-1828 2.4-9.4 
Luteal phase 1.0-11.4 1.7-7.7 161-775 5.3-86.0 
Postmenopausal 7.7-58.5 25.8-134.8 <18-201 0.3-2.5 
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